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Abstract 
 
Background 
Congenital cardiovascular malformations (CVM) affects approximately 7 in every 1000 
live births and exhibits familial predisposition but the specific genetic factors involved 
are unknown. It was hypothsised that rare variants in genes of the bone morphogenetic 
protein (BMP) signaling pathway, which is known to play a key role in cardiac 
development, could influence the risk of CVM. Therefore, five genes of the BMP 
signaling pathway were surveyed for novel variants predisposing to CVM risk. 
 
Methods and Results   
The exonic, splice site and untranslated regions of the BMP2, BMP4, BMPR1A, BMPR2, 
and SMAD6 genes were sequenced in 90 unrelated Caucasian cases of CVM. One non-
synonymous variant (p.C484F) in the MH2 domain of SMAD6 was identified with 
predicted impaired protein function. Sequencing of the MH2 domain of SMAD6 in an 
additional 348 cases showed two further non-synonymous variants, one of which 
(p.P415L) was also predicted to affect protein function. Both non-synonymous variants 
were absent in 1000 controls. SMAD6 is an intracellular inhibitor of BMP signaling and 
functional effects of both variants were investigated using BRE-luciferase 
transcriptional reporter and alkaline phosphatase assays. Both SMAD6 variants had 
significantly (p<0.05) lower activity than wild-type SMAD6 in inhibiting BMP 
signaling in the BRE-luciferase assay. In addition, the p.C484F variant had a 
significantly (p<0.05) lower capacity to inhibit alkaline phosphatase generation in 
response to BMP signaling. This was consistent with the phenotype of the patient 
carrying the p.C484F variant, which featured aortic ossification with coarctation.   
 
Conclusions   
Inadequate inhibition of BMP signaling due to genetic variation in SMAD6 can be a 
cause of CVM in man. The potential significant SMAD6 variants were identified in 
approximately 1% of the CVM patients or 6% in patients with coarctation and/or aortic 
stenosis. These findings show that SMAD6 mutations in the MH2 domain may be 
important in abnormal cardiac development. 
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Chapter 1  Introduction 
 
1.1 Heart development 
 
The heart is the first organ to function in the development of the vertebrate embryo. 
Heart development is a continuous complex remodelling process that begins from the 
formation of the heart tube during the third week of gestation in man, followed by 
looping of the heart, chamber formation and valve development (Table 1.1). This 
process is induced by several interacting molecular signaling pathways that drive 
various cell populations to sculpt the heart. Formation of the heart is also governed by 
anterior-posterior (A-P), dorsal-ventral (D-V) and left-right (L-R) polarity.  
 
Mouse has become the most popular animal model for understanding the normal or 
abnormal cardiac development. This is because the mouse and human heart are 
anatomically relatively similar throughout development apart form the differences in 
sizes and heart rate (Wessels and Sedmera 2003). Eventhough avians and mammals 
have four-chambered heart there are a few anatomical differences between both species. 
In birds, the sinus venosus is still present and the aortic arch is developed to the right 
whereas in mammals, the sinus venosus is almost gone and the aortic arch is developed 
to the left.  
 
In this section, the major processes in heart formation and key cell populations involved 
is discussed briefly. The morphogenesis of the heart is summarised in Figure 1.1.  
 
 
1.1.1 Heart tube formation – cellular sources 
 
Cardiac progenitor cells are located on both sides of the primitive streak and caudal to 
the Hensen’s node in the the avian epiblast (Lopez-Sanchez et al. 2001). The cardiac 
precursors in the mouse are similar to chick, they are located laterally of the midline at 
E6.5 (Tam et al. 1997). These cells migrate in an anterior-lateral fashion to the lateral 
plate mesoderm where the formation of bilateral cardiogenic fields occurs (Yang et al. 
2002). In the chick, the bilateral heart-forming regions are two separate entities (Colas 
et al. 2000), but in the mouse, the cardiogenic fields merge in the midline, forming the 
cardiac crescent (Cai et al. 2003). Formation of the heart tube begins when the  
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Human 
development 
(days) 
Developmental process 
13-14 Primitive streak formation  
15-17 Formation of the three primary germ layers: ectoderm, mesoderm, and endoderm; 
primitive streak cells migrate to an anterior and lateral position to form the bilateral 
primary heart field 
17-18 Lateral plate mesoderm splits into the somatopleuric mesoderm and 
splanchnopleuric mesoderm; splanchnopleuric mesoderm contains the myocardial 
and endocardial cardiogenic precursors in the regions of the primary heart field 
18-26 Neurulation (formation of the neural tube) 
20 Cephalocaudal and lateral folding brings the bilateral endocardial tubes into the 
ventral midline of the embryo 
Aortic arch is forming 
21-22 Heart tube fusion 
22 Heart tube begins to beat 
Aortic arches I and II are forming 
24 Heart looping and the accretion of cells from the primary and secondary heart fields; 
neural crest migration starts 
Atria are beginning to bulge 
Rigth and left ventricles act like two pumps in series 
Outflow tract is distinguishable from right ventricle 
Late fourth 
week 
Sinus venosus is becoming incorporated into right atrium 
Endocardial cushions appear 
Early septum I appears between left and right atria 
Muscular interventricular septum is forming 
Truncoconal ridges are forming 
Aortic arch I is regressing, aortic arch III is formed, aortic arch IV is forming 
Early fifth 
week 
Cardiac neural crest migrates through the aortic arches and enters the outflow tract 
of the heart 
Endocardial cushions are coming together; forming right and left atrioventricular 
canals 
Further growth of interatrial spetum I and muscular interventricular septum occurs 
Truncus arteriosus is dividing into aorta and pulmonary artery 
Atrioventricular bundle is forming; possible neurogenic control of heart beat 
Pulmonary veins are becoming incorporated into left atrium 
Aortic arches I and II have regressed, aortic arches III and IV have formed aortic 
arch VI is forming 
Conduction system forms 
Late fift h to 
early sixth 
week 
Endocardial cushions fuse 
Interatrial foramen II is forming 
Interatrial septum I is almost contacting endocaridal cushion 
Membranous part of interventricular septum starts to form  
Semilunar valves begin to form 
Late sixth 
week 
Interatrial foramen II is large 
Interatrial septum II starts to form 
Atrioventricular valves and papillary muscles are forming 
Interventricular septum is almost complete 
Coronary circulation is becoming established 
57+ Outflow tract and ventricular septation complete (membranous part of 
interventriculat septum is completed) 
Birth Functional septation of the atrial chambers, as well as the pulmonary and systemic 
circulatory systems 
 
Table 1.1 Developmental timeline of normal human heart embryology  
(adapted from Carlson, 2004 and Iaizzo, 2009) (Carlson 2004; Iaizzo 2009) 
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A)   B)    C) 
 
 
D)    E)   F)  
 
Figure 1.1 A brief schematic overview of the mouse heart development 
A) The migration of the primitive streak (PS) to the anterior-lateral region of embryo at 
E6.5. B) Formation of the cardiac crescent at E7.5. C) Linear heart tube at E8. D) The 
heart tube elongates and loops rightward from E8.5-E10.5. E) The looped heart tube 
with well-defined cardiac chambers (upper panel, ventral view; lower panel, dorsal 
view). F) E12.5 four chambered heart. 
A, anterior; P, posterior; R, right; L, left; AA, aortic arch; Ao, aorta; AVC, 
atrioventricular canal; HF, head folds; IFT, inflow tract; IVC, inferior vena cava; IVS, 
interventricular septum; LA, left atrium; LV, left ventricle; ML, midline; OFT, outflow 
tract; PLA, primitive left atrium; PRA, primitive right atrium; PS, primitive streak; PT, 
pulmonary trunk; PV, pulmonary vein; RA, right atrium; RV, right ventricle; SVC 
superior vena cava; Tr, trabeculae. (Adapted from Buckingham et al. 2005) 
(Buckingham et al. 2005). 
 4
cardiogenic fields move to the ventral midline in a rostrocaudal orientation fusing from 
anterior to posterior (Arguello et al. 1975). Figure 1.2 shows the formation of the heart 
tube from bilateral cardiogenic fields. During the fusion process, cardiac jelly, a thick 
acellular matrix, is secreted, thus resulting in three layers in the cardiac tube: cardiac 
jelly layer sandwiched between an inner endocardial layer and outer myocardial layer 
(Kirby 2007). 
 
Cells continue to be added to the arterial pole to form the outflow tract and to the 
venous pole to form the inflow region of the heart. In the arterial pole, mesenchymal 
cells in the pharyngeal splanchnic mesoderm caudal to the heart tube are mobilized to 
the outflow tract (Waldo et al. 2001). In the venous pole, nearby mesenchyme is 
recruited at each phase of development to form myocardial cells for maturation of the 
atria and veins (van den Hoff et al. 2001).     
 
 
1.1.2 Looping of the heart 
 
The establishment of left-right axis occurs during the early gastrulation, before the 
looping process to induce asymmetric morphogenesis of the heart (Levin 2005). 
Disruption of the left-right axis results in randomised cardiac looping (Lowe et al. 2001). 
Initially, the heart tube is suspended at the inner curvature of the ventral foregut through 
dorsal mesocardium. The heart tube bends ventrally first to obtain C-shaped loop, and 
then undergoes dextral looping (D-looping) by rotating to the right where the left side of 
the tube is brought to the front and the inner curvature to the left (Manner 2000). Not 
much shifting is observed during this period as the intact dorsal mesocardium restricts 
the move. The dorsal mesocardium disappears as the looping process continues. During 
looping, lengthening of the heart tube occurs concurrently to form S-shaped loop (de la 
Cruz and Markwald 1998). The venous and arterial poles of the tube incorporate 
myocardium at both ends respectively. These myocardial cells express Islet1 (Isl1) and 
originate from the second heart field (Cai et al. 2003). The migration of the tube from 
the ventral foregut happens earlier in mice than other vertebrate organisms, resulting in 
the formation of atria and right ventricle from the cells recruited from the poles of the 
tube (Cai et al., 2003). The process of convergence proceeds along S-shaped looping, 
closing the distance between outflow and inflow poles of the heart through the addition 
of cells from the secondary heart field (Waldo et al. 2005). The wedging process, where  
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Figure 1.2 Diagrams showing the formation of heart tube 
Panels A-D showing the stages of a midline heart tube from bilateral primary heart 
fields in chick (adapted from Kirby, 2007) (Kirby 2007). The two bilateral heart fields 
are brought into the opposition by the formation of pharynx that fused at the ventral 
midline, thus giving rise to three layers: endocardial layer, cardiac jelly and myocardial 
layer.    
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the aorta moves behind the pulmonary trunk and becomes wedged between the mitral 
and tricuspid valves, takes place during septation (Yelbuz et al. 2002). In short, looping 
involves formation of the C-shaped loop, formation of the S-shaped loop by elongation, 
convergence of the arterial and venous poles of the tube and wedging of the aorta.  
 
 
1.1.3 Cardiac neural crest cells 
 
Neural crest cells (NCC) are multipotential cells that arise from the dorsal neural tube. 
NCC then delaminate and migrate extensively throughout the body. NCC are divided 
into cranial and trunk regions depending on the cells’ original location in the neural tube. 
Cardiac NCC is a sub-population of the cranial NCC that stem from the middle of the 
otic placode to the border of somite 3 (Kirby and Stewart 1983). Cardiac NCC give rise 
to ectomesenchymal cells. Ectomesenchymal cells are implicated in the development of 
the aorticopulmonary septum, the smooth muscle tunics of the great arteries and the 
connective tissue of the thymus, thyroid and parathyroids (Kirby et al. 1983). Cardiac 
NCC also contribute to the semilunar valves and the atrioventricular valves, especially 
in the septal leaflets (Nakamura et al. 2006).  
 
The term ‘cardiac neural crest’ was derived from the ablation studies of the neural crest 
cells in quail-chick chimeras that showed this population of cells are important for 
normal heart development (Kirby et al. 1985). The cardiac NCC ablation model 
displayed various cardiovascular and non-cardiovascular defects. The cardiovascular 
phenotypes are abnormal outflow tract including persistent truncus arteriosus and 
outflow malalignment, aberrant patterning of the great arteries and myocardial 
dysfunction whereas the non-cardiovascular phenotypes are hypoplasia or aplasia of the 
thymus, parathyroids and sometimes the thyroid gland (Hutson and Kirby 2007; 
Nishibatake et al. 1987; Yelbuz et al. 2002).  
 
During the looping process, myocardium is recruited to the outflow tract from the 
splanchnic mesoderm to lengthen the heart tube. Ablation of the cardiac NCC results in 
a straighter and shorter heart tube (Yelbuz et al. 2002). The myocardium that forms the 
outflow tract is generated by secondary heart field, indicating that abnormal 
cardiovascular phenotypes might involve the dysregulation of secondary heart field.  
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1.1.4 Anterior and secondary heart field 
 
The classical perception on the development of the heart was based on the segmental 
model of the pre-patterned myocardial cells in the primitive streak that give rise to the 
outflow tract, right ventricle, left ventricle, atrioventricular canal, right atrium and left 
atrium in the anterior-posterior axis (de la Cruz and Markwald 1998). However, recent 
experiments indicated the absence of segmental regionalization and proposed rather the 
concept of a heart field, where potential myocardial cells are located in the embryonic 
region that contribute cells to the developing heart. The heart field consisted of an 
anterior heart field (AHF) and a secondary heart field (SHF) (Buckingham et al. 2005) 
(Figure 1.3).  
 
In the chick embryo, the AHF is situated immediately anterior to the developing heart 
tube and consisted of cranial pharyngeal mesoderm surrounding the aortic sac 
(Mjaatvedt et al. 2001). Fate mapping of the cells showed that they contributed to the 
conal and truncal regions of the outflow tract. Another group, Waldo and colleagues, 
described the SHF in the splanchnic mesoderm that underlies the caudal pharynx 
(Waldo et al. 2001). SHF cells are added to the outflow tract of the heart tube during 
looping. Cells in the SHF express Nkx2.5 and Gata4 before myocardial differentiation.  
 
In the mouse embryo, the lacZ transgene with the myosin light chain promoter inserted 
114kb upstream of Fgf10 and proposed to be controlled by the Fgf10 regulatory 
elements, showed the transcription of lacZ in part of the pharyngeal mesoderm (Kelly et 
al. 2001). The region that showed β-galactosidase (β-gal) activity from the transgene 
has been described as the AHF. Initially, the AHF cells lie medially to the cardiac 
crescent. The dynamic pattern of β-gal activity and cell labelling experiments indicated 
that the AHF cells moved from the pharyngeal mesoderm into the arterial pole of the 
heart between E8.25-E10.5 in the mouse embryo (Kelly et al., 2001). The experiments 
performed by Zaffran and colleagues using lineage tracing approach of the movement of 
AHF cells in the right ventricle and outflow tract myocardium (Zaffran et al. 2004). 
Retrospective clonal analysis of myocardial cells indicated two categories of clones: the 
second lineage contributes to the outflow tract and all other regions of heart, except the 
left ventricle, which was generated solely from the first lineage (Meilhac et al. 2004). 
The second lineage, marked by the Isl1 expression, corresponds to the contribution of 
SHF cells (Cai et al. 2003). Isl1 mutant mouse showed a decrease expression of BMP 
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(BMP2, 4, 6 and 7) and FGF genes (FGF4, 8, 10), indicating BMPs and FGFs are also 
expressed in secondary heart field (Cai et al. 2003). BMPs and FGFs are required for 
the activation of myocardial regulatory genes such as NKX2.5 and GATA4, whereas 
WNT signaling exhibits inhibitory effect (Brand 2003).     
 
 
 
 
 
Figure 1.3 Anterior and secondary heart fields 
Panels A-E show the location, extend and contribution of the cells of anterior and 
secondary heart field that were identified by Mjaatvedt et al. (Mjaatvedt et al. 2001), 
Kelly et al. (Kelly et al. 2001) and Waldo et al. (Waldo et al., 2001) (Adapted from 
Abu-Issa et al. 2004), AoS, aortic sac; T, truncus; C, conus; RV, right ventricle. 
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1.1.5 Chamber formation  
 
During the process of convergence, myocardium is added to the proximal part of the 
sinus venosus to form the atria. The expanding atria will be segregated into right and 
left atrium by a primary atrial septum. The primary atrial septum is generated from 
splanchnic mesoderm near the venous pole that differentiates into myocardium. The 
primary septum enlarges in the direction of the atrioventricular cushions thus separating 
the atrium into two chambers. As this septum grows, an opening between the lower rim 
of the septum primum and the endocardial cushions, ostium primum (foramen primum), 
is formed. The ostium primum becomes smaller and disappears as the primary septum 
fused with the endocardial cushions. Before the closure is completed, perforations 
appear in the central part of the primary septum. Perforations coalesce to form ostium 
secundum (foramen secundum), another opening that enables the blood to flow from the 
right to the left atrium (Moore and Persaud 1998). The primary septum grows on the 
right side of the pulmonary pit, resulting in the developing pulmonary vein being 
assigned to the left atrium (Webb et al. 2000). The secondary atrial septum completes 
the process of atrial septation. This secondary septum is located on the right of the 
primary septum and originates from the myocardium on the left (Franco et al. 2000). 
Secondary septum forms an incomplete partition between the atria, resulting in foramen 
ovale. The cranial part of the primary septum gradually disappears. The remaining of 
the septum becomes the valve of the foramen ovale. The leaflets of the primary and 
secondary septum fuse at birth, thus becoming a complete partition between the atria 
(Moore and Persaud 1998). 
 
The atrium and the prospective left ventricle are connected by the lumen of the 
atrioventricular canal. Endocardial cushions form on the dorsal and ventral walls of the 
atrioventricular canal. These cushions are enlarged by the inclusion of mesenchymal 
cells. The endocardial cushions on the opposite ends approach each other and fuse, thus 
dividing the atrioventricular canal into right and left canal (Moore and Persaud 1998). 
  
The right and left ventricles arise from a narrowed area that joins the inflow and outflow 
poles. The ballooning of the outer curvature myocardium expands the ventricular 
chambers (Christoffels et al. 2000). The trabeculae, which are myocardial diverticulae, 
grow towards the lumen from the outer wall of the myocardium, which is formed 
simultaneously, to separate the chamber into right and left ventricles (van Mierop and 
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Kutsche 1985). The ventricular septum develops from the merging of trabeculae (Ben-
Shachar et al. 1985), becoming the muscular interventricular septum. The fusion 
between the free edge of the interventricular septum and the endocardial cushions is not 
complete, resulting in interventricular foramen, permitting communication between the 
right and left ventricles. This opening is later closed by the membranous interventricular 
septum. The closure of the foramen and the formation of the membranous 
interventricular septum is due to the fusion of tissues from the right bulbar ridge, the left 
bulbar ridge and the endocardial cushion (Moore and Persaud 1998).      
 
The active proliferations of the mesenchymal cells invade the walls of the bulbus cordis 
results in the formation of bulbar ridges. At about the same time, similar ridges form in 
the truncus arteriosus. These ridges (bulbar and truncal rigdes) are derived mainly from 
the neural crest mesenchyme (Kirby et al. 1983). The bulbar and the truncal ridges 
undergo 180° spiralling as they grow, resulting in the aorticopulmonary septum when 
the ridges fuse. This septum divides the bulbus cordis and the truncus arteriosus into an 
aortic and a pulmonary trunk. The bulbus cordis is incorporated into the walls of the 
definitive ventricles: the bulbus cordis forms the walls of the aortic vertibule inferior to 
the aortic valve in the left ventricle and forms the conus arteriosus in the right ventricle 
where the pulmonary trunk arises.  
 
 
1.1.6 Valve development 
 
After looping of the heart, in the region between the common atria and ventricle, the 
cardiac jelly expands into swellings called cardiac cushions (Anderson 2003) (Figure 
1.4). Cardiac jelly separates the myocardium (outer layer) and endothelium (inner layer) 
of the heart tube. During valve formation, a subset of cells from the inner endothelium 
transform into mesenchymal cells that invade the cardiac jelly. This process is called 
epithelial-to-mesenchymal transformation (EMT) (Markwald et al. 1977). In short, 
EMT and cushion formation involve activation and delamination of endothelial cells 
which then migrate into the cardiac jelly and proliferate.  
 
Atrioventricular cushion mesenchyme gives rise to the tricuspid and mitral valves. 
Chordae tendineae and the papillary muscles connect the valve leaflets to the 
atrioventricular cushion. The leaflets consist of three layers: the atrialis, the spongiosa 
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and the fibrosa from the atrial to the ventricular sides (Lincoln et al. 2006). The septal 
leaflets of the mitral and tricuspid valves stem from the dorsal and ventral 
atrioventricular cushions and delaminate from the ventricular septal wall while the 
mural leaflets develop from the myocardium of the atrioventricular canal and the 
myocardium below the leaflet subsequently disappear due to cell death (de Lange et al. 
2004).  
 
The aortic and pulmonary semilunar valves originate from the mesenchyme that formed 
truncal cushions during septation of the outflow tract. The cushions are composed of 
mesenchyme from various locations: cardiac neural crest from the pharyngeal arches, 
the pharynx, and epithelial-mesenchynmal transformation of the endocardium. There 
are three leaflets in each valve. The leaflets form from three pairs of ridges extending 
into the lumen of the truncus. These early leaflets comprise of a main msenchymal 
tissue overlaid with endocardium. The interaction of endocardium and the mesenchyme 
creates an arterial face of the leaflets thus detaching the leaflets (Hurle et al. 1980).   
 
 
 
 
 
 
 
Figure 1.4 Heart valve development 
Diagrammatic overview of the heart valve development (Adapted from Armstrong and 
Bischoff, 2004) (Armstrong and Bischoff 2004). 
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1.1.7  Aortic arch derivatives 
 
The pharyngeal arches are formed during the 4th and 5th week of development, they each 
received their own arteries known as aortic arches that arise from the aortic sac. The 
aortic arches begin from the aortic sac and terminate in the dorsal aorta. The aortic arch 
arteries begin as symmetrical sets of vessels. A total of six pairs of aortic arches are 
developed. However, these aortic arches are not all present at the same time. When the 
fourth and sixth arches are the in the process of formation, the first two pairs have 
regressed (Moore and Persaud 1998).  
  
The first aortic arch has largely disappeared, but a remaining small portion forms the 
maxillary artery and may also contribute to the formation of the external carotid arteries. 
The second aortic arch also regresses. The dorsal parts of these vessels remain and form 
the stapedial arteries, which are small vessels that run through the ring of the stapes, a 
small ear bone, in the embryo. The fifth pair aortic arch exists briefly and is never well 
developed. The remaining aortic arches: third, fourth and sixth, persist (Moore and 
Persaud 1998). 
 
During further development of the aortic arches, the system gradually loses its 
symmetrical pattern of arteries due to remodelling that leads to to the mature aortic arch 
and great vessel patterning (Kameda 2009) (Figure 1.5). The repatterning of the arteries 
into the asymmetric great arteries is due to the interaction of neural crest cells with the 
aortic arch arteries (Kirby 2007). The third aortic arch forms the common carotid artery 
and the first part of the internal carotid artery. The fourth aortic arch developes 
differently on the right and left sides (Moore and Persaud 1998). The left fourth aortic 
arch forms part of the aorta, between the left common carotid and the left subclavian 
arteries. On the right, it forms the proximal part of the right subclavian artery .The distal 
part of the subclavian artery is formed from the right dorsal aorta and the seventh 
intersegmental artery (Moore and Persaud 1998). The proximal part of the right sixth 
aortic arch becomes the proximal part of the right pulmonary artery whereas the distal 
part disappears. The proximal part of the left sixth aortic arch persists as the proximal 
part of the left pulmonary artery. The distal part forms the ductus arteriosus during fetal 
life (Moore and Persaud 1998).  Irregularities of the embryonic heart such as interrupted 
aortic arch and coarctation of the aorta result from the persistence of parts of the aortic 
arches that usually disappear, or from disappearance of parts that normally persist.  
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Figure 1.5 Diagrams of the aortic arch system 
A) Aortic arches at 6 weeks of embryonic development, the first two pairs of aortic 
arches have regressed. The obliterated components are indicated by broken lines.  
B) Diagram of the aortic arches after remodelling at 8 weeks.  
C) Diagram of the aortic arches in the adult.  
The ductus arteriosus in B) is essential for the communication between pulmonary trunk 
and aorta, however, in C) the ductus arteriosus becomes the ligamentum arteriosum 
after birth (adapted from Moore and Persaud, 1998) (Moore and Persaud 1998).     
A) 
B) C) 
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1.2 Congenital cardiovascular malformation 
1.2.1 Epidemiology of cardiovascular malformation 
 
Congenital cardiovascular malformation (CVM) is a major group of birth defects that 
consists of developmental defects of the heart leading to impaired cardiovascular 
function. CVM affects approximately 7 in every 1000 live births (Hoffman and Kaplan 
2002) and is the most common human birth defect worldwide (Christianson et al. 2006) 
(Table 1.1). The prevalence of CVM would be higher if the proportion of pregnancies 
which do not continue to term, and patients with bicuspid aortic valve who were 
diagnosed later in life, were included (Ward 2000). Advancement in medical and 
cardiac surgical care have resulted in most patients with CVM surviving to adulthood. 
There are now many adults living with CVM, and studies on CVM recurrence have 
shown that this patient population has increased risk of an affected child than the 
general population (Burn et al. 1998). CVM is thought to arise from the cumulative 
effects of genetic and environmental factors (Nora 1968). Some proportion of CVM 
occurs in patients with chromosomal abnormalities (7-14% in different series) and a 
handful of families with multiple affected individuals, due to Mendelian transmission, 
have been described (see below). Some genetic defects and certain environmental 
factors that contribute to CVM have been identified (Jenkins et al. 2007; Pierpont et al. 
2007). However, the majority of the cause of CVM remains unknown.  
 
Anomalies of the heart can be classified using several systems. In this project, CVM is 
categorised in individual patients based on the nature of the CVM that was judged 
clinically most important (usually, the malformation requiring surgery). It has been 
noted that classification systems do vary from study to study, especially on how 
multiple lesions are classified. The complex phenotypic spectrum of CVM may present 
challenges in identifying genetic predisposing factors (Pierpont et al. 2007). An 
alternative approach to classification involves grouping together of particular defects 
based upon what is known of developmental pathways in cardiogenesis. However, there 
remains considerable uncertainty regarding the processes involved in clinically 
observed CVM phenotypes. Moreover, new knowledge can substantially alter such 
classification schemes. For example, prior to the discovery of the second heart field, 
malformations of the cardiac outflow tract were generally thought to be mediated 
through cardiac neural crest cells functioning incorrectly during development. It has 
subsequently become clear that complex interactions, for example between neural crest 
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cells and cells derived from the second heart field, are critical to outflow tract 
morphogenesis. In the following paragraphs, the principal clinical CVM phenotypes are 
briefly listed and described.  
 
Aortic stenosis (AS) occurs in 3-6% of CVM cases and is observed more frequently in 
males than in females, with the ratio of 4:1. This defect consists of variable degree of 
thickening of the valve that does not function properly, resulting in the impairment of 
the left ventricle to pump blood out of the heart into the aorta. Patent ductus arteriosus 
(PDA) and coarctation of the aorta (CoA) frequently coexist with AS (Braunwald 1997). 
Treatment using balloon dilatation or surgery is usually performed to palliate the 
symptoms and valve replacement will be carried out later in life (Hoffman et al. 2004). 
 
Bicuspid aortic valve (BAV) is a congenital deformity where the aortic valve has only 
two cusps, instead of three cusps in normal heart development. BAV may become 
calcified later in life due to calcium deposition and lead to various degrees of severity of 
aortic stenosis and aortic regurgitation (Braunwald 1997). However, unlike other defects, 
BAV can functional normally at birth and only develop stenosis or incompetence after 
40 years of age. Therefore, the incidence of BAV is usually not recorded in paediatric 
population studies and varies from about 0.4-2.25% (Hoffman and Kaplan 2002). BAV 
can lead to calcified aortic valve with severe stenosis, aortic regurgitation, infective 
endocarditis and dilatation of the aortic root with dissection of the aorta. Therefore, 
surgical valve replacement is usually needed in middle life.  
 
Coarctation of the aorta (CoA) could be detected during infancy if the defect is critical. 
This critical CoA accounts for one third of all CoA and if left untreated, leads to early 
death (Hoffman et al. 2004). In other cases, CoA would only manifest significant 
symptoms after 20 to 30 years (Braunwald 1997). This defect is a condition in which 
the aorta is significantly narrowed due to the thickening of the posterolateral aortic wall 
opposite the ductus arteriousus (Braunwald 1997). CoA might arise due to the small 
involution of the left aorta that moves cranially with the left subclavian artery during the 
remodelling of the aortic arches. The other common anomalies associated with this 
defect are BAV, VSD, and mitral stenosis or regurgitation. Surgery or balloon dilatation 
could relieve the symptoms but sometimes CoA may reoccur as the child grows. 
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Atrial septal defect (ASD) is one of the most common congenital cardiovascular 
malformations that occur with an average incidence of 941 per million live births 
(Hoffman and Kaplan 2002). The true incidence is higher as this malformation may be 
undetected in early life. ASD results in a left to right shunt of blood. The locations of 
ASD vary from ostrium primum atrial defect, ostium secundum defect in midseptal 
region involving fossa ovalis and defects of the sinus venosus located high in the atrial 
septum (Braunwald 1997). Ostium primum defect is an atrioventricular septal defect 
(AVSD) and is discussed later. The most significant ASD is the ostium secundum 
defect, whereby a large opening between the left and right atria is present. This anomaly 
is due to excessive resorption of the septum primum or due to the inadequate 
development of the septum secundum. Patent foramen ovale (PFO) occurs when the 
foramen ovale failed to fuse with septum primum postnatally (Braunwald 1997). 
Patients with ASD may exhibit congestive heart failure, pulmonary vascular disease, 
mitral incompetence, atrial arrhythmias and thrombosis of large pulmonary arteries if 
left untreated. Uncomplicated ASD is suitable for closure with a device introduced 
while the patient is undergoing cardiac catheterisation. Surgery would be recommended 
for more severe cases (Braunwald 1997).  
 
Atrioventricular septal defect (AVSD) occurs in 4-5% of CVM cases. AVSD is 
frequently observed in Down syndrome (Trisomy 21) patients, where the mothers 
involved are usually more than 34 years old (Hoffmann and Kaplan 2002), and Ellis-
van Creveld syndrome and asplenia or polysplenia syndromes (Braunwald 1997). The 
endocardial cushions of the atrioventricular canal divide the canal into two (left and 
right) and also participates in the formation of the membranous portion of 
interventricular septum and in the closure of the ostium primum. Failure of fusion of the 
endocardial cushions results in AVSD. This anomaly is characterised by an atrial and a 
ventricular component separated by abnormal valve leaflets in the single atrioventricular 
orifice (Moore and Persaud 1998). If the endocardial cushions fuse only partially, where 
the ostium primum failed to fuse with endocardial cushions but the interventricular 
septum is closed, this defect is known as ostium primum defect. The defect is usually 
combined with deformed and incompetent AV valves (Braunwald 1997). Surgical repair 
is the recommended treatment for AVSD patients. If the left AV leaflet tissue is 
significantly deformed, mitral valve replacement would also be carried out (Braunwald 
1997).    
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Double outlet right ventricle (DORV) occurs in average 157 out of one million live 
births (Hoffman and Kaplan 2002). The definition of double outlet right ventricle 
(DORV) varies but generally occurs when both the pulmonary and the aorta are exiting 
from the right ventricle (Braunwald 1997). More than 50% of the DORV patients 
display defects of the right AV valves; some patients have mitral atresia with a 
hypoplastic left ventricle and in a handful of patients exhibit tricuspid stenosis. Due to 
the various anatomic defects in the patients, infants are given palliation. Corrective 
surgery is carried out when the patient is age 1-2 years old. In constrast, double outlet 
left ventricle (DOLV) is one of the rarest cardiac anomalies (Braunwald 1997). DOLV 
refers to the origin of both great arteries from the left ventricle. Various defects are 
associated with DOLV, the most common are VSD and PS. Operative repair to close 
the VSD and positioning of a right ventricle-pulmonary artery conduit is usually 
performed on the patient.  
  
Ebstein’s anomaly occurs due to the anomalous attachment of the tricuspid leaflets, 
where the downward displacement of the tricuspid valve is located into the right 
ventricle (Braunwald 1997). Associated malformations such as patent foramen ovale or 
ASD is present in more than half the cases. This defect has a mean of 114 incidences 
per million live births (Hoffman and Kaplan 2002). Surgical approach such as 
valvoplasty or replacement of the tricuspid valve is used to treat the patients.   
 
Hypoplastic left heart  (HLH) occurs in average 266 cases in one million live births 
(Hoffman and Kaplan 2002). HLH consists of underdevelopment of the left cardiac 
chambers, atresia or stenosis of the aortic and/or the mitral orifices, and hypoplasia of 
the aorta; which usually cause heart failure during the first week of life. Pulmonary 
venous blood enters the right side of the heart through a PFO and the systemic 
circulation is sustained by PDA (Braunwald 1997). Reparative surgeries are performed 
in stages to alleviate the symptoms or cardiac transplantation is required.  
 
Patent ductus arteriosus (PDA) is another common anomaly that varies with the 
gestational age of the subject. Preterm infants usually have higher incidence rate of 
PDA due to the abnormal physiology whereas in term infants have lower incidence rate. 
However, spontaneous closure can occur in some cases that may further inflate the 
incidence of PDA (Hoffman and Kaplan 2002). PDA is the abnormal existence of the 
ductus arteriosus after birth. The ductus arteriousus present in the fetus as a vessel 
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connecting the pulmonary trunk and the descending aorta distal to the left subclavian 
artery, to enable the fetus to bypass the pulmonary circulation. This channel is usually 
closed at birth. However, a small shunt of blood from the aorta to the left pulmonary 
artery is present in a normal full-term infant for 24 to 48 hours (Sansoucie and Cavaliere 
1997). In the adult, the obliterated ductus arteriosus forms the ligamentum arteriosum. 
Closure of the ductus arteriosus in full-term infants is regulated by oxygen (Bernstein 
1996). Bradykinin, a substance realised from the lungs during their initial inflation, 
causes the smooth muscle to contract. This substance is dependent on the high oxygen 
level of the aortic blood after aeration of the lungs at birth. PDA that persists weeks 
after birth is pathological entity. Surgical closure of PDA would be carried out to 
alleviate the symptoms.  
 
Pulmonary atresia (PA) is an uncommon malformation that is highly lethal. PA is 
characterized by atretic pulmonic valve, due to the hypoplastic development of both the 
pulmonary valve and artery or occasionally accompanied by extremely narrowed right 
ventricle, resulting in obstruction of the pulmonary circulation (Braunwald 1997). 
Aggressive medical and surgical treatment would be prescribed during the neonatal 
period. 
 
Pulmonary stenosis (PS) occurs in about 7% of CVM patients. However, this number 
does not mirror the true estimate of the incidence as there are unknown number of 
patients with very mild PS that do not require medical attention. PS results from fusion 
of the pulmonary valve cusps leading to obstruction of the pulmonary circulation and 
thickening of the right ventricle (Braunwald 1997). This anomaly is frequently observed 
in patients with Noonan syndrome. Surgical or balloon valvotomy is necessary for these 
patients.  
  
Single ventricle is a lesion where both atrioventricular valves, or a common 
atrioventricular valve open into a single ventricular chamber (Braunwald 1997). The 
associated anomalies are abnormal great artery (L-malposition or D-malposition of the 
great artery), pulmonic valvular stenosis, subaortic stenosis, and coarctation of the aorta 
(Braunwald 1997). This lesion has an average incidence of 106 per million live births 
(Hoffman and Kaplan 2002). Surgical treatment using Fontan procedure is applied to 
the patients.  
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Tetralogy of Fallot (TOF) is one of the malformations of the cardiac outflow tract (OFT) 
and is the most common form of cyanotic CVM (Braunwald 1997). There are four heart 
defects in TOF: ventricular septal defect, right ventricular outflow obstruction to the 
lungs (pulmonary stenosis), an overriding aorta that receives blood from both ventricles 
and right ventricular hypertrophy. The fourth feature, right ventricular hypertrophy, 
arose due to the physiological consequence of the other three features as the right 
ventricular has to pump deoxygenated blood through the narrowed pulmonary valve. 
TOF patients would undergo open-heart surgery to correct these defects. However, the 
patients often have residual VSD and right ventricular outflow tract obstruction and 
pulmonic valve incompetence. Occasionally these patients suffer from complete heart 
block and sudden death.   
  
Total anomalous pulmonary venous connection (TAPVC) occurs when connection of 
all the pulmonary veins to the right atrium or to the systemic veins, resulting in systemic 
venous circulation. Other cardiac malformations such as single ventricle, truncus 
arteriosus, and anomalies of the systemic veins occur in some TAPVC patients 
(Braunwald 1997). TAPVC occurs in average 94 patients out of one million live births. 
Reparative surgery is performed for the TAPVC patient as soon as possible as survival 
without treatment after 1 year of age is rare (Hoffman et al. 2004).  
 
Transposition of the great arteries (TGA) occurs in 315 infants in one million live births 
(Hoffman and Kaplan 2002). TGA is a malformation characterized by the aberrant 
origin of the aorta from the right ventricle and the pulmonary artery from the left 
ventricle. This defect results in two parallel circulations communicate through ASD, 
PDA or VSD (Braunwald 1997). Additional cardiac malformations are small PDA and 
PFO that occurs in two thirds of TGA patients. The remaining of the patients exhibit 
either a large PDA or ASD, a VSD, subpulmonic stenosis or some combination of these 
defects (Hoffman et al. 2004). Arterial switch is usually performed on TGA patients.   
 
The absence or fusion of the tricuspid valves, an interatrial communication, ventricular 
septal defect, hypoplasia of the right ventricle and hypertrophy of the left ventricle 
characterizes tricuspid atresia (Braunwald 1997). Additional CVMs, like TGA, PDA 
and CoA are usually present in patients with tricuspid atresia. The Fontan-Kreutzer 
procedure is carried out to correct the anomaly.  
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Truncus arteriosus is a rare but lethal lesion whereby the defect results from the failure 
of septation of the aortapulmonary trunk and is always accompanied by a VSD. Thus 
the single outflow tract vessel containing systemic, pulmonary and coronary arteries, 
overrides both ventricles and receives blood from both sides (Braunwald 1997). The 
operation would be carried out to close the VSD and the pulmonary arteries are excised 
from the truncus and an extracardiac valved conduit is used to establish the link between 
the right ventricle and the pulmonary arteries (Braunwald 1997). 
 
Ventricular septal defect (VSD) is the most prevalent form of CVM, with an incidence 
rate of 2-5% (Hoffman and Kaplan 2002). The incidence might be higher as in some 
cases the defect closes within the first year of life. This defect occurs both as an isolated 
anomaly and also in combination with other anomalies. The ventricular septum consists 
of four compartments (the membranous septum, the inlet septum, the trabecular septum, 
and the infundibular septum). Defects that lead to VSD are due to deficiency of growth 
or failure of alignment in any of the compartment (Braunwald 1997). Incomplete 
closure of the interventricular foramen due to the failure of the membranous part of the 
interventricular septum to develop is the most common type of VSD (Moore and 
Persaud 1998). The severity of this defect depends on the size of the opening. If the 
opening is small, no treatment or operation is required as these defects usually close 
spontaneously. However, for larger defects causing significant left to right shunting, 
operation is required as large defects if left untreated would result in early congestive 
heart failure and death.   
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Types of CVM Mean Incidence 
Aortic stenosis 401 
Atrial septal defect 941 
Atrioventricular septal defect 348 
Bicuspid aortic valve 13,556 
Coarctation of the aorta 409 
Double outlet right ventricle 157 
Ebstein’s anomaly 114 
Hypoplastic left heart 266 
Hypoplastic right heart 222 
Patent ductus arteriosus 799 
Pulmonary atresia 132 
Pulmonary stenosis 729 
Single ventricle 106 
Tetralogy of Fallot 421 
Total anomalous pulmonary venous connection 94 
Transposition of the great arteries 315 
Tricuspid atresia 79 
Truncus arteriosus 107 
Ventricular septal defect 3570 
 
 
Table 1.2 Mean incidence of CVM per million live births 
 
The mean incidences of major CVMs per million live births is shown in Table 1.2.1 
(Hoffman and Kaplan 2002).    
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1.2.2 Non-inherited risk factors for cardiovascular malformation 
 
Several non-inherited risk factors for CVM have been identified (Jenkins et al. 2007) 
(Table 1.2). One of the most potentially exciting discoveries was the reduced incidence 
of heart defects observed with maternal periconceptional use of multivitamins 
containing folic acid. In the Hungarian randomized trial study, maternal consumption of 
multivitamin supplements containing folic acid was associated with an approximately 
60% reduction in risk for CVMs, with odds ratios of 0.42, confidence interval (CI) 0.19-
0.98 (Czeizel et al. 1998). This discovery was confirmed by another independent study 
using a population-based case-control approach in Atlanta that showed an 
approximately 25% reduction in risk for CVMs in the offspring when periconceptional 
multivitamin was used with odds ratios of 0.76, CI 0.60-0.97 (Botto et al. 2000). A 
study has been carried out by Ionescu-Ittu and colleagues that showed reduced 
incidence rate of CVM by 6% per year for seven consecutive years after the 
implementation of the Canadian government policy of folic acid fortification of grain 
product when compared to the seven years before fortification (Ionescu-Ittu et al. 2009). 
This study supported the role of folate in reducing CVM but the required level of folate 
intake was unknown.   
 
Folic acid is known to reduce risk of neural tube defects. This was conclusively shown 
in the MRC randomized folate trial (MRC 1991). Despite the studies of CVM 
referenced above, a recent consensus statement from the American Heart Association 
(Jenkins et al. 2007) described the relationship between folate and CVM as uncertain. 
This is a reasonable view, as the Hungarian and Atlanta studies used multivitamins 
rather than folate, and the Atlanta study was non-randomized. It is possible that the 
relationships observed in those studies were due to confounding. It would now be 
unethical to perform trials with an arm not including folate supplementation, so further 
randomized evidence will not be forthcoming. In this context, examining the 
relationship between genetic polymorphisms known to affect plasma folate and the risk 
of CVM could identify a causal association. Studies have shown the association of 
folate metabolism with homozygous 677C>T variant of methylenetetrahydrofolate 
reductase, MTHFR (Bailey and Berry 2005). MTHFR is an enzyme that catalyses the 
conversion of 5,10-methylenetetrahydrofolate into 5-methyltetrahydrofolate, which is 
the bioactive form of folate. The homozygous TT genotype of 677C>T results in  
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Non-inherited factors Defects  
Multivitamin supplements  
(including folic acid) 
Any defects, particularly: 
VSD 
Phenylketonuria  Any defects  
Maternal diabetes Any defects, particularly: 
Complete AVSD 
Cardiomyopathy 
Laterality and looping 
TGA 
Maternal rubella Any defects, particularly: 
VSD 
PDA 
Pulmonary valve abnomalities 
Peripheral pulmonic stenosis 
Maternal febrile illnesses Any defects, particularly: 
Pulmonic stenosis 
Conotruncal defects 
Right-sided obstructive defects 
Tricuspid atresia 
All left-sided obstructive defects 
Coarctation of the aorta 
VSD 
Maternal influenze Any defects, particularly: 
TGA 
All right-sided obstructive defects 
All left-sided obstructive defects 
Coarctation of the aorta 
VSD 
Anticonvulsants Any defects 
Indomethacin tocolysis PDA 
Ibuprofen Any defects, particularly: 
TGA 
VSD 
Bicuspid aortic valve 
Thalidomide Any defects 
 
 
Table 1.3 Non-inherited risk factors for CVM 
The non-inherited risk factors/ materal exposure associated with CVM or specific type 
of CVMs (adapted from Jenkins et al., 2007) 
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reduced activity of the MTHFR enzyme and decreased level of plasma folate (Blom et 
al. 2006). 
 
Thus, a causal relationship between plasma folate and CVM could be inferred if robust 
association between TT genotype and CVM could be established. Meta-analysis of 
thirteen studies on the relationship between MTHFR polymorphism and CMVs gave 
overall odds ratios of 1.3 (95%, CI 0.97-1.73) and 1.2 (95%, CI 0.83-1.74) for fetal and 
maternal MTHFR C/T genotypes respectively (van Beynum et al. 2007). 
 
The caveats of van Beynum’s study are the heterogeneity of the population of the 
thirteen studies and the small total number of cases involved. Not all of the studies 
analysed considered the intake of folic acid in the maternal diet. Analysing patients with 
various types of CVMs also complicated the study, as it might be possible that specific 
types of CVM could be associated with folate metabolism. Therefore, folate is thought 
to be still an open question that may be resolved by larger meta-analyses.      
 
A number of maternal illnesses and conditions have been association with an increasing 
risk of CVMs. Untreated maternal phenylketonuria resulting in high basal phenylalanine 
level (≥ 900µM) was associated with a greater than six-fold-increased risk of having an 
offspring with CVM when compared to the metabolic control group (with phenylalanine 
level < 600µM)  (Levy et al. 2001). The most frequent defects observed are coarctation 
of the aorta and hypoplastic left heart syndrome. 
 
Maternal pregestational diabetes has been consistently associated with an increased risk 
of CVM in offspring, with an odds ratio of 4.7 (95% CI 2.8-7.9) (Loffredo et al. 2001). 
The defects observed in the offspring are cardiomyopathy (OR=15.1, 95% CI 5.5-41.3), 
laterality and looping defects (OR=10.0, 95% CI 3.7-27.0), transposition of the great 
vessels (OR=6.6, 95% 3.2-13.3), and complete atrioventricular septal defects (OR =22.8, 
95% CI 7.4-70.5).     
 
Maternal rubella infection early in gestation causes CVM in offspring, in particularly 
PDA, pulmonary valve abnormalities, peripheral pulmonary stenosis and VSDs (Jenkins 
et al. 2007). Maternal influenza in the first trimester of pregnancy has been described as 
a probable risk factor for CVM (Scanlon et al. 1998; Zhang and Cai 1993). Other 
maternal febrile illnesses during the first trimester of pregnancy might lead to defects 
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such as pulmonic stenosis, tricuspid atresia, all right-sided obstructive defects, 
coarctation of the aorta, all left-sided obstructive defects, conotruncal defects and VSDs 
(Botto et al. 2001; Ferencz et al. 1997), though data are at present inconclusive.   
 
Maternal therapeutic drug exposure has been associated with an increased risk of CVM. 
Maternal ingestion of drugs such as Thalidomide, Anticonvulsants, and nonsteriodal 
anti-inflammatory drugs (Indomethacin tocolysis, and Ibuprofen), will lead to offspring 
having various CVMs (Ericson and Kallen 2001; Norton 1997; Schardein 2000; 
Smithells and Newman 1992; Wilson et al. 1998).  
 
Some findings have demonstrated a conclusive link of environmental factors to CVM in 
offspring, for example, rubella, Thalidomide, diabetes and anticonvulsants. However, 
the majority of the findings in this area remain inconclusive. This is because prospective 
epidemiological studies of environmental exposures are difficult to perform because the 
condition is uncommon and therefore pre-conceptual populations of hundreds of 
thousands of women would need to be enrolled for sufficient disease outcomes to be 
observed. On the other hand, retrospective studies have limitations as they utilize the 
possible exposure-outcome relationships from cases and controls that may be subject to 
recall or reporting bias. Studies of other adverse pregnancy outcomes have suggested 
that the effect of such biases could be substantial. Therefore, there may be many more 
hitherto undiscovered environmental factors that cause CVM. One potential use of 
genetic studies could be to identify some of these factors. If variants in genes mediating 
an individual’s response to environmental exposures – for example through vitamin or 
xenobiotic metabolism – were found to be associated with CVM, then this would 
implicate the environmental exposure in disease causation.  
 
 
 
 
 
 
 
 
 
 
 26
1.2.3 Genetic basis for cardiovascular malformation 
1.2.3.1 “Sporadic” CVM 
 
Although the incidence of CVM is higher when the fetus is exposed to non-inherited 
risk factors, most fetuses remain unaffected, suggesting there may be interaction 
between environmental exposures and genetic susceptibility factors. Familial recurrence 
and transmission risks indicate a significant genetic contribution to CVM (Burn et al. 
1998; Oyen et al. 2009). Many studies have explored familial recurrence risks since the 
original proposal of a multifactorial aetiology to CVM by Nora in 1966 (Nora and 
Meyer 1966). However, almost all of these have issues with possible ascertainment bias 
that could have influenced their results (Burn et al. 1998; Lie et al. 1994; Nora and Nora 
1987; Pradat 1994). Two contrasting studies, one British, one Danish, that attempted 
complete population ascertainment are more likely to have made accurate estimates of 
familial recurrence risks, and are discussed here in more detail. These studies addressed 
recurrence risk in the ~80% of cases that cannot be attributed to particular genetic 
syndromes or environmental causes.  
 
The British offspring study by Burn and colleagues (Burn et al. 1998) showed the 
variable heritability among non-syndromic heart defects. They identified 727 
individuals with disturbance of situs or segmental connection, with atrioventricular 
septal defect or with tetralogy of Fallot that survived surgery before 1970. Each 
individual was examined and interviewed. The CVM recurrence in the offspring of this 
population was 4.1%, which was 16 out of 393 live offspring, excluding miscarriages 
and terminated pregnancies. This risk was significantly different from sibling risk (2.1%, 
with p=0.021) and substantially higher than the population baseline risk of 0.7%. When 
recurrence risk for specific cardiac defects was investigated, no cases of recurrent CVM 
in the offspring of probands with TGA were found, there was a 7.8% risk in the 
offspring of 88 individuals with AVSD and 3.1% recurrence risk in the offspring of 395 
individuals with TOF. These results suggested AVSD and TOF were particularly 
influenced by genes. Computer modelling predicted that TGA is a sporadic defect, 
AVSD a single-gene defect and TOF a polygenic disorder of three genetic loci. 
However, the study conducted by Burn and colleagues might have included 
undiagnosed syndromic cases with CVM and did not include all of the CVM patients of 
reproductive age that have undergone surgery, achieving a~70% participation rate 
among identified probands.  
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Oyen and colleagues utilized large and carefully annotated Danish population registries 
over three decades to investigate the recurrence risk for offspring of CVMs patients and 
to estimate the contribution of CVMs in families to the general population (Oyen et al. 
2009). The recurrence risk ratio for all types of CVM was 3.21 among the first-degree 
relatives of a proband with CVM. However, this risk decreased when CVM was 
identified only in second and third-degree relatives. This result strongly suggested that 
genetic component played an important role to the manifestation of CVM. In a 
commentary on this paper, Shieh and Srivastava (Shieh and Srivastava 2009) reiterated 
the hypothesis that sporadic CVM is caused by genetic defects with variable penetrance 
that will only manifest as disease in conjuction with other genetic, epigenetic, 
environmental or hemodynamic factors. Oyen et al showed that specific CVMs 
demonstrated significant higher risk in first-degree relatives. Heterotaxia has a high 
recurrence risk ratio of 79.1 (95% CI 32.9-190), followed by right ventricular outflow 
tract obstruction with 48.6 (95% CI 2.5-85.6), atrioventricular septal defect with 24.3 
(95% CI 12.2-48.7), left ventricular outflow tract obstruction with 12.9 (95% CI 7.48-
22.2), conotruncal defects with 11.7 (95% CI 8.0-17.0), isolated atrial septal defect with 
7.1 (95% CI 4.5-11.1) and isolated ventricular septal defect with 3.4 (95% CI 2.2-5.3). 
However, the contribution of multiple affected CVM families to the general population 
with CVM was 2.2% to 4.2% (excluding chromosomal cases), indicating that only a 
small proportion of CVM cases were from CVM families. 
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1.2.3.2 CVM as part of particular genetic syndromes  
 
A number of CVMs have been associated with a single gene or chromosomal 
aberrations. However, CVM even within the syndromic and isolated cases demonstrated 
incomplete penetrance and variable expression. The 22q11 deletion syndrome has been 
described as several overlapping clinical syndromes including DiGeorge Syndrome, 
Velocardiofacial (Shprintzen) Syndrome or conotruncal anomaly face syndromes. 
Individuals with this deletion often display palate anomalies, feeding disorders, speech 
and learning disabilities, renal anomalies, behavioural disorders and CVMs. The 
common CVMs associated with a 22q11 deletion are tetralogy of Fallot, truncus 
arteriosus, conoventricular VSDs, and aortic arch anomalies (Goldmuntz et al. 1998; 
Marino et al. 2001; Momma et al. 1995). Approximately 6-28% of del22q11 cases are 
inherited from a parent in an autosomal dominant fashion while the remainder are de 
novo (Digilio et al. 2003). Not infrequently, a parent is identified with the deletion after 
a child with CVM has been cytogenetically diagnosed.  
 
Williams-Beuren Syndrome is associated with specific CVMs, infantile hypercalcemia, 
skeletal and renal anomalies, cognitive deficits, “social personality” and elfin faces. The 
specific CVMs for this syndrome are supravalvular aortic stenosis, in conjunction with 
supravalvular pulmonary stenosis and peripheral pulmonary stenosis (Eronen et al. 
2002). About 90% of the individuals affected with this syndrome can be diagnosed with 
microdeletion at chromosome 7q1.23 by fluorescence in situ hybridization (FISH).   
 
The trisomies are chromosomal aberrations that are commonly associated with CVMs. 
Trisomy 13 (Patau syndrome) show a high incidence of atrial and ventricular septal 
defects, and disturbance of cardiac position. Patients diagnosed with Edwards syndrome 
(trisomy 18) have a 90-100% chance of having CVMs. About 40-50% of the patients 
with trisomy 21 (Down syndrome) have CVMs, and of these, almost half are diagnosed 
with AVSD (Pierpont et al. 2007).  
    
There are other syndromes that are associated with single-gene defects. Alagille 
syndrome patients showed 20p12 deletion or JAG1 mutation (located in 20p12.2-
p11.23). JAG1 encodes a Notch ligand protein (Krantz et al. 1997; Li et al. 1997). This 
syndrome is an autosomal dominant disorder. The clinical features of this syndrome are 
highly variable due to variable penetrance. The most common features are anomalies of 
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the liver, face, eyes, renal, neurons and heart. The specific heart defects occur in more 
than 90% of individuals with Alagille syndrome and include peripheral pulmonary 
hypoplasia, tetralogy of Fallot, and pulmonary valve stenosis (McElhinney et al. 2002).  
 
Noonan syndrome is characterized by short stature, typical facial dysmorphism, webbed 
neck, chest deformity and CVMs. Approximately 80-90% of the individuals affected 
with Noonan syndrome are diagnosed with CVM. The most common observed cardiac 
anomalies are pulmonic valve stenosis and hypertrophic cardiomyopathy (Marino et al. 
1999; Noonan 1994). Other defects such as secundum atrial septal defect, 
atrioventricular septal defect, mitral valve abnormalities, aortic coarctation and tetralogy 
of Fallot also occur. This genetically heterogeneous syndrome is associated with at least 
3 genes: PTPN11, SOS1, and KRAS (Digilio et al. 2002; Roberts et al. 2007; Schubbert 
et al. 2006).  
 
Holt-Oram syndrome is caused by mutations in the TBX5 transcription factor gene 
located in chromosome 12q24.1 (Basson et al. 1997). This syndrome is characterized by 
upper-limb deformities and CVMs. Approximately 75% of these patients have ASD or 
VSD and/or progressive atrioventricular conduction disease.  
 
Patients with CHARGE syndrome are characterized by coloboma of the eye, heart 
defects, atresia of the choanae, retardation, genital and ear abnormalies (Tellier et al. 
1998). More than 50% of the patients were identified with mutation in the CHD7 gene 
(Vissers et al. 2004). Mutations in the TFAP2B gene, a transcription factor expressed in 
neural crest cells, have been identified in two families with Char syndrome (Satoda et al. 
2000). Individuals with Char syndrome are characterized by facial dysmorphism, hand 
anomalies and patent ductus arteriosus. These single-gene and chromosomal aberration 
show autosomal dominant inheritance and majority of these syndromes arise de novo. 
Table 1.3 summarizes the genetic syndromes associated with CVM.  
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Syndrome Causal gene/ loci Type of CVMs 
Down syndrome Trisomy 21 ASD, VSD, disturbance of cardiac position 
Patau syndrome Trisomy 18 
ASD, VSD, PDA,TOF, DORV, D-
TGA, CoA, BAV, BPV, 
polyvalvular nodular dysplasia 
Edwards syndrome Trisomy 13 AVSD, VSD, ASD 
DiGeorge syndrome 22q11 deletion IAA-B, TOF, PTA, VSD, isolated AA anomalies 
Williams-Beuren 
syndrome 7q11.23 deletion Supravalvar AS, PS, PPS 
Alagille syndrome 20p12 deletion or JAG1 mutation PS, PH, TOF 
Noonan syndrome PTPN11, SOS1, 
and KRAS 
Valvular PS, hypertrophic 
cardiomyopathy, secundum ASD, 
AVSE, mitral valve abnomalities, 
CoA, TOF 
Holt-Oram syndrome TBX5 ASD, VSD, progressive AV 
conduction disease 
CHARGE syndrome CHD7 TOF, AV canal defects, VSD, ASD, CoA, PDA 
Char syndrome TFAP2B PDA 
 
 
Table 1.4 Genetic syndromes associated with CVM  
The genetic syndromes and the causal genes/ locus that are associated with CVM 
(adapted from Pierpont et al, 2007) (Pierpont et al. 2007).  
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1.2.3.3 Non-syndromic Mendelian families 
 
Very few large families with autosomal dominant inheritance of non-syndromic CVM 
have been described. A number of genes have been identified by performing linkage 
analysis. Mutations in NKX2.5 have been identified in 4 kindreds with atrial septal 
defects and atrioventricular conduction delay without syndromic defects (Schott et al. 
1998). Two separate families with abnormal aortic valve that leads to severe valve 
calcification have NOTCH1 mutations resulting in truncated polypeptide or altered 
polypeptide (Garg et al. 2005). Members of two families with ASD only or with ASD 
and other septal defects were identified with mutations in the GATA4 transcription 
factor (Garg et al. 2003). In sporadic non-syndromic CVM cases, where no immediate 
family members were diagnosed with CVM, a handful of genes have been implicated. 
Screening of non-syndromic TOF patients performed by Goldmuntz and colleagues 
found more non-synonymous genetic variants of NKX2.5 (Goldmuntz et al. 2001). 
Other investigations have identified mutations in cardiac candidate genes in CVM 
patients, for example CRELD1 in AVSD cases (Zatyka et al. 2005) and CONNEXIN43 
in HLH cases (Dasgupta et al. 2001). Table 1.4 shows the genes that are associated with 
non-syndromic CVM. It must be emphasised that such non-syndromic Mendelian CVM 
families are very rare and contribute much less than 1% to the population burden of 
disease. 
 
 
Gene Type of CVMs 
NKX2.5 Familial ASD, AV block 
GATA4 ASD or VSD 
CRELD1 AVSD 
CONNEXIN43 HLH 
TAPVR1 TAPVR 
 
Table 1.5 Genes associated with non-syndromic CVM 
Genes associated with autosomal dominant inheritance of non-syndromic CVM that 
have been described.   
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1.3 Bone Morphogenetic Protein signaling pathway 
1.3.1 BMP signaling during heart formation 
 
Bone morphogenetic proteins (BMPs) were originally named for their ability to induce 
bone formation (Urist 1965). Since then, BMPs have been implicated in a plethora of 
cellular functions during development and in adult life. Early heart development 
requires BMPs, particularly cardiomyocyte differentiation (Ghosh-Choudhury et al. 
2003; Schlange et al. 2000; Shi et al. 2000). BMPs belong to the transforming growth 
factor-β (TGF-β) superfamily and comprise a subfamily of more than 20 members. 
BMPs are synthesized as large precursor proteins. After dimerization, these proteins are 
activated by endoprotyeolytic cleavage to produce mature dimer. The N-terminal of the 
protein controls the stability of the processed mature protein and the C-terminal adjacent 
to the cleavage site determines the cleavage efficiency (Constam and Robertson 1999). 
Activated BMPs are then glycosylated and secreted as homo- and heterodimers.  
 
BMPs signal through the assembly of hetero-tetrameric serine/threonie kinase receptors, 
which comprise of two type I and two type II receptors (Figure 1.5). To date, three type 
I receptors and three type II receptors have been identified to mediate BMP signaling 
(Koenig et al. 1994; Liu et al. 1995; ten Dijke et al. 1994). These receptors are distinct 
form each other and form their own subgroups (Kawabata et al. 1998). However, they 
share sequence similarity among TGF-β family receptors. The type II receptors are 
BMPR2 (BRK3), ACVR2A (ActRIIA) and ACVR2B (ActRIIIB) and the type I receptors 
are ACVR1 (ALK2), BMPR1A (ALK3) and BMPR1B (ALK6). BMPR2 is specific to 
BMP signaling whereas the other type II receptors ACVR2A (ActRII) and ACVR2B 
(ActRIIB) not only transduce BMP signals but also bind to activins for signaling 
(Kawabata et al., 1995). Among the type I receptors, BMPR1B is unlikely perhaps to 
play a part in cardiogenesis, as it is not expressed in the embryonic heart (Dewulf et al. 
1995). Endothelial-specific ACVR1 mutant mice generated using the Cre/loxP system 
display defects in the atrioventricular septa and valves, resulting from a failure of 
endocardial cells to differentiate into the mesenchyme in the atrioventricular canal 
(Wang et al. 2005a). BMPR1A is expressed in embryonic hearts and is discussed further 
in section 1.3.4. BMPR1A and BMPR1B preferentially mediate different BMP ligands 
from ACVR1. The BMP ligands that bind to BMPR1A and BMPR1B are BMP2 and 
BMP4 while BMP7 binds to these receptors with low affinity. By contrast, ALK2 
primarily mediates BMP5, BMP6 and BMP7 signaling (de Caestecker 2004).  
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When BMP ligands bind to the heteromeric complex of type I and type II receptors, the 
type II receptor, which is constitutively in an active state, phosphorylates the type I 
receptor through the glycine-serine domain (Miyazono et al. 2005). Intracellular events 
after receptor activation have been shown to be mediated by SMAD (small mother 
against decapentaplegic) proteins (Heldin et al. 1997). Type I receptors in turn trigger 
intracellular signaling by phosphorylating the downstream components, which are 
receptor-activated SMADs (R-SMADs: SMAD1/5/8). After releasing from the receptor, 
the phosphrylated R-SMADs will form a complex with a common SMAD (SMAD4) 
and translocate into the nucleus where they participate in gene transcription by 
interacting with other transcription factors. SMAD6 and SMAD7 are inhibitory SMAD 
proteins (I-SMADs) induced by BMPs which inhibit the BMP signaling pathway 
through a negative feedback loop (Imamura et al. 1997; Souchelnytskyi et al. 1998).   
 
Regulation of BMP signaling occurs at three levels: extracellularly, membrane level and 
intracellularly. At the extracellular level, Noggin (NOG) and other cysteine knot 
containing BMP antagonists bind directly to BMPs, thus inhibiting BMP signaling 
(Waldo et al. 2001). Co-receptors at the membrane level on one hand inhibit signal 
transduction by intercepting with receptor complex formation, e.g. BAMBI (Balemans 
and Van Hul 2002) and on the other hand may enhance signaling by presenting BMPs 
to receptors, e.g. RGMB (DRAGON) (Samad et al. 2005). Intracellular regulation occurs 
both in the cytoplasm and nucleus. SMAD6 and SMURF1 modulate BMP signals in the 
cytoplasm and also in the nucleus (Goto et al. 2007; Murakami et al. 2003). BMP 
signaling can be mediated by other intracellular proteins including 
MAP3K7/MAP3K7IP1 to induce p38 MAPK, PI3 kinase, RAS, MAPK1 and MAPK8 
(Kinbara et al. 2003; Nohe et al. 2004 ; Roux and Blenis 2004; Vanhaesebroeck et al. 
2001).   
 
BMP signaling is phylogenetically conserved in heart development. BMP is present not 
only in vertebrate, but also in Drosophila where it is known as Decapentaplegic (Dpp), 
which is an orthologue of vertebrate BMP2 and BMP4. Dpp induces both tinman and 
pannier (Sorrentino et al. 2005). Tinman is a transcription factor, whose vertebrate 
homolog is the critical cardiac transcription factor Nkx2.5 whereas pannier is a Gata 
transcription factor family member. Dpp maintains the expression of tinman during 
differentiation of the cardioblasts (Xu et al. 1998). The observation that BMP2 
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expression in the anterior endoderm of drosophila, chick, zebrafish, frog and mouse is 
required to induce myocardial differentiation further strengthen the essential role of 
BMP signaling in heart formation throughout evolution (Andree et al. 1998; Brand 2003; 
Kishimoto et al. 1997; Lough and Sugi 2000; Schultheiss et al. 1997; Shi et al. 2000).  
 
Five genes from the BMP signaling pathway were selected as candidates that might be 
involved in susceptibility to CVM in BMP signaling. BMP2 and BMP4 are BMP 
ligands at the extracellular level, BMPR2 and BMPR1A at the membrane level and 
SMAD6 at the intracellular level. These genes were selected based on their expression 
pattern during embryonic heart development, the cardiac abnormalities demonstrated by 
mutant animal models where available, and their role and specificity to BMP signaling. 
Detailed background on the selected candidate genes is presented in the following 
sections.    
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Figure 1.6 BMP signaling pathway 
Activated BMP ligands bind to type I and type II receptors, type II receptor will then 
phosphorylate the type I receptor, which in turn phosphorylates receptor-activated 
SMADs (R-SMADs). The activated SMAD binds to common SMAD4 upon which the 
complexes are translocated to the nucleus and participate in transcription.  
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1.3.2 BMP2 
 
Bone morphogenetic protein 2 (BMP2), also known as BMP2A, is located on 
chromosome 20p12 and has three exons (Figure 2.1 – Methods). The total transcript 
length is 3.6kb, producing a polypeptide of 396 amino acids in human. This gene has a 
TGF-β propeptide in the N-terminal and a TGF-β domain in the C-terminal that serves 
as a multifunctional peptide.  
  
In situ hybridization in chicken embryonic hearts showed that the avian Bmp2 gene was 
expressed in the endoderm at HH stage 5, and that it is essential for forming cardiac 
mesoderm (Somi et al. 2004). This experiment confirmed the previous study 
demonstrating that the delivery of Bmp2 soaked beads to regions of non-cardiogenic 
mesoderm in vivo triggered the expression of cardiac transcription factors like Nkx2.5 
and Gata4 (Schultheiss et al. 1997). At HH stage 8, Bmp2 was expressed in the paired 
lateral heart-forming regions. Bmp2 was later seen in the myocardium of the inflow 
tract at the venous pole of the heart tube at HH stage 10 (Somi et al. 2004). Inactivation 
of Bmp2 by the addition of Noggin (an inhibitor that binds to TGF-β family ligands 
[including BMP ligands] with high affinity to prevent the ligands from binding to 
receptors and thus inhibits signal transduction) to the explants at HH stage 5-8, inhibited 
expression of cardiac transcription factors like Nkx2.5 and eHand. This further suggests 
that Bmp2 is an important molecule for downstream cardiac specification (Schlange et 
al. 2000). At HH stage 16, in the arterial pole, Bmp2 was expressed in the myocardium 
of the distal OFT and in the mesenchyme distal to the OFT but not in the pharyngeal 
arches. In the venous pole, Bmp2 was expressed in the myocardial layer of the inflow 
tract. From HH stage 16-23, expression of Bmp2 was restricted to the primary 
myocardium of the atrioventricular canal (AVC). At HH stage 23, Bmp2 was expressed 
in the mesenchyme of the distal OFT ridges and the forming aorticopulmonary septum. 
Bmp2 was expressed throughout the entire AVC at this stage. Bmp2 was also present in 
the cardiomyocytes that protrude into the mesenchyme during muscularization of the 
AV cushions and tricuspid valve (Somi et al. 2004). In vitro cultures of cells from 
endocardial cushions of chick showed that Bmp2 could phosphorylate Smad1/5/8 and 
induce the expression of cartilage markers, such as sox9 and aggrecan. This further 
reaffirmed the role of Bmp2 in heart valve development (Lincoln et al. 2006). In the 
venous pole, BMP2 was expressed in the distal myocardial border of caval vein and in 
the distal myocardium around the pulmonary vein (Somi et al. 2004).  
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Tbx2 and Tbx3 are T-box DNA binding proteins with T-domain proteins that are 
phylogenetically conserved and function as transcription factors to regulate a variety of 
developmental processes, including heart development (Naiche et al. 2005). The 
expression of Tbx2 and Tbx3 closely overlapped with the regions that express Bmp2 in 
chicks. Treatment with Bmp2 in non-cardiogenic embryonic tissue leads to the 
expression of Tbx2 and Tbx3, demonstrating that Bmp2 mediates heart development 
upstream of Tbx2 and Tbx3 (Yamada et al. 2000). 
 
MEF2A (Myocyte-specific enhancer factor 2A) is a transcription factor initailly 
implicated in the development of heart and cardiac contractility in zebrafish (Naya et al. 
2002; Wang et al. 2005b). Investigation of Bmp2 and Mef2a in zebrafish and neonatal 
rat cardiomyocytes showed that Bmp2 is required for cardiac contractility and Bmp2 
could activate Mef2a transcriptional activity (Wang et al. 2007). This study indicates 
that Bmp2 acts upstream of Mef2a in the development of functionally contractive 
cardiomyocytes. 
 
To elucidate the function of BMP2 in the development of the mouse heart, targeted 
deletion of Bmp2 was performed (Zhang and Bradley 1996). The homozygous Bmp2 
knockout mouse died between E7.0 and E10.5, after formation of the heart tube. In the 
mutant mouse, the heart tube was formed inside the exocoelomic cavity instead of 
inside the amniotic cavity in the wild type. The expression of Bmp2 was detected at 
E7.5 in the mesoderm of normal mouse (Zhang and Bradley 1996). At E9.5, Bmp2 was 
presented in the outer myocardial cells of the AVC (Lyons et al. 1990; Zhang and 
Bradley 1996).  
       
To overcome the embryonic lethality of homozygous BMP2 knockout mouse, Ma and 
colleagues generated a Bmp2 null allele by deleting the exon3 of Bmp2 and crossed with 
Nkx2.5cre knock-in allele (Ma et al. 2005). BMP signaling was disrupted in the 
endocardial cells in the AVC at E9.5, resulting in severe AVC defects, a defect in 
cardiac jelly formation and the failure of mesenchymal cells to migrate to the AVC (Ma 
et al. 2005).  The deletion of Bmp2 in cardiac progenitors also results in changes of cell 
fate, where differentiated chamber myocardium was observed in heart-valve forming 
region (Rivera-Feliciano and Tabin 2006). 
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The expression and ablation of BMP2 in the animal models suggest a role in the 
aetiology of conotruncal cardiovascular malformations and AVC defects. However, no 
re-sequencing of the BMP2 in CVM patients had been performed at the start of this 
study. Therefore, investigation on whether mutations in BMP2 could cause sporadic 
CVM in man was performed.  

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1.3.3 BMP4 
 
Bone morphogenetic protein 4 (BMP4) is also known as BMP2B. This gene is located 
on chromosome 14q22-q23 and has three isoforms (Figure 2.2 – Methods). The 4 exons 
of BMP4 generate a polypeptide of 408 amino acids. The functional domains of BMP4 
consist of a TGF-β propeptide in the N-terminal and the TGF-β domain in the C-
terminal, similar to other BMP ligands.  
 
In zebrafish, Bmp4 has been shown to regulate left-right (LR) patterning both during 
early segmentation and during late segmentation (Chocron et al. 2007). During early 
segmentation, BMP signaling is required in the right lateral plate mesoderm to regulate 
both visceral and heart laterality; whereas during late segmentation, BMP signaling is 
required in the left lateral plate mesoderm to regulate left-sided gene expression and 
heart laterality. Restricted morpholino knock down experiments targeting the splice 
donor site between exon 1 and exon 2 of Bmp4 to produce aberrant Bmp4 protein in 
Kupffer’s vesicle results in LR patterning defects (Chocron et al. 2007). In both 
zebrafish and Xenopus, Bmp4 is expressed strongly on the left of the linear heart tube. 
Ectopic overexpression of Bmp4 bilaterally in the heart tube results in randomized 
looping (Breckenridge et al. 2001). 
 
Somi and colleagues carried out a study to identify which Bmp ligand might be 
principally involved in myocardium formation in intra- and extracardiac mesenchyme in 
vivo by visualizing the expression patterns of Bmp2, Bmp4, Bmp5, Bmp6 and Bmp7 
mRNA using in situ hybridisation in avian embryonic hearts from Hambuger-Hamilton 
(HH) stage 5 to 44 (Somi et al. 2004). At HH stage 5, Bmp4 was expressed in the 
ectoderm adjacent to the cardiac precursor cells (Schultheiss et al. 1997; Somi et al. 
2004). The cardiac precursor cells are located in the mesoderm in the anterior bilateral 
regions of the embryo. When a straight heart tube is formed at HH stage 10, Bmp4 was 
observed in the myocardium of the arterial pole and adjacent mesenchyme at both sides 
of the linear heart tube. Bmp4 was expressed in the distal myocardial border (arterial 
pole) and the flanking mesenchyme at HH stage 10-23 and the expression was restricted 
to the mesenchyme later on. Expression of Bmp4 was not seen in the inflow tract 
myocardium but it was present in the adjacent mesenchyme flanking the tract (Somi et 
al. 2004). Loss of function of Bmp4 by the misexpression of Noggin, which binds to 
BMP ligands and inhibits BMP signaling in the developing heart from HH stage 10-12 
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revealed abnormalities of the outflow tract cushions development, resulting in a 
ventricular septal defect with double-outlet right ventricle or common arterial trunk 
(Allen et al. 2001). Between HH stage 16-23, when muscularization of the 
atrioventricular cushions and the tricuspid valve takes place, Bmp4 was expressed in 
part of the mesenchyme of the mitral valve and the myocardium of the tricuspid valve, 
at the ventricular level (Somi et al. 2004). Bmp4 expression was detected in the ventral 
layer of the right sinus horn at HH stage 13 and by HH stage 17, Bmp4 was expressed 
in the proepicardium at the venous pole of the developing heart (Schlueter et al. 2006). 
From HH stage 36 onward, Bmp4 was expressed in the endocardium throughout the 
entire heart (Somi et al. 2004). These studies showed the dynamic patterns of Bmp4 
throughout chicken heart development. 
 
RNA of Bmp4 was detected in mouse embryos from E6.5 to E10.5 using RT-PCR 
(Winnier et al. 1995). At E6.5, low levels of Bmp4 was expressed in the posterior 
primitive streak and by E7.5, the expression of Bmp4 was stronger. In the knockout 
mouse, where targeted deletion of Bmp4 without the first exon after amino acid position 
seven was generated by homologous recombination in embryonic stem (ES) cells, 
homozygous mutant embryos died between E6.5 and E9.5, during gastrulation (Winnier 
et al. 1995). In embryos heterozygous for the Bmp4lacZ allele, where the lacZ reporter 
gene was knocked into the Bmp4 locus, expression of Bmp4 was observed in the OFT 
at E8.5 and was maintained until birth; whereas in the inflow region, Bmp4 was 
detected in the sinus venosus at E8.5 (Jiao et al. 2003). At E9.0, Bmp4 was visualized in 
the dorsal midline of the common atrium and weakly in the atrioventricular canal 
(AVC). Cells from these regions will form the atrial septum primum (ASP) and inferior 
endocardial cushion (IEC). Bmp4 expression was later observed in cardiomyocytes 
covering the IEC from E9.5 to E12.5 and the ASP from E10.5 to birth, indicating that 
Bmp4 might play an important role during septation and valvulogenesis. In order to test 
this hypothesis and to circumvent the early lethality of Bmp knockout mice, a Cre/loxP 
approach, where the transcription of Cre recombinase is driven by the rat cardiac 
Troponin T (cTnT) promoter (Wang et al. 2001; Wang et al. 2000b), was crossed with 
floxed Bmp4 allele (Bmp4loxp-lacZ/oxp-lacZ) or (Bmp4loxp-lacZ/tm1), to specifically inactivate 
Bmp4 expression in cardiomyocytes was utilized. The generated mutant mice showed 
atrioventricular canal defect (AVCD), a single atrioventricular junction with a common 
valve at E15.5-16.5, similar to the human patient with phenotypic defect of AVCD (Jiao 
et al. 2003). Bmp4 mutants with different genotypes [Bmp4loxp-lacZ/tm1, cTnT-Cre; 
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Bmp4loxp-lacZ;loxp-lacZ1 and cTnT-Cre; Bmp4cre;loxp-lacZ/tm1]; also displayed cardiac defects, 
ranging from atrial septal defect (ASD), partial AVCD, complete AVCD to double 
outlet right ventricle (DORV), successfully recapitulating a variety of cardiac 
phenotypic defects in patients.   
 
Bmp4 expression was detectable in the OFT myocardium and within mesoderm ventral 
to the branchial-arch arteries (BAAs) at E9.0 (Liu et al. 2004). Deletion of Bmp4 from 
myocardium of the developing heart in mouse using a conditional null allele of Bmp4 
and the Nkx2.5cre recombinase allele showed aberrant septation of the proximal OFT 
and reduced proliferation of OFT mesenchyme (Liu et al. 2004).   
 
The cardiac defects observed in Bmp4 animal models demonstrate that Bmp4 has a 
pivotal role in heart development. Thus it remains to be elucidated whether mutations of 
BMP4 in human result in CVM. 
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1.3.4 BMPR1A 
 
BMPR1A, bone morphogenetic protein type 1A, is one of the three type I receptors that 
can mediate BMP signals. BMPR1A is also known as ALK3, ACVRLK3, and CD292. 
BMPR1A is located on chromosome 10q22.3 and has two isoforms (Figure 2.4 – 
Methods). This gene comprises 13 exons, encoding an approximately 3.6kb transcript, 
that generates a polypeptide of 532 amino acids in humans. There are four functional 
domains in the mature protein of BMPR1A: the extracellular ligand binding domain, the 
transmembrance domain, a serine/threonine kinase domain and the cytoplasmic domain.  
 
In chick, Okagawa and colleagues showed the presence of mRNA of Bmpr1a by RT-
PCR in chick AV endocardium at HH stage 14, during the transformation of 
endocardial endothelial cells into invasive mesenchymal cells (EMT) (Okagawa et al. 
2007). No studies have been carried out to visualize the expression patterns of Bmpr1a 
mRNA in different stages of developing avian embryonic heart.    
 
In mouse, Bmpr1a is broadly expressed during early mouse embryogenesis. Bmpr1a 
was detected throughout the epiblast and mesoderm at E7.0 and at E8.5, Bmpr1a was 
observed in the three germ layers and in most adult mouse tissues (Mishina et al. 1995). 
Homozygous mutant mice generated by deleting the first two exons of Bmpr1a died 
during embryogenesis (Mishina et al. 1995). At E7.0 and E8.5, abnormal or 
degenerative embryos were observed. The abnormal embryos did not have a primitive 
streak at E7.0, and were approximately half the size of the normal embryos. Histological 
and molecular analysis of the mutant embryos showed that no mesoderm had formed in 
the Bmpr1a mutant embryos (Mishina et al. 1995). At E8.0, no organized structures 
were observed in the abnormal embryos, which were much smaller in size than the 
advanced normal embryos that had formed head folds. No homozygous mutants were 
recovered at E9.5 (Mishina et al. 1995).  
 
In a study performed by Klaus and colleagues, it was shown that the cardiac crescent 
and the primitive ventricle were absent in mice carrying a Bmpr1a deletion in cardiac 
mesoderm (Klaus et al. 2007). The mesoderm progenitors contribute to both first and 
second heart fields. This study showed that Bmpr1a is essential for the differentiation of 
the linear heart tube.  
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Deletion of exon 2 of Bmpr1a (encoding approximately 35% of the extracellular ligand-
binding domain) from the myocardium using a Cre/lox system results in abnormal 
development of the trabeculae, compact myocardium, interventriuclar septum and 
endocardial cushions (Gaussin et al. 2002). In another knockout mouse with a deleted 
floxed Bmpr1a allele directed to the cardiac myocytes of the atrioventricular canal 
(AVC), the tricuspid mural leaflet and mitral septal leaflet were longer, the tricuspid 
posterior leaflet was displaced and adherent to the ventricular wall, and the annulus 
fibrosus was disrupted (Gaussin et al. 2005). 
 
Deletion of Bmpr1a in the endocardium of mice resulted in loss of AV cushion 
formation, demonstrating the effect of BMP signaling on endocardium (Ma et al. 2005). 
The mutant mice showed the expression of phosphorylated-Smad1/5/8 in endocardial 
cells was decreased compared to the wild type and two-thirds of the mutants had 
hypoplastic cushions (Ma et al. 2005). Ablation of Bmpr1a in neural crest cells resulted 
in a shortened cardiac outflow tract and septation defects (Stottmann et al. 2004). The 
mutant embryos died in mid-gestation (at around E11.5-12) due to acute heart failure. 
Deletion of Bmpr1a in Isl1-expressing cells showed abnormal right ventricular and 
outflow tract from E9.5. At E13.5, persistent truncus arteriosus (PTA) and 
underdeveloped valves, severe aberreant morphology of the outflow tract, ventricular 
and atrial septal defects were seen in the mutant hearts (Yang et al. 2006).   
  
The cardiac abnormalities observed in the mouse model with heart field specific 
ablation of Bmpr1a coupled with its role as a receptor in BMP signaling suggest 
BMPR1A as a candidate gene for CVM.  
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1.3.5 BMPR2 
 
BMPR2, bone morphogenetic protein receptor type 2, is the type II receptor specific to 
BMP signaling. BMPR2 is also known as BMPR-II, BRK-3, T-ALK, and BMPR3. 
BMPR2 is located on chromosome 2q33-q34 and has three isoforms (Figure 2.5 – 
Methods). The genomic structure of BMPR2 is approximately 190kb, comprising 13 
exons, and the gene generates a polypepetide of 1,038 amino acids in humans. There are 
four functional domains in the mature protein of BMPR2: the extracellular ligand 
binding domain encoded by exons 2 and 3, the transmembrane domain generated by 
exon 4, a serine/threonine kinase domain from exon 5 to exon 11, and the cytoplasmic 
domain encoded by exons 12 and 13. Unlike the three other domains, the precise 
function of the BMPR2 cytoplasmic domain at the C-terminal remains unknown, as a 
construct lacking this domain was able to activate Smad protein when expressed in vitro 
(Kawabata et al. 1995).  
 
The pattern of expression of the other type II receptors (ActR-IIA and –IIB) in avian 
embryos can be observed in the primitive streak, indicating that these genes may be 
activated when mesoderm induction began (Stern et al. 1995). The ActR-IIA expression 
could be seen throughout the anterior mesoderm with the strongest expression in the 
lateral prospective heart cells (Ehrman and Yutzey 1999). However, no comprehensive 
studies have been carried out to investigate the expression patterns of Bmpr2 in the 
developing avian heart.  
 
In mice, the expression pattern of Bmpr2 at E6.5-7.5 was uniform in embryonic and 
extraembryonic regions (Beppu et al. 2000). The Bmpr2 mutant mice generated by gene 
targeting without the entire transmembrane domain and the amino-terminal region of 
the kinase domain (exons 4 and 5) died during embryogenesis (Beppu et al. 2000). 
However, the heterozygous mice were morphologically normal and fertile. The growth 
of the homozygous Bmpr2 mutant embryos was arrested at E6.5, and they lacked a 
morphologically discernible primitive streak at E7.5. At E8.5, the sizes of the mutant 
embryos were similar to the E7.5 mutant embryos. No homozygous mutants were 
recovered at E9.5, suggesting that the development of Bmpr2 mutant embryos were 
arrested before gastrulation (Beppu et al. 2000). The embryonic lethal Bmpr2 knockouts 
during gastrulation obscure the possible role of Bmpr2 in early heart formation.  
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A Bmpr2 construct with deleted exon 2, resulting in a protein that lacked half of the 
extracellular ligand-binding domain was generated by Delot et al. This protein was 
expressed at levels comparable with the wild type construct, but has reduced signaling 
capability (Delot et al. 2003). Homozygous mutant mice died at mid-gestation with 
cardiovascular and skeletal defects (Delot et al. 2003). The onset of lethality occurred 
between E12 and birth. The most striking defect was in the outflow tract with the 
absence of septation of the conotruncus below the valve level. In addition, the knockout 
mice also revealed interruption of the aortic arch with varying severity, between the 
roots of the left common carotid and the left subclavian artery, resulting in 
communication between the pulmonary trunk and the descending aorta through the 
ductus arteriosus, which is similar to the phenotypic defect of interrupted aortic arch in 
humans. No semilunar valves was observed in the outflow tract of the mutant. However, 
the atrioventricular valves were normal, indicating that atrioventricular cushions can 
develop normally when BMP signaling is impaired in certain circumstances.     
 
The early lethality and cardiac specific lesions observed in the mouse models showed 
the importance of Bmpr2 in heart development. Therefore, mutations in BMPR2 may 
give risk to CVM in man. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 46
1.3.6 SMAD6 
 
Human SMAD6, also known as MADH6, is located on chromosome 15q21-q22 and has 
three isoforms (Figure 2.3 – Methods). SMAD6 is a member of the SMAD (small 
mother against decapentaplegic) protein family. It functions as an inhibitory SMAD (I-
SMAD) to block BMP signaling intracellularly. In non-stimulated cells with BMP 
ligands, SMAD6 is mainly located in the nucleus, however, when activated, SMAD6 can 
be observed in the cytoplasm and the nucleus. There are two main functional domains in 
SMAD6: the carboxy terminal (C-terminal) and the amino terminal (N-terminal). The 
C-terminal and N-terminal regions are termed Mad homology 1 (MH1) and MH2 
domains respectively. The MH2 domain is highly conserved among SMAD proteins 
and plays important roles in receptor recognition, interaction with transcription factors, 
dimerization (homo- and hetero-oligomerization among SMAD proteins) and their 
nuclear transport (Chacko et al. 2004). However, SMAD6 lacks the SSXS motif at the 
end of the MH2 domain. This motif serves as a receptor phosphorylation site that is 
present in receptor-activated SMADs (R-SMADs). The MH1 domain of SMAD6 is 
highly divergent from the MH1 domains of other SMADs. In addition, the similarity of 
MH1 domain between SMAD6 and SMAD7 (another I-SMAD) is only 36.7% (Hanyu 
et al. 2001). The MH1 domain determines the subcellular localization of SMAD6 
(Hanyu et al. 2001), exhibits sequence-specific DNA binding activity and negatively 
regulates the functions of the MH2 domain through physical interaction. The interaction 
between MH1 and MH2 domains is released when activated by type I receptor (Hata et 
al. 1998). The MH1 domain is not effective in antagonizing BMP signaling but the 
MH2 domain is responsible for the inhibition of BMP signaling, in which it is nearly as 
potent as the full-length SMAD6 (Hanyu et al. 2001).  
 
In chick, Smad6 was expressed in the posterior primitive streak and the lateral margins 
of the embryos at Hamburger-Hamilton (HH) stage 4 (Yamada et al. 1999). At HH 
stage 5, expression was observed in the anterior lateral cardiogenic region and 
overlapped with the expression of Nkx2.5, Bmp2, Bmp4 and Bmp7. The intensity of the 
expression of Smad6 in the same region was increased by HH stage 7. At HH stage 8, 
Smad6 expression was localized to the anterior lateral plate mesoderm and the 
underlying endoderm in the bilateral heart tubes. As the heart tube forms at HH stage 10, 
Smad6 was highly expressed in the myocardium and in the endocardium, throughout the 
primitive heart tube. The expression of Smad6 continued even after the process of 
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looping has begun and persisted at least to HH stage 28. At this time (HH stage 11), 
Smad6 expression was similar to Nkx2.5 and Bmp7, but not to Bmp2 and Bmp4 
(Yamada et al. 1999).  
 
At the later stages of chick heart development, at HH stage 20, Smad6 was expressed 
throughout the heart, both in the myocardium and in the endocardium (Yamada et al. 
1999). The expression was particularly high in the myocardium in the atrioventriuclar 
junction. By HH stages 26-28, when the septation process was nearly completed, Smad6 
was expressed throughout the heart: in the myocardium, endocardium, and 
atrioventricular (AV) endocardial cushion. The expression of Smad6 was particularly 
strong in the regions of ventricular septum and the aorticopulmonary septum, but the 
outflow tract cushions did not express Smad6. Expression patterns of Nkx2.5, Bmp2, 
Bmp4 and Bmp7 covered all areas of Smad6 expression, except the endocardial cushions 
(Yamada et al. 1999). Over-expression of Smad6 in chick AV cushion endocardial cells 
resulted in a decrease of epithelial-mesenchymal transformation (EMT) (Desgrosellier 
et al. 2005) suggesting that Smad6 is a negative regulator of EMT.  
 
A Smad6 knockout mouse was generated by inserting a nuclear-localized 
LacZ/neomycin resistance cassette into the 5’ terminus of the MH2 domain of Smad6 
(Galvin et al. 2000). Smad6 was expressed by E7. At E9.5-E13.5, expression of Smad6 
was high in the outflow tract and atrioventicular cushion regions of the heart in the 
homozygous mutant embryos. These expressions persisted at later embryonic stages but 
the staining pattern expanded to vascular endothelium of larger vessels (Galvin et al. 
2000).  
 
In the adult heart, the expression of Smad6 was high in cardiac valves and outflow 
tracts, including both endocardial and endothelial cells, mesenchymal cells in the valves 
and vascular smooth muscle cells around the aortic and pulmonary roots (Galvin et al. 
2000). There was no difference between the homozygous and heterozygous adult mice 
for Smad6 expression generally, except in the epicardial and endocardial cells of the 
right atrium, where the expression of Smad6 was stronger in the homozygous mutant 
mice (Galvin et al. 2000). However, the mechanism for this localized upregulation in 
the homozygous mutant mice was not determined.  
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Smad6 mutant mice demonstrated defects confined to the cardiovascular system, 
including hyperplastic valves and abnormal septation of the outflow tract, often 
resulting in narrow ascending aorta and large pulmonary trunk or vice versa (Galvin et 
al. 2000). These defects are in line with the Smad6 expression in the endocardium and 
cushion mesenchyme of the atrioventricular cushion and outflow tract. The 
development in homozygous null mice of Smad6 of valvular hyperplasia is consistent 
with the enhanced EMT in the endocardial cushions (Desgrosellier et al. 2005). 
Homozygous null mutant mouse examined at or after 6 weeks of birth showed 
ossification around the outflow tracts of the heart, but not in the wild type, indicating 
that Smad6 plays a role in the homeostasis of the adult cardiovascular system (Galvin et 
al. 2000).   
 
The expression patterns of Smad6 during embryonic heart development in animal 
models and the defects in the cardiovascular development of Smad6 mutant mice 
indicate a prominent role of SMAD6 in cardiac development. Thus, mutation of SMAD6 
might cause CVM.   
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1.4 RNA processing 
 
A gene is first transcribed into a pre-messenger RNA (pre-mRNA) that is 
complementary to the entire length of the genomic DNA, including both intronic 
regions and exonic sequences. The introns of the pre-mRNA are then excised while the 
exonic segments are joined end-to-end during a process known as RNA splicing, to 
produce a mature mRNA for translation.  
 
The splicing process takes place at splice sites, which are well-conserved motifs defined 
by consensus sequences (5’ splice site, 3’ splice site and branch site) (Figure 1.6). The 
two bases at the end of introns (5’ splice site and 3’ splice site) are highly conserved, 
where most of the introns start with a GU and ends with an AG, although they are not 
the only important bases (Aebi et al. 1987). Another conserved motif is the branch site 
that contains an A nucleotide that is universally conserved, followed by the 
polypyrimidine tract, both of which are located upstream of the 3’ splice site (Kol et al., 
2005). Other sequences are also present in exons and introns to promote splicing. These 
sequences act in a cis manner to increase (namely exonic or intronic splicing enhancers: 
ESE or ISE) or decrease (exonic or intronic splicing silencers: ESS or ISS) recognition 
of the splice sites (Cartegni et al. 2002).  
    
The splicing mechanism involves a nucleophilic attack on the G nucleotide of the 5’ 
splice site carried out by the 2’ OH group on the conserved A nucleotide of the branch 
site, located upstream of the 3’ splice site. This reaction results in a lariat formation, 
where the exon/intron junction at the 5’ splice site is being cleaved. The 3’OH at the 3’ 
end of the upstream exon of the 5’ splice site performs a nucleophilic attack on the 3’ 
splice site to generate splice products and to release the intronic RNA as a lariat-shaped 
structure (Baralle and Baralle 2005) (Figure 1.6).  
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Figure 1.6 The process of RNA splicing 
A) The universally conserved motifs correspond to functionally important regions in 
splicing: the GU and AG dinucleotides spanning the 5’ and 3’ boundaries of the intron, 
the A nucleotide that serves as a branch site and the polypyrimidine tract (Py)n 
preceding the 3’AG are shown in two-exon pre-mRNA.  
B) The mechanism of RNA splicing takes place in two catalytic steps. During step 1, 
the conserved A of the branch site carries out a nucleophilic attack on the G of the 5’ 
splice site and results in the lariat structure (free exon 1 and lariat-exon 2). During step 
2, the 3’OH at the 3’ end of the exon 1 attacks the 3’ splice site, causing the release of 
the intronic RNA (as a lariat-shaped structure) and spliced exon (adapted from Baralle 
and Baralle, 2005) (Baralle and Baralle 2005).  
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1.5 Mutation nomenclature 
 
The descriptions of sequence variations were based on the guidelines for mutation 
nomenclature recommended by Human Genome Variation Society (HGVS), version 2.0, 
(www.hgvs.org/mutnomen/recs.html) (den Dunnen and Antonarakis 2000). Variants 
can be described at DNA, RNA and protein level in relation to a reference sequence, 
either a genomic or a coding DNA reference sequence. The letter in front of the 
nucleotide number indicates the type of the reference sequence used: “c.” for a coding 
DNA sequence (e.g. c.76A>T), “g.” for a genomic sequence, “m.” for a mitochondrial 
sequence, “r.” for an RNA sequence, “p.” for a protein sequence. The variants described 
at DNA level are in capitals, starting with a number referring to the first nucleotide 
affected (e.g. c.76A>T); at RNA level, the variants are in lower-case, starting with a 
number referring to the first nucleotide affected (e.g. r.76a>u); and at protein level, the 
variants are in capitals, starting with a letter referring to the first amino acid affected or 
three letter amino acid code (e.g. p.K76S or p.Lys76Ser), where the three letter amino 
acid code is preferred to described the amino acids. 
 
The symbol “>” indicates a substitution, e.g. c.76A>T denotes the change from the 
reference sequence A to a T. Deletions are designated by “del”, duplications are 
designated by “dup”, and insertions are designated by “ins”. The symbol “_” 
(underscore) indicates a range of affected residues.  
 
Nucleotide numbering for coding DNA sequences starts with +1, which is the A of the 
ATG-translation initiation codon. The nucleotide 5’ of +1 is numbered -1. There is no 
nucleotide zero. The nucleotide 3’ of the translation stop codon is *1. Nucleotides at the 
beginning of the intron are positive numbered from the last nucleotide of the preceding 
exon, e.g. c.76+1C>T whereas nucleotides at the end of the intron are negative 
numbered upstream in the intron from the first nucleotide of the following exon, e.g. 
c.76-1A>G.  
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1.6 Aims and objectives of the study 
 
The principal aim of the study was to identify and investigate the candidate genes in the 
BMP signaling pathway that could be involved in susceptibility to CVM in humans. 
Animal models of CVM have previously shown that certain genes in the BMP signaling 
pathway, when disrupted, cause CVM in the mouse. However, previous investigations 
of these genes in man either have not been previously conducted, or have been 
conducted in samples where parental information has been unavailable. Moreover, not 
all previous human mutation detection studies have involved functional investigation of 
identified mutations. Therefore, candidate genes were identified based on the 
phenotypes of the animal models in the literature. The exons of the candidate genes 
were then re-sequenced in a panel of non-syndromic CVM probands as it was believed 
that rare variants located in the protein coding regions that might affect protein function 
will have a large impact on disease phenotype. Parents (if available) of the probands 
with the newly identified novel variants were re-sequenced to establish whether the 
variant was inherited or was a de novo mutation. The variants were genotyped in an 
ethnically matched control population free of CVM to determine whether the variants 
are unique to the patient group.  
 
Novel variants that were located at the intron/ exon boundaries and were predicted to 
affect splicing mechanisms were investigated using minigene assays. In vitro functional 
studies were carried out on novel variants that resulted in amino acid substitution which 
are predicted to be probably damaging to protein function. Figure 1.6 shows the 
sequential flow of the study.  
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Figure 1.7  Experimental process 
Diagram illustrating the sequential steps taken in this study. Candidate genes of the 
BMP signalling pathway were selected for sequencing in a panel of 93 CVM probands. 
Novel variants identified in the patients cohort were investigated with minigene assays, 
luciferase assays and alkaline phosphatase assays. 
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Chapter 2  Materials and Methods 
 
2.1 Sample collection 
2.1.1 CVM cases 
 
Patients with CVM and their parents (when available) were recruited in the Freeman 
Hospital, Newcastle. Ethical approval was given for this study by the Northern and 
Yorkshire Multicentre Research Ethics Committee. Recruited patients were of European 
ancestry. Each participating subject or, in the case of the minors, their parents gave 
informed consent. Those patients diagnosed with del22q11 syndrome, other known 
chromosomal abnormalities, recognised multi-organ malformation syndromes, known 
maternal exposure to teratogens during pregnancy and/or learning difficulties were 
excluded from the study. All CVM phenotypes were eligible for inclusion. Blood or 
saliva samples were collected. For the blood samples, DNA was extracted using the 
phenol/chloroform method (performed by Mr. James Eden). For the saliva samples, 
DNA was extracted according to the Oragene Self-Collection Kit protocol (performed 
by Mr. Rafiqul Hussain). DNA was then tested for del22q11 using the SALSA-MLPA 
kit (MRC Holland) following the manufacturer’s protocol (performed by Dr. Ana Topf).  
 
A total of 446 patients in 442 families were available for analysis in this study. Of these, 
90 patients were re-sequenced for the coding sequences of the genes of interest (BMP2, 
BMP4, BMPR1A, BMPR2 and SMAD6). Additional 180 patients were sequenced for 
BMP4 and another 348 patients were resequenced for the MH2 domain of SMAD6.  
 
An additional 357 patients in 354 families with tetralogy of Fallot (TOF) of European 
ancestry that were recruited by the host laboratory for the CHANGE study (Congenital 
Hearts: A National Gene/Environment Study), were also available for analyses focused 
on that specific CVM phenotype. Ethical approval was given for the CHANGE study 
and informed consent was obtained from patients or their parents. Blood or saliva 
samples of the patients were collected in Newcastle, Leeds, Bristol and Liverpool. 
Patients and their families that were available for analysis were of Caucasian ancestry. 
TOF patients diagnosed with del22q11 syndrome, other known chromosomal 
abnormalities and learning difficulties were excluded from the study. This population of 
patient was genotyped for the SMAD6 p.Cys484Phe (c.1451G>T) variant. 
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2.1.2 Control populations 
 
Two control populations were used in this study to exclude any novel variants detected 
being hitherto undiscovered moderate-frequency SNPs. Variants absent in controls were 
considered of greater interest for functional studies. Typically, in studies of Mendelian 
families, control samples of 100-200 chromosomes are used for this purpose. In 
complex inheritance, where the prior probability that a variant is causative of disease is 
substantially lower, larger control samples are needed. The number of chromosomes 
that must be sampled to provide support for the hypothesis that a variant detected in 
cases is not an uncommon polymorphism is dependent upon the allele frequency we 
wish to exclude at a given power, and can be calculated using the binomial distribution. 
Thus, if the population frequency of a variant was 1/n, and n individuals were sampled, 
the probability that the variant would not be detected would be around 36%. However, 
if 2n individuals were sampled, the probability of non-detection would fall to around 
13% (that is, 87% power). Our study screened 3000 control chromosomes, therefore we 
had around 90% power to detect SNPs with an allele frequency of 1/1500. 
 
The first control population was a collection of 1425 British Caucasian individuals from 
255 families that were ascertained through a proband with essential hypertension, as 
described by Palomino-Doza et. al. (Palomino-Doza et al. 2008), who had no evidence 
of CVM at echocardiography. The families consisted of at least three siblings if at least 
one parent of the sibship was available and consisted of at least four siblings if no 
parent was available. Thus, screening of these families surveyed over 1000 founder 
chromosomes. This population was genotyped for the variants identified in BMP2, 
BMP4 and SMAD6 (except SMAD6 p.Ala325Thr [c.973G>A] and SMAD6 
p.Pro415Leu [c.1244C>T]). 
 
A second control population was derived from the North Cumbria Community Genetics 
Project (NCCGP). This population consisted of 1000 DNA samples of unrelated healthy 
offspring of healthy mothers born in Cumbria who were recruited between 1999 and 
2002, as described by Dorak et. al.(Dorak et al. 2009). This population was added in the 
screening of variants SMAD6 p.Ala325Thr (c.973G>A) and SMAD6 p.Prp415Leu 
(c.1244C>T) (see below). The NCCGP project was carried out to store DNA, plasma 
and viable cells from mother-child pairs in Cumbria for future epidemiological studies. 
As the population collected were healthy individuals, they have not undergone 
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echocardiogram, but no screened patient had been clinically diagnosed with CVM. This 
population was genotyped for SMAD6 p.Ala325Thr (c.973G>A) and SMAD6 
p.Pro415Leu (c.1244C>T) variants (performed by Dr. Darroch Hall).  
 
 
2.2 Screening of candidate genes 
2.2.1 Sequencing primers 
 
Primers were designed to amplify the exonic and splice site regions of five genes of 
interest; BMP2, BMP4, BMPR1A, BMPR2 and SMAD6 in a discovery cohort of 90 
CVM patients. Sequences of the genes were obtained from Ensembl version 43 
(http://www.ensembl.org/index.html). See Figures 2.1-2.5 for the location of the 
sequencing primers. Primers are listed in Table 2.1. Parameters for sequencing primers 
included: primers about 18-25 nucleotides long, similar GC content for both primers 
and no repetitive sequences. Base complementarity between the two primers was 
avoided to prevent primer dimer formation. Each primer was checked   for   specificity   
to   the   region   desired   using   the   BLAST programme 
(http://www.ncbi.nlm.nih.gov). Both primer pairs were designed approximately 80bp 
into the intronic sequence, so that good readable sequences at the beginning and at the 
end of exons could be obtained, as sequence data is often most accurate about 50bp 
from the primer. PCR products were usually between 350-700bp, as that was the 
achievable average read length of the MegaBACE sequencer. Larger exons (more than 
700bp) were amplified in smaller amplicons, with overlapping 3’ and 5’ ends. The same 
primers were used for sequencing reactions. 
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Exon        1        2           3 
 
(bp)    (1212)    (353)           (2019) 
 
 
 
Figure 2.1  BMP2 Structure and Sequencing Primer Location 
Diagram of BMP2 (ENST 00000378827). Boxes represent exons and adjoining lines represent introns. Exons are numbered and the sizes are indicated 
in base pair. Locations of the primers are located above the exons. 5’UTR and 3’UTR are in black colour. Location of the TGF-beta propeptide domain 
is labelled above the exons. 
 
 
TGF-beta propeptide 
1A2F/AR 1CF/CR 
1BF/BR 
2F/2R 
3AF/AR 
3BF/3B2R 
3AF/3FR 3AF/3FR 
3CF/3CR 3EF/3ER 
3BF/3B2R 
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A) 
 
 
 
 
B) 
 
 
 
C) 
 
Exon           1A            1B           2          3     4  
 
(bp)        (262/ 78)       (132)      (125)     (377)           (1150/ 1153)  
 
 
Figure 2.2 BMP4 Structure and Sequencing Primer Location 
Diagram of BMP4 isoforms A (ENST 00000245451), B (ENST 00000395600) and C (ENST 00000417573). Boxes represent exons and adjoining 
lines represent introns. Exons are numbered and the sizes are indicated in base pairs. Locations of the primers are located above the exons. 5’UTR and 
3’UTR are in black colour. Location of the TGF-beta propeptide domain is labelled above the exons.   
 
1F/1R 2F/2R 
3F/3R 
4F/4R 
5F/5R 7F/7R 
6F/6R 8F/8R 
10F/10R 
TGF-beta propeptide 
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A) 
 
 
 
B) 
 
 
 
C) 
 
 
Exon    1A  1B         2   3    4B     4A               
  
(bp)    (1744/ 1780)   (34)       (57)             (78)        (65)     (1004/ 989) 
    
Figure 2.3 SMAD6 Structure and Sequencing Primer Location 
Diagram of SMAD6 isoforms A (ENST 00000288840), B (ENST 00000338426) and C (ENST 00000457357). Boxes represent exons and adjoining 
lines represent introns. Exons are numbered and the sizes are indicated in base pairs. Locations of the primers are located above the exons. 5’UTR and 
3’UTR are in black colour. Location of the MH1 and MH2 domains are labelled above the exons.   
 
 
MH1 MH2 
1F/1R 
2F/2R 
3F/3R 
4F/4R 
5F/5R 
6F/6R 
7F/7R 
8F/8R 
10F/10R 11F/11R 
12F/12R 
14F/14R 
13F/13R 15F/15R 
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A) 
 
 
 
B) 
 
 
 
Exon          1    2              3       4           5          6        7         8       9            10      11      12       13 
 
(bp)                (281/ 270) (115)       (219/ 227)  (163)        (103)     (97)     (100)      (145)      (193)      (298)      (176)      (131)(1592/ 1595)          
    
 
Figure 2.4 BMPR1A Structure and Sequencing Primer Location  
Diagram of BMPR1A isoforms A (ENST 00000224764) and B (ENST 00000372037). Boxes represent exons and adjoining lines or broken lines 
represent introns. Exons are numbered and the sizes are indicated in base pairs. Locations of the primers are located above the exons. 5’UTR and 
3’UTR are in black colour. Location of the kinase-like domain is labelled above the exons.   
 
Kinase-like domain 
1F/1R 
2F/2R 
3F/3R 
4F/4R 
5F/5R 6F/6R 
7F/7R 8F/8R 
9F/9R 
10F/10R 
11F/11R 
12F/12R 
13F/13R 
14F/14R 
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A) 
 
 
B) 
 
 
C) 
 
Exon  1          2           3           4 5              6       7    8 9 10        11        12         13          
       
(bp)      (615/ 117/ 1124)       (171)     (171)    (111)    (92)         (231)    (115)            (161)    (148)      (137)    (173)   (1280/ 4)  (8056) 
 
 
Figure 2.5 BMPR2 Structure and Sequencing Primer Location  
Diagram of BMPR2 isoforms A (ENST 00000374580), B (ENST 00000363702) and C (ENST 00000445231). Boxes represent exons and adjoining 
lines or broken lines represent introns. Exons are numbered and the sizes are indicated in base pairs. Locations of the primers are located above the 
exons. 5’UTR and 3’UTR are in black colour. Location of the kinase-like domain is labelled above the exons.  
Kinase-like domain 
1F/1R 
2F/2R 
3F/3R 
4F/4R 5F/5R 
6F/6R 
7F/7R 
8F/8R 
9F/9R 
10F/10R 
11F/11R 
12F/12R 
13F/13R 
14F/14R 
15F/15R 
16F/16R 
17F/17R 
18F/18R 
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Sequencing Primers Sequence (5’      3’) 
BMP2-1A2-F TCCACACCCCTGCGCGCAGC 
BMP2-1A-R GCGCTAGGGATCGGCTCCGG 
BMP2-1B-F CAGCGCCGAGTGGATCACCG 
BMP2-1B-R CTGTCGTCCTCCTTAGGAACC 
BMP2-1C-F ATGGGCCGCGGCGGAGCTAG 
BMP2-1C-R CTGCAGGGCTCCGTTGCACG 
BMP2-2F GACTCGTGAGTGTGCCAAGC 
BMP2-2R GGCCAAGCTGCCTCTACAGG 
BMP2-3A-F TCCTGGTATGCAATGCATGATGAC 
BMP2-3A-R CAATGGCCTTATCTGTGACCAGC 
BMP2-3B-F TGGATTCGTGGTGGAAGTGG 
BMP2-3B2-R AATATTAAAGTGTCAACTGGGGT 
BMP2-3C-F CTATCAGGACATGGTTGTGGAGG 
BMP2-3C-R GTGAACTCAACAGTAGCACTGCAA 
BMP2-3D-F CAGCACATGAAGTATAATGGTCAG 
BMP2-3D-R TGAATACTTTGGCCAGATCAGCC 
BMP2-3E-F TTGGATAAGAACCAGACATTGCTG 
BMP2-3E-R TCCAGCCATTCATTACCTTTCCC 
BMP2-3A-F TCCTGGTATGCAATGCATGATGAC 
BMP2-3F-R CCACGTCACTGAAGTCCACG 
BMP2-3G-F ACTCAGTGCTATCTCGATGC 
BMP2-3B2-R AATATTAAAGTGTCAACTGGGGT 
BMP4-1F GCCTGCTAGGCGAGGTCGG 
BMP4-1R TGCCTCGGTCACAGCCTGTG 
BMP4-2F AAGCCCTTTCGCCGCCTGC 
BMP4-2R AAGGGAGCGACAGTGCTGCC 
BMP4-3F TTGACTGTAAACAAGTTAGACC 
BMP4-3R CCGCATGTAGTCCGGAATGA 
BMP4-4F TAACCGAATGCTGATGGTCG 
BMP4-4R GGCTTTGATGTAACCCGAAC 
BMP4-5F CAGAATTCACCATTCATTGCC 
BMP4-5R ATCGGCTAATCCTGACATGC 
BMP4-6F ACCACAATGTGACACGGTGG 
BMP4-6R CAGAATTGACCAGGGTCTGC 
BMP4-7F CCACTCGCTCTATGTGGACT 
BMP4-7R AAGTCCAGCTATAAGGAAGCA 
BMP4-8F CCTGGATGAGTATGATAAGGTG 
BMP4-8BR CTCCAACTCACCTGAACAGAA 
BMP4-10F GCAGCATCTTCGATTAGTCAGG 
BMP4-10R GGCTCGAAGCTCCGGGCAG 
Smad6-1F GTCTAGACTGGCATATGATGG 
Smad6-1R TCCCTGGATTTGCATGCACG 
Smad6-2F CAGCCTCGGCGCACGAAGC 
Smad6-2R AAGTTGTGCGGCTGGTCCATG 
Smad6-3F ATCAACAAGCCTGCCTTTCG 
Smad6-3R GAGGCGGTCTCCGGTTAC 
Smad6-4BF GCTCGGCGTGCGCGTGTTCC 
Smad6-4BR ACTTCGGAGCGGCCGCAGCC 
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Smad6-5F GGATATCGTATGTTCAGGTCCA 
Smad6-5R AGCGCGCTTCGCGACTCCG 
Smad6-6F AGGCCCATGTCGGAGCCAG 
Smad6-6R CACGGCGTGCTGCAGGTCG 
Smad6-7F AACCGTCACGTACTCGCTGC 
Smad6-7R TGCGCCGACCCGCAGTGTC 
Smad6-8F CACCAGTCCAGATCCACAGG 
Smad6-8R ACCACCATCTAAACACAAGACA 
Smad6-10F GGCTTTAACTGTTGAGGGGA 
Smad6-10R CACAGCAACCAGTCCGGCT 
Smad6-11F GGTGACATCAGAAAGTTGGG 
Smad6-11R GCAACCTTCCCATCCAAGGA 
Smad6-12F ATGTGAAGGGTCAGAAGATTG 
Smad6-12R CACAGCCATCCAGACATGC 
Smad6-13F ACATGACTGCTGAATGCTGG 
Smad6-13R GAACACCTTGATGGAGTAGC 
Smad6-14F GAACGCGCAGCAAGATCGG 
Smad6-14R TCCATATACACACATTGCACC 
Smad6-15F CCGATGCCCAGAGACACAG 
Smad6-15R AACTGAGGTCAAGTTTCAAGG 
BMPR1A-1F CTTCCCAGTGCGCGCGCGCC 
BMPR1A-1BR CGCGCCCAGCTGCCTCTGCA 
BMPR1A-2F ATAGTTGTACATGCGAAACG 
BMPR1A-2R ATTACTTATGAACTCGTCAGG 
BMPR1A-3F AGCAAGGATACCTTTAATCTT 
BMPR1A-3R AGGCTGGGCCTAACTATTC 
BMPR1A-4F AGAAGAATCATAACTTGTCTC 
BMPR1A-4R CATGAAGACAGCTATATCAC 
BMPR1A-5F GCTACAATTATTGTGATAAGAA 
BMPR1A-5R AGTAACTCACCTATCAATCAT 
BMPR1A-6F GGCGTTGCCAATAAATCACG 
BMPR1A-6R ACATACAGCGATGTGTACAC 
BMPR1A-7F CCATCCACATAGATATGTTC 
BMPR1A-7R AATAATCTGACGTGTTCAATTC 
BMPR1A-8F AGTCGGAGCATGCTTCTCAA 
BMPR1A-8R CCTTAAGAGAACTATAGTCTAG 
BMPR1A-9F AACATGATACATAGAACTCTG 
BMPR1A-9R ACCTTGCAATACTGCATACC 
BMPR1A-10F AACTGGAGTTGGTTGGGTAC 
BMPR1A-10R GTATATAGTTGAACTCACACAT 
BMPR1A-11F TATCTGCACATGATACCTAAG 
BMPR1A-11R CCAACTATACATTTATGTAACTA 
BMPR1A-12F GATGTCATGTAGTATGTAGCA 
BMPR1A-12R AAAGTTATATAACTGGAGCTG 
BMPR1A-13F ACATACATCTACTATTAAGAG 
BMPR1A-13R CTCGTAGACACTGAAAAGTA 
BMPR1A-14F GTGATGAAGTGAGTGGAACT 
BMPR1A-14R TGAGAACCAAGTTAACATCC 
BMPR2-1F GACTGTGAGCTTGTCCATGG 
BMPR2-1R TCTTCTCTCCCGTGGACTG 
 64
BMPR2-2F TGATATCGTGAAACTACGAGG 
BMPR2-2R ATGGCGAAGGGCAAGCACA 
BMPR2-3F TCATGAACAGAAGAACGTCAT 
BMPR2-3R AACAGGATTTTAACATACTCC 
BMPR2-4F CATAGCTTACACGTACTCTC 
BMPR2-4R ACGCCTGGCTTCAACCTTG 
BMPR2-5AF AGGAGCACATCTACTTGGTG 
BMPR2-5AR TAATCCAGTGGCATGGAAAG 
BMPR2-5BF ATCTATACAGAATAGTCTGTATG 
BMPR2-5BR ACAATACTGTCCATACGTGAT 
BMPR2-6F TTACTCCTATTGACATTAGGC 
BMPR2-6R TGCCTAGAATAGGCCTTGAC 
BMPR2-7F TCAGCCATACTAGAACAGAAT 
BMPR2-7R CACCTGCCTTAGCCTCCA 
BMPR2-8F TAGATCTTCATGGAATCCTAG 
BMPR2-8R CAACTGACTAATAATAAATCTCC 
BMPR2-9BF CTGAAGTGGCAGCATGTTTGT 
BMPR2-9AR CAAAGTACATCAGTGTGATACC 
BMPR2-10F TAATGACATGGTTAGGGTCAA 
BMPR2-10R CTTACATAAAAGTTGAGTTAGG 
BMPR2-11F GCTTACTTGGTATCAGAAATAC 
BMPR2-11R AACTATTAACGTTATTAACAGTC 
BMPR2-12F AGCATGTTCCGTAATCCTTG 
BMPR2-12R TCATTGAACTATTAGGCTGGT 
BMPR2-13F TATCAAGTTATTAATTGACACTTG 
BMPR2-13R CTCAGATATAGTAGTCATGCC 
BMPR2-14F CATCATACTGACAGCATCGTG 
BMPR2-14R TTGCAGTCTGTGTGAAGTCC 
BMPR2-15F TGTCTGCTTACAGCTGACAG 
BMPR2-15R TTGGCCAGATAGTACTGTCC 
BMPR2-16F CAAGAGACCTACTAGTTTGC 
BMPR2-16R GAATTAGTTCGGCCACCTTC 
BMPR2-17F CTGCCACAACCCAATATGC 
BMPR2-17R AAGGTAAATAATCACTAGTTGA 
BMPR2-18F CAAGAAATGTTCATTAGCACC 
BMPR2-18R TTCTGCATAGCTGAAATCTAT 
 
 
Table 2.1  Primers used for sequencing 
Sequences of the primers used to sequence the coding regions of BMP2, BMP4, 
BMPR1A, BMPR2 and SMAD6.  
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2.2.2 Polymerase Chain Reactions (PCR) 
 
PCR were performed using HotStarTaqTM DNA Polymerase (Qiagen). PCR was 
conducted in a 15µl reaction mixture which comprised of 1x PCR Buffer, 1.5mM 
MgCl2 or 1x Q solution, 0.2mM of each dNTPs, 0.5µM of each primer (forward and 
reverse), 2.5units of HotStarTaq DNA Polymerase, 20ng of DNA and ddH2O to a final 
volume of 15µl.  
 
The PCR cycling programme started at 95°C for 15 minutes, to heat-activate the 
HotStarTaq DNA Polymerase, followed by 35 cycles of 95°C (or 97°C) for 30 seconds, 
the primer set specific annealing temperature for 30 seconds and 72°C for 1 minute, and 
a final extension of 5 minutes at 72°C.  
 
In order to identify the optimum conditions for each of the primer sets, PCR were 
carried out in a gradient temperature from 50°C–70°C. PCR reactions were first tested 
with 1.5mM of MgCl2. If that failed to obtain a clear PCR band, Q solution was utilized. 
For regions with high GC content (60% or more), the denaturing temperature was 
increased to 97°C. The PCR conditions for each primer set are detailed in Table 2.2.      
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Primer Pair Denaturing 
Temp. (°C) 
Annealing 
Temp. (°C) 
MgCl2 Concentration 
(mM)/ Q solution  
BMP2_1A2F/1AR 97 64.6 Q solution 
BMP2_1BF/1BR 95 61.8 Q solution 
BMP2_1CF/1CR 95 66.8 Q solution 
BMP2_2F/2R 95 66.8 1.5 
BMP2_3AF/3AR 95 68.4 1.5 
BMP2_3BF/3B2R 95 61.8 1.5 
BMP2_3CF/3CR 95 67.6 1.5 
BMP2_3DF/3DR 95 66.8 1.5 
BMP2_3EF/ER 95 61.8 1.5 
BMP2_3AF/3FR 95 61.8 1.5 
BMP2_3GF/3B2R 95 61.8 1.7 
BMP4_1F/1R 95 68.4 1.5 
BMP4_2F/2R 95 68.4 1.5 
BMP4_3F/3R 95 61.8 1.5 
BMP4_4F/4R 95 61.8 1.5 
BMP4_5F/5R 95 58.4 1.5 
BMP4_6F/6R 95 61.8 1.5 
BMP4_7F/7R 95 58.4 1.5 
BMP4_8F/8BR 95 61.8 1.5 
BMP4_10F/10R 95 61.8 Q solution 
Smad6_1F/1R 97 61.8 1.5 
Smad6_2F/2R 95 69.6 1.5 
Smad6_3F/3R 97 58.4 Q solution 
Smad6_4BF/4BR 97 61.8 Q solution 
Smad6_5F/5R 97 58.4 Q solution 
Smad6_6F/6R 97 58.4 Q solution 
Smad6_7F/7R 97 58.4 Q solution 
Smad6_8F/8R 95 61.8 1.5 
Smad6_10F/10R 95 61.8 1.5 
Smad6_11F/11R 95 61.8 1.5 
Smad6_12F/12R 95 64.6 1.5 
Smad6_13F/13R 95 61.8 1.5 
Smad6_14F/14R 95 61.8 1.5 
Smad6_15F/15R 95 66.8 1.5 
BMPR1A_1F/1BR 97 64.6 1.5 
BMPR1A_2F/2R 95 58.4 1.5 
BMPR1A_3F/3R 95 58.4 1.5 
BMPR1A_4F/4R 95 58.4 1.5 
BMPR1A_5F/5R 95 58.4 1.5 
BMPR1A_6F/6R 95 58.4 1.5 
BMPR1A_7F/7R 95 58.4 1.5 
BMPR1A_8F/8R 95 58.4 1.5 
BMPR1A_9F/9R 95 58.4 1.5 
BMPR1A_10F/10R 95 58.4 1.5 
BMPR1A_11F/11R 95 58.4 1.5 
BMPR1A_12F/12R 95 58.4 1.5 
BMPR1A_13F/13R 95 58.4 1.5 
BMPR1A_14F/14R 95 58.4 1.5 
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BMPR2_1F/1R 95 61.8 1.5 
BMPR2_2F/2R 95 58.4 Q solution 
BMPR2_3F/3R 95 58.4 1.5 
BMPR2_4F/4R 95 58.4 1.5 
BMPR2_5AF/5BR 95 58.4 1.5 
BMPR2_6F/6R 95 58.4 1.5 
BMPR2_7F/7R 95 55.5 Q solution 
BMPR2_8F/8R 95 58.4 1.5 
BMPR2_9BF/9AR 95 58.4 1.5 
BMPR2_10F/10R 95 58.4 1.5 
BMPR2_11F/11R 95 58.4 1.5 
BMPR2_12F/12R 95 58.4 1.5 
BMPR2_13F/13R 95 58.4 1.5 
BMPR2_14F/14R 95 58.4 1.5 
BMPR2_15F/15R 95 58.4 1.5 
BMPR2_16F/16R 95 58.4 1.5 
BMPR2_17F/17R 95 58.4 1.5 
BMPR2_18F/18R 95 58.4 1.5 
 
Table 2.2  PCR Conditions 
The optimum PCR conditions used for each of the primer sets. 
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2.2.3  Gel electrophoresis 
 
2% gels were prepared using SeaKem® LE Agarose (Cambrex), 1x TAE buffer, and 1x 
Gel Red (Biotium). 5µl of PCR product was loaded with 5µl of Orange G dye, 
alongside 2.5µl of 100bp DNA Ladder (Fermentas) and were run at 150V for 50 
minutes. Gels were then visualized under UV light to check the size and approximate 
quantification of the amplified products. 
 
 
2.2.4 PCR clean up 
 
ExoSAP-IT (GE Healthcare) was utilised to clean up PCR products by removing 
excessive dNTPs and primers. 2µl of ExoSAP-IT which contains two hydrolytic 
enzymes, Exonuclease I and Shrimp Alkaline Phosphatase was added to 5µl of PCR 
product. This was then incubated at 37°C for 15 minutes followed by inactivation at 
80°C for 15 minutes.   
 
 
2.2.5 Sequencing reactions 
 
Sequencing was carried out using the DYEnamic ET dye terminator cycle sequencing 
kit for MegaBace DNA analysis systems (GE Healthcare). Reactions were conducted in 
a 96-well skirted plate and each reaction comprised 3µl of cleaned-up PCR product, 
5pmol of forward or reverse primer, 4µl of DYEnamic ET terminator reagent premix 
and ddH2O to a final volume of 10µl. For regions with high GC content, a final 
concentration of 0.5M Betaine or 5% DMSO was added to the reaction. 
 
The cycling programme started with 95°C for 2 minutes, followed by 35 cycles of 95°C 
for 30 seconds, 55°C for 15 seconds, and 60°C for 1 minute. Products were cleaned-up 
by isopropanol precipitation. 27µl of 80% isopropanol was added to each reaction, 
vortexed briefly, incubated for a minimum of 30 minutes at room temperature and 
centrifuged at 4°C for 30 minutes at 3313g. The supernatant was discarded by inverting 
and gently shaking the plate. The DNA pellets were washed in 100µl of 60% ice-cold 
ethanol and centrifuged for 10minutes at 3313g. The supernatant was removed by 
inverting the plate and centrifuged upside down on tissue for 10 seconds at 200g, then 
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was air-dried for 5 minutes. The DNA pellets were re-suspended in 10µl of MegaBACE 
loading solution and run on a MegaBACE 1000 sequencing instrument (GE Healthcare) 
by the sequencing service at the Institute of Human Genetics (Newcastle University, 
UK).      
 
 
2.2.6 Sequence analysis 
Sequences were analyzed using Staden Package software 
(http://staden.sourceforge.net/). Forward and reverse sequences were compiled against a 
text file of consensus sequence taken from ENSEMBL. Using the Pregap4 programme, 
sequences were pre-processed for Gap4 using Gap4 shotgun assembly configuration. 
Sequences were then aligned using Gap4 with a maximum mismatch of 20%. Single 
nucleotide polymorphisms (SNPs) and novel variations were detected by comparing all 
sequences together.  
 
 
2.2.7 Identifying variants in parents 
 
Regions where novel variants were identified in probands were re-sequenced in their 
parents (when available) to determine whether the variants were inherited or de novo.    
 
 
2.2.8 Genotyping rare variants 
 
Newly identified variants were genotyped in the control population. This was carried 
out either by Sequenom or Taqman methods (see below). Positive controls were 
included in the assay to confirm the reliability of the assay and the presence of the 
variants. Frequencies of the alleles identified in the controls and probands were 
calculated by genotype counting. Goodness of fit to Hardy Weinberg equilibrium was 
tested. The frequencies of the variants that were present in the controls were compared 
to the frequencies of the alleles in the probands, and the hypothesis that these were 
different in the two populations was tested using Fisher’s exact test in Minitab software. 
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2.2.8.1 Sequenom genotyping 
 
Multiplex assays were designed using the SEQUENOM RealSNPTM Programme 
(https://www.realsnp.com/default.asp) and Assay Design software. SNPs with 200bp of 
surrounding sequences were prepared in a text file and then uploaded into the ProxSNP 
programme to map for proximal SNPs that could interfere with assay design. Using the 
PreXTEND programme, PCR primers were designed and checked for their specificity 
to the desired regions. The output file was then run on the PleXTEND programme, to 
ensure the specificity of the design. Three plexes (15-plex, 11-plex and 5-plex) were 
designed to accommodate 31 novel genetic variants. The assay designs and the primer 
sequences are listed in Table 2.3. 
 
10µl of multiplex reactions were set up using HotStarTaqTM DNA Polymerase (Qiagen). 
Multiplex PCR reactions consisted of 1.25x of HotStarTaq Buffer, 1.63mM of MgCl2, 
0.5mM of dNTPs, 0.1µM of each primer, 1unit of HotStarTaq DNA Polymerase, 20ng 
of genomic DNA, pool of primer sets (primer PCR_P1 and primer PCR_P2) and ddH2O. 
This procedure amplified many individual loci of specific fragments of genomic DNA.  
 
The PCR cycling programme consisted of an initial step at 95°C for 15 minutes, 
followed by 35 cycles of 97°C for 20 seconds, 59°C for 30 seconds and 72°C for 
1minute and a final extension at 72°C for 3 minutes. 
 
5µl of each PCR product were loaded into a 384-well plate (ABgene) and treated with 
Shrimp Alkaline Phosphatase (SAP) to dephosphorylate unincorporated dNTPs. SAP 
mixture was made up of 1x SAP buffer (Sequenom®), 1unit of SAP enzyme 
(Sequenom®) and ddH2O made up to 2µl. The reactions were gently vortexed and 
incubated at 37°C for 20 minutes and 85°C for 5 minutes in a thermocycler.  
 
iPLEX extension reaction cocktail was prepared according to the number of primers in 
the plexes. Primers (extension primer [EXT]) were divided into 4 groups dependent on 
their mass: 0.625µM, 0.83µM, 1.04µM, and 1.25µM. Briefly, the mixture for each 
reaction was made up of 0.222x of iPLEX buffer (Sequenom®), 1x of iPLEX 
termination mix (Sequenom®), primer mix, 1x iPLEX enzyme (Sequenom®), and 
ddH2O to a final volume of 2µl. The iPLEX reaction was carried out to detect single-
base polymorphisms or small insertion/deletion polymorphisms in amplified DNA. 
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During the iPLEX reaction, the primer is extended by one mass-modified nucleotide 
depending on the allele and the design of the assay. 
 
The iPLEX reaction was cycled at 94°C for 30 seconds, 94°C for 5 seconds, 5 cycles of 
52°C for 5 seconds and 80°C for 5 seconds, followed by another 39 cycles of 94°C for 5 
seconds, 52°C for 5 seconds, and 80°C for 5 seconds. The cycle concluded with a final 
extension at 72°C for 3 minutes. 
 
iPLEX reactions were desalted with 6mg of resin. 16µl of ddH2O was added to the 
reaction mix. The plate was inverted for 30minutes before centrifugation at 1864g for 
10 minutes and stored at -20°C. 
 
The 384-element SpectroCHIP bioarray and the operation of the MALDI-TOF machine 
were performed by the Sequenom facility at the Institute of Human Genetics (Newcastle 
University). The readout was viewed using MassARRAY Typer v3.4 software. 
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15-Plex Primers 
SNP_ID PCR_P1 Primer Sequence (5’      3’) PCR_P2 Primer Sequence (5’       3’) EXT Primer Sequence (5’     3’) 
BMP4_7551C_T  ACGTTGGATGGTCCAGCTATAAGGAAGCAG ACGTTGGATGACATACACCACACACACACG GTTCCCATCCACTCACC 
Smad6_80102T_C  ACGTTGGATGGAGGAAGGAGGAAGAGAAAG ACGTTGGATGGGACAAAACAAGAAAGACGC AGACGCACTTTGGCTTA 
BMP4_5348T_C  ACGTTGGATGGGTCGTTTTATTATGCCAAG ACGTTGGATGCGACTTTTTTCTTCCCCGTC cCCCCGTCTCAGGTATCA 
BMP4_4140C_T  ACGTTGGATGCAAACTTGCTGGAAAGGCTC ACGTTGGATGTCCTTTTAGGAGCCATTCCG AGCCATTCCGTAGTGCCAT 
Smad6_79800G_T  ACGTTGGATGCACTATCTGGGGTTGTTGAG ACGTTGGATGTGCTACTCCCGGCAGTTCAT tctGCAGTTCATCACCTCCT 
Smad6_1520C_T  ACGTTGGATGACATACGATATCCTTTGGCG ACGTTGGATGCCTCGCTGAGGGAACGGAC AGGGAACGGACCCCCGGTAA 
BMP2_11292G_A  ACGTTGGATGACAATCCAGTCATTCCACCC ACGTTGGATGCGGAAACGCCTTAAGTCCAG cctCCTTAAGTCCAGCTGTAA 
BMP4_5619C_T  ACGTTGGATGAGCACTGGTCTTGAGTATCC ACGTTGGATGAGAGACTGACCTTCGTGGTG gttGTGGAAGCTCCTCACGGT 
BMP4_3036C_T  ACGTTGGATGGAGTCGAGAAAACGGTGAAC ACGTTGGATGAATAAGGGAAGCCGAGGCGA acgaAGAGGTCGAGCGCAGGC 
BMP4_3071C_A  ACGTTGGATGTTCACCGTTTTCTCGACTCC ACGTTGGATGTGTGGCCGAGGTTTTACAAC cgccGAAAGGAAATCCCACCAT 
BMP2_12528delATTT  ACGTTGGATGAAATTGATATCTCGTGGCCC ACGTTGGATGGCTCTCAGATGAGGTAAAGG tAGGTAAAGGTAAAACACAAAT 
Smad6_2274C_T  ACGTTGGATGAAGCTGTGGCAGCCGCAC ACGTTGGATGTGCTGCTCGGCCGCCTCTTT aagaGCTGGCCCGACCTGCAGCA 
BMP4_795G_C  ACGTTGGATGTGAGGGACGCGAGCCTGAGA ACGTTGGATGTTGGACGGGAATCCCATCG aatctGGGAGACAAGCTAGATACT 
Smad6_15336C_G  ACGTTGGATGCAGTGGTTTCTGTGTCTCTC ACGTTGGATGGACAGAGGACTCCAAACCAC cccaaTCCAAACCACGGTTCCCTCG 
BMP4_2912G_C  ACGTTGGATGGAAGGAGTATTTGCTGCGTG ACGTTGGATGTTCCTTCCCCCACCCCCTTC gaaCCTTCCTCCGTTGCACCAGCAG 
 
11-Plex Primers 
SNP_ID PCR_P1 Primer Sequence (5’      3’) PCR_P2 Primer Sequence (5’       3’) EXT Primer Sequence (5’     3’) 
Smad6_1274G_C  ACGTTGGATGAGCGGCTACATGGACCACAG ACGTTGGATGCCGCCTGCAGCCCCCCTA TCAACAACTCCAGCCCC 
BMP4_2912G_A  ACGTTGGATGTTCCTTCCCCCACCCCCTTC ACGTTGGATGGAAGGAGTATTTGCTGCGTG CTCCGTTGCACCAGCAG 
Smad6_1624G_A  ACGTTGGATGGACTTTGGCGAAGTCGTGTG ACGTTGGATGTCCCATCCTCGTCGCCGCCA CGAAGTCGTGTGGTCCCC 
BMP4_6756G_A  ACGTTGGATGGGGGCTTCATAACCTCATA ACGTTGGATGTGGACCAGGGCCCTGATTG TGTTTATACGGTGGAAGC 
BMP4_5670G_A  ACGTTGGATGTTTCACTGCCCCTCTAGCCA ACGTTGGATGTTCCACCACGAAGGTCAGTC CCAGTCCCACCAGCCCTCC 
BMP2_1044delTGT  ACGTTGGATGTTTCTCCCTTCCCTTCCCTGC ACGTTGGATGAAGAAGTCCCCAGCCAAGTG TCCCCCTGCTCGCTGTTGT 
BMP4_3071C_T  ACGTTGGATGTGTGGCCGAGGTTTTACAAC ACGTTGGATGTTCACCGTTTTCTCGACTCC ccGAAAGGAAATCCCACCAT 
BMP2_480C_T  ACGTTGGATGGGATCGGCTCCGGAGTCCC ACGTTGGATGAGCGCCGTGGCCTCTGCT TCCCCGGCGCTCTGCGCGCCC 
BMP2_11547A_G  ACGTTGGATGTCTCGATGCTGTACCTTGAC ACGTTGGATGACACCCACAACCCTCCACAA CGAGAATGAAAAGGTTGTATT 
BMP4_4140C_T  ACGTTGGATGGAACAAACTTGCTGGAAAGG ACGTTGGATGTTAGGAGCCATTCCGTAGTG ccACTTGCTGGAAAGGCTCAGG 
Smad6_1136A_T  ACGTTGGATGAAAGCCCATGTAGTTAAGCG ACGTTGGATGGAACCCCTAAATGTGTCTGG GGTTTAAAAAAAAGGCAAGGTA 
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5-Plex Primers 
SNP_ID PCR_P1 Primer Sequence (5’      3’) PCR_P2 Primer Sequence (5’       3’) EXT Primer Sequence (5’     3’) 
Smad6_1683C_T  ACGTTGGATGTGGCGGCGACGAGGATGGGA ACGTTGGATGTGGCGGCGACGAGGATGGGA GAGGATGGGAGCTTGGG 
Smad6_80159T_A  ACGTTGGATGTCTCTTCCTCCTTCCTCTTC ACGTTGGATGTCTCTTCCTCCTTCCTCTTC TCCTTCCTCTTCCTTACTTT 
BMP2_713G_A  ACGTTGGATGCTCGACTCGCCGGAGAATG ACGTTGGATGCTCGACTCGCCGGAGAATG GAATGCGCCCGAGGACGACG 
BMP4_3036C_G  ACGTTGGATGAATAAGGGAAGCCGAGGCGA ACGTTGGATGAATAAGGGAAGCCGAGGCGA acgaAGAGGTCGAGCGCAGGC 
BMP4_7611A_T  ACGTTGGATGGGTCAAGGTGAATGTTTAGG ACGTTGGATGGGTCAAGGTGAATGTTTAGG TGAATGTTTAGGGATTTTTTCC 
 
Table 2.3  Primers used for Sequenom assay.   
PCR_P1 primers and PCR P2 primers were used to amplify the fragments of interest and extension primers (EXT primer) for iPLEX reaction to 
identify the SNP alleles.  
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2.2.8.2 Taqman genotyping  
 
SMAD6 c.1451G>T was genotyped using a Custom designed TaqMan® SNP 
Genotyping Assay (Applied Biosystems), following the manufacturer’s design and 
ordering guide. A file of the SNP and about 300bp of sequence surrounding the SNP 
was prepared and verified that met the manufacturer’s criteria for allele frequency, 
length, accuracy and uniqueness. The file was then uploaded into Filebuilder software 
(Applied Biosystems) and submitted to Applied Biosystems for Custom TaqMan® 
Assay Design. The sequences for the primers and probes are listed in Table 2.4.  
 
The reactions were conducted in a 384-well skirted plate (ABgene). Each well 
contained a single 5µl reaction which consisted of 1x TaqMan ® Universal PCR Master 
Mix, with no AmpErase® UNG (Applied Biosystems), 1x Assay Mix (Applied 
Biosystems), 20ng of DNA and ddH2O.  
 
The thermal cycler conditions started with 95°C for 10 minutes, followed by 40 cycles 
of 92°C for 15 seconds and 60°C for 1 minute. The plates were then read with a 
7900HT Fast Real-Time PCR System (Applied Biosystems). 
 
 
Primers/ Probes 5’      3’ Sequence 
S6_79800GT-S6GTForward AGCGTCCGCATCAGCTT 
S6_79800GT-S6GTReverse GGGCCGCCACTATCTGG 
S6_79800GT-S6GTV1_VIC ACCTCCTGCCCCTGC 
S6_79800GT-S6GTM1_FAM CACCTCCTTCCCCTGC 
 
Table 2.4 Primers and probes for TaqMan assay 
Sequences of the PCR primers and probes used for the TaqMan assay to genotype 
SMAD6 c.1451G>T variant.  
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2.3 In silico analysis of novel rare variants 
 
Non-synonymous genetic variants were analysed for evolutionary conservation using 
ClustalW2 programme from EMBL-EBI (European Bioinformatics Institute) 
(http://www.ebi.ac.uk/Tools/clustalw2/index.html). Protein sequences of the organisms 
were taken from Ensembl and were uploaded into the programme for protein alignments. 
 
The potential functional effect of the non-synonymous genetic variants were analyzed 
with the SIFT (http://blocks.fhcrc.org/sift/SIFT.html) and PolyPhen 
(http://genetics.bwh.harvard.edu/pph/) programmes to predict whether the substitutions 
were likely to affect protein structure and subsequently protein function. 
 
The splicing effects for all of the genetic variants were predicted by the ESE finder 3.0 
programme (http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi?process=home), to 
identify whether they were likely to result in changes of splice sites (Cartegni et al. 
2003; Smith et al. 2006). This program predicts whether variants increase or decrease 
the threshold value in the splice donor site, splice acceptor site and branch site.  
 
Another in-house programme generated by Dr. S. Grellscheid (Grellscheid, unpublished) 
was utilized to predict whether the genetic variants were likely to result in changes of 
splice sites. This programme plots the calculated strength of exonic splice enhancer 
(ESE) versus exonic splice silencer (ESS) sites using a custom Python script to generate 
a z-score for each nucleotide position for the wild type and mutant variants. These are 
compared graphically to estimate the effect of the variants on splicing.  
 
Analysis of the crystal structure of the SMAD6 C484F variant was carried out in 
collaboration with Professor Rick Lewis of Institute for Cell and Molecular  
Biosciences, Newcastle University.  Homology modelling of the MH2 domain of 
SMAD6 was implemented using the ‘Coot’ software package using SMAD2 as a 
template. 
 
Variants that were identified in the 3’UTR of the candidate genes were checked for their 
miRNA target binding sites and expressions using MicroCosm Targets version 5 
(formerly miRBase Targets) http://www.ebi.ac.uk/enright-
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srv/microcosm/htdocs/targets/v5/ that contains computationally predicted targets for 
microRNAs in many species.  
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2.4 Investigation of the effects of novel rare variants on splicing  
2.4.1 Experimental design 
 
Minigene approach was utilized to investigate the effects of certain novel variants 
predicted to affect splicing. The minigene approach consists of inserting an exon of 
interest, namely the one in which the novel variant was found, and its flanking introns 
into a vector containing a constitutive small ‘gene’ and thus creating a new artificial 
minigene which includes the relevant exon.  
 
The pXJ41 vector was used as backbone for the minigene construct. pXJ41 harbours a 
human cytomegalovirus (hCMV) promoter that drives the expression of the inserted 
gene; rabbit β-globin intron II containing an MfeI site, which facilitates the splicing 
event and is flanked by fragments of rabbit β-globin exon 2 and exon 3; T7 promoter; a 
multiple cloning site (MCS); SV40 polyadenylation site; and BSM13+ sequence that 
include an origin of replication and the ampicillin resistance gene (Xiao et al. 1991) 
(Figure 2.6).   
  
The fragment to be cloned into the vector is selected so that it comprises around 500 
nucleotides upstream and downstream of the exon of interest. Oligonucleotides were 
designed so that after amplification a restriction site would be included at the flanking 
sites of the region of interest. Thus, the oligonucleotide consisted six nucleotides 
(GAGAGA) were included as the first nucleotides of the oligonucleotides, followed by 
the restriction sites and 18-20 nucleotides that were complementary to the fragment of 
interest. Six nucleotides were included because restriction enzymes do not cleave 
efficiently at the end of the molecule. PCRs were performed using high fidelity 
polymerase in order to obtain an error-free amplicon.  
 
Both the wild type and the variant genomic regions (from control and patient’s DNAs 
respectively) were amplified and cloned into the vector, in order to generate two 
“alleles” of the minigene construct. The effect of the relevant variants can be 
determined by comparing the mRNAs produced by a human cell line transiently 
transfected with the two alleles of the minigene construct. Figure 2.7 shows the method 
schematically and Figure 2.8 an example from the literature of this system in use. 
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Figure 2.6 Map of pXJ41 vector  
Map of pXJ41 vector with a human cytomegalovirus (hCMV) promoter, rabbit β-globin 
intron II, T7 promoter, a multiple cloning site (MCS), SV40 polyadenylation site and 
BSM13+ sequence.  
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Figure 2.7 Overview of in vivo splicing analysis with the minigene approach 
(Adapted from Stoss et al., 1999) (Stoss et al. 1999) 
A) Using high-fidelity Taq polymerase, the alternatively spliced exon (black box) and 
its flanking intronic regions (±500bps) were amplified from control and patient’s 
genomic DNA and cloned into pXJ41. B) Resulting wild type and mutant mingene 
constructs, where the exon of interest was flanked by fragments β-globin exon 2 and 
exon 3. C) 24 hours after transfection, mRNA is analyzed by RT-PCR using primers of 
the flanking exons. D) Possible PCR products are shown, depending on whether the 
relevant exon was spliced out correctly. 
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Figure 2.8 Example of the splicing pattern of TLE4 pre-mRNA (Extracted from 
Liu et al., 2009) (Liu et al. 2009) 
RT-PCR analysis of the splicing pattern of the TLE4-T minigene from cells co-
transfected with different splicing factors along with a constant amount of Tra2β. Tra2β 
activated the splicing to TLE4-T and also induced splicing inclusion of a further TLE4-
B splicing isoform annotated as TLE4-B. The upper bands on the agarose gel 
correspond to the product including TLE4-B, the middle bands include TLE4-T and the 
lower bands correspond to the flanking exons.   
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2.4.2 Media and reagents 
 
LB medium was prepared by adding 5g of tryptone, 2.5g of yeast extract and 5g of 
NaCl to 500ml of ddH2O. Medium was then autoclaved. 
 
LB agar was prepared by adding 15g of agar to 1litre of LB media. The media was 
autoclaved and allowed to cool to around 55°C. 100mg/ml of ampicillin was then added 
to the cooled media, mixed well, and poured into petri-dishes. LB agar plates were 
stored at 4°C for later use. 
 
NZY+ broth was prepared as described in the QuickChange® Site-Directed 
Mutagenesis Kit instruction manual. Briefly, NZY+ broth consisted of 10g of NZ amine, 
5g of yeast extract and 5g of NaCl to 1litre of ddH2O. pH was adjusted to pH7.5 using 
5M NaOH. Medium was then autoclaved. Prior to use, filter-sterilized supplements of 
12.5ml of 1M MgCl2, 12.5ml of 1M MgSO4, and 20ml of 20% glucose were added to 
the medium.          
 
 
2.4.3 Cloning 
 
2.4.3.1 Primer designs and PCR 
 
Primers were designed as in section 2.2.1 to amplify the exon of interest plus 500bp 
flanking intronic sequences. In view of the requirement for downstream applications, a 
restriction map for the fragment to be amplified was obtained. If the region to be 
amplified did not contain an EcoRI site, an EcoRI recognition sequence was added to 
the 5’ end of both primers (5’ – GAGAGAGAATTC – 3’). However, if the region 
contained an EcoRI site, an MfeI recognition sequence was added instead to the 5’ end 
of both primers (5’ – GAGAGACAATTG – 3’).  
 
PCR was carried out using Phusion High-Fidelity DNA Polymerase (Finnzymes). PCR 
reactions were set up on ice. The master mix comprised 1x of 5x Phusion GC Buffer 
(for regions with high GC content); 200µM of each dNTP, 0.5µM of each primer 
(forward and reverse), 0.02U/µl of Phusion DNA Polymerase, 30ng of DNA (proband 
with the variant identified) and ddH2O to a final volume of 50µl. 
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The PCR cycling programme started with initial denaturation at 98°C for 30 seconds, 
followed by 35 cycles of 98°C for 10 seconds, annealing temperature (69.6°C)  for 30 
seconds and 72°C for 30 seconds (depending on the amplicon’s length). A final 
extension of 72°C for 5 minutes concluded the programme. Primer sequences and 
primer pairs are listed in Table 2.5. 
 
The PCR amplicon was then purified using QIAquick PCR Purification Kit (QIAGEN), 
following manufacturer’s protocol. Concentration of the purified PCR amplicon was 
determined by NanoDrop spectrophometer. 
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Cloning Primers Sequence (5’      3’) 
MG-BMP4DF (EcoRI) GAGAGAGAATTCGGCATCCACGGTCGGGAGGG 
MG-BMP4AR (EcoRI) GAGAGAGAATTCGCTCCCAATGACAGCCAGTC 
MG-BMP4EF (MfeI) GAGAGACAATTGAGCACGACGCACCGCGCCGA 
MG-BMP4BR (MfeI) GAGAGACAATTGGCTAACCGGGTGGCTTGAGG 
MG-BMP4ER (MfeI) GAGAGACAATTGGAAGCCGAGAAGGTGGTCTGG 
MG-BMP4FF (MfeI) GAGAGACAATTGGTTCGAGCTGGGAGACGCAG 
MG-BMP4FR (MfeI) GAGAGACAATTGTCCGGAGAGACCTCTGTGAG 
MG-BMP4GF (MfeI) GAGAGACAATTGATCCTCTGGCTTCAGGTGGC 
MG-BMP4GR (MfeI) GAGAGACAATTGCAGTTGGTTCAGAGCCAGAGG 
 
 
Novel Variants Cloning Primer Pairs 
BMP4 c.-295G>A MG-BMP4DF/4AR 
BMP4 c.-136C>G MG-BMP4DF/4AR 
BMP4 c.-87C>T MG-BMP4EF/4BR 
BMP4 c.-87C>T MG-BMP4EF/4ER 
BMP4 c.-87C>T MG-BMP4FF/4FR 
BMP4 c.-87C>T MG-BMP4GF/4GR 
BMP4 c.-87C>T MG-BMP4FF/4GR 
BMP4 c.-87C>T MG-BMP4GF/4FR 
 
Table 2.5 Cloning primers sequences and the combination of primer pairs  
Sequences of the primers used for cloning and the combination of primer pairs for each 
novel variants: BMP4 c.-295G>A, BMP4 c.-136C>G and BMP4 c.-87C>T. 
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2.4.3.2 Restriction enzyme digestions 
 
The purified PCR amplicon was digested with MfeI or EcoRI (NEB) as described in the 
manufacturer’s protocol. The digestion reaction consisted of 5µl of NEBuffer 4, 1.5µl 
of MfeI or EcoRI, (0.5µl of BSA was added for EcoRI reactions), 1µg of purified PCR 
product, and ddH20 to a final volume of 50µl. In parallel, 1µg of vector pXJ41 was 
digested with MfeI. The vector pXJ41 was obtained from Prof. David Elliott, Institute of 
Human Genetics. The reaction was incubated at 37°C for 3 hours and deactivated at 
65°C.  
 
 
2.4.3.3 Dephosphorylation of vector 
 
The linearized minigene vector pXJ41 was treated with phosphatase. 1x Antartctic 
Phosphatase Reaction Buffer (NEB) and 1µl of Antarctic Phosphatase (NEB) were 
added to 1µg of linearized vector. The reaction was mixed and incubated for 40 minutes 
at 37°C. The reaction was then heat inactivated for 20 minutes at 80°C.  
 
 
2.4.3.4 Ligation 
 
Before ligation, insert DNA and vector DNA were purified using the QIAquick PCR 
Purification Kit (QIAGEN), following the manufacturer’s protocol. The vector and 
insert DNA were ligated using T4 DNA Ligase (Promega). The molar ratio of vector to 
insert DNA was 1 to 3. If the ligation was not successful, different molar ratios were 
used. The reaction consisted of 1x Ligase Buffer, 20units of T4 DNA Ligase, 100ng of 
vector DNA, 100ng of insert DNA and ddH20 to a final volume of 20µl. The reaction 
was incubated at 4°C overnight and was deactivated at 65°C for 20 minutes.  
 
 
2.4.3.5 Transformation of competent cells 
 
Ligation mixtures were transformed into JM109 competent cells (Promega), following 
the product’s technical bulletin. Competent cells were thawed on ice and then 50µl of 
cells were transferred to a chilled eppendorf tube which contained 5µl ligation product 
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(approximately 100ng). The tube was flicked gently to mix and incubated on ice for 30 
minutes. The cells were then heat-shocked for 90 seconds at 42°C and incubated on ice 
for 15 minutes. 500µl of LB medium was added to each transformation reaction and 
incubated for 60 minutes at 37°C with constant shaking at 200rpm. 50µl of cell culture 
was spread onto LB-Amp agar plate. The tube was spun down at 1864g for 1 min, most 
of the LB medium discarded, the pellet resuspended in the remaining LB medium and 
spread onto another LB-Amp agar plate. The plates were then incubated upside down at 
37°C for 12-14 hours.   
 
 
2.4.3.6 Screening PCR 
 
Ampicillin-resistant colonies were individually picked and screened for insertion of the 
amplicon using colony PCR. A library of the colonies picked was kept. 1µl of colony 
DNA was used to perform PCR. PCR reactions were performed using HotStarTaqTM 
DNA Polymerase (Qiagen) as section 2.2.2, with vector primers pXJ_B1 5’ – 
GTAACCATTATAAGCTGCAA – 3’ and pXJ_RTF 5’ – 
GCTCCGGATCGATCCTGAGAACT – 3’, the annealing temperature was 58°C for 30 
seconds and the elongation temperature was 72°C for 1 minute and 30 seconds. 
Amplified PCR products were then run on 1% gel alongside 1kb DNA Ladder 
(Fermentas) as in section 2.2.3. Positive colonies were identified by the size of the 
amplification products, which were around 1.5kb (when the exon was inserted). The 
size of the empty plasmid was around 200bp. Positive colonies underwent another PCR 
amplification using a forward primer complementary to the region of interest and a 
reverse vector primer (pXJ_RTF) or a forward vector primer (pXJ_B1) and a reverse 
primer on the region of interest. Only positive colonies containing the fragments 
inserted in the correct orientation will produce amplified products.  
 
 
2.4.3.7 Sequencing of insertions 
 
Positive colonies with the insert cloned into pXJ41 vector in the correct orientation were 
cultured in LB medium containing 50mg/ml Ampicillin at 37°C for 16 hours. DNA was 
then extracted using the QIAprep Spin Miniprep Kit (Qiagen) following the 
manufacturer’s protocol. The plasmid was sent to MWG for sequencing with pXJ_B1 
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and pXJ_RTF primers to confirm the inclusion and the correct direction of the region of 
interest. 
 
 
2.4.4 Transfection of HEK293 cells 
 
HEK293 cells were cultured in Dulbecco’s modified Eagle’s medium (Invitrogen) 
supplemented with 10% fetal bovine serum (FBS). Cells were grown at 37°C in a 5% 
CO2 humidified atmosphere and were passaged every 3 days. HEK293 cells were 
seeded in 6-well plates (Nunc Corporation) for 24 hours before transfection. Cells were 
approximately 70% confluent when transfected. For each well, 500ng of plasmid DNA 
was added to 97µl of DMEM medium without serum and was mixed with 3µl of 
GeneJammer (Stratagene). The transfection reaction was incubated for 15 minutes at 
room temperature. The reaction was then added to the cells maintained in 2ml of 
DMEM with FBS drop by drop. Cells were incubated at 37°C in 5% CO2 for another 24 
hours after transfection.  
 
 
2.4.5 RNA Extration 
 
24 hours after tranfection, cells were trypsinised and centrifuged at 3300g for 2 minutes. 
The media was removed and cell pellets were resuspended in 100µl of Trizol 
(Invitrogen) in a hood and vortexed. 20µl chloroform was added and mixed vigorously 
for 15 seconds. The tube was then left at room temperature for 2 minutes and 
centrifuged at 15700g for 15 minutes at 4°C. The aqueous layer was transferred to a 
new eppendorf tube. RNA was precipitated by adding 50µl of 100% isopropanol and 
vortexed for a few seconds. The mixture was then left at room temperature for 15 
minutes and centrifuged at 15700g for 10 minutes at 4°C. The supernatant was 
discarded and the pellet was washed with 100µl of 70% ethanol. The mixture was 
centrifuged at 9300g for 8 minutes at 4°C. Ethanol was then discarded and pellets were 
air-dried for 10 minutes. Pellets were resuspended in 60µl of RNAse free water and the 
concentration of RNA was determined using NanoDrop spectrophometer. 
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2.4.6 Reverse Transcription PCR 
 
RT-PCR was performed using OneStep RT-PCR Kit (Qiagen) following manufacturer’s 
protocol. 5µl RT-PCR reaction consisted of 1x of OneStep RT-PCR buffer, 1x Q 
solution, 10mM of dNTPs, 0.2µl of HotStarTaq DNA Polymerase, 10mM of pXJ41_B1 
primer, 10mM of pXJ_RTF primer (the sequences of the primers are described in 
section 2.4.2.6) and 50ng of RNA.   
 
The thermal cycler programme was 50°C for 30minutes, and then 95°C for 15minutes, 
followed by 25cycles of 94°C for 30seconds, 56°C for 30seconds and 72°C for 1minute, 
with a final extension at 72°C for 10minutes. 
 
The PCR products were resolved on 1% agarose gel with gel red by electrophoresis to 
visualize bands under UV.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 88
2.5 Luciferase assay of SMAD6 variants 
2.5.1 Experimental design 
 
The effects of the novel coding variants discovered in SMAD6 on BMP signaling were 
investigated by dual luciferase assay. The constitutively active form of the BMP type I 
receptor used in these experiments, c.a.BMPR1A, was described by Fujii and colleagues 
(Fujii et al. 1999). The BMPR1A cDNA was mutagenised so that an amino acid 
substitution was created at position 233 of the translated protein when subcloned into 
pcDNA3. The glutamine to aspartic acid change results in the activation of BMPR1A in 
the absence of ligands or the type I receptor. The c.a.BMPR1A was sequenced by me 
before use to confirm the presence of the mutation in the construct. The c.a.BMPR1A 
construct also contained a HA tag [YPYDVPDYA] at the C-terminal.  
 
BRE-Luc was the luciferase reporter construct used to measure the transcriptional 
activation induced by BMP signaling (Korchynskyi and ten Dijke 2001). BRE-Luc 
consists of two Smad binding elements (SBEs) and a GGCGCC palindromic sequence 
flanked by two CAGC and two CGCC sites cloned into pGL3-basic vector. The pGL3 
luciferase reporter vector contains a modified coding region for firefly (Photinus pyralis) 
luciferase. This vector lacked promoter and enhancer sequences, meaning that the 
luciferase reporter gene activity obtained would be solely driven by the inserted BMP-
responsive elements. The Renilla luciferase cDNA, encoding the renilla luciferase from 
the marine organism sea pansy (Renilla reniformis), was contained within the pRL-TK 
vector. The luciferase activity was normalised against Renilla luciferase activity, which 
acted as an internal control for transfection efficiency.  
 
Wild-type SMAD6C inhibits BMP signaling through at least three possible mechanisms 
(see below). Goto and colleagues have previously utilized this system to investigate the 
effects of inhibitory Smads (Smad6 and Smad7) on BRE-Luc induced by c.a.BMPR1A 
or c.a.ALK2 in C2C12 cells (Goto et al. 2007).     
 
The genetic variants p.Ala325Thr (c.973G>A), p.Pro415Leu (c.1244C>T) and 
p.Cys484Phe (c.1451G>T), were introduced into SMAD6 expression constructs using 
site-directed mutagenesis. The wild-type SMAD6 construct (SMAD6C) used which 
consists of the MH2 domain of SMAD6 inserted into a pcDNA3 vector, has been 
previously reported (Hanyu et al. 2001). The construct was FLAG tagged 
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[DYKDDDDK] at the N-terminal end of SMAD6. The presence of mutations was 
confirmed by sequencing. Each of the constructs was then transfected into the cell 
system along with BMP-responsive element luciferase reporter (BRE-Luc), Renilla 
luciferase reporter (REN) and constitutively active BMPR1A (c.a.BMPR1A).  The 
experimental system is summarized in Figure 2.9.  
 
There were six combinations of constructs used in this assay (Table 2.6). All of these 
combinations contained BRE-Luc and Renilla constructs. The first combination 
contained empty vector pcDNA3.1, which acted as a negative control. The second 
combination contained c.a.BMPR1A and pcDNA3.1, which acted as a positive control. 
The subsequent combination of constructs contained c.a.BMPR1A and either 
wtSMAD6C, SMAD6C p.Ala325Thr (c.973G>A), SMAD6C p.Pro415Leu (c.1244C>T) 
or SMAD6C p.Cys484Phe (c.1451G>T). This combination was selected to enable the 
identification of any difference in the ability of the wild-type and mutant constructs to 
inhibit the activation of BRE-Luc activity. 
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Figure 2.9  BMP signaling in C2C12 cells for luciferase assay  
BMP signaling in the system of C2C12 cells that were transfected with different 
combination of constructs for luciferase assay. The constructs that were transfected are 
in red colour.   
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     Combinations 
 
Constructs 
1 2 3 4 5 6 
BRE-Luc       
Renilla       
pcDNA3.1       
c.a.BMPR1A       
SMAD6C wt       
SMAD6C 
p.Ala325Thr 
(c.973G>A) 
   
 
  
SMAD6C 
p.Pro415Leu 
(c.1244C>T) 
    
 
 
SMAD6C 
p.Cys484Phe 
(c.1451G>T) 
     
 
 
Table 2.6 Combination of constructs for luciferase assay  
The combinations of constructs that were used in the luciferase assay. 
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2.5.2 Cell lines and tissue culture 
 
Mouse myoblast C2C12 cells were maintained in Dulbecco’s modified Eagle’s medium 
(Invitrogen) in 10% fetal bovine serum (FBS) with 50 units/ml penicillin and 50µl/ml 
streptomycin (Invitrogen). Cells were grown at 37°C in a 5% CO2 humidified 
atmosphere and were passaged every 2 days; split at a ratio of 1:10. The cells were 
detached from the flasks using 0.05% Trypsin (1X) with EDTA (Invitrogen). 
 
 
2.5.3 Constructs 
 
The four constructs were as follow: (1) a luciferase reporter construct containing BMP-
responsive elements (BRE-luc), which was previously described by Korchynskyi and 
ten Dijke, 2002 (Figure 2.10) (Korchynskyi and ten Dijke 2001); (2) pRL-TK Renilla 
luciferase reporter; (3) constitutively active BMPR1A, which was described by 
Miyazono 1999 (Figure 2.11) (Miyazono 1999); and (4) SMAD6C wild type, described 
by Hanyu et. al., 2001 (Figure 2.12) (Hanyu et al. 2001). All these were kindly donated 
by Prof. Peter ten Dijke, Leiden University Medical Center, Leiden, The Netherlands. 
Empty vector pcDNA3.1 (Invitrogen) was used as control. Constitutively active 
BMPR1A and SMAD6C wild type were sent to GATC to confirm their sequences. 
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Figure 2.10 BRE-Luc inserted at NheI site in pGL3-basic vector circle map 
Map of the BMP-responsive elements luciferase (BRE-Luc) vector inserted at NheI site 
in pGL3-basic vector, which lacks promoter and enhancer sequences. 
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Figure 2.11 c.a.BMPR1A with HA tag inserted at EcoRI and XhoI sites in 
pcDNA3  
Map of the c.a.BMPR1A vector with HA tag in pcDNA3. The BMPR1A cDNA was 
mutagenised so that an amino acid substitution was created at position 233 in the 
serine/threonine kinase domain. 
 
 
Insert: c.a.BMPR1A (HA tag) 
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Figure 2.12 SMAD6C wild type with FLAG tag inserted at BamHI and XhoI 
sites in pcDNA3  
The wild type SMAD6 construct (SMAD6C) consists of the MH2 domain of SMAD6 
inserted into a pcDNA3 vector.  
 
 
 
 
 
 
Insert: wtSMAD6C  (FLAG tag) 
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2.5.4 Site-directed mutagenesis 
 
Site directed mutagenesis was performed using the QuickChange® Site-Directed 
Mutagenesis Kit (Stratagene). Mutagenic primers were designed using Stratagene’s 
primer design programme at http://www.stratagene.com/qcprimerdesign.  HPLC 
primers were ordered from Metabion. Primer sequences and conditions are listed in 
Table 2.7. 
 
SMAD6 sample reactions comprised of 1x reaction buffer, 50ng of construct DNA, 
125ng of each mutagenic primer, dNTP mix, 2.5U of Pfu DNA polymerase and ddH2O 
to a final volume of 50µl. 50µl control reaction comprised of 1x reaction buffer, 10ng of 
pWhitescript 4.5kb control plasmid, 125ng of each control primer, dNTP mix, 2.5U of 
Pfu DNA polymerase and ddH2O. 
 
The thermal cycling programme started at 95°C for 30 seconds, followed by 12 cycles 
of 95°C or 97°C for 30 seconds (depending on the primer sets), 55°C for 1 minute and 
68°C for 6 minutes or 10 minutes. 5µl of amplified product were run on 1% agarose gel 
to check for product amplification. 1µl of Dpn I restriction enzyme (10U/µl) was added 
to each reaction. Reactions were incubated at 37°C for 1 hour to digest the parental 
dsDNA. Resulting constructs were transformed into XL1-Blue supercompetent cells 
(Stratagene) as described in the QuickChange® Site-Directed Mutagenesis Kit 
instruction manual. 500µl of NZY+ broth preheated to 42°C was added to the 
transformation reactions and was incubated at 37°C for 1 hour with shaking at 225rpm. 
250µl of cell culture was spread onto LB-Amp agar plate. The plates were then 
incubated upside down at 37°C for 16 hours. 
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Primer pairs Primer (5’      3’ Sequence) Denaturing  Elongation  
 Forward Reverse Temp. (°C) Time (min) 
SMAD6_C484F_G307T ggcagttcatcacctccttcccctgctgg ccagcaggggaaggaggtgatgaactgcc 95 6 
SMAD6_A325T_G475A catgtctccggacaccaccaagccgag ctcggcttggtggtgtccggagacatg 97 10 
SMAD6_P415L_C746T ttcgtcaactccctgacgctggacgcg cgcgtccagcgtcagggagttgacgaa 97 10 
 
Table 2.7 Primers and reaction conditions used for the site-directed mutagenesis. 
Sequences of the primers and the PCR conditions used for the site-directed mutagenesis to generate variants SMAD6 p.Ala325Thr 
(c.973G>A), SMAD6 p.Pro415Leu (c.1244C>T) and SMAD6 p.Cys484Phe (c.1451G>T). 
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2.5.5 Sequencing of constructs 
 
XL1-Blue cell positive colonies were picked and were incubated with NZY+ broth 
containing 50mg/ml Ampicillin at 37°C for 16 hours. Construct DNA was then 
extracted using the QIAprep Spin Miniprep Kit (Qiagen) following the protocol. The 
constructs were nanodropped to determine the concentration before sending to GATC 
for sequencing with T7 and Sp6 primers in order to identify the mutations. 
 
 
2.5.6 Transfection of C2C12 cells 
 
C2C12 cells were seeded in 12-well plates (Nunc Corporation) for 24 hours before 
being transfected with plasmid DNA using FuGENE® HD Transfection Reagent 
(Roche) according to the manufacturer’s protocol. The combination of constructs 
consisted of 450ng of BRE-luc (Firefly luciferase reporter with BMP Responsive 
Elements), 50ng of pRL-TK (Renilla luciferase reporter) and 500ng of pcDNA3.1 
(empty plasmid as control) or 250ng of caBMPR1A (constitutive active BMPR1A) with 
either 250ng of pcDNA3.1, 250ng of SMAD6 wild type or 250ng of SMAD6 mutant 
constructs. Each combination of constructs was carried out in triplicate. Cells were 
incubated at 37°C in 5% CO2 for another 24 hours after transfection. 
 
 
2.5.7 Measurement of luciferase acitivity 
 
Cells were lysed and luciferase activity measurement was performed using the Dual-
Luciferase Reporter Assay System (Promega) according to the manufacturer’s protocol. 
A Fluoroskan Ascent plate reader (Thermo Scientific) was utilised to read the 
luminescence activities of the cells. Firefly luminescence signal was measured first, 
followed by Renilla luciferase. The firefly luminescence readings were then normalized 
to the Renilla luciferase, to account for experimental variability caused by differences in 
cell viability or transfection efficiency.  
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2.5.8 Immunoblotting 
 
1x NuPAGE® Sample Reducing Agent (Invitrogen) and 1x NuPAGE® LDS Sample 
Buffer (Invitrogen) were added to 15µl of previously lysed cells, which were then 
heated at 95°C for 10 minutes and allowed to cool. 4–12% NuPAGE® Novex Bis-Tris 
Gel (Invitrogen) was assembled in 1x MES SDS Running Buffer (Invitrogen) following 
NuPAGE® Technical Guide (Invitrogen). Samples were loaded into the wells alongside 
10µl of PageRulerTM Prestained Protein Ladder (Fermentas) and were run at 200V until 
the yellow loading buffer tide line reached the bottom of the gel. 
 
Two pieces of filter paper (8cm x 10cm), a piece of Hybond-C Extra nitrocellulose 
membrane (7cm x 9cm) (GE Healthcare) and 2 pieces of sponge were soaked in pre-
cooled transfer buffer (2.93g Glycine, 5.81g Tris Base, 3.75ml 10% SDS, 200ml 
Methanol, made up to 1litre with ddH2O). The transfer apparatus was set up on the 
black part of the cassette in the following order: 1 piece of sponge, 1 filter paper, gel, 
membrane, 1 filter paper, 1 piece of sponge; to form the gel sandwich. The cassette was 
then placed into a transfer tank filled with chilled transfer buffer and an ice block. 
Samples were transferred onto the membrane at 350mA for 1 hour. 
The membrane was then stained with Ponceau-S solution (Sigma) to check for protein 
transfer. The membrane was cut into two at around 40kDa and was rinsed with ddH2O 
until the background was clean. It was then incubated in TBST (8.75g NaCl, 6.5g Tris-
HCl, 2ml Tween 20, made up to 1litre with ddH2O) with 5% marvel (non-fat dried milk) 
to block non-specific binding sites for 1 hour at room temperature or overnight in the 
cold room on a shaker. The membrane containing proteins of less than 40kDa was 
incubated with monoclonal anti-FLAG M2-Peroxidase (HRP) antibody produced in 
mouse (Sigma) at 1/10000 in blocking reagent for 2 hours at room temperature. The 
other part of the membrane was incubated with anti-HA-Peroxidase, High Affinity 
(3F10) (Roche) at 1/1000 in blocking reagent for 2 hours at room temperature. Three 
ten minutes washes in TBST were carried out and then both membranes were incubated 
with Supersignal® West Dura Extended Duration Substrate (Thermo Scientific) 
according to the manufacturer’s instructions for 5 minutes. The membranes were placed 
against Biomax MR Film (Kodak) for 5 seconds, which was then developed in a 
compact X4 developer (Xograph Imaging Systems).  
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The membrane which contained proteins larger than 40kDa was washed 3 times with 
TBST, for ten minutes each. It was then incubated with stripping buffer (6.7ml of 0.5M 
Tris-HCl pH6.7, 10ml 20% SDS, 780µl β-mercaptoethanol, made up to 100ml with 
ddH2O) at 50°C for 30–40 minutes with gentle agitation. The membrane was rinsed 
with ddH2O three times followed by extensive washing in TBST for 15 minutes. The 
membrane was then blocked in TBST with 5% marvel for 1 hour at room temperature 
or overnight at 4°C on shaker. Monoclonal anti-α-tubulin primary antibody (Sigma) 
diluted in blocking reagent 1/1000 was added to the membrane and incubated for 2 
hours at room temperature or overnight at 4°C. Three ten-minute washes in TBST were 
carried out. The membrane was then incubated for 1 hour with goat anti-mouse HRP 
secondary antibody (Thermo Scientific) diluted 1/1000 in blocking reagent. Following 
another three ten minutes washes in TBST, the relevant protein bands were detected by 
enhanced chemiluminescent (ECL) detection process as described above.  
 
This membrane (which contained proteins larger than 40kDa) was then washed, 
stripped and checked with ECL to ensure that the previous antibodies had been removed. 
The blot was then blocked as described above. Smad1 antibody (Santa Cruz) diluted in 
blocking reagent 1/50 was added to the membrane and incubated overnight at 4°C. 
Three ten-minute washes in TBST were carried out. The membrane was then incubated 
for 1 hour with goat anti-mouse HRP secondary antibody (Thermo Scientific) diluted 
1/300 in blocking reagent. After another three ten minutes washes in TBST, the protein 
bands were detected by the ECL detection process as above.  
 
The same membrane underwent the same process (washed, stripped, checked with ECL 
and blocked), before incubating overnight with phospho-Smad1/ Smad5/ Smad8 
antibody (Cell Signaling) at 1/1000 in blocking agent. Three ten-minute washes in 
TBST were carried out. The membrane was then incubated for 1 hour with goat anti-
rabbit HRP secondary antibody (Jackson ImmunoResearch) diluted in 1/10,000 in 
blocking reagent. Following another three ten minutes washes in TBST, the protein 
bands were detected by ECL detection process.   
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2.6 Alkaline phosphatase assay of SMAD6 variants 
2.6.1 Experimental design 
 
It has been reported by Katagiri and colleagues (Katagiri et al. 1994) that C2C12 cells 
will inhibit their myoblastic differentiation and convert to the osteoblastic 
differentiation pathway instead when treated with BMP2. The phenotype of one patient 
with a SMAD6 mutation included calcification of the aorta as a prominent feature. 
Therefore investigation on whether the SMAD6 mutations that were discovered failed 
to inhibit osteoblastic differentiation in vitro was performed. Extracellular bone matrix 
proteins and alkaline phosphatase (ALP) are expressed early during the commitment to 
the osteoblast lineage. To measure the inhibitory effect of wild-type and mutant 
SMAD6C constructs on osteoblastic differentiation, two experimental approaches were 
devised.  
 
In the first experiment, cells were transiently transfected with either empty vector 
pcDNA3.1, SMAD6C wt, SMAD6C p.Pro415Leu (c.1244C>T) or SMAD6C 
p.Cys484Phe (c.1451G>T). The transfected cells were then treated with exogenous 
BMP2 or BMP6 ligands to stimulate alkaline phosphatase activity (Figure 2.13). 
Alkaline phosphatase is an osteogenic marker that will reflect the commitment of 
myoblast cells to osteoblastic differentiation. Both BMP2 and BMP6 were utilized to 
stimulate the cells as it has been reported that Smad6 inhibits BMP2 signaling more 
efficiently than BMP6 signaling but BMP6 induced more sustained signaling than 
BMP2 (Goto et al. 2007). 
 
The second method of investigation of the inhibitory effect of wild type SMAD6 
compared to the mutant SMAD6C constructs on ALP activity was carried out in 
collaboration with Dr. Elise Glen. Cells were transfected with c.a.BMPR1A and either 
SMAD6C wt, SMAD6C p.Pro415Leu (c.1244C>T) or SMAD6C p.Cys484Phe 
(c.1451G>T) as Fujii and colleagues have reported that c.a.BMPR1A induced ALP 
activity in C2C12 cells (Fujii et al. 1999) (Figure 2.14).   
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Figure 2.13 BMP signaling in C2C12 cells stimulated with BMP ligands for 
alkaline phosphatase assay  
BMP signaling in the system of C2C12 cells that were transfected with either empty 
vector pcDNA3.1, SMAD6C wt, SMAD6C p.Pro415Leu (c.1244C>T) or SMAD6C 
p.Cys484Phe (c.1451G>T) and treated with BMP2 or BMP6 ligands to stimulate 
alkaline phosphatase transcription. The constructs that were transfected are in red colour 
and the stimulating molecules are in green.   
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Figure 2.14 BMP signaling in C2C12 cells transfected with c.a.BMPR1A for 
alkaline phosphatase assay  
BMP signaling in the system of C2C12 cells that were transfected with c.a.BMPR1A 
and either empty vector pcDNA3.1, SMAD6C wt, SMAD6C p.Pro415Leu (c.1244C>T) 
or SMAD6C p.Cys484Phe (c.1451G>T) for alkaline phosphatase assay. The constructs 
that were transfected are in red colour.   
 
 
 
 
 
 
 
c.a.BMPR1A 
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2.6.2 Transfection and stimulation of C2C12 cells with BMP ligands 
 
The cell lines and constructs used for this experiment are described in sections 2.5.2 – 
2.5.5. C2C12 cells were seeded in 12-well plates (Nunc Corporation) for 24 hours 
before transfecting with plasmid DNA using FuGENE® HD Transfection Reagent 
(Roche) according to the manufacturer’s protocol. The cells were transiently transfected 
with either 1µg of pcDNA3.1, 1µg of SMAD6 wild type, 1µg of SMAD6 p.Cys484Phe 
(c.1451 G>T) or 1µg of SMAD6 p.Pro415Leu (c.1244C>T). Each transfection was 
carried out in duplicate. The growth medium was replaced with DMEM containing 
2.5% FBS, 6 hours or 24 hours after transfection. Osteoblast differentiation of cells was 
induced by 300ng/ml recombinant human BMP-2 or BMP-6 in DMEM. The transfected 
and stimulated cells were then incubated at 37°C in 5% CO2 for another 60 hours or 48 
hours. 
 
 
2.6.3 Transfection of C2C12 cells with c.a.BMPR1A 
 
C2C12 cells were seeded in 12-well plates (Nunc Corporation) for 24 hours before 
transfecting with plasmid DNA using FuGENE® HD Transfection Reagent (Roche) 
according to the manufacturer’s protocol. The cells were transiently transfected with 
0.5µg of c.a.BMPR1A and either 0.5µg of pcDNA3.1, 0.5µg of SMAD6 wild type, 
0.5µg SMAD6 p.Cys484Phe (c.1451G>T) or 0.5µg of SMAD6 p.Pro415Leu 
(c.1244C>T). Each transfection was carried out in duplicate. The growth medium was 
replaced with DMEM containing 2.5% FBS, 24 hours after transfection. Osteoblast 
differentiation of cells was induced by the constitutively active BMPR1A. The 
transfected and stimulated cells were then incubated at 37°C in 5% CO2 for another 24 
hours. 
 
 
2.6.4 Measurement of alkaline phosphatase activity 
 
After removing the culture medium, cells were washed with PBS, lysed with 250µl of 
lysis buffer (50mM Tris-HCl, 0.1% Triton-X, pH7.5) and sonicated to disrupt the cell 
membranes. ALP activity was determined in 20µl aliquots of each cell lysate in buffer 
containing 100mM glycine (Sigma), 1mM MgCl2 (Sigma) and 0.1mM ZnCl2 (Sigma), 
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pH 10.5, using p-nitrophenyl phosphate (Sigma) as a substrate. Each sample was 
measured in duplicate. The absorbance was measured at 405nm at different time point 
for 2 hours using Multiskan (Thermo Scientific).  Immunoblotting was carried out on 
the cell lysates as described in section 2.5.8. 
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2.7 Statistical analysis 
 
The mean reading and standard mean deviation (SEM) for each combination of 
constructs were used to identify the difference between the wild type and mutant 
constructs for both luciferase assay and alkaline phosphatase assay.  
 
For the luciferase assay, the data set was assessed by one-way analysis of variance 
(ANOVA) in Minitab 15 to rule out any significant differences across the data set 
between the replicates, as the assay was performed three times independently. The 
pooled data was logarithmic transformed to conform to a Normal distribution. Using the 
transformed data, pairwise comparisons for the three replicates of each combination of 
plasmids were calculated.  
 
For the alkaline phosphatase assay, the data set was assessed by two-way analysis of 
variance. The data from three independent experiments that were performed in duplicate 
was pooled together. Two way analysis of variance (ANOVA) was used to analyse the 
data between the wild type and mutant constructs, with each independent experiment as 
another factor. The group of cells that were transfected with constitutively active 
BMPR1A and empty vector pcDNA3.1, acted as a positive control. These were, 
however, excluded from the analysis examining differences between the wild-type and 
mutant SMAD6 constructs. 
 
All p-values were two-sided and p<0.05 was accepted as the threshold for statistical 
significance.  
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Chapter 3 Results of mutation screening and in vitro 
splicing studies 
 
 
3.1 Overview 
 
This chapter presents the results from the screening of candidate genes in the BMP 
signaling pathway for rare variants which could predispose to cardiovascular 
malformations (CVM). The results of the in vitro splicing assays are also presented in 
this chapter. The objectives of this part of the project were: 
• To sequence the coding regions, including exon/intron boundaries of the 
candidate genes in the patient panel 
• To determine whether the novel variants identified are transmitted or de novo 
• To determine whether the novel variants identified are polymorphisms 
• To analyse the identified novel variants using in silico approaches  
• To analyse the effect of variants predicted to influence splicing using a minigene 
assay 
 
Five genes that are involved in the BMP signaling pathway were chosen. These genes 
consisted of two ligands (BMP2 and BMP4), two receptors (BMPR1A and BMPR2), and 
one signal transduction molecule (SMAD6). The exonic and the exon/intron boundaries 
of these genes were sequenced in a panel of 90 probands with various types of CVM. 
The dye-termination or Sanger sequencing method was utilized due to the state of the 
available technology at that time. The previously unreported genetic variants were then 
checked in their parents (whenever available) to determine inheritance and also were 
genotyped in a population of British Caucasian controls that are free of CVM.  
 
The rare and novel variants were then analysed using in silico approaches to determine 
evolutionary conservation, the potential functional effect of the non-synonymous 
variants and the potential for splicing effects. Potentially significant splicing effects 
were assessed in vitro using the minigene splicing assay.  
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3.2 Phenotypes of the analyzed CVM patient cohort 
 
A panel of 92 CVM patients were screened for del22q11 using Multiplex Ligation 
Probe-dependent Amplification (MLPA) (performed by Dr. Ana Topf). Two patients 
were identified with the deletion and were subsequently removed from the study. The 
remaining 90 patients were re-sequenced for the coding sequences, including 
exon/intron boundaries of BMP2, BMP4, BMPR2, BMPR1A and SMAD6. The cardiac 
phenotypes of the 90 patients were categorized into 16 main groups (Table 3.1). The 
phenotypes of a further 348 patients that were re-sequenced for the MH2 domain of 
SMAD6 as a replication cohort are also listed in Table 3.1. 
 
 
Cardiac phenotype N=90   N=348   Total=438   
Aortic stenosis 4 
 
19  23 
  
ASD   24  47  71  
 
AVSD 8  11  19  
 
Coarctation of aorta 5  18  23   
DILV 1  1  2   
Ebstein's anomaly 3  6  9   
Hypoplastic left heart 2  4  6   
PDA 3  15  18   
PFO 4  6  10   
Pulmonary atresia   0  4  4   
Pulmonary stenosis 1  2  3   
TGA 4  53  57   
Tricuspid atresia 1  4  5   
Truncus arteriosus 0  7  7   
VSD   5  19  24   
Complex/Multiple phenotypes 25   132   157   
        
 
Table 3.1 Phenotypes of the analysed CVM patients 
CVM patients were categorized into 16 main groups. The panel of 90 patients were re-
sequenced for the coding sequences of BMP2, BMP4, BMPR2, BMPR1A and SMAD6 
whereas the panel of 348 patients were re-sequenced for the MH2 domain of SMAD6 as 
a replication cohort. 
(ASD: atrial septal defect, AVSD: atrioventricular septal defect, DILV: double inlet left 
ventricle, PDA: patent ductus arteriosus, PFO: patent foramen ovale, TGA: 
transposition of the great arteries, VSD: ventricular septal defect)  
 
 
 
 109
3.3 BMP2 
 
The novel variants identified in BMP2 in 90 patients are summarized in Table 3.2. The 
location of the variants is shown in Figure 3.1. These variants were genotyped in the 
first control population. Three variants were observed in the 5’UTR of exon one. The c.-
906C>T variant was seen in a patient with membranous subaortic stenosis and was 
maternally inherited. This variant was not seen in the control population. The two other 
variants in the 5’UTR, c.-673G>A and c.-342_-340delTGT, were both present in the 
controls with a minor allele frequency of 0.03 and 0.024 respectively. Two other novel 
genetic variants were found in the TGF-beta domain of the coding region in exon three. 
The TGF-beta domain is present in a variety of proteins: transforming growth factor 
beta, decaptentaplegic proteins and bone morphogenetic proteins, all of which are 
members of the TGF-beta family. These variants were synonymous nucleotide 
substitutions, thus amino acid residues were not affected. The c.891G>A variant was 
paternally inherited, whereas the c.1146A>G variant was maternally inherited. Both 
variants were absent in the controls. In the 3’UTR region, a four-base pair deletion was 
identified in three probands and was present in the control population with a minor 
allele frequency of 0.19. For those variants present in cases and controls, the allele 
frequencies were compared using Fisher’s exact test. There was a significant difference 
in allele frequency between cases and controls for the c.-342_-340delTGT variant, 
which had a frequency of 0.044 in cases and 0.024 in controls (p=0.0057). There was no 
significant difference in allele frequency between cases and controls for the c.-673G>A 
and c.*936-939delATTT variants. 
 
The effect of the 5’UTR variants on splicing was predicted in silico using ESE Finder 
3.0. The c.-906C>T variant resulted in the loss of the predicted branch site. However, 
since branch site sequences are very degenerative, and therefore loss of a single site is 
unlikely to affect splicing (see section 3.4 for more detailed discussion of this issue). 
There was no predicted effect on splicing for the c.-713G>A and c.-342_-340del3 
variants. Hence, no in vitro assessment of potential effects of these variants on splicing 
was carried out.       
 
Using the MicroCosm Targets programme, the c.*936_939delATTT variant was not 
located at predicted sites for microRNAs.  
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Position Nucleotide Change Location Amino Acid 
Substitution 
Number 
of Patients 
Type of CVMs Inheritance Controls 
(N=1425) 
Fisher’s exact 
test (p value) 
Exon 1 c.-906C>T 5’UTR - 1 Aortic stenosis Mother Absent - 
c.-673G>A 5’UTR - 4 1. Ebstein’s anomaly 
2. PFO 
3-4. Complex 
N/A f(G)=0.97 
f(A)=0.03 
0.512 
c.-342_-340delTGT 5’UTR - 8 1-4. ASD  
5. TGA 
6. AVSD 
7-8. Complex 
N/A f(TGT)=0.976 
f(delTGT)= 
0.024 
0.0057 
Exon 3 c.891G>A Exonic p.Lys297Lys 1 TGA Father Absent  
c.1146A>G Exonic p.Leu382Leu 1 ASD Mother Absent  
c.*936_939delATTT 3’UTR  3 1. Tricuspid atresia 
2. ASD 
3. Complex 
NA f(ATTT)=0.981 
f(delATTT)= 
0.019 
0.406 
 
Table 3.2 BMP2 – Genetic variants 
The genetic variants identified in BMP2 in the panel of 90 probands.  
(PFO, patent foramen ovale; ASD, atrial septal defect; TGA, transposition of the great arteries; AVSD, atrioventricular septal defect) 
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Exon        1        2           3 
 
(bp)    (1212)    (353)           (2019) 
 
 
 
Figure 3.1 BMP2 – Location of genetic variants 
Location of the genetic variation identified in BMP2, in the panel of 90 probands. Boxes represent exons and adjoining lines represent introns. Exons 
are numbered and the sizes are indicated in base pairs. 5’UTR and 3’UTR are in black colour. Location of the TGF-beta propeptide domain is labelled 
above the exons.   
(TGF-beta: Transforming growth factor-beta) 
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3.4 BMP4 
3.4.1 Sequencing results 
 
Five exons (including the alternative first exon) of BMP4 were sequenced and analysed 
for previously unreported genetic variants in 270 probands with cardiovascular 
malformation where 55 probands were diagnosed with Transposition of the Great 
Arteries (TGA) or TGA with other malformations. The numbers of patients sequenced 
were increased and the sequenced cohort for TGA patients was enriched, as during the 
period this work was conducted, Thienpont and colleagues (Thienpont et al. 2007) 
identified a deletion on 14q21.3, near BMP4, which is located at 14q22.2, in a patient 
with TGA, microtia, microphthalmia and polydactyly. A total of nine previously 
unreported genetic variants in BMP4 were identified (Table 3.3) and the location of the 
variants is shown in Figure 3.2. The novel variants were genotyped in the first control 
population consisted of a collection of 1425 British Caucasian individuals.  
 
A proband with complex transposition of great arteries with right sided atrioventricular 
valve atresia was interesting as three novel genetic variants were detected. The c.-
283G>C variant was located in the 5’UTR of exon 1A, c.-295G>A variant was located 
in the intron/exon boundary of exon 1B and c.-87C>T variant was located in 5’UTR, 
exon two. Subsequent sequencing carried out on the parents indicated that the genetic 
variants were inherited from the father who is unaffected and has another unaffected 
child (not studied). All of these variants were absent in the controls.  
 
Two variants, c.-171C>G and c.-136C>G, were observed in the alternative exon 1B in 
the 5’UTR. c.-171C>G was found in a total of 10 patients and was seen in the controls, 
but at a significantly lower frequency (p=0.00007). The c.-136C>G variant was 
identified in a patient with TGA, pulmonary atresia and ventricular septal defect (VSD). 
This variant was inherited from the father and was absent in the controls.  
 
The non-coding variants that were absent in the controls were prioritized for in silico 
analysis. The c.-283G>C variant was not examined for its effect on in silico splicing as 
it was located in the first exon (see section 3.4.2.1). Other non-coding variants that were 
not observed in the controls (c.-295G>A, c.-136C>G and c.-87C>T) were investigated 
for effects on splicing (see section 3.4.2.1).     
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Position Nucleotide 
Change 
Location Amino Acid 
Substitution 
Number of 
Patients 
Type of CVMs Inheritance Controls 
(N=1425) 
Fisher’s 
exact test 
(p value) 
Exon 1A c.-283G>C 5’UTR - 1 TGA Father Absent  
Intron 1 c.-295G>A Intron - 1 TGA Father  Absent  
Exon 1B c.-171C>G 5’UTR - 10 1-5. Complex 
6-8. ASD 
9. AVSD 
10. Tricuspid atresia  
NA f(C)=0.983 
f(G)=0.017 
0.00007 
 c.-136C>G 5’UTR - 1 TGA Father  Absent  
Exon 2 c.-87C>T 5’UTR - 1 TGA Father  Absent  
Exon 3 c.76T>C Exonic p.Leu26Leu 1 TGA Father NA f(T)=0.999 
f(C)=0.001 
0.282 
c.345C>T Exonic p.Asn115Asn 1 TGA  Mother f(C)=0.998 
f(T)=0.002 
0.282 
Intron 4 c.370+28G>A Intronic  2 1. Coarctation of aorta 
2. Hypoplastic left heart 
Mother, 
Father 
f(G)=0.963 
f(A)=0.037  
0.753 
Exon 4 c.520G>A Exonic p.Gly174Ser 1 ASD Mother Absent  
 
Table 3.3 BMP4 – Genetic variants 
The genetic variants identified in BMP4 in the panel of 270 probands.  
(TGA, transposition of the great arteries; ASD, atrial septal defect; AVSD, atrioventricular septal defect)  
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Exon           1A      1B           2          3     4  
 
(bp)        (262)   (132)      (125)     (377)           (1153)  
 
 
Figure 3.2 BMP4 – Location of genetic variants 
Location of the genetic variation identified in BMP4, in the panel of 270 probands. Boxes represent exons and adjoining lines represent introns. Exons 
are numbered and the sizes are indicated in base pairs. 5’UTR and 3’UTR are in black colour. Location of the TGF-beta propeptide domain is labelled 
above the exons.   
(TGF-beta: Transforming growth factor-beta) 
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Two synonymous variants were seen in exon three. The c.76T>C variant encoding 
leucine residue was not paternally inherited in a patient with TGA but the DNA from 
the mother was not available. The c.345C>T variant encoding for the residue asparagine 
was maternally inherited in a patient with TGA and VSD. Both of these variants were 
present in the controls. The c.370+28G>A variant was located in the intron of exon 
three and was seen in two patients, one with coarctation of the aorta and the other with 
hypoplastic left heart syndrome. This variant was present in the controls. 
 
A non-synonymous substitution occurred in c.520G>A, in a patient with complete ASD, 
resulting in a glycine to serine change in residue number 174. This variant was 
maternally inherited and was not seen in the controls. The evolutionary conservation of 
the amino acid showed that the residue is highly conserved in all species examined, 
except fruitfly (Figure 3.3). However, in silico analysis of the protein function carried 
out using SIFT and PolyPhen predicted that the change is benign, therefore further in 
vitro investigation was not carried out.  
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BMP4 p.G174S (c.520G>A) 
 
Human           GPDWERGFHRINIYEV  
Chimpanzee      GPDWERGFHRINIYEV 
Mouse           GPDWEQGFHRINIYEV 
Chicken         SAAWERGFHRINIYEV  
Frog            GPAWEEGFHRINIYEV  
Zebrafish       DQTGDHGLHRINIYEV  
Fruitfly        RSSANRTRYQVLVYDI 
 
 
Figure 3.3 BMP4 – Evolutionary conservation of the variant p.G174S 
(c.520G>A) 
Evolutionary conservation of the non-synonymous unreported variant in BMP4 
p.G174S (c.520G>A) and the surrounding sequences from human to fruitfly. (Blue: 
Non conserved region and red: amino acid residues of interest) 
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3.4.2 Investigation of effects on splicing of BMP4 
3.4.2.1 In silico prediction 

The possibility that the four novel variants (c.-283G>C, c.-295G>A, c.-136C>G and c.-
87C>T) that were not located in the translated region and were not found in the controls 
could affect splicing was investigated. The variant located in the first exon was 
considered to be unlikely to affect splicing, as exons located at the terminal ends of the 
gene, i.e. the first and the last exons, are known to require special mechanisms for their 
recognition (Berget 1995). Ohno and colleagues (Ohno et al. 1987) indicated that first 
exons end with a 5’ splice site but have no processing signal in their beginning. They 
possess a modification at the beginning via the 7-methyl-guanosine cap which is 
essential for recognition and removal of the first intron. This cap also inhibits the 
formation of the spliceosome. The last exons are identified by factors recognizing the 3’ 
splice site of the exons and interacting with factors recognizing poly(A) sites (Niwa et 
al. 1990). Therefore, it would be expected that the variants located in the first and last 
exons will not affect splicing.  
 
The remaining three novel variants (c.-295G>A, c.-136C>G and c.-87C>T) were 
analysed using two in silico approaches. The first was the splice sites matrix library of 
ESE finder 3.0 (Cartegni et al. 2003; Smith et al. 2006) which is a web-based 
programme that analyses sequences to identify putative 5’ splice sites, 3’ splice sites 
and branch sites and to predict whether the mutations will disrupt these sites; the second 
was an in-house programme written by Dr. Sushma Grellscheid. The results of the ESE 
finder 3.0 analyses are shown in Table 3.4. A branch site was predicted to be created by 
the c.-295G>A variant. The branch site (BS) sequence is required for lariat formation 
and plays an important step in mRNA splicing. The computational method used a 
combination of both the branch site sequence and the polypyrimidine tract length to 
identify the putative branch site (Kol et al. 2005). However, the branch site sequences 
recognized by the splicing factors are known to be very degenerative (Gao et al. 2008). 
If a branch site were abolished, there would be other branch sites sequences upstream or 
downstream to facilitate splicing. Therefore, creation and or deletion of individual 
branch sites are unlikely to significantly affect splicing efficiency (Gao et al. 2008). The 
c.-136C>G variant was predicted to slightly decrease the affinity of 5’ splicing if this 
nucleotide position were at a 5’ splice site whereas the affinity of the branch site was 
predicted to decrease in variant c.-87C>T by the ESE finder programme. The matrices  
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Position Variant ESE Finder 3.0 
Exon 1B c.-295G>A Branch site created 
 c.-136C>G 5’ splice site (donor) decreased 
Exon 2 c.-87C>T Branch site decreased 
 
 
Table 3.4 BMP4 – Potential effect of variation on splicing 
Effects of the genetic variants located in the 5’UTR or intronic region on putative 
exonic splicing elements predicted in silico using ESE Finder 3.0. 
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for 5’ and 3’ splice sites used by ESE finder were derived from dbCASE, a database of 
classified alternative splicing events (Zhang et al. 2007) to identify putative 5’ and 3’ 
splice sites. The sequences recognized by the splicing factors (branch sites, 5’ and 3’ 
splice sites) seem to be very degenerate; therefore it is difficult for the programme to 
discern the pseudo splice site from the authentic splice sites. When predicting the effect 
the variant may have on splicing, the computational method implemented in ESE finder 
3.0 does not take into consideration the real exon/intron boundaries being analysed: it 
will analyse the sequence and will search for the possible 5’ and 3’ sites and attribute a 
score to those sites identified. Thus, it is possible for the programme to find a decreased 
5’ site where there is no 5’ site in the input sequence. c.-136C>G is not at a 5’ splice site 
so these results are difficult to interpret. Besides that, the default threshold values used 
by ESE finder are, although based on statistical analysis and empirical data, somewhat 
arbitrary. Given the ambiguity of these results from ESE finder, a second programme 
was used to analyse these variants for potential effects on splicing. 
 
The second in silico analysis was performed using an in-house programme that was 
generated by Dr. Grellscheid. In figures 3.4 to 3.6, the x-axis shows the sequence, the 
positive and negative y-axis indicates ESE and ESS scores respectively. The threshold 
region within which any variation is not considered significant is shown in yellow. 
 
The programme predicted that an ESE site that was present in the c.-295G variant was 
abolished when the variant was substituted to c.-295A (Figure 3.4). The change seemed 
to be significant, as a big peak (i.e. an important ESE) is lost. Since a potential ESE site 
is lost, this might imply that the spliceosome cannot bind to this site anymore. For the 
c.-136C>G and c.-87C>T variants, the effect of the substitution was not important, as 
the scores fell in the ‘acceptable threshold region’ (the yellow part) (Figure 3.5 and 
Figure 3.6). Therefore, based on the prediction, it would be expected that the c.-295 
wild type allele (G) to splice correctly whereas the variant allele (A) might splice 
incorrectly, leading to the inclusion of the intronic sequence before the inserted exon 1B 
in the minigene assay. The c.-136C>G and c.-87C>T variants would be less likely to 
have effects on splicing. Nevertheless, these results generated by the programmes are 
prediction only, and cannot be considered conclusive. As these variants were absent in 
the 1000 controls, in vitro functional analysis using a minigene assay was carried out. 
The variant of principal interest was c.-295A>G, but having invested the effort to 
develop the assay, the c.-136C>G and c.-87C>T variants were investigated too. 
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Figure 3.4 BMP4 c.-295G>A in silico prediction 
In silico analysis of c.-295G>A variant using the programme created by Dr. Sushma 
Grellscheid showed the loss of an ESE site (the blue line).  
 
 
Figure 3.5 BMP4 c.-136C>G in silico prediction 
In silico analysis of c.-136C>G variant using the programme created by Dr. Sushma 
Grellscheid showed the decrease score of an ESE site but the reduction of the score (the 
blue line) was within the ‘acceptable range’ (yellow part).    
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Figure 3.6 BMP4 c.-87C>T in silico prediction 
In silico analysis of c.-87C>T variant using the programme created by Dr. Sushma 
Grellscheid showed the reduction of the score (the blue line) but within the acceptable 
range (yellow part).  
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3.4.2.2 Minigene assays for BMP4 variants 
 
Three novel variants (c.-295G>A, c.-136C>G and c.-87C>T) that were predicted to 
affect splicing and were absent in normal controls were investigated further using 
minigene assays. The aims of this experiment were: 
• To clone the genomic segments containing the wild-type and variant alleles into 
the minigene construct. 
• To determine whether the allelic variants had any effect on splicing efficiency. 
 
 
3.4.2.2.1 Novel variant c.-295G>A 
 
The novel variant c.-295G>A was predicted to create a branch site in silico by ESE 
finder 3.0. Further in silico analysis utilising the programme generated by Dr. 
Grellscheid predicted the variant to have a significant effect on splicing as an important 
ESE site is lost. Hence, an in vitro functional assay was carried out to determine 
whether the variant has any effect on splicing. The wild type (c.-295G) and the mutant 
(c.-295A) BMP minigene constructs were transfected into HEK293 cells. The variant 
was hypothesized might result in the inclusion of the intron between β-globin exon 2 
and the inserted exon of BMP4, i.e. a failure of splicing between β-globin exon 2 and 
the inserted BMP4 exon (as shown in Methods chapter, Figure 2.7)  
 
PCR-amplified genomic fragments containing the c.-295 variants were cloned into the 
pXJ41 vector using primers complementary to regions in BMP4. Positive colonies that 
were Ampicillin resistant were picked and amplified (Figure 3.7). A total of six colonies 
which contained the fragment of interest were identified. PCR of the six colonies carried 
out to determine the orientation of the insert showed that two colonies had the BMP4 
fragment inserted in the correct orientation (Figure 3.8). These constructs were then 
sequenced to identify the wild type allele minigene construct and the mutant allele 
minigene construct. Fortuitously, one colony carried the wild type allele and one carried 
the mutant allele. 
 
HEK293 cells were transfected with wild type and mutant minigene constructs, and RT-
PCR of RNA extracted from these cells was used for comparison. The same size 
products were observed from both minigenes at about 200bps, showing that the 
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fragment of interest was correctly spliced, with β-globin exons (18bps of exon 2 and 
53bps of exon 3) flanking the fragment (132bps) (Figure 3.9, lanes 1 and 2).  Hence, 
this variant did not affect splicing in this assay. 
 
 
3.4.2.2.2 Novel variant c.-136C>G 
 
The novel variant c.-136C>G was predicted by ESE finder 3.0 to decrease the 5’ splice 
site. However, the variant is not located at the exon/intron boundary. Therefore, the 
prediction of that programme is probably not relevant for this variant. Another in silico 
programme did not predict a strong effect of the variant on splicing. Nevertheless, the 
absence of this variant in 1000 controls warranted further investigation.  
 
After transfection of wild type and mutant constructs, a total of eleven positive colonies 
that were Ampicillin resistant and contained the fragment of interest were identified. 
However, only three colonies had the fragment of interest inserted in the correct 
orientation. Constructs were sequenced to identify the allele of the minigene, one wild 
type and two mutant constructs were obtained. RT-PCR of RNA extracted from cells 
transfected with these two minigene constructs showed only one band at about 200bps, 
indicating no difference between the wild type and the mutant allele splicing pattern. 
Figure 3.9, lanes 3 and 4, shows the results of the splicing analysis after transfection in 
HEK 293 for the wild type (c.-136C) and mutant (c.-136G) minigene constructs. These 
results indicate that the variant did not have an effect on splicing in vitro.  
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Figure 3.7 PCR screening of Ampicillin resistant colonies  
Example of colonies that contained the fragment of interest, approximately 1.5kb, are 
indicated with arrows (lanes 4, 9, 10, 11, 13 and 19). The smaller bands are colonies 
containing empty plasmids.   
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Figure 3.8 Determination of fragment orientation  
On the gel, lanes A show a colony in which the construct (wild type or mutant) is in the 
correct orientation, and lanes B show a colony in which the construct is in the incorrect 
orientation. 
Lanes marked 1 on the gel contain product generated using primers pXJ-Forward (     ) 
and pXJ-Reverse (       ) shown in schematic. Regardless of orientation, a ~1.7kb band is 
expected. 
Lanes marked 2 on the gel contain product generated using pXJ-Forward (       ) and a 
primer that is reverse complementary to the fragment of interest (       ). A correctly 
oriented insertaion will produce a ~1.5kb band, and an incorrectly oriented insertion no 
band. 
Lanes marked 3 on the gel contain product generated using a forward primer 
complementary to the fragment of interest (      ) and pXJ-Reverse (      ). A correctly 
oriented insertion will produce a ~1.5kb band, and an incorrectly oriented insertion no 
band.  
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Figure 3.9 Splicing patterns of the variants 
The splicing patterns of the wild type allele BMP4 c.-295G (lane 1), mutant allele 
BMP4 c.-295A (lane 2), wild type allele BMP4 c.-136C (lane 3) and mutant allele 
BMP4 c.-136G (lane 4) analysed using RT-PCR. (Ladders not shown). No band was 
seen at 700bp which was what would have been expected if splicing had not taken place 
correctly between β-globin exon 2 and the inserted exon 1B of BMP4. The blue boxes 
indicate β-globin exons and the black box indicates BMP4 exon.  
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3.4.2.2.3 Novel variant c.-87C>T 
 
The novel variant c.-87C>T was predicted by ESE finder 3.0 to decrease branch site 
efficiency. As stated previously, branch sites consensus sequences are degenerative in 
the genome. For this reason, the predicted branch site might be a false positive and have 
no effect on splicing. The second in silico programme did not predict a major effect of 
this variant on splicing. Nevertheless, since this variant is absent in 1000 controls, the 
minigene assay was proceeded.  
 
The amplification of the fragment from the patient’s DNA showed a clear specific band. 
This fragment was then digested with restriction enzyme and ligated with the vector and 
transformed into competent cells as described in chapter 2. The first screening of the 
transformed cells (approximately 50 colonies) showed that the fragment of interest was 
not inserted into the vector. The second screening PCR of the transformed cells also 
yielded negative results.  
 
The next step taken was to use different ratios of vector to insert DNA during ligation. 
The ratios used were 1:3, 1:1 and 3:1. The different ligation reactions were then 
transformed into competent cells as described in chapter 2. Subsequent screening PCR 
of these cells showed that the cells did not contain the fragment of interest.  
 
Alternative primer pairs were then designed to amplify the fragment of interest in order 
to optimize ligation. The fragments were successfully amplified using the Phusion 
High-Fidelity DNA Polymerase as shown in Figure 3.10. However, the screening PCR 
of the transformed cells again yielded negative results. It was concluded that more 
optimization of the cloning parameters would have been needed in order to clone this 
fragment. As time was a constraint and potentially more significant results had been 
found in other genes screened, this experiment further was not pursued further.  
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Figure 3.10 Amplified fragments of variant BMP4 c.-87>T using different 
primer pairs 
All of the amplified fragments are around 1kb. Lanes 1 and 2 are of primers MG-
BMP4EF/MG-BMP4ER. Lanes 3 and 4 are of primers MG-BMP4FF/MG-BMP4FR. 
Lanes 5 and 6 are of primers MG-BMP4GF/MG-BMP4GR. Lanes 7 and 8 are of 
primers MG-BMP4FF/MG-BMP4GR. Lanes 9 and 10 are of primers MG-
BMP4GF/MG-BMP4FR. 
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3.5 SMAD6 
 
The three isoforms of SMAD6 with alternative first and fourth exons were sequenced in 
90 probands. The genetic variants identified are recorded in Table 3.5 and the locations 
of the variants are shown in Figure 3.11. These variants were genotyped in the first 
control population. Ten previously unreported genetic variants were identified. Of these 
novel genetic variants, five did not result in amino acid changes; three variants were 
located in the 5’UTR and two variants in the 3’UTR region. In the 5’UTR region, 
variant c.-428A>T was identified in a patient with Patent Foramen Ovale (PFO) and 
variant c.-290G>C was found in a patient with complex phenotypes. Both variants were 
absent in the control population. However, as these variants (c.-428A>T and c.-290G>C) 
were located in exon 1 (see section 3.4.2.1), their effects on splicing were not 
investigated. Variant c.-44C>T was found in three patients: one patient with complex 
phenotypes and two patients with AVSD. This variant was seen in the controls with a 
minor allele frequency of 0.027. In the 3’UTR region, the c.*262T>C variant was 
inherited from the parent and was present in the controls with a minor allele frequency 
of 0.023. The c.*319T>A variant was identified in a patient with PFO and was not seen 
in the control population. 
 
Three novel variants were identified in the MH1 domain. c.61G>A was seen in an ASD 
patient, resulting in p.Asp21Asn. It was inherited from the patient’s father. Two 
synonymous single base substitutions occurred. c.120C>T was heterozygous in 7 
probands and c.711C>T was seen in a patient with Ebstein’s anomaly. All these three 
variants were present in the controls with a minor allele frequency of 0.022, 0.029 and 
0.002 respectively. 
 
A non-synonymous substitution was identified in the alternatively spliced region of 
SMAD6 isoform C, in exon 4B, in a patient with large secundum ASD. The c.975C>G 
variant resulted in p.Ser325Arg substitution. DNA of the parents was not available. This 
variant was not seen in the controls. However, as this variant is located in the linker 
region with relatively less likely functional effects when compared to the MH1 and 
MH2 domains of SMAD6, further investigation was not performed. 
 
A non-synonymous variant, c.1451G>T, resulting in p.Cys484Phe, located in the MH2 
domain, was identified in a patient with coarctation and calcification of the aorta. This  
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Position Nucleotide 
Change 
Location Amino Acid 
Substitution 
Number of 
Patients 
Type of CVMs Inheritance Controls 
(N=1425) 
Fisher’s 
exact test 
(p value) 
Exon 1 c.-428A>T 5’UTR - 1 PFO N/A Absent  
 c.-290G>C 5’UTR - 1 Complex N/A Absent  
 c.-44C>T 5’UTR - 3 1. Complex 
2-3. AVSD 
N/A f(C)=0.973 
f(T)=0.027 
0.722 
 c.61G>A Exonic p.Asp21Asn 1 ASD   Father N/A f(G)=0.978 
f(A)=0.022 
1.000 
 c.120C>T Exonic p.Gly40Gly 7 1-2. VSD 
3-4. PFO 
5. Pulmonary stenosis 
6-7. Complex 
N/A f(C)=0.971 
f(T)=0.029 
0.029 
 c.711C>T Exonic p.His237His 1 Ebstein’s anomaly  Mother f(C)=0.998 
f(T)=0.002 
0.282 
Exon 4B c.975C>G Exonic p.Ser325Arg 1 ASD N/A Absent  
Exon 4A c.1451G>T Exonic p.Cys484Phe 1 Coarctation of aorta N/A Absent  
 c.*262T>C 3’UTR - 2 1. ASD 
2. Aortic stenosis 
Mother; 
Father N/A 
f(T)=0.977 
f(C)=0.023 
1.000 
 c.*319T>A 3’UTR - 1 PFO N/A Absent  
 
Table 3.5 SMAD6 – Genetic variants 
The genetic variants identified in SMAD6 in the panel of 90 probands.  
(PFO, patent foramen ovale; AVSD, atrioventricular septal defect; VSD, ventricular septal defect; ASD, atrial septal defect)  
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Exon    1A  1B         2   3    4B     4A               
  
(bp)             (1780)   (34)       (57)             (78)        (65)     (1004) 
    
 
Figure 3.11 SMAD6 – Location of genetic variants 
Location of the genetic variation identified in SMAD6, in the panel of 90 probands (except variants c.973G>A and c.1451G>T). Variants c.973G>A 
and c.1451G>T were subsequently identified in additional 348 probands. Boxes represent exons and adjoining lines represent introns. Exons are 
numbered and the sizes are indicated in base pairs. 5’UTR and 3’UTR are in black colour. Location of the MH1 and MH2 domains are labelled above 
the exons.   
(MH1: Mad homology 1, MH2: Mad homology 2) 
 
c
.
-
4
2
8
A
>
T
 
c
.
-
2
9
0
G
>
C
 
c
.
-
4
4
C
>
T
 
c
.
6
1
G
>
A
 
c
.
1
2
0
C
>
T
 
c
.
7
1
1
C
>
T
 
c
.
9
7
5
C
>
G
 
c
.
1
2
4
4
C
>
T
 
c
.
*
2
6
2
T
>
C
 
c
.
*
3
1
9
T
>
A
 
c
.
1
4
5
1
G
>
T
 
c
.
9
7
3
G
>
A
 
MH1 MH2 
 132
variant was not seen in the controls. The inheritance of the variant was not known as 
both parents were deceased. 
 
The potential functional effect of the non-synonymous novel variants was analysed 
using SIFT and PolyPhen programmes. For p.Asp21Asn (c.61G>A) and p.Ser325Arg 
(c.975C>G) (alternatively spliced exon 4B) variants, SIFT predicted both variants to be 
poorly tolerated but PolyPhen predicted them to be benign. However, both algorithms 
predicted the p.Cys484Phe (c.1451G>T) variant to affect protein function.  
 
Therefore, the crystal structure of the variant predicted to be damaging was further 
investigated in silico. The crystal structure of the SMAD1 homotrimeric complex 
(Protein Data Bank entry 1KHU), which is homologous to the MH2 domain of SMAD6, 
was utilised as a basis for modelling the SMAD6 structure and the p.Cys484Phe 
(c.1451G>T) variant. Models of the wildtype SMAD6 and the p.Cys484Phe 
(c.1451G>T) variant structures were generated using the same procedures for their 
comparison. The change of the cysteine to the phenylalanine resulted in significant 
changes in structure that were limited to the immediate vicinity of residue 484. In the 
wildtype model, Cys484 is buried from solvent by the ‘L3 loop’ of the MH2 domain 
and the thiol packs, in particular, against the indole ring of Trp472. To accommodate 
the extra bulk of a phenylalanine sidechain in the mutant protein, the structure in the 
immediate vicinity of the L3 adopted an altered conformation (Figure 3.12). Glycines 
471 and 473, which immediately flank the tryptophan, provide the potential for the 
necessary flexibility in this part of the structure of the L3 loop. Since the L3 loop is 
known to interact with the L45 loop of BMPR1A (Imamura et al. 1997), it seems most 
likely that the p.Cys484Phe (c.1451G>T) variant affects binding of SMAD6 to 
BMPR1A, which is an inhibitory interaction.  
 
Based on this finding, the MH2 domain of SMAD6 was re-sequenced in an additional 
348 probands with a broad range of CVM. Two further non-synonymous variants were 
identified in SMAD6: c.973G>A resulted in the amino acid substitution of p.Ala325Thr 
in a patient with congenital mitral regurgitation and c.1244C>T that resulted in 
p.Pro415Leu substitution was found in a patient with congenital aortic stenosis. Both of 
these variants were inherited from phenotypically normal fathers (Table 3.6) (Figure 
3.11). These two variants were genotyped in the second control population consisted of 
1000 individuals that was derived from the North Cumbria Community Genetics Project  
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Figure 3.12 Predicted crystal structure of SMAD6 p.Cys484Phe (c.1451G>T) 
The homology models of wildtype (pink) and Cys484Phe (cyan) SMAD6 are 
superimposed, with residue 484 highlighted in both models in yellow. The individual 
amino acids in the L3 loop are drawn as stick models and the remainder of the structure 
as a ribbon cartoon. Note that Trp472 (W472) in particular has to move to accommodate 
the extra bulk presented by the mutation of Cys484 to Phe (performed by Prof. Rick 
Lewis). 
 
 
 
 
 
 
 
 
 
 
 
W472 
C484F 
P485 
S483 
I481 
F480 
Q479 
Y476 
S478 
R478 
C475 
P474 
K470 
 134
 
 
 
 
 
 
 
 
 
Table 3.6 MH2 domain of SMAD6 – Genetic variants 
The genetic variants identified in the MH2 domain of SMAD6 in the replication cohort of 348 probands. Both variants were inherited from their 
respective father. These variants were genotyped in the second control population consisted of 1000 individuals. The p.Ala325Thr (c.973G>A) variant 
was not successfully genotyped in the controls but the p.Pro415Leu (c.1244C>T) variant was not observed in the controls (performed by Dr. Darroch 
Hall). 
 
 
 
 
 
 
 
Position Nucleotide 
Change 
Location Amino Acid 
Substitution 
Number of 
Patients 
Type of CVMs Inheritance 
Exon 4A c.973G>A Exonic p.Ala325Thr 1 Mitral valve regurgitation Father 
 c.1244C>T Exonic p.Pro415Leu 1 Aortic stenosis Father 
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(NCCGP) (performed by Dr. Darroch Hall). The p.Pro415Leu (c.1244C>T) variant was 
successfully genotyped in the controls (not present in the controls) but the p.Ala324Thr 
(c.973G>A) variant failed. 
 
In silico analyses by both SIFT and Polyphen programmes predicted the p.Ala325Thr 
(c.973G>A) variant to be benign but the p.Pro415Leu (c.1244C>T) variant to be 
probably damaging to protein function, as might be expected since prolines are 
generally accepted to be important for protein folding and stability. Similar comparative 
structural modelling of the p.Pro415Leu (c.1244C>T) variation suggests that H2, which, 
unusually, is N-capped by Pro415, is destabilised by mutation to leucine. Residue 415 is 
solvent accessible and on the same face of the MH2 domain as the L3 loop, perhaps 
suggesting that p.Pro415Leu (c.1244C>T) is also affected in receptor signaling (not 
shown). The p.Pro415Leu (c.1244C>T) variant was also absent in 1000 control 
individuals. The p.Ala325Thr (c.973G>A) variant falls outside the structurally 
characterised region of the MH2 domain of the SMAD family, and thus the likely 
effects of the mutation cannot be determined in this way.  
 
The evolutionary conservation of the amino acid substitutions are shown in Figure 3.13. 
The aspartic acid of p.Asp21Asn (c.61G>A) was conserved only in chimpanzee. The 
p.Ser325Arg (c.975C>G) (alternative exon 4B) variant was not conserved. The alanine 
of the p.Ala325Thr (c.973G>A) substitution was conserved in chimpanzee, mouse and 
chicken. The proline residue of p.Pro415Leu (c.1244C>T) and cysteine residue of 
p.Cys484Phe (c.1451G>T) showed very high degree of conservation, from human to 
fruitfly.   
 
The c.*262T>C variant was predicted in silico to increase base pairing of hsa-miR-219-
2-3p (Figure 3.14) but this variant was observed in the controls. No predicted 
microRNAs was located at the c.*319T>A variant eventhough this variant was not 
observed in the controls. Therefore, both variants were not pursued further. 
 
Based upon these results, functional analysis of the non-synonymous variants 
p.Ala325Thr (c.973G>A), p.Pro415Leu (c.1244C>T) and p.Cys484Phe (c.1451G>T) 
was carried out, results of which are presented in the next chapter. 
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   SMAD6 p.D21N (c.61G>A) 
 
HUMAN           VRRLWRS-RVVPDREEGGSGGGG 
CHIMPANZEE      ------------DREEGGSGGGG 
MOUSE           VRRLWRSRVVPDREEGSG--GGG 
CHICKEN         VRRLWRSRVIPERDGGDGNGQS- 
FROG            VRRLWRS---------------- 
ZEBRAFISH       ----------------------- 
FRUITFLY        ----------------------- 
 
SMAD6 p.S325R (c.975C>G) 
 
HUMAN           ----------SRG-------- 
CHIMPANZEE      SKEPDGVWAYNRGEHPIFVNS 
MOUSE           SKEPDGVWAYNRGEHPIFVNS 
XENOPUS         SREADGVWAYNRSDHPIFVNS 
CHICKEN         SKEPDGVWAYNRSEHPIFVNS 
ZEBRAFISH       SKEPDGVWAYNRSQHPIFVNS 
FRUITFLY        SLENGDVWIYNRGNTTIFVDS 
 
 
 
 p.A325T 
(c.973G>A) 
p.P415L 
(c.1244C>T) 
p.C484F 
(c.1451G>T) 
HUMAN           
CHIMPANZEE      
MOUSE           
CHICKEN 
XENOPUS         
ZEBRAFISH  
FRUITFLY   
SMSPDATKPSH 
SMSPDATKPSH 
SMSPDATKPSH 
STSPDAVKRSH 
SLSPDMSKQGH 
SMSPSSLAQNH 
DGKDHNINSQV 
IFVNSPTLDAP 
IFVNSPTLDAP 
IFVNSPTLDAP 
IFVNSPTLDIP 
IFVNSPTLDAP 
IFVNSPTLEHH 
IFVDSPTLSEN 
QFITSCPCWLE 
QFITSCPCWLE 
QFITSCPCWLE 
QFITSCPCWLE 
QMITSCPCWLE 
QFITSCPCWLE 
QDIMGCPCWLE 
 
 
 
Figure 3.13 SMAD6 – Evolutionary conservation of the variants 
Evolutionary conservation of the non-synonymous variants discovered in SMAD6: 
p.Aps21Asn (c.61G>A), p.Ala325Thr (c.973G>A), p.Pro415Leu (c.1244C>T), 
p.Cys484Phe (c.1451G>T) and p.Ser325Arg (c.975C>G). (Blue: Non conserved region 
and red: amino acid residues of interest) 
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UGUCUACAGGUCGGUGUUAAGA 
||: |  |: : ::|:|||||| 
ACGCACTTTGGCTTATAATTCT 
 
    SMAD6 c.*262T>C 
 
 
Figure 3.14 SMAD6 – Predicted miRNA binding site 
In silico prediction that the c.*262T>C variant will increase base pairing of hsa-miR-
219-2-3p. However, this variant was observed in the controls. 
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3.6  BMPR1A 
 
The genetic variants identified in BMPR1A are summarised in Table 3.7. Only one 
previously unreported variant was present in this gene in a patient with atrial septal 
defect (ASD) out of 90 patients that were sequenced. The location of the variant is 
shown in Figure 3.15. This variant was located in intron seven, 59 bases upstream of 
exon eight. This variant was not genotyped in the control population. However, data 
from the 1000 genome project (Durbin et al. 2010) that became available at a later date 
showed that this variant (rs118172017) is present in the normal population, indicating 
that this variant is a polymorphism.  
 
Position Nucleotide Change Location Type of CVM 
Exon 1 - - - 
Exon 2 - - - 
Exon 3 - - - 
Exon 4 - - - 
Exon 5 - - - 
Exon 6 - - - 
Exon 7 - - - 
Intron 7 c. 534-59T>C intronic ASD 
Exon 8 - - - 
Exon 9 - - - 
Exon 10 - - - 
Exon 11 - - - 
Exon 12 - - - 
Exon 13 - - - 
 
 
Table 3.7 BMPR1A – Genetic variant 
The genetic variant identified in the intronic region of BMPR1A in the panel of 90 
probands.  
(ASD, atrial septal defect)  
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Exon          1    2              3       4           5          6        7    8 9         10 11 12  13 
 
(bp)         (281) (115)       (227)        (163)         (103)     (97)     (100)               (145)      (193)      (298)      (176)      (131) (1595)          
    
 
 
Figure 3.15 BMPR1A – Location of the genetic variant 
Location of the genetic variation identified in BMPR1A, in the panel of 90 probands. Boxes represent exons and adjoining lines or broken lines 
represent introns. Exons are numbered and the sizes are indicated in base pairs. 5’UTR and 3’UTR are in black colour. Location of the kinase-like 
domain is labelled above the exons.   
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3.7 BMPR2 
 
BMPR2 was sequenced in 90 patients. A total of eight genetic variants were identified. 
This is summarized in Table 3.8. The locations of the variants are shown in Figure 3.16. 
However, these variants were not genotyped in the control population. Variants that 
were located in the coding region were: c.-301G>A in the 5’UTR, c.600A>C in exon 
five and c.2887G>T in exon thirteen. The c.600A>C variant resulted in a synonymous 
leucine substitution and was reported by Machado et al. (Machado et al. 2006), to be a 
polymorphism, with frequency of 2.4%. The c.2887G>T variant which results in the 
substitution p.Gly963Cys was found in an ASD patient. This variant was predicted by 
both SIFT and Polyphen programmes to be probably damaging. The glycine residue is 
conserved in chimpanzee, mouse, chicken and zebrafish but is substituted to serine in 
frog and arginine in fruitfly (Figure 3.17). A total of 5 variants were located in the 
intronic region. As rare non-synonymous variants located in the coding region are 
expected to have greater effect on disease susceptibility than non-coding variants 
(Kryukov et al., 2007), therefore these non-coding variants were not pursued. The 
detailed functional analysis of this gene, the p.Gly963Cys (c.2887G>T) variant, was not 
pursued as Rudarakanchana and colleagues (Rudarakanchana et al., 2002) have shown 
that BMPR2 construct with truncated cytoplasmic tail or missense mutations in the 
cytoplasmic tail were able to transduce BMP signal in the functional analysis. Therefore, 
this variant might not obliterate BMP signaling.  
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Position Nucleotide Change Location Amino Acid 
Substitution 
Number of 
Patients 
Type of CVMs 
Exon 1 c.-301G>A 5’UTR  4 1-2. Ebstein anomaly 
3-4. Complex  
Exon 2 - -   - 
Exon 3 - -   - 
Exon 4 - -   - 
Exon 5 c.600A>C exonic p.Leu200Leu 1 ASD 
Intron 5 c.621+30_32delGTT intronic  1 ASD 
Exon 6 - -   - 
Intron 6 c.855-22T>C intronic  8 1. Coarctation of aorta  
2. Ebstein’s anomaly 
3. ASD  
4. Aortic stenosis,  
5-8. Complex   
Exon 7 - -   - 
Intron 7 c.969-122_124delTCT intronic  2 1. Coarctation of aorta 
2. VSD 
Intron 7 c.969-122T>C intronic  1 1. Ebstein’s anomaly 
Intron 7 c.969-118_116delTTT intronic  25  
Exon 8 - -   - 
Exon 9 - -   - 
Exon 10 - -   - 
Exon 11 - -   - 
Exon 12 - -   - 
Exon 13 c.2887G>T exonic p.Gly963Cys 1 ASD 
 
Table 3.8 BMPR2 – Genetic variants 
The genetic variants identified in BMPR2 in the panel of 90 probands. (ASD, atrial septal defect; VSD, ventricular septal defect.) 
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Exon  1          2           3           4 5              6       7    8 9 10        11        12         13          
       
(bp)            (615)        (171)     (171)    (111)    (92)         (231)    (115) (161) (148)      (137)    (173)   (1280)  (8056) 
 
 
 
 
Figure 3.16 BMPR2 – Location of the genetic variants 
Location of the genetic variations identified in BMPR2, in the panel of 90 probands. Boxes represent exons and adjoining lines or broken lines 
represent introns. Exons are numbered and the sizes are indicated in base pairs. 5’UTR and 3’UTR are in black colour. Location of the kinase-like 
domain is labelled above the exons.   
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     BMPR2 p.G963C (c.2887G>T) 
 
Human           SIQIGESTQDGKSGSGEKIKK 
Chimpanzee      SIQIGESTQDGKSGSGEKIKK 
Mouse           SIQIGESTQDGKSGSGEKIKR 
Chicken         SMQLGDSSQDGKSGSGEKIKK 
Frog            STQC-ETLSDSRSGSGEKIKK 
Zebrafish       SLLGEAVSQEGKAGSAEKIKK 
Fruitfly        -VFSGRGSSERLRDPSERVKT 
 
 
Figure 3.17 BMPR2 – Evolutionary conservation of the variant 
Evolutionary conservation of the non-synonymous unreported variant in BMPR2 
p.G963C (c.2887G>T) and the surrounding sequences from human to fruitfly. (Blue: 
Non conserved region and red: amino acid residues of interest) 
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3.8 Summary  
 
Re-sequencing of five candidate genes in the BMP signaling pathway for rare variants 
in a panel of 90 patients with a wide range of CVMs successfully identified a number of 
novel variants. Six novel variants were identified in BMP2, nine novel variants in BMP4 
(in a total of 270 patients), ten novel variants in SMAD6, one novel variant in BMPR1A 
and seven novel variants in BMPR2. Further re-sequencing of the SMAD6 MH2 domain 
yielded another two novel variants. In total, 35 unreported novel genetic variants were 
identified. Three novel variants of BMP4 located in the non-coding region that were 
absent in the controls and were predicted to affect splicing were investigated further 
using minigene assays. However, two of the three variants that were successfully carried 
out showed no significant difference between wild type and variant alleles whereas 
another variant needs more optimization of the cloning parameters. Three novel variants 
identified in the MH2 domain of SMAD6 resulted in non-synonymous substitution 
warrant further investigation for their functional effect as in silico prediction 
programmes, SIFT and Polyphen, predicted two variants (p.Pro415Leu [c.1244C>T] 
and p.C484F [c.1451G>T]) to be damaging and one variant (p.Ala325Thr [c.973G>A]) 
to be benign.         
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Chapter 4 In vitro functional analysis of novel SMAD6 
variants 
 
4.1 Overview 
 
In vitro functional studies have the potential to give us an insight on how mutant 
proteins function in the cellular environment. This chapter describes the in vitro 
functional analyses of the three non-synonymous SMAD6 variants reported in chapter 3.  
The aims of these experiments were: 
 
• To assess the inhibitory effect of the mutant proteins compared to that of the 
wild type protein on BMP- responsive reporter transcriptional activity.  
• To assess the inhibitory effect of the mutant proteins compared to that of the 
wild type protein on osteoblastic differentiation, assessed by alkaline 
phosphatase production in response to BMP signaling. 
 
The C2C12 cells used in these experiments are mouse myoblast cells established by 
Yaffe and Saxel (Yaffe and Saxel 1977). These cells are capable of differentiation, form 
contractile myotubes and produce characteristic muscle proteins. This cell line has been 
used for many BMP signaling pathway in vitro functional studies (Fujii et al. 1999; 
Goto et al. 2007; Korchynskyi and ten Dijke 2001).  
 
Two assays were selected to assess function of the mutant SMAD proteins. The first 
assay investigated their ability to inhibit transcription of a reporter under the control of a 
BMP-responsive element (BRE) and the second assay was to determine their ability to 
inhibit osteoblastic differentiation of C2C12 cells.   
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4.2 Optimization of transfection 
 
Initially, C2C12 cells were transiently transfected with 2µg of constructs (900ng of 
BRE-luciferase, 1µg of constitutively active BMPR1A and 100ng of Renilla luciferase 
construct) in different volumes of transfection reagent: 3µl, 5µl, and 7µl, to evaluate the 
effect of different transfection reagent to DNA ratios. The luciferase reading showed 
that there was no positive effect with higher volume of transfection reagent (Figure 4.1). 
Therefore, the lowest volume of transfection reagent (3µl) was used for subsequent 
experiments.  
 
C2C12 cells were then transfected with 1µg (450ng of BRE-luciferase, 500ng of 
constitutively active BMPR1A [or empty vector] and 50ng of Renilla luciferase 
construct) or 2µg of constructs (900ng of BRE-luciferase, 1µg of constitutively active 
BMPR1A [or empty vector] and 100ng of Renilla luciferase construct) to evaluate the 
effect of different DNA concentrations on luciferase readout. Experiments were carried 
out in triplicate. Firefly luciferase reading was normalised to Renilla luciferase reading 
for each measurement. The mean reading for each combination of contructs are shown 
in Figure 4.2. The luciferase reading for c.a.BMPR1A compared to the empty control 
clearly shows that the constitutively active form of BMPR1A induced BMP signaling, 
in the transiently transfected cells. Optimal expression was achieved using the ratio of 
3µl of transfection reagent to 1µg of constructs. Not only was the reading for 
c.a.BMPR1A higher but also the difference between empty vector (pcDNA3.1) and 
constitutively active BMPR1A is larger. This is crucial to be able to quantify the effect 
of the SMAD6C variants in the following experiments.  
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Figure 4.1 Optimization of the ratio of transfection reagent to construct DNA   
The effect of 3µl, 5 µl and 7µl of transfection reagent on the luciferase readout induced 
by constitutively active BMPR1A transfected with 2µg of construct DNA. The lowest 
volume of transfection reagent 3µl was used for subsequent experiments as there was no 
positive effect with higher volume of transfection reagent. 
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Figure 4.2 Optimization of the amount of construct DNA 
The effect of different ratio of construct DNA (1µg of DNA to 2µg of DNA) with 3µl of 
transfection reagent on the luciferase reading induced by constitutively active BMPR1A 
(pcDNA3.1, an empty vector, acted as a negative control). Optimal expression was 
observed with the ratio of 3µl of transfection reagent to 1µg of DNA construct. 
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4.3 Inhibitory effects of SMAD6 variants on BMP-Responsive 
element reporter  
 
To confirm that wild type SMAD6C protein inhibits the transactivation of BRE-Luc 
induced by constitutively active BMPR1A, as previously described (Goto et al. 2007), 
luciferase assay of C2C12 cells transfected with BRE-Luc and renilla with either 
pcDNA3.1 or c.a.BMPR1A and pcDNA3.1 or c.a.BMPR1A and SMAD6C wild type 
constructs were performed. Reporter gene activity for each well was measured for both 
the firefly luciferase and the renilla activity. The mean relative luciferase activity for 
this experiment is displayed in Figure 4.3. Results of the relative luciferase activity 
suggest that the SMAD6C protein inhibits c.a.BMPR1A by approximately 30 fold.  
 
The inhibitory activity of the mutant SMAD6C proteins compared to the wild type was 
assessed. Three independent experiments were performed in triplicate for each 
combination of constructs. Figure 4.4 shows the overall mean reading of all three 
replicates. 
 
Mean relative luciferase activities for all nine readings for each combination of 
constructs were log transformed before one way ANOVA was performed. The mean 
relative luciferase activity of the p.Ala325Thr (c.973G>A) mutant was not significantly 
different from wild-type (p value > 0.05), indicating that this variant does not affect the 
inhibitory activity of SMAD6. However, both p.Pro415Leu (c.1244C>T) and 
p.Cys484Phe (c.1451G>T) mutants failed to inhibit BMP signaling compared to the 
SMAD6 wild type, with 6 fold increase in relative luciferase activity for p.Pro415Leu 
(c.1244C>T) mutant and 17 fold increase for p.Cys484Phe (c.1451G>T) mutant. The 
ANOVA results for both p.Pro415Leu (c.1244C>T) and p.Cys484Phe (c.1451G>T) 
mutants showed significant difference with a p value of less than 0.05 compared to wild 
type SMAD6. Comparing the relative luciferase activity of c.a.BMPR1A to the mutants, 
the p.Pro415Leu (c.1244C>T) mutant appeared to be hypomorphic, being significantly 
different from c.a.BMPR1A (p value < 0.05) whereas p.Cys484Phe (c.1451G>T) 
mutant appeared to be a null allele, not significantly different from the uninhibited 
c.a.BMPR1A (Figure 4.4).  
 
Having shown the induction by c.a.BMPR1A and the inhibition by SMAD6 wild type in 
the luciferase assay, a western blot was performed using the same cell lysates that were  
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Figure 4.3  Luciferase activity in C2C12 cells transfected with c.a.BMPR1A and 
wild type SMAD6C 
The effect of wild type SMAD6C on the luciferase reading induced by constitutively 
active BMPR1A (pcDNA3.1, an empty vector, acted as a negative control). The 
SMAD6C protein inhibits the luciferase activity generated by c.a.BMPR1A by 
approximately 30 fold. 
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c.a.BMPR1A-HA - + 
SMAD6C-FLAG - - + 
Blot: HA 
Blot: FLAG 
Blot: α-tubulin 
Figure 4.4 Overall SMAD6C variants inhibitory effect of three replicates and immunoblot images 
The mean relative luciferase activity of three separate transfection experiments performed in triplicate for each combination of constructs (pcDNA3.1, 
an empty vector, acted as a negative control). One-way ANOVA was used to determine statistical significance of the readings between the 
SMAD6C(wt) and mutants. SMAD6C p.Cys484Phe (c.1245G>T) and p.Pro415Leu (c.1244C>T) were significantly different from the wild type but 
not the p.Ala325Thr (c.973G>A) mutant. The three panels below show levels of protein expression of c.a.BMPR1A (HA) (top blot), SMAD6C 
constructs (FLAG) (middle blot) and α-tubulin (loading control) (bottom blot) in the functional protein complexes from luciferase reading.   
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used for dual luciferase reading to determine that differences in readout could not be 
due to differences in levels, either of c.a.BMPR1A or SMAD6 proteins. 
 
The molecular weight of the c.a.BMPR1A protein with a copy of the HA tag is 
approximately 62 kilodaltons (kDa). The molecular weight of the SMAD6C protein 
with a copy of the FLAG tag is approximately 29kDa. These tags do not modify the 
expression of the proteins to which they are appended (Brizzard et al. 1994; Kolodziej 
and Young 1991). Antibodies to the tags were used to detect c.a.BMPR1A and SMAD6 
respectively. Endogenous tubulin was used as a loading control. The molecular weight 
of α-tubulin is approximately 55kDa.  
 
The c.a.BMPR1A bands (probed with anti-HA) for the cell lysates transfected with 
p.Cys484Phe (c.1451G>T) and p.Pro415Leu (c.1244C>T) and wild type SMAD6 
constructs were equally strong. The BMPR1A band for the p.Ala325Thr (c.973G>A) 
construct was weaker. It could be argued that lower luciferase activity seen in these 
cells is actually a consequence of lower levels of c.a.BMPR1A being expressed. 
However, the intensity of the band is similar to the one from the group of cells that were 
transfected with c.a.BMPR1A and empty vector alone, which showed maximum 
luciferase activity indicating that the respective amount of c.a.BMPR1A being 
expressed was sufficient to induce maximum BMP signaling. 
 
The intensity of the bands for SMAD6 proteins (probed with anti-FLAG) were of 
similar intensity. The faint bands that were seen in the first two lanes (cells that were 
transfected with empty vector only, and cells that were transfected with c.a.BMPR1A 
and empty vector) are non-specific bands, as there was no FLAG-tagged protein 
expressed in those two groups of cells. The blots demonstrated that the difference in the 
luciferase readout observed for the SMAD6 variants were not due to SMAD6 protein 
not being expressed (or being expressed in different amounts) but they truly represent 
differences in the inhibitory activities of such proteins (Figure 4.4). However, as the 
bands for the SMAD6 mutant proteins were slightly weaker that the wild type, in 
addition to the fact that the presence of the very weak non-specific bands in the cells not 
transfected with SMAD6, it would be better to quantify the intensity of the western 
bands in order to conclusively interpret the protein expression of SMAD6 mutants and 
wild type.  
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The mean relative luciferase activity of the cells transfected with the SMAD6C 
p.Cys484Phe (c.1451G>T) variant and the wild type SMAD6C construct in the 
presence of c.a.BMPR1A was not significantly different from the cells that were 
transfected with wild type only (p value > 0.05).  Thus, when coexpressed with wild 
type SMAD6C, the SMAD6C p.Cys484Phe (c.1451G>T) variant did not serve as a 
dominant-negative mutant (Figure 4.5).  
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Figure 4.5 Effect of a 50:50 mixture of SMAD6C p.Cys484Phe (c.1451G>T) variant with SMAD6C wild type constructs 
The SMAD6C p.Cys484Phe (c.1451G>T) variant did not show dominant-negative effect when coexpressed with wild type SMAD6C, since a 50:50 
mix of variant and wild-type constructs was able to successfully inhibit BMP signaling (last column). (pcDNA3.1, an empty vector, acted as a negative 
control whereas c.a.BMPR1A activated BMP signaling)
P>0.05 
P<0.05 
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The investigation on whether the diminution of the inhibitory action of SMAD6 
affected the phosphorylation of the BMP-specific SMADs (SMAD1, SMAD5 and 
SMAD8) was performed using immunoblotting, in a manner analogous to that used by 
Goto and colleagues (Goto et al. 2007). The intensity of protein bands on western blots 
probed with antibody specific for phospho-SMAD1/5/8 and for unphosphorylated 
SMAD1 were compared between lysates for the six combinations of transfected 
plasmids. The molecular weight of the phospho-SMAD1/5/8 is 60kDa whereas the 
molecular weight of SMAD1 is approximately 56kDa. Results are presented in Figure 
4.6. Under the culture conditions that were used, which involved 10% FBS, there was a 
high background level of SMAD phosphorylation, although unphosphorylated SMAD1 
was also strongly detected. No differences in the ratio between phosphorylated and 
unphosphorylated SMADs between the different combinations of constructs were 
observed. This was probably due to a combination of the high background level of 
SMAD phosphorylation, and the inefficiency of transfection. Experiments described 
below suggested that only about 10% of cells were successfully transfected, and 
therefore any effects of SMAD6 construct transfection might have been obscured. 
Alternative explanations might have been either that the phospho-SMAD antibody was 
also detecting unphosphorylated SMAD proteins, or that the FBS used contained 
ligands which were influencing SMAD phosphorylation. It is of interest that the 
experiments of Goto et al. were described as having been conducted using 20% FBS; at 
that concentration, very little phosphorylation of SMADs was detected in the absence of 
BMP ligand stimulation. By contrast, however, unpublished data from our collaborator 
Dr. Helen Arthur’s group produced during the period of this work suggested that at 
lower concentrations of FBS (0.2%-1%) phosphorylation of SMADs in the absence of 
ligand stimulation was observed. Therefore the possibility of nonspecific binding by the 
phospho-SMAD antibody and the effect of different concentrations of FBS on the 
SMAD/ phospho-SMAD ratio were investigated. Non-transfected cell lysates were 
cultured in medium containing 5% or 10% of FBS and treated with 1µl of ExoSAP-IT 
to remove the phosphate. These were probed with phospho-Smad1/5/8 and Smad1 
antibodies respectively. The blots showed that phospho-Smad1/5/8 is indeed specific 
antibody as it does not bind to the unphosphorylated cell lysates (lysates that were 
treated with ExoSAP for 30 minutes and 1 hour) (Figure 4.7).  
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Combination of 
plasmids  
(BRE-Luc + 
Renilla) 
pcDNA3.1 c.a.BMPR1A + pcDNA3.1 
c.a.BMPR1A + 
SMAD6C (wt) 
c.a.BMPR1A + 
SMAD6C 
(p.Cys484 Phe) 
(c.1451G>T) 
c.a.BMPR1A + 
SMAD6C 
(p.Pro415Leu) 
(c.1244C>T) 
c.a.BMPR1A + 
SMAD6C 
(p.Ala325Thr) 
(c.973G>A) 
 
Blot: phospho- 
Smad1/5/8 
 
Blot: Smad1 
 
 
Figure 4.6 Immunoblot images of phospho-Smad1/5/8 and Smad1  
The panels above show protein expressions of phospho-Smad1/5/8 and Smad1 in the functional protein complexes from luciferase reading (in 
collaboration with Dr. Elise Glen). No differences in the ratio between phosphorylated and unphosphorylated SMADs between the different 
combinations of constructs were observed.  
(pcDNA3.1, an empty vector, acted as a negative control; c.a.BMPR1A, activated BMP signaling; SMAD6C(wt), inhibited BMP signaling) 
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Blot: phospho-Smad1/5/8 
 
Blot: Smad1 
 
Duration treated with 
ExoSAP (hour) 
0 0.5 1 0 0.5 1   
 
       5% FBS      10% FBS    
 
Figure 4.7 Immunoblot images of phospho-Smad1/5/8 and Smad1 treated with ExoSAP and cultured in different concentration of FBS 
The panels above show protein expressions of phospho-Smad1/5/8 and Smad1 in the treated with 1µl of ExoSAP for 0 hour, 30 minutes and 1 hour in 
cell lysates that were cultured in medium with 5% or 10% of FBS (in collaboration with Dr. Elise Glen). The blots showed that phospho-Smad1/5/8 is 
indeed specific antibody as it does not bind to the unphosphorylated cell lysates (lysates that were treated with ExoSAP for 30 minutes and 1 hour. 
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At 10% FBS, as in Figure 4.7, both non-phosphorylated and phosphorylated SMADs 
are detectable. Somewhat surprisingly, at 5% FBS, there is more phosphorylated (i.e. 
active) SMAD signal detectable than non-phosphorylated SMAD. This suggests that 
possibly FBS contains both ligands and inhibitors of this signaling pathway, since based 
on the data generated and the results from Goto et al., the relationship between FBS 
concentration and SMAD activation does not seem to be monotonic.  
 
Based on these experiments, it was concluded that further optimisation of culture 
conditions would be required to demonstrate differential effects of wild type and mutant 
SMAD6 on SMAD1/5/8/ phosphorylation. From the experiments performed, the 
possible mechanism whereby SMAD6 inhibits BMP signalling affected by the novel 
variants discovered was not conclusive.  
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4.4 Inhibitory effects of SMAD6 variants on alkaline phosphatase 
activity 
 
4.4.1 Inhibitory effects of SMAD6 variants with BMP ligands 
 
The inhibitory activities of the mutant SMAD6C proteins (p.Pro415Leu [c.1244C>T] 
and p.Cys484Phe [c.1451 G>T]) on alkaline phosphatase activity induced by 300 ng/ml 
of BMP2 or BMP6 were compared to that of the wild type SMAD6C, as previously 
described by Katagiri and colleagues (Katagiri et al. 1994). The p.Ala325Thr 
(c.973G>A) mutant was not tested in this assay as this mutant was not significantly 
different from the wild type protein in the luciferase assay. The ALP activity of the cell 
lysates was measured using p-nitrophenol phosphate as a substrate.  
 
Various variables were assessed using empty vector pcDNA3.1 and wt SMAD6C 
before undertaking the experiment with the mutant constructs. Quantitative analysis of 
ALP activity yielded different results for cells that were stimulated with BMP2 or 
BMP6 for 60 hours or 48 hours. Generally, cells that were stimulated with BMP6 
produced ALP activity around twice as high than BMP2 (Figure 4.8, upper and lower 
panels), which is in accordance with the results demonstrated by Goto and colleagues 
that BMP6 induced more sustained signaling (Goto et al. 2007).  The non-BMP treated 
cells (NTC) yielded very little alkaline phosphatase activity for all sets of cells. 
 
The ALP activity of the cells that were cultured for 48 hours after stimulation is shown 
in Figure 4.8. For both BMP2 and BMP6 stimulation, there was no apparent difference 
between untransfected controls and cells transfected either with empty vector or wild 
type SMAD6.  
 
Therefore, cells were cultured for 60 hours after stimulation with the hope that the 
difference between the wild-type and the empty vector could be discerned (Figure 4.9). 
In this experiment, the expected inhibition of BMP-stimulated ALP expression with the 
SMAD6Cwt construct was not observed – indeed, the ALP expression when 
SMAD6Cwt was transfected appeared if anything higher than in the BMP treated but 
untransfected cells. Surprisingly, ALP expression when empty vector was transfected 
appeared marginally higher than in the BMP treated but untransfected cells (ANOVA p-
value = 0.04). Since only an independent experiment was performed in duplicate for  
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Figure 4.8 ALP activity of the cell lysates that were stimulated with ligands and 
cultured for 48 hours 
The mean ALP activity of an independent experiment with duplicated cell lysates that 
were cultured for 48 hours. C2C12 cells were transfected with empty vector pcDNA3.1 
and wtSMAD6C, then stimulated with 300ng/ml of BMP-2 or BMP-6 24 hours after 
transfection. A) ALP activity of the cells stimulated with BMP-2. B) ALP activity of the 
cells stimulated with BMP-6. 
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Figure 4.9 ALP activity of the cell lysates that were stimulated with ligands and 
were cultured for 60 hours 
The mean ALP activity of an independent experiment with duplicated cell lysates that 
were cultured for 60 hours. C2C12 cells were transfected with empty vector pcDNA3.1 
and wtSMAD6C then stimulated with 300ng/ml of BMP-2 or BMP-6 6 hours after 
transfection. A) ALP activity of the cells stimulated with BMP-2. B) ALP activity of the 
cells stimulated with BMP-6. 
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each combination of constructs that were harvested at two different timepoint, this 
apparent difference could be due to a chance lower response in the BMP transfected 
cells; whatever the reason, it was clear that in this system SMAD6wt transfection was 
not suppressing ALP expression. 
 
It was hypothesised that the transfection efficiency could be responsible for the failure 
of wild type SMAD6 to inhibit ALP in the system. To assess transfection efficiency, 
C2C12 cells were transfected with an expression plasmid encoding a visible reporter 
gene, a GFP construct that encodes green fluorescent protein, using FuGENE® HD 
Transfection Reagent as described in chapter 2. Images of the fluorescent cells were 
identified using a fluorescent microscope 24 hours post-transfection. Transfection 
efficiency was determined by comparing the number of cells expressing the reporter 
protein to the total number of cells in the population. Transfection efficiency was 
approximately 10% (Figure 4.10).   
 
Given that the untransfected cells (90% of the cells present) also respond to BMP2/6, it 
was concluded that this was likely to mask any differences between the wild type 
SMAD6C construct and empty vector in the remaining 10% of cells. It was essential to 
have a system where a response would only be measured in cells transfected with wild 
type or mutant SMAD6. To limit BMP stimulation to transfected cells, the 
constitutively active BMPR1A construct was utilised. 
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Figure 4.10 Fluorescent microscope image of GFP transfected cells 
Microscope image of transient transfection with GFP plasmid DNA produced 
fluorescent protein that was observed in C2C12 cells (magnification 10X). Transfection 
efficiency observed was approximately 10%. 
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4.4.2 Assessment of inhibitory effects of SMAD6 variants on alkaline 
phosphatase activity with c.a.BMPR1A 
 
To overcome the limitations of transfection efficiency, the inhibitory activity of the 
mutant SMAD6C proteins on the inhibition of osteoblastic differentiation (ALP activity) 
compared to the wild type was assessed by transfecting c.a.BMPR1A and either empty 
vector, wild type SMAD6, p.Pro415Leu (c.1244C>T) or p.Cys484 Phe (c.1451G>T). 
Three independent experiments were performed in duplicate for each combination of 
constructs. The mean reading of the ALP activities taken at the 13 hour time point is 
shown in Figure 4.11. Two-way ANOVA was used to determine the statistical 
significance of the differences between readings from the wild type SMAD6 and both 
mutants (p.Pro415Leu [c.1244C>T] and p.Cys484Phe [c.1451G>T]).  SMAD6 
p.Cys484Phe (c.1451G>T) showed 1.3 fold higher ALP activity compared to wild type 
with a p value of < 0.05. The ANOVA suggested a non-significant difference in the 
p.Pro415Leu (c.1244C>T) mutant compared to the wild type SMAD6 (p value > 0.05). 
This might be due to the size of the effect of p.Pro415Leu (c.1244C>T) mutant being 
too small to be detected with the number of replicates that were performed, or the effect 
of this mutant may not be optimally captured with the timepoint that was used. However, 
SMAD6 p.Cys484Phe (c.1451G>T) clearly failed to inhibit osteoblastic differentiation 
when compared to wild type SMAD6. This is in line with the results of the luciferase 
assay. 
 
Similar protein expression levels of HA-tagged c.a.BMPR1A and FLAG-tagged 
SMAD6C wild type or mutants were observed when immunoblotting was carried out, as 
shown in Figure 4.11. The same intensity was observed in the loading control, nucleolin, 
showing that the concentration of the proteins for each combination of constructs was 
even. The blots demonstrated that the difference in the ALP activity observed for the 
SMAD6 variants were not due to the SMAD6 or c.a.BMPR1A protein being 
differentially expressed but rather due to differences in the inhibitory activities of the 
wild type and mutant SMAD6. 
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Figure 4.11 ALP activities in the cell lysates that were transfected with c.a.BMPR1A 
Alkaline phosphatase activity of c.a.BMPR1A transfected C2C12 cells with or without SMAD6C variants was measured at a single timepoint as absorbance of p-nitrophenyl 
at 405nm per mg/ml protein using p-nitrophenylphosphate as a substrate (in collaboration with Dr. Elise Glen). The results represent the average of three separate 
transfection experiments performed in duplicate. 2-way ANOVA was used to determine statistical significance of the readings at a single timepoint (+13 hours after start of 
assay) between the SMAD6C(wt) and both mutants. SMAD6C p.Cys484Phe (c.1451G>T) was found to show significantly greater ALP activity than SMAD6C(wt) after 13 
hours (p < 0.05) however SMAD6C p.Pro415Leu (c.1244C>T) was not found to show significantly different ALP activity to the SMAD6C(wt) at the 13 hour timepoint. The 
blots below show the protein expression of c.a.BMPR1A (HA), SMAD6 wild type or mutant constructs (FLAG) and nucleolin (loading control), demonstrating that the 
difference in the ALP activity observed for the SMAD6 variants were not due to the SMAD6 or c.a.BMPR1A protein being differentially expressed but rather due to 
differences in the inhibitory activities of the wild type and mutant SMAD6.  
p <0.05 
NS 
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4.5 Summary 
 
Using a site-directed mutagenesis technique, three non-synonymous SMAD6 variants 
were introduced into SMAD6C expression constructs. Dual luciferase assays showed 
that the SMAD6 p.Cys484Phe (c.1451G>T) variant resulted in abolition of the 
inhibitory effect of SMAD6, the p.Pro415Leu (c.1244C>T) variant reduced the 
inhibitory activity by half whereas the p.Ala325Thr (c.973G>A) variant did not differ 
from the wild type. Western blotting demonstrated that equal amounts of protein were 
present in each case. Therefore, the loss or partial loss of the inhibitory effect was not 
due to the absence of mutant proteins. Investigation of the p.Cys484Phe (c.1451G>T) 
and p.Pro415Leu (c.1244C>T) variants using an alkaline phosphatase assay showed that 
p.Cys484Phe (c.1451G>T) had diminished ability to inhibit osteoblastic differentiation, 
resulting in higher alkaline phosphatase activity than the wild type protein and 
providing a potential mechanistic explanation for the aortic calcification phenotype seen 
in the patient carrying the p.Cys484Phe (c.1451G>T) variant.   
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Chapter 5  Discussion 
 
5.1 Overview 
 
This is the first study of the relationship between rare genetic variations in multiple key 
genes of the BMP signaling pathway and CVM. The BMP signaling pathway plays an 
important role during development and adult life. The five candidate genes, BMP2, 
BMP4, BMPR1A, BMPR2 and SMAD6 were selected based on previous reports that 
have shown them to be essential for normal heart development. It was hypothesized that 
rare functional variation in members of this pathway could predispose individuals to 
increased risk of CVMs. In order to investigate the presence of rare genetic variants, the 
exons of the candidate genes were sequenced in a panel of 90 CVM patients with a 
range of congenital heart disease phenotypes. The inheritance of the variants was 
determined when parents of the patient were available. The unreported genetic variants 
were genotyped in a collection of 1425 individuals from 255 nuclear families, 
contributing 1000 control chromosomes. A total of 35 unreported genetic variants were 
identified; of these, 27 variants were genotyped in the controls. All these variants were 
inherited either from mother or father. De novo variants were not identified in this study.  
 
Among the previously unreported genetic variants identified in the candidate genes, the 
genetic variants seen in the 5’UTR or in the introns of BMP4 were investigated further 
as they were absent in the controls and the location of the variants suggested they might 
affect splicing. The genetic variants were analyzed with two different programmes to 
identify any putative effects on pre-mRNA splicing and were investigated by minigene 
assay. The minigene assays for two of the three novel rare variants in BMP4 showed 
that these two variants did not result in aberrant splicing, whereas the third assay was 
inconclusive.  
 
A total of seven non-synonymous variants were identified in this study: one in BMP4, 
one in BMPR2 and five in SMAD6.  Two variants of SMAD6 (p.Asp21Asn [c.61G>A] 
and p.Ser325Arg [c.975C>G]) were not evolutionarily conserved. Furthermore, 
SMAD6 p.Asp21Asn (c.61G>A) was present in the controls. The potential functional 
effect of the remaining non-synonymous variants were analyzed with the SIFT and 
PolyPhen programmes. BMPR2 p.Gly963Cys (c.2887G>T) and SMAD6 p.Cys484Phe 
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(c.1451G>T) variants were predicted to affect protein function by both algorithms. 
BMPR2 p.Gly963Cys (c.2887G>T) was not further investigated as a study carried out 
by Rudarakanchana and colleagues showed that cytoplasmic tail of BMPR2 (the 
location of the variant) is not vital in transducing BMP signals (Rudarakanchana et al. 
2002). Further re-sequencing of the MH2 domain of SMAD6 in an additional 348 
probands with a broad range of CVM phenotypes yielded two further non-synonymous 
variants. One of the variants, SMAD6 p.Pro415Leu (c.1244C>T), was also predicted to 
affect protein function. Both non-synonymous variants of SMAD6, p.Cys484Phe 
(c.1451G>T) and p.Pro415Leu (c.1244C>T), were absent in the control population.  
 
In vitro functional analyses of the three non-synonymous SMAD6 variants that were 
located in the MH2 domain were carried out to assess the inhibitory effect of the mutant 
proteins compared to that of the wild type protein on the BMP-signaling pathway. 
Luciferase assay showed that p.Pro415Leu (c.1244C>T) and p.Cys484Phe (c.1451G>T) 
variants were significantly different from the wild type in the inhibition of BMP 
signaling (p <0.05). Based upon the known functions of the BMP signaling pathway and 
the phenotypes of the patients carrying these variants, these two variants were further 
investigated using an alkaline phosphatase assay to investigate osteogenic 
transformation during development. This assay revealed that the p.Cys484Phe 
(c.1451G>T) variant failed to inhibit alkaline phosphatase activity compared to the wild 
type (p<0.05). The inefficiency of the p.Cys484Phe (c.1451G>T) variant in inhibiting 
osteogenic differentiation is in accordance with the phenotype of the patient that 
exhibited calcification (and coarctation) of the aorta. The principal novel finding of this 
study is that inhibitory failure of BMP signaling due to genetic variation in SMAD6 can 
be one of the factors that contribute to CVM in man. Table 5.1 summarizes the findings 
of this study in the five candidate genes sequenced.  
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Characteristic of the previously 
unreported variants  
Number of 
variants 
Variants 
Absent in controls, coding region, 
predicted deleterious 2 
SMAD6 p.Pro415Leu (c.1244C>T);  SMAD6 p.Cys484Phe (c.1451G>T) 
Absent in controls, coding region, 
predicted non deleterious 5 
SMAD6 p.Ser325Arg (c.975C>G) #; SMAD6 p.Ala325Thr (c.973G>A)∝ 
BMP4 p.Gly174Ser (c.520G>A)  
BMP2 c.891G>A (p.Lys297Lys); BMP2 c.1146A>G (p.Leu283Leu) 
Absent in controls, non-coding 
region, putative regulation 8 
SMAD6 c.-428A>T; SMAD6 c.-290G>C; SMAD6 c.*319T>A 
BMP4 c.-283G>C; BMP4 c.-295G>A; BMP4 c.-136C>G; BMP4 c.-87C>T 
BMP2 c.-906C>T 
Present in controls, significant 
MAF difference in 180 cases/ 1000 
control chromosomes 
3 
SMAD6 c.120C>T 
BMP4 c.-171C>G  
BMP2 c.-342_-340delTGT 
Present in controls, no MAF 
difference in 180 cases/ 1000 
control chromosomes 
9 
SMAD6 c.-44C>T; SMAD6 c.61G>A; SMAD6 c.711C>T; SMAD6 c.*262T>C  
BMP4 c.76T>C; BMP4 c.345C>T; BMP4 c.370+28G>A  
BMP2 c.-673G>A; BMP2 c.*936_939delATTT 
Coding region, predicted 
deleterious 1 
BMPR2 p.Gly963Cys (c.2887G>T) 
Non-coding region 
7 
BMPR1A c.534-59T>C 
BMPR2 c.-301G>A; BMPR2 c.621+30_32delGTT; BMPR2 c.855-22T>C; BMPR2 
c.969-122_124delTCT; BMPR2 c.969-122T>C; BMPR2 c.969-118_116delTTT 
# Alternatively spliced exon 4B of SMAD6, SIFT predicted deleterious but PolyPhen predicted non-deleterious 
∝ 
Requires another attempt of genotyping in 1000 controls  
 
Table 5.1  Thirty-five previously unreported variants identified in the candidate genes 
Summary of the findings in this study in the five candidate genes sequenced.  
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5.2 The SMAD6 gene and CVM 
 
In SMAD6, ten previously unreported variants were identified in a panel of 90 CVM 
patients. Five of these variants were present in the controls. The minor allele 
frequencies (MAF) in controls and cases for four variants: c.-44C>T, c.61G>A, 
c.711C>T and c.*262T>C, were not significantly different, indicating that these variants 
are unlikely to confer substantial risks of CVM. However, they would require further 
study in more patients and controls to rule out small to moderate effects on risk of CVM. 
This is especially important for variant c.*262T>C as this variant is predicted to 
increase base pairing of the miRNA has-miR-219-2-3p and it has been shown that SNPs 
that alter miRNA target binding are implicated in breast cancer susceptibility (Nicoloso 
et al. 2010). miRNAs are small non-coding RNAs (approximately 22 nucleotides in 
length that inhibit translation by base pairing with the 3’UTR of mRNAs. Nicoloso et al. 
have identified two SNPs (rs1982073-TGFB1 and rs1799782-XRCC1) that could 
modulate gene expression by modifying the binding of miRNA with mRNA.  
 
The c.12-C>T variant was found in 7 patients with various phenotypic defects and was 
observed in the control population with a frequency of 0.029. The difference of MAF 
between controls and probands was significant (p=0.029), providing weak evidence in 
forming of a relationship with CVM. However, further genotyping of the variant in a 
larger number of cases and controls would be necessary to confirm the association of 
the variant with CVM. It is possible that the relatively weak association observed was a 
chance finding due to multiple comparisons of allele frequencies between cases and 
controls.  
 
Five variants were absent in the controls: c.-428A>T, c.-290G>C, c.975C>G, 
c.1244C>T and c.*319T>A. Sequencing 1000 control chromosomes has 90% power to 
detect a polymorphism with 1/500 population frequency. However, the power to detect 
a very rare variant would be considerably lower (e.g. around 65% power to detect a 
variant of frequency 1/1000). There is an arbitrary element to the selection of the 
number of controls necessary to suggest a possible pathogenic role for a newly 
described variant (Collins and Schwartz 2002). Moreover, since the families recruited 
for this study did not show Mendelian inheritance patterns, the variants found were not 
expected to be “private” mutations. It is likely that if sufficient control chromosomes 
were sequenced, additional carriers would be found. Recognizing this, the absence of a 
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variant in 1000 control chromosomes was indicated as a variant of possible interest 
warranting further functional investigation. The control population was selected with 
great care: racial, ethnic and geographic background were similar to the cases and CVM 
had been ruled out by echocardiography.  
 
The c.-428A>T and c.-290G>C variants were located in the 5’UTR of SMAD6. Such 
variants might have significant effects on gene expression. Variants in the promoter 
region of many genes have been shown to influence gene expression and in some cases 
disease susceptibility. For example, Signori and colleagues showed that a mutation in 
the 5’UTR of the BRCA1 gene resulted in a 30-50% lower translation efficiency than 
the wild type allele and was associated with breast cancer risk (Signori et al. 2001). One 
potential drawback of classical transfection assays to assess the effect of promoter 
variants is that the variant is examined outside of its genomic context. Approaches such 
as allelic expression imbalance assays have the potential to overcome this issue. As a 
recent example, Cunnington and colleagues showed that chromosome 9p21 SNPs 
previously associated with coronary heart disease in genome wide association studies 
influence allelic expression of 3 nearby genes (Cunnington et al. 2010). Although the 
target issue for these gene expression changes is likely to be vascular smooth muscle 
cells, that study provided strong evidence for cis-acting effects on gene transcription 
using RNA from peripheral blood white cells. Similar approaches could be adopted for 
the further investigation of the c.-428A>T and c.-290G>C variants in future studies. 
However, this project focus on those novel variants affecting protein coding.  
 
A non-synonymous variant p.Ser325Arg (c.975C>G) in alternative exon 4B was 
identified in an ASD patient. The patient’s parents were unavailable for investigation. 
The absence of this variant in the controls suggested the change might be a rare variant 
specific to a CVM family. However, as this variant is located in the linker region with 
relatively less likely functional effects when compared to the MH1 and MH2 domains 
of SMAD6, functional studies were not performed on this variant.  
 
The c.*319T>A variant was seen in a proband with PFO and was not seen in the control 
population. However, the variant was predicted not to bind to miRNA by the in silico 
programmes and it was therefore not prioritized for functional investigation. 
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The variant that was predicted to be deleterious to protein function in bioinformatic and 
structural analysis in silico was c.1451G>T, resulting in the amino acid substitution 
p.Cys484Phe. Unfortunately, it was not possible to establish the pattern of inheritance 
for this variant, as both parents of the patient were deceased. Screening of the siblings 
of this patient would give a better insight into the inheritance of the variant but that was 
not possible, as ethics of this study did not permit patients to be re-contacted. The 
absence of the variant in the controls indicates that variants in the MH2 domain might 
be associated with CVM. Therefore, the MH2 domain of SMAD6 was further re-
sequenced in a replication cohort of 348 patients. Two previously unreported variants 
were identified in the second screening. The c.973G>A variant was assumed to result in 
the amino acid substitution p.Ala325Thr in a patient with mitral valve regurgitation. 
This variant was inherited from a phenotypically normal father. The variant was not 
investigated in the control population as it was not successfully incorporated into the 
iPLEX sequenom assay. It might have been possible to design another sequenom assay 
for this variant or use a Taqman genotyping assay to check on the controls. However, 
since an in vitro functional assay system to investigate other SMAD6 variants had been 
set up by this time, the study of p.Ala325Thr (c.973G>A) variant in that system directly 
was elected as an alternative approach. The p.Ala325 residue was evolutionarily 
conserved in human, chimpanzee, mouse and chicken but not in frog, zebrafish and 
fruitfly; indicating that this substitution was perhaps unlikely to have a major effect on 
the protein function. This was in accordance with the in silico analysis that predicted 
this variant not to affect protein function.   
 
The c.1244C>T variant resulting in p.Pro415Leu substitution was identified in a patient 
with aortic stenosis and was inherited from an unaffected father. Therefore, the variant 
might interact with other sequence variants and environmental factors to cause CVM. 
The substitution was not detected in the control population. The p.Pro415 residue 
showed a complete conservation from human to fruitfly, and an effect on protein 
structure was predicted when mutated to leucine. In addition, both SIFT and Polyphen 
algorithms predicted this variant to be probably damaging.  
 
The effects on the inhibitory activities of the variants were assessed by dual luciferase 
assay using a protein expression construct of the MH2 domain of SMAD6. No 
significant difference in inhibitory activity of the p.Ala325Thr (c.973G>A) variant was 
observed when compared to the wild type, as expected by the outcome of the prediction 
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programmes and also the lack of evolutionary conservation. The p.Pro415Leu 
(c.1244C>T) variant revealed significantly lower inhibitory ability than the wild type 
and the p.Cys484Phe (c.1451G>T) variant failed to inhibit the BMP signaling 
completely, appearing to be a null allele. The potential mechanisms of the impaired 
variants in the BMP signaling pathway are discussed below.  
 
Based on the knowledge of BMP signaling in regulating calcification, the additional 
effects of the mutations (p.Pro415Leu [c.1244C>T] and p.Cys484Phe [c.1451G>T]) on 
osteogenic potential was investigated. The p.Cys484Phe (c.1451G>T) variant has 
reduced ability to inhibit alkaline phosphatase activity but not the p.Pro415Leu 
(c.1244C>T) variant. This suggests that p.Cys484Phe (c.1451G>T) variant might be 
less efficient in preventing tissue calcification, which is in accordance with the 
diagnosis of the patient. The patient was diagnosed with coarctation, bicuspid aortic 
valve and mild aortic stenosis following the discovery of hypertension as a young man. 
The patient had a coarctation repair at age 30 years. He subsequently developed 
significant aortic stenosis and underwent aortic valve replacement and repair of the 
aortic arch again. At the second operation, the transverse aortic arch proximal to the 
previous conduit, was found to be heavily calcified. There was no evidence of 
inappropriate calcification in non-cardiovascular tissues. 
 
The p.Pro415Leu (c.1244C>T) variant was found in a patient who presented with a 
murmur at 18 months and was found to have a bicuspid aortic valve with moderate 
aortic stenosis. No evidence of coarctation or ectopic calcification was observed in this 
patient. Both patients demonstrated functionally significant SMAD6 variants in the 
luciferase assay and had phenotypes involving the aortic valve, suggesting that variation 
in SMAD6 function might particularly affect the development of the aortic valve. The 
prevalence of the pathogenic non-synonymous SMAD6 variants among the 47 patients 
with bicuspid aortic valve and/or aortic stenosis defects out of a total of 436 CVM 
patients was approximately 4%.  
 
Galvin and colleagues generated Smad6 mutant mice by targeting insertion of a LacZ 
reporter into the 5’terminus of the Smad6 MH2 domain in embryonic stem cells (Galvin 
et al. 2000). Analysis of the mouse model revealed that Smad6 was expressed by 
embryonic day seven (E7) using northern-blot analysis. During development of Smad6 
mutant embryos, X-gal staining showed that Smad6 was expressed in the developing 
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outflow tract and atrioventricular cushion regions of the heart (E9.5-E13.5). The X-gal 
staining pattern expanded to the blood vessels at later embryonic stages, indicating that 
Smad6 played an important role during the development of the heart, especially the 
outflow tract and atrioventricular cushion regions. Smad6 mutant mice showed 
hyperplastic thickening of the pulmonary and mitral valves, including misplaced 
septation of the cardiac outflow tract, resulting in an extremely narrow ascending aorta 
with a large pulmonary trunk or the reverse. Both patients with the functionally 
significant variants identified in this project had phenotypic defects involving the aorta 
and outflow tract. Genotyping ratios of the knockout mouse showed reduced numbers of 
the homozygous mutants than expected, indicating partial lethality. The viable mutant 
adult mice showed ossification of the outflow tracts of the heart at or after 6 weeks of 
age. These defects are in keeping with the phenotypic defects of the patient with variant 
p.Cys484Phe (c.1451G>T) (coarctation of the aorta) that completely failed to inhibit 
BMP signaling in the luciferase assay and also resulted in osteogenic expression in the 
alkaline phosphatase assay (calcification of the aorta that was discovered at the second 
operation a few years later); the patient with variant p.Pro415Leu (c.1244C>T) (aortic 
stenosis) was significantly unable to inhibit BMP signaling in the luciferase assay but 
did not reveal any enhanced osteogenic potential in the alkaline phosphatase assay.  
 
This is the first description of a human disease associated with mutations in SMAD6. No 
previous studies have been carried out on the identification of SMAD6 mutations in 
CVM. Sequencing of SMAD6 in 100 patients with colorectal cancer (Fukushima et al. 
2003), in 52 hepatocellular carcinoma samples (Kawate et al. 2001), in 30 human 
ovarian cancers (Wang et al. 2000a), and in 12 pancreatic cancer patients (Jonson et al. 
1999), in previous studies has not identified any mutations of likely phenotypic 
relevance. Therefore, the functionally significant mutations that have been identified in 
patients with lesions of the aortic valve and aorta demonstrate that SMAD6 might play 
an important role in the development and homeostasis of these structures.  
 
Of the five genes investigated in the study, only targeted mutation of SMAD6 MH2 
domain shows a role in the development and homeostasis of the cardiovascular system. 
BMP2, BMP4, BMPR1A and BMPR2 are more broadly expressed, and have important 
additional functions outside of the heart, as the knockout mice of these genes are non-
viable. This is consistent with the known extra-cardiac phenotypic consequences of 
mutations in these genes in humans.  
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5.3 The BMP2 gene and CVM 
 
In BMP2, 6 novel variants were identified, of which three variants were absent in 
controls. The three variants that were present in the controls are: c.-673G>A, c.-342_-
340delTGT and c.*936_939delATTT. The minor allele frequencies (MAF) of controls 
and cases for both c.-673G>A and c.*936_939delATTT variants were not significantly 
different (p=0.512 and p=0.406 respectively). It is not possible to conclusively rule out 
association between these variants and CVM from the data. Studies of very much larger 
numbers of cases would be reuquired to do this. The allele frequencies for both variants 
are in the range 0.02 to 0.03, and they would therefore be considered low frequency 
variants. Unless the phenotypic consequences of such low frequency variants are large, 
it will be very difficult to establish their definite involvement in disease. This is because 
amassing enough cases that carry the variant to be able to detect moderate odds ratios 
would require studies of tens of thousands of patients. With respect to functional 
annotation, the c.*936_939delATTT variant was predicted not to alter miRNA binding.  
 
The c.-342_-340delTGT variant in exon 1 was identified in 8 out of 90 probands and 
observed in controls with a frequency of 0.024. The difference of MAF between 
controls and probands was significant (p=0.0057). This suggests that the c.-342_-
340delTGT variant might predispose to CVM. Further analysis of this variant in a larger 
number of cases and controls will be required to answer the question whether the 
association with CVM is robust.    
 
One of the variants that were absent in the controls was c.-906C>T. This variant was 
located in 5’UTR of exon 1 and was maternally inherited by a proband with aortic 
stenosis, indicating incomplete penetrance. The variant was absent in the control 
population. It remains to be investigated by functional analysis whether the variant 
results in the increment/decrement of translation efficiency, allelic expression analysis 
or expression in tissue, whereby it could play a role in CVM susceptibility. 
  
The synonymous c.891G>A and c.1146A>G variants were identified in exon 3. Variant 
c.891G>A was inherited from an unaffected father, whereas variant c.1146A>G was 
inherited from an unaffected mother. These variants were absent in the controls and 
only observed in families with affected CVM probands and healthy parents, indicating 
that these variants, if significant, are susceptibility factors rather than sufficient 
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causative factors. The manner in which these synonymous mutations might be causing 
an effect is however, unknown, and would need further investigation if these findings 
were to be pursued. Future work might include the generation of a BMP2 construct 
subcloned into an expression vector, and introduction of the variants by site-directed 
mutagenesis. Constructs would then be transiently transfected into a mammalian cell 
line followed by RNA extraction, reverse transcription and immunoblotting. The protein 
levels in the cell lysates for the variants would then be compared to that of the wild type.  
 
No previous studies have been carried out on screening of BMP2 mutations in patients 
with CVM. Previously studies have reported BMP2 polymorphisms to be associated 
with certain other phenotypes. A missense polymorphism (p.Ser37Ala) and two SNP 
haplotypes (haplotype one is defined by three SNPs – TSC0271643(T), P9313(T) and 
rs235764(G), haplotype two is defined by two SNPs – rs1116867(A) and D35548(T)) in 
BMP2 were shown to be associated with low bone mineral density (BMD) and 
associated fractures in Icelandic and Danish populations using linkage analysis 
(Styrkarsdottir et al. 2003).  
 
Another study performed by Dathe and colleagues (Dathe et al. 2009) found CNV, but 
no point mutations in BMP2 in individuals in two unrelated families affected with 
brachydactyly type A2 (BDA2), a limb malformation characterized by hypoplastic or 
aplastic middle phalanges of the second and fifth finger without any CVM. One of the 
pedigrees is part of a large Brazilian kindred of German origin (five generations, of 
which 26 individuals were clinically examined and molecular analysis was performed) 
while another family is smaller (three generations, only 2 individuals were investigated) 
and also of European origin. They detected a microduplication of approximately 5.5kb 
in a non-coding region 11kb downstream of BMP2 in these families using high-density 
array CGH. They further investigated the evolutionary highly conserved noncoding 
duplicated region in vivo, using a transgenic mouse model, and showed that the 
duplicated region was able to regulate the expression of an X-Gal reporter construct in 
the limbs and resulted in increased expression of BMP2. This suggests that a regulatory 
element around BMP2 that is affected by the duplication might affect the expression of 
BMP2 in limb development, and that dysregulation of BMP2 expression can lead to 
BDA2.  
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In conclusion, no definite association of the BMP2 gene with CVM was identified. No 
previous studies have investigated this gene in human CVM. With respect to further 
studies, the findings of Dathe and colleagues on BDA2 have demonstrated the existence 
of important BMP2 regulatory elements distant from the coding sequence. This study 
was not designed to examine such genomic features. Although investigation of longer-
range regulatory sequences on BMP2 expression and CVM could be considered, such 
work lay outside the primary hypothesis for this study.  
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5.4 The BMP4 gene and CVM 
 
In BMP4, nine previously unreported nucleotide variants were identified. Five of these 
variants were absent in controls whereas four variants were present in the controls. The 
minor allele frequencies (MAF) in controls and cases were not significantly different for 
three variants: c.370+28G>A variant in intron 3, c.76T>C and c.345C>T (synonymous 
variants), with p values of 0.753, 0.282 and 0.282 respectively. Since the allele 
frequencies observed in the controls for these variants are low, studies of many 
thousands of patients would be required to rule out odds ratios for diseases of 2 or less.  
 
The c.-171C>G variant was identified in 10 out of 90 probands and present in the 
controls with a frequency of 0.017. The difference of MAF between cases and controls 
was significant, with a p value of 0.00007, indicating that the variant is more frequent in 
the probands. It would be interesting to genotype the c.-171C>G variant in further cases 
and controls to confirm the significance of this association. Genome wide association 
studies (GWAS) in over 2000 cases and controls are in progress in the host laboratory; 
for the purpose of this thesis and its focus on rare variants, it was decided not to pursue 
this preliminary, though interesting, observation in relatively small numbers of patients.  
 
The c.-283G>C variant in exon 1A, c.-295G>A variant in intronic region of exon 1B an 
c.-87C>T variant in exon 2 were all identified in a patient with TGA and were all 
inherited from a phenotypically normal father indicating that these variants are part of a 
haplotype. Moreover, these variants were not seen in the controls. Another variant, c.-
136C>G, located in the 5’UTR, was found in another patient with TGA and was 
inherited from the father but was absent in the controls. These variants were further 
investigated using the minigene approach.  
 
The minigene approach has been used in previous papers to analyse whether 
synonymous allelic variants found in patients affect splicing efficiency (Fernandez-
Guerra et al. 2010; Wilson et al. 2009). This approach has the advantage that RNA is 
not required and genomic DNA can be used instead. For the c.-295G>A variant in 
intron 1 no aberrant splicing was observed when the variant was compared to the wild 
type, even though the ESE finder programme predicted the creation of a branch site in 
the variant and the programme generated by Dr. Grellscheid predicted the loss of an 
ESE site. This might be because this variant was part of a haplotype. It is possible that 
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c.-295G>A on its own does not affect splicing, whereas the full haplotype does. The 
approach that could be adopted to analyse this is to clone the segment of interest 
consisting of exon 1B and exon 2 with variant c.-295G>A and c.-87C>T including their 
flanking regions into the pXJ41 vector. A similar approach was used by Kereszturi and 
colleagues (Kereszturi et al. 2009) to study multiple intronic variants in common 
SPINK1 (serine protease inhibitor Kazal type 1) haplotypes associated with chronic 
pancreatitis. Wild type and mutant version of introns 1,2 and 3 of the the two haplotypes 
were studied in parallel (Figure 5.1). They identified the haplotype consisting of the 
c.194+2T>C intronic alteration abolished SPINK1 expression in the mRNA level. No 
detectable functional effect was observed in another haplotype comprising the 
p.Asn34Ser missense variant and four intronic alterations. However, it would be 
technically challenging to amplify a substantial fragment of genomic DNA such as the 
BMP4 promoter region, and insert the fragment into the vector. 
 
The ESE finder prediction of c.-136C>G variant in exon 1B was not accurate: the 
programme predicted a decrease of splicing efficiency but the variant was not located at 
the exon/intron boundary in the context of the gene. The minigene assay demonstrated 
that there was no difference between the wild type and the mutant variant. Further in 
silico analysis, using the programme by Dr. Grellscheid which only became available in 
the later stages of this work, showed the change was within the acceptable threshold, in 
accordance with the minigene results.      
 
For the c.-87C>T variant, more optimization of the cloning parameters would be 
required in the future in order to clone the variant into the vector, if this line of 
experimentation were pursued. However, this would have low priority in further work, 
as both prediction programmes did not predict aberrant splicing for the variant.  
 
Only one previously unreported variant that resulted in a non-synonymous substitution 
was identified, in exon 4 of BMP4. The c.520G>A variant resulted in a glycine to serine 
substitution (p.Gly174Ser). The variant was not detected in the controls. However, 
protein prediction programmes predicted this change not to affect protein function. This 
variant is evolutionarily conserved from human to zebrafish but not in fruitfly. It 
remains to be investigated by functional analysis; one possible approach would be the  
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Figure 5.1 SPINK1 gene haplotypes (A) and SPINK1 minigenes (B)  
Common pathogenic SPINK1 gene haplotypes (A) and SPINK1 minigenes used (B) in 
the study of Kereszturi et al., (Kereszturi et al. 2009).  
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study described by Tabatabaeifar and colleagues (Tabatabaeifar et al. 2009), who 
investigated the characteristic of BMP4 mutations identified in patients with congenital 
anomalies of the kidney and urinary tract (CAKUT). Three missense mutations 
(p.Ser91Cys, p.Thr116Ser and p.Asn150Lys) found in five patients were studied in vitro 
using the full-length complement DNA clone of human BMP4. The mutants resulted in 
lower level of mRNA abundance of BMP4 in the cellular systems when checked with 
real time reverse-transcription polymerase chain reaction (RT-PCR) and reaffirmed with 
western blotting. However, as the variant identified was predicted to be benign, it was 
not prioritized for functional analysis.  
 
The coding region of BMP4 had previously been analysed in 205 patients with 
congenital septal defects by Posch and colleagues (Posch et al. 2008), as cardiac septal 
defects are among the major CVMs. Mutations in transcription factors (NKX2.5 and 
GATA4) had been previously identified in patients with septal defects (Garg et al. 2003; 
Schott et al. 1998). BMP4 is required for development of the endocardial cushions and 
inactivation of this gene in a mouse model caused atrioventircular septal defects 
(AVSD). The study of Posch et al. was published after the commencement of this work. 
110 patients in that study were diagnosed with ostium secundum atrial septal defects 
(ASDII) and 95 patients were diagnosed with different congenital septal defects and 
concomitant minor cardiac malformations. By contrast, in this study, BMP4 was 
sequenced in a total of 270 patients with a broad range of CVM. Of these, 55 patients 
were diagnosed with TGA or TGA with other cardiac defects, and 65 patients with 
septal defects. Posch et al. identified 2 patients with a c.845+30G>A variant that had not 
been described previously. No investigation was performed on the inheritance of 
variants. Posch et al. also investigated the reported non-synonymous SNP, p.Val152Ala 
located in exon 4 of BMP4 in cases and in 360 control alleles from unaffected 
individuals and found that the differences in allele frequencies between cases and 
controls was not significant. They concluded that patients with septal defects in general 
do not exhibit mutation in BMP4. A non-synonymous mutation, p.Gly174Ser 
(c.520G>A), was identified in a patient with ASD that was inherited from a 
phenotypically normal mother, suggesting that this allele, if causative, has reduced 
penetrance and might require environmental factors to cause CVM. This variant is 
absent in the controls but was predicted to be benign. Subsequent in vitro functional 
investigation on the rare variants located in the untranslated region that were absent in 
the controls showed that they did not abrogate splicing. Both this study and the study 
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conducted by Posch and colleagues, did not identify rare variants in patients with 
AVSD, the phenotype observed in the BMP4 knockout mouse, but the number of 
AVSD patients were small in both studies (10 in this study and 16 in Posch et al.). This 
study focused on a larger number of TGA patients instead due to the work by Thienpont 
and colleagues that identified a deletion on 14q21.3, which is near BMP4 (14q22.2), in 
a patient with TGA and other phenotypic defects (Thienpont et al. 2007). However, no 
BMP4 mutations were found in TGA patients in this study.    
 
BMP4 has been associated with other phenotypic defects. A study performed by Suzuki 
and colleagues (Suzuki et al. 2009) identified a novel missense mutation, p.Ala346Val, 
in a patient with microform cleft lip and a cleft palate. The mutation was inherited from 
the father who had a bifid uvula and microform cleft lip. Suzuki et al. also identified 
two missense mutations, p.Ser91Cys and p.Arg28His, in parents with orbicularis oris 
muscle (OOM) defects and a child with unilateral cleft lip and palate. Another five 
previously unreported missense or nonsense mutations were identified in 968 patients 
with cleft lip and/or cleft palate (CL/P) in that study. One of these mutations, 
p.Arg162Gln, was inherited from a phenotypically normal father. None of these 
mutations were found in 529 controls. SIFT and Polyphen programmes predicted the 
p.Ser91Cys, p.Arg162Gln and p.Ala346Val variants to be possibly damaging. No 
functional investigation was performed on these variants to ascertain the effects. That 
study showed increased severity of the phenotype in children than in carrier parents, i.e. 
anticipation. However, the numbers of cases with parent-to-child anticipation identified 
were small in that study. If the anticipation seen in the Suzuki study were a general 
finding with BMP4 mutations, the haplotype identified in this study (c.-283G>C, c.-
295G>A and c.-87C>T) that was inherited from a phenotypically normal father (who 
did not have an echocardiogram evaluation) in a TGA proband might be exhibiting this 
phenomenon.  
 
In another study, using a positional candidate gene approach, Bakrania and colleagues 
(Bakrania et al. 2008) sequenced the coding region of BMP4 and identified a frame-shift 
mutation c.226del2, resulting in a truncated protein at amino acid 104, p.Ser76fs104X, 
in a proband who had anophthalmia-microphthalmia (AM), retinal dystrophy, myopia, 
poly- and/or syndactyly, and brain anomalies. The proband’s mother, grandmother and 
maternal aunt carried the same mutation and had high myopia but not AM. The 
proband’s normal two half-brothers did not carry the mutation. Further investigation 
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revealed that the proband also had a c.1-125G>A change in the 5’UTR of SHH (Sonic 
Hedgehog). BMP4 interacts with HH signaling genes in animals in optic development. 
The SHH c.1-125G>A was also present in 16/191 controls. Other family members of 
this proband had a mutation in either BMP4 or SHH, but not both, indicating that the 
combination of mutations might have contributed to the more severe defects observed in 
the proband. That study shows the potential for gene-gene interaction involving BMP4 
to affect the manifestation of developmental disorders. It is possible that such 
interaction is of importance in CVM.  
 
In conclusion, previous studies have shown that mutations in BMP4 were infrequently 
observed in CVM patients but were strongly associated with other phenotypic defects, 
suggesting that BMP4 is important during development of multiple organ systems. This 
study did not identify association of BMP4 with CVM (enriched with TGA). However, 
the suggestion of a link between AVSD with BMP4 based on a mouse model would 
require further study in larger numbers of AVSD patients to clarify such relationship. 
Moreover, the ascertainment scheme for the present study would have tended to exclude 
patients with multiple and possibly syndromic phenotypes.     
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5.5 The BMPR1A gene and CVM 
 
Only one previously unreported variant (c.543-59T>C) was identified in intron 7, 59 
bases upstream from the 5’ end of exon 8 in a patient with atrial septal defect (ASD). It 
remains to be investigated whether this variant is present or absent in the control 
population and also to determine its inheritance. This variant was located in an intron 
and no novel variant was observed in the coding region. As discussed previously, rare 
non-synonymous variants located in the coding region are expected to have greater 
effect on disease susceptibility than non-coding variants (Kryukov et al. 2007), and 
therefore this gene was not prioritized for further study. 
 
BMPR1A mutations have been previously observed in patients with juvenile intestinal 
polyposis, which carries a risk of gastrointestinal cancers. Howe and colleagues 
established that between 35- 60% of juvenile polyposis syndrome (JPS) cases in North 
America were due to mutations in the SMAD4 gene (Howe et al. 1998). To detect 
additional polyposis genes, they used genome wide screening in four multiplex families 
who were known to carry no mutation in SMAD4. Howe and colleagues (Howe et al. 
2001) identified linkage with markers from chromosome 10q22-23, leading them to 
sequence the BMPR1A gene in those kindreds. Mutations in BMPR1A were discovered 
in each of the 4 families. One family had a four base pair deletion in exon one resulting 
in a stop codon at nucleotide 104-106. A second family had a one base pair deletion in 
exon 8 resulting in a stop codon, and two nucleotide substitutions causing stop codons 
(p.Gln238X and p.Trp271X) were found in the remaining two kindreds. None of these 
mutations were observed in 250 normal control individuals. The nonsense mutations 
were located at the serine-threonine kinase domain and were predicted to abrogate BMP 
signaling. However, no in vitro functional study was carried out on these mutations. 
Interrogation of other genes in the TGF-beta superfamily, including BMP signaling, 
(SMAD1, SMAD2, SMAD3, SMAD5, SMAD7, BMPR1B, ACVR1, and BMPR2) have 
yielded negative results (Bevan et al. 1999; Howe et al. 2004; Roth et al. 1999), 
suggesting that other genes predisposing to juvenile polyposis remain to be discovered.  
 
In another study, principally focused on JPS, Zhou and colleagues (Zhou et al. 2001) 
found 2 patients with both cardiac anomalies (one with ventricular septal defects and the 
other with Ebstein’s anomaly) and juvenile polyposis syndrome harboured mutations in 
BMPR1A without mutation in SMAD4. They studied 18 unrelated families and 7 
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unrelated patients. The mutation in the patient with ventricular septal defects was 
located in the 5’ UTR (IVS1-3C>G). It was a splice site mutation resulting in the 
skipping of exon 1, and was predicted to result in truncated receptors. The patient with 
Ebstein’s anomaly and JPS also had Wilms’ tumour. The mutation discovered in that 
patient resulted in a cysteine to tyrosine substitution (p.Cys376Tyr) in the kinase 
domain of BMPR1A. These two mutations were absent in the 100 normal race-matched 
control chromosomes. However, Zhou and colleagues did not identify any BMPR1A 
mutation in two further patients with juvenile polyposis and cardiac anomalies: one 
diagnosed with ventricular septal defect and the other with aortic regurgitation. The 
frequency of patients with JPS and cardiac anomalies was not significantly different 
among mutation carriers (2/10 carriers) and non-carriers (2/15 non-carriers) due to the 
small sample size. Therefore, genotype-phenotype association of JPS and cardiac 
anomalies with mutation in BMPR1A could not be established.   
 
In spite of this, the mouse model with the targeted deletion of BMPR1A in cardiac 
myocytes of the atrioventricular canal displayed tricuspid valve abnormalities 
reminiscent of Ebstein’s anomaly (Gaussin et al. 2005). There were longer tricupsid 
mural leaflets and the tricuspid posterior leaflet was displaced and adherent to the 
ventricular wall. These defects potentially support a role for BMPR1A in human 
Ebstein’s anomaly. As only 3 of the 90 sequenced probands were diagnosed with 
Ebstein’s anomaly in this work, it remains of interest to sequence a larger number of 
patients with this defect in order to increase the power of detecting novel variants in 
BMPR1A.   
 
In summary, this study did not find any association of BMPR1A gene with CVM. It 
might be that BMPR1A mutations might be found in a subset of patients with CVM and 
also predispose to cancer but not in patients with sporadic CVM only. The suggestion of 
a link between Ebstein’s anomaly and BMPR1A would require further study to establish 
this relationship.    
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5.6 The BMPR2 gene and CVM 
 
Seven genetic variants were identified in BMPR2. One was located in the 5’UTR, 5 
variants were seen in the intronic regions, and one non-synonymous variant in exon 13 
resulted in a glycine to cysteine substitution. Due to the pressure of more significant 
results in other genes screened, these results were not pursued further. The next step in 
the investigation of these variants would be genotyping in the parents of cases, and in 
the control population. If the variant in the 5’UTR were not seen in the controls, 
functional analysis using luciferase assay could be performed to investigate whether the 
variant increases or decreases expression of the gene. The 5 variants located in the 
intronic regions could be investigated with prediction programmes and minigene assays. 
Depending on the outcome of the genotyping, if the c.2887G>T (p.Gly963Cys) variant 
seen in an ASD patient were not detected in the 1000 control chromosomes, it would be 
interesting to investigate by co-transfecting wild type or mutant BMPR2 construct, 
BMPR1A construct and a p3TP-Lux promoter-reporter construct or BRE-Luc construct 
to determine whether this non-synonymous variant will affect the BMP signaling 
activity, as the in silico analysis predicted that the variant to be damaging. The BMPR2 
construct and p3TP-Lux promoter-reporter construct have been published (Rosenzweig 
et al. 1995; Wrana et al. 1992). The p3TP-Lux promoter-reporter is a luciferase reporter 
gene with the 3TP promoter that contains three consecutive TPA response elements 
(TREs) and a portion of the plasminogen activator inhibitor 1 (PAI-1) promoter region. 
These regions were chosen based on the responsiveness of these elements to TGFβ.  
 
A previous study performed by Roberts and colleagues (Roberts et al. 2004) identified 
mutations in BMPR2 in patients with both pulmonary arterial hypertension (PAH) and 
CVM, in whom the PAH was due to pulmonary vascular obstructive disease. The 
subjects of their study consisted of two cohorts: 40 adults and 66 children. A total of six 
non-synonymous mutations were found in the combination of 106 patients (Figure 5.2). 
Three mutations (p.Gln42Arg, p.Thr102Ala and p.Ser107Pro) located in exon 2 and 3 
were identified in three out of four adult patients with atrioventricular canals. Another 
three mutations (p.Gly47Asn, p.Met186Val and p.Glu503Asp) located in exon 2, 5 and 
11, were identified in the children. One of the children had an atrial septal defect and 
patent ductus arteriosus, one had an atrial septal defect, patent ductus arteriosus and  
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           ECD   TM      KD   CD 
 
ECD Extracellular domain 
TM Transmembrane 
KD Kinase domain 
CD  Cytoplasmic domain 
 
 
 
Figure 5.2 Location of the mutations in BMPR2 identified by Roberts et al., 
2004 
Location of the mutations in the BMPR2 identified by Roberts et al. with exons 1-13 
indicated, and the receptor domains shown below the exons (Roberts et al. 2004). 
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partial anomalous pulmonary venous return; and one had an aortopulmonary window 
and a ventricular septal defect. These mutations were located in the extracellular 
domains (exon 2 and 3) and might interfere with heterodimer formation or ligand 
binding, in the kinase domain (exon 5) that might disrupt the phosphorylation and the 
long cytoplasmic tail (exon 11) with unknown function. It was noted that no children 
with atrioventricular canal defects had mutations in BMPR2. Roberts and colleagues did 
not exclude syndromic patients from their analysis. The patient with complete atrial 
ventricular canal defect and the p.Gln42Arg mutation also had Down syndrome and the 
patient with atrial septal defect and patent ductus arteriosus with the p.Met186Val 
mutation had a ring 14 chromosome. The cardiac defects in these patients might 
therefore have arisen principally from the chromosomal abnormalities rather than the 
BMPR2 mutations. The p.Gly47Asn and p.Ser107Pro mutations were not inherited from 
the parents, demonstrating that these are de novo mutations. The altered amino acids of 
these two mutations are conserved only in man and mouse, in contrast to the other four 
mutations that are conserved across human, mouse, chicken, frog and puffer fish. 
 
Other mutations were not checked for inheritance, as the parents’ DNA were not 
available. However, Roberts and colleagues did not check the mutations that they found 
in a control population, giving rise to the question whether these mutations are 
polymorphisms or they are indeed rare mutations predisposing to defects. The mutations 
were interspersed in different domains of BMPR2, suggesting that there is no one 
particular domain that causes the defects. Even though the function of the long 
cytoplasmic tail domain (p.Glu503Asp in exon 11) in the study of Roberts et al. and the 
mutation that have been identified in this study (p.Gly963Cys [c.2887G>T] in exon 13) 
is still unknown, the presence of two mutations suggest that this domain might be of 
importance. Taken together, the findings of Roberts and colleagues, although suggestive, 
do not establish a conclusive role for BMPR2 mutations in CVM. Since mutations in 
BMPR2 are known to cause primary PAH, their study design would not have enabled 
mutations causing CVM to be distinguished from mutations that could cause PAH but 
were ‘innocent bystanders’ with regard to CVM.  
 
Nevertheless, the study of Roberts and colleagues raises important questions. In the 
setting of CVM, the development of pulmonary hypertension due to left to right 
shunting is variable among patients with the same malformation. It remains unknown 
whether there is genetic susceptibility to the development of PAH in the context of 
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CVM. In order to address this question with the greatest power, it would be necessary to 
establish a large cohort of patients with the same phenotype, and relate their 
susceptibility to the development of PAH to common or rare genetic factors. While this 
is an approach that would potentially yield clinically significant and useful results, the 
practical difficulties of establishing phenotypically homogeneous cohorts of many 
thousands of CVM patients are substantial.  
 
Mutations in BMPR2 have been identified in many patients with pulmonary arterial 
hypertension (PAH), be it idiopathic PAH (IPAH) or familial PAH (FPAH).  These 
heterozygous mutations comprise nonsense, missense, splice site defects, small 
insertions or deletions and duplications, and partial gene deletions or duplications 
(Machado et al. 2006). Cell-based in vitro analysis of mutations in BMPR2 carried out 
by Rudarakanchana and colleagues (Rudarakanchana et al. 2002) to test their abilities to 
transduce BMP signals have shown that missense mutations located within the 
extracellular and kinase domains abrogated their signal-transducing abilities. However, 
the mutant BMPR2 constructs with truncated cytoplasmic tail or missense mutations as 
observed in the PAH patients (Machado et al. 2001) were able to transduce a BMP 
signal, suggesting that the mutant might affect BMP signaling through an alternative 
pathway independent of Smads. They then examined the effect of the BMPR2 mutants 
(including the cytoplasmic tail mutants) on p38MAPK, one of the MAP kinases activated 
by BMPs. It was shown that overexpression of the mutants lead to the activation of 
p38MAPK in the absence of ligand but the wild type receptor required the presence of 
BMP4 to activate p38MAPK. Therefore, the p.Gly963Cys (c.2887G>T) variant that have 
been identified in the cytoplasmic tail might disrupt p38MAPK signaling but not through 
SMAD signaling. 
 
In conclusion, the preliminary findings of this study and the study of Roberts et al. 
(Roberts et al. 2004) suggest a possible association of BMPR2 and CVM. However, as 
no previous investigation on the occurrence of BMPR2 mutation in CVM patients 
without PAH have been performed, further investigation will be required to differentiate 
the role of BMPR2 in PAH from any role of BMPR2 in CVM. The mutations in 
BMPR2, especially the ones located in the cytoplasmic domain (p.Gly963Cys 
[c.2887G>T] in this study and p.Glu503Asp in Roberts’ study), where both patients had 
ASD, might disrupt the BMP signaling involving p38MAPK activation rather than SMAD 
signaling resulting in heart malformation. 
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5.7 Possible mechanisms whereby SMAD6 variants identified in this 
study affect BMP signaling and CVM 
5.7.1 BMPR1A binding 
 
Several mechanisms have been reported for the inhibitory effect of SMAD6 on BMP 
signaling. SMAD6 has been demonstrated to preferentially bind to BMPR1A through 
the N-terminal lobe of the kinase domain and inhibit phosphorylation of BMP-specific 
R-Smads (Receptor activated Smads: Smad1, Smad5 and Smad8) to repress BMP 
signaling (Goto et al. 2007; Imamura et al. 1997). The residues in type I receptors that 
are involved in SMAD6 binding are located around the phosphate binding loop of the 
BMPR1A kinase domain, not on the L45 loop (Goto et al. 2007). The L45 loop is the 
structure that protrudes from the kinase domain of type I receptors that is responsible 
for intracellular signaling (Huse et al. 1999). It has been shown to activate specific R-
Smad isoforms (Chen et al. 1998; Feng and Derynck 1997). Thus, it would be 
interesting to carry out studies on the mode of interaction between I-Smads (especially 
the mutant SMAD6s identified in this study) and BMPR1A, which would provide 
insights into how these mutants might affect the binding of SMAD6-BMPR1A and 
inhibit BMP signaling. The L3 loop is an important structure in the MH2 domain that 
determines SMAD recognition by BMPR1A (Lo et al. 1998). As the alteration to the 
crystal structure consequent upon the SMAD6 p.Cys484Phe (c.1451G>T) variant was 
predicted to disrupt the structure of the L3 loop, and p.Pro415Leu (c.1244C>T) was 
predicted to destabilize the structure located on the same face as the L3 loop, we 
hypothesized that these variants will affect binding of SMAD6 to BMPR1A. Lo and 
colleagues (Lo et al. 1998) have shown that mutating residues that are highly conserved 
in this loop in Smad2 resulted in greatly diminished or abolished Smad2 binding to the 
TGF-β receptor complex. However, mutations of highly conserved residues in other 
structures, for example, α-helix 2 and α-helix 3 did not affect the binding of Smad2 to 
the receptor complex, indicating that these other regions are not crucial for SMAD-
receptor interaction.  
 
The cysteine 484 residue of SMAD6 is highly conserved from human to Drosophila, 
and this residue is also observed in SMAD7, another inhibitory Smad, suggesting that 
this residue is important in inhibiting BMP/TGFβ signals. This hypothesis is confirmed 
by the luciferase assays which demonstrated the complete loss of inhibitory effect of 
this mutant. The functional analysis and analysis of the crystal structure may also imply 
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that the change from cysteine to phenylalanine failed to inhibit BMP signaling due to 
the failure of the SMAD6 to stably bind to BMPR1A.  
 
Another mutant that was identified was the proline 415 residue of SMAD6. This residue 
is highly conserved from human to drosophila for SMAD6 but differs in SMAD7, 
suggesting that this residue is specific to BMP signaling but not TGFβ signaling. The 
functional study performed on this variant showed significant loss of inhibitory effect in 
BMP signaling, but to a lesser extent than the p.Cys484Phe (c.1451G>T) variant. 
Analysis of crystal structure of both mutants suggested the most probable mechanism is 
due to the defective binding of the mutants to BMPR1A, resulting in loss of inhibitory 
effects. To test this mechanistic hypothesis, immunoblotting of SMAD1/5/8 and 
phospho-SMAD1/5/8 were carried out. If the SMAD6-BMPR1A complex were formed, 
it would be expected that the intensity of the phospho-SMAD1/5/8 bands to be lesser 
(or not visible at all) than the SMAD1/5/8 bands and vice versa. However, the 
difference was not visible as the serum in the culture medium and the low transfection 
efficiency masked the expression of the transfected cells.   
 
 
5.7.2 Diminished competition with co-Smads 
 
Smad6 has been demonstrated to bind to phosphorylated Smad1, interfering with the 
complex formation of phospho-Smad1 and Smad4 by acting as a Smad4 decoy (Hata et 
al. 1998). Using a yeast two-hybrid system these authors showed that Smad1-Smad6 
interaction was mediated by the C-domains (MH2 domains) of these proteins. In 
addition, these authors generated a Smad6 mutant, p.Gly471Ser, located in the L3 loop, 
and showed that the mutant did not interact with the phospho-Smad1 and failed to 
inhibit signaling. However, the mutant was able to bind to BMPR1B (type I receptor). 
The results of the western blot probed with SMAD1/5/8 and phospho-SMAD1/5/8 of 
the cell lysates from the luciferase assay that was performed was not conclusive. Further 
work to establish whether the mutant SMAD6s in this study failed to repress BMP 
signaling through this mechanism would be of interest. 
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5.7.3 Impaired cooperative inhibition with Smurf1 
 
Smurf1 (Smad ubiquitin regulatory factor) is a type of E3 ubiquitin ligase that induces 
the ubiquitination and degradation of the BMP-specific Smads (Smad1/5/8) independent 
of signal activation (Zhu et al. 1999). Murakami and colleagues (Murakami et al. 2003) 
demonstrated that Smad6 enhanced the interaction of Smurf1 with BMP type I receptors 
to prevent the phosphorylation of Smad1/5/8 and to remove the receptor complex 
through ubiquitin-dependent degradation. They also showed that Smad6 enhanced the 
interaction of phophosrylated R-Smads with Smurf1 and promoted proteasome-
dependent degradation of this complex. These mechanisms raise the possibility that the 
functionally significant variants of SMAD6 were not able to link BMPR1A to SMURF1 
(due to the lack of interaction of SMAD6 and SMURF1) and subsequently promote 
degradation of the complex. Alternatively, it is possible that the mutant SMAD6s were 
not able to associate SMURF1 to phosphorylated-SMAD1/5/8 and thereby repress BMP 
signaling.  
 
Smad6 recruits Smurf1 to degrade the Smad6-Tbx6 protein complex (Chen et al. 2009b), 
indicating that Smad6 and Smurf1 not only cooperate to regulate the Smad proteins but 
also to regulate other proteins. Tbx6 is a member of the family of transcription factors 
that share a common T-box domain which is highly conserved evolutionarily. The p.Pro 
415Leu (c.1244C>T) and p.Cys484Phe (c.1451G>T) variants that have been identified 
might impair the capacity of SMAD6 to interact with TBX6, or possibly other cardiac 
transcription factors. Further work would be necessary to establish the interaction 
between SMAD6 and other transcription factors downstream of BMP signaling. If this 
could be achieved, it would be interesting to investigate whether gene-gene interaction 
between SMAD6 and variants in other transcription factors was responsible for the 
variable penetrance we observed with SMAD6 variants in this study.  
 
 
5.7.4 Nuclear actions 
 
In COS7 cells and HepG2 cells, Smad6 was observed in the nuclei as well as in the 
cytoplasm (Hanyu et al. 2001), indicating that the Smad6 mechanisms take place at the 
nuclear level in mammalian cells. Smad6 has also been shown to interact with 
transcription factors to inhibit BMP signaling in the nucleus (Bai et al. 2000). The 
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carboxyl-terminal domain (MH2 domain) of Smad6 was found to interact with Hoxc-8 
transcription factor, thereby inhibiting Smad1-mediated transcriptional activity in the 
nucleus. Therefore, the SMAD6 mutants could affect interaction with transcription 
factors to inhibit BMP signaling. Such a mechanism would not necessarily imply that 
levels of phospho-SMAD1/5/8 would differ between wild-type and mutant, as the effect 
of the mutation would be downstream of co-SMAD phosphorylation. 
 
This study raises questions on how the variants identified in SMAD6 affect the 
mechanism of SMAD6 repression of BMP signaling. This section has discussed the 
possible mechanisms of SMAD6 action and possible future experiments are discussed 
in section 5.12.   
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5.8 This study in the context of previous resequencing studies of 
CVM 
5.8.1 Other genes in the BMP signaling pathway 
 
Based on my results, further investigation of genes involved in BMP signaling is 
indicated. During the time this work was being done, Smith and colleagues (Smith et al. 
2009) sequenced 32 candidate genes known to be important in atrioventricular septum 
(AVS) development in 190 patients with AVS defects and identified three missense 
mutations in ACVR1 (ALK2). ALK2 is a type I BMP receptor that transduces BMP 
signaling. Loss of ALK2 in the endocardium of a knockout mouse was previously 
shown to result in hypoplastic endocardial cushions (Wang et al. 2005a). The results of 
Wang et al. supported the investigation of AVS defects in the study by Smith et al. as 
endocardial cushion contribute to the valves and septa of the heart during development. 
The three missense mutations discovered by Smith et al. were p.Ala15Gly, 
p.Arg307Leu and p.Leu343Pro. Nine of the 350 control individuals genotyped carried 
the p.Ala15Gly mutation, implying that this variant is common to the general 
population. However, the p.Arg307Leu and p.Leu343Pro mutations were absent in the 
350 controls. Pedigree analysis of these mutations found the p.Arg307Leu mutation was 
inherited from a phenotypically normal father. The p.Leu343Pro mutation was inherited 
from the father who had a cardiac murmur but the inheritance of the mutation with a 
cardiac phenotype could not be established. Only the p.Leu343Pro mutation was 
predicted to affect protein function when the missense mutations were analyzed with the 
SIFT and PolyPhen programmes. Crystal structure of the p.Leu343Pro mutation 
modeled on transforming growth factor-β receptor I showed that when leucine is 
substituted with proline, the β sheet would be disrupted, destabilizing the structure of 
the kinase domain of the receptor. Functional analysis showed that wild type ALK2 was 
able to transduce signaling in a luciferase assay. Luciferase assay of the mutations 
showed that there was no significant difference in the ability of the p.Ala15Gly and 
p.Arg307Leu mutants to induce BMP signaling compared to the wild type. However, 
the p.Leu343Pro mutant resulted in significantly lower activity than the wild type. This 
is compatible with the dominant-negative form of the receptor where the mutant and the 
wild type constructs were co-expressed in the cells; the expression of the wild type 
construct was suppressed (Visser et al. 2001). This dominant-negative ALK2 mutant 
was further investigated in vivo in a zebrafish model where wild type or mutant ALK2 
RNA was injected into zebrafish embryos at the single-cell stage. Mutant RNA revealed 
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severe dorsalization whereas wild type ALK2 RNA showed mild ventralization, 
indicating that ALK2 is important in dorsoventral patterning of the zebrafish embryo. 
The absence of the SMAD6 p.Pro415Leu (c.1244C>T) and p.Cys484Phe (c.1451G>T) 
mutant in the control population, analysis of the crystal structures and the subsequently 
demonstrated functional significance in my study was similar to the study on ALK2. 
However, ALK2 was sequenced in 190 phenotypically more homogenous cases of CVM, 
all of whom had septal defects whereas in this study, the MH2 domain of SMAD6 in 
was sequenced in 438 patients with a broad range of phenotypic defects. The 
functionally significant ALK2 mutation was present in one out of 190 patients (0.5%) 
with AVS defects. The two functionally significant SMAD6 mutations were observed in 
two out of 438 CVM patients (0.5%) but the prevalence of these mutations is higher, 
4.3%, in the subset of 46 patients with aortic stenosis or coarctation of the aorta that 
have been sequenced. Both the study of Smith et al. and my study identified mutations 
inherited from phenotypically normal fathers (ALK2 p.Arg307Leu and SMAD6 
p.Pro415Leu), indicating that they likely interact with other variants and environmental 
factors to cause CVM. The study on ALK2 and my study on SMAD6 suggest that 
mutations in these genes might be causative for particular CVMs: ALK2 for AVS 
defects and SMAD6 for aortic stenosis or coarctation of the aorta. While the results of 
Smith et al showed that down regulation of BMP signaling by a dominant negative form 
of ALK2 could result in septal defects, this study has shown that an inappropriately high 
level of BMP signaling, due to loss of function mutations in the inhibitory SMAD6, 
could lead to malformations of the aortic valve and aorta. These results suggest a 
differential sensitivity to higher or lower levels of BMP signaling among the different 
anatomical regions of the developing heart, since low BMP signaling did not affect the 
aortic valve in the study of Smith et al., while overactivity of the pathway did not affect 
septal structures in the patients that were identified with mutations in SMAD6. This 
observation could be of importance for future studies. If up regulation or down 
regulation of particular signaling pathways only has significant implications for 
particular subgroups of CVM phenotypes, this will substantially complicate the 
identification of robust genotype-phenotype relationships. 
 
 
 
 
 
  
 195
5.8.2 Genes in other signaling pathways 
 
A subset of genes has been implicated as non-syndromic causes of CVM in previous re-
sequencing studies. Large families with autosomal dominant inheritance of CVM 
without other organ malformations have demonstrated that CVM can result from single-
gene defects. Mutations in the homeodomain of homoebox transcription factor NKX2.5 
were found to cause non-syndromic Mendelian CVM in four large families with 
multiple affected individuals (23 individuals with secundum ASDs, 4 individuals with 
secundum ASDs and other CVM and 4 individuals with other structural heart 
malformations) (Schott et al. 1998). A multiplex family with aortic valve anomalies and 
severe valve calcification inherited in a Mendelian fashion was identified with 
premature stop codons in the NOTCH1 gene (Garg et al. 2005).  In GATA4, a 
p.Gly296Ser mutation was identified in a Mendelian family with septal defects and a 
frameshift mutation resulting in premature stop codon in a second family (Garg et al. 
2003). These mutations segregated with the phenotypes and were not observed in 
controls, indicating that they are responsible for familial CVM. However, the incidence 
of large families with a Mendelian inheritance pattern of non-syndromic CVMs is rare. 
Most cases of CVM observed are sporadic cases, where no immediate family member is 
diagnosed with CVM. A number of resequencing studies in such non-syndromic cases 
have been performed. In general they have focused on transcription factors that are 
important in cardiac development. An example is the studies on NKX2.5. Here, 
mutations in the gene have been found, but they are present in less than 5% of CVM 
patients (Goldmuntz et al. 2001; McElhinney et al. 2003). Goldmuntz and colleagues 
(Goldmuntz et al. 2001) sequenced NKX2.5 in 114 non-syndromic sporadic TOF 
patients and found 4 mutations that were not identified in 100 normal chromosomes. 
Mutations p.Glu21Gln, p.Arg216Cys and p.Ala219Val resulted in substitution of 
evolutionary highly conserved amino acids and therefore were considered to be 
significant missense mutations. The p.Arg216Cys and p.Ala219Val mutations were 
located in the functionally important NK2 domain. Some phenotypically normal family 
members of p.Glu21Gln and p.Ala219Val mutations were however found to carry these 
mutations. The fourth mutation, p.Arg25Cys, was identified in 3 unrelated probands and 
was inherited from affected or normal parents. This mutation is located in the coding 
region outside of conserved domains. Functional studies performed by Kasahara and 
colleagues (Kasahara et al. 2000)on this mutation showed impaired DNA binding, 
supporting a role in CVM. However, this mutation was identified largely in African-
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American probands, and screening of this mutation in controls of the same ethnicity 
showed that it existed in 4.7% of normal subjects. Thus, the notion that this variant 
predisposes to CVM appears to be a false positive. This finding demonstrated the 
importance of ethnically matched cases and controls, in resequencing studies. There are 
other examples of false positive results due to ethnic heterogeneity. For example, in a 
mixed population of patients the FIBRILLIN-1 p.Pro1148Ala substitution was believed 
to be a mutation causing Marfan syndrome as it was not seen in white or African-
American controls, but it was found to be a polymorphism in the Asian population 
(Wang et al. 1997). My patients and controls are of Caucasian ancestry, therefore the 
question of population stratification between cases and controls should not arise. 
Subsequently McElhinney et al. sequenced NKX2.5 in a panel of 608 patients with a 
broad range of CVM and showed that NKX2.5 mutations occur in a small percentage of 
patients (3%) (McElhinney et al. 2003). 4% of the mutations were identified in patients 
with TOF (9 out of 201 TOF patients) and 4% (3 out of 71) in patients with a secundum 
ASD. These proportions are similar to those of the SMAD6 mutations observed in this 
study, which occur in 4% of patients with defects in the aorta.  
 
Another study that investigated non-syndromic sporadic CVM population with a broad 
range of defects for mutations in a single gene, similar to my study, was performed by 
Sperling and colleagues (Sperling et al. 2005). A cohort of 392 patients with various 
sporadic non-syndromic CVM was sequenced for CITED2 mutations (Sperling et al. 
2005). CITED2 is a ubiquitously expressed transcriptional cofactor that coactivates 
TFAP2 and interacts with the histone acetylases CREBBP/EP300 through the C-
terminus (Bhattacharya et al. 1999). This complex can be detected at the Pitx2c 
promoter in embryonic mouse heart, suggesting that CITED2 plays a role in left-right 
patterning of the heart through Nodal-PITX2C pathway (Bamforth et al. 2004). The 
high affinity binding of CITED2 with CREBBP/EP300 resulted in competitive 
inhibition of the interaction of EP300 and the transcription factor HIF1A. Seven novel 
variants in CITED2 from 8 patients were identified; they were absent in 192 control 
individuals. Of these, three variants resulted in deletion or insertion of amino acids, 
namely p.Ser170_Gly178del, p.Gly178_Ser179ins9 and p.Ser198_Gly199del, each in a 
patient with perimembranous ventricular septal defect, secundum atrial septal defect and 
sinus venosus atrial septal defect with abnormal pulmonary venous return to the right 
atria. These mutations were located in the serine-glycine rich junction but not in the 
EP300 binding domain. Analysis of these mutations using luciferase assays showed a 
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significant loss of ability to repress HIF1A transcriptional activity, suggesting that the 
variations in the serine-glycine rich junction might alter the activity of CITED2, 
affecting the EP300 binding domain to interact with CREBBP and EP300 or other 
cofactors. One shortcoming of this study is that the parents’ DNA were not available for 
investigation. This study showed that 3 out of 392 CVM patients carried functionally 
significant variants (0.77%), which is similar to the functionally significant variants 
identified in SMAD6. This study also revealed that CITED2 is associated with CVM, in 
particularly septal defects and malrotations of the great arteries.  
 
No studies have been performed systematically investigating a particular signaling 
pathway in a cohort of patients with a broad range of defects. In common with my work, 
previous resequencing studies that have had parental DNA available have consistently 
shown inheritance of potentially significant variants from unaffected parents. This 
observation highlights the difficulty of moving from Mendelian inheritance of rare 
variants with very strong variant-phenotype concordance, to the study of variants 
anticipated to have only intermediate penetrance. Using the Sanger sequencing 
methodology available to me for this study, it would not have been possible to sequence 
sufficient cases and controls to arrive at a statistically significant result comparing 
mutation frequency between case and control groups. Indeed, even with next-generation 
sequencing technology, this is anticipated to present significant challenges in data 
interpretation. Assuming that these functionally significant mutations in genes 
important for heart development are accepted as susceptibility factors, these 
observations show that gene-gene and gene-environmental interaction are likely to be 
important in determining whether individuals who carry such mutations develop CVM. 
This is in keeping with the ‘complex disease’ model of CVM causation.  
 
 
 
 
 
 
 
 
 
  
 198
5.9 Common polymorphism and CVM 
 
My work has focused on the impact of rare variation in candidate genes on CVM. 
However, during the work, several new common polymorphisms with potential 
relationships to CVM risk were discovered in both the cases and the controls. It is 
therefore appropriate to consider the potential contribution of such variants to CVM risk 
in greater detail. 
 
 
5.9.1 Effect sizes of rare and common variants 
 
Definition of linkage disequilibrium relationships throughout the human genome in the 
HapMap project enabled the search for common variants that may cause susceptibility 
to CVM to study haplotype tagging SNPs in candidate genes. With the advent of array 
genotyping technology, the characterization of such common variants throughout the 
human genome using SNP arrays in large number of cases and controls to foster our 
understanding on the contribution of common variants to disease risk has been realized 
for many conditions e.g. coronary heart disease and diabetes. However, the architecture 
of the genetic component, i.e. the number of the effects and their sizes, that define 
disease susceptibility remains unclear in any condition. Population genetic theory 
suggests that alleles that are common in the population should have small biological 
effects, whereas large effects will be restricted to rare alleles. Figure 5.3 (adapted from 
Cunnington and Keavney, 2009) (Cunnington and Keavney 2009) shows the concept. 
The prediction has been demonstrated to be true for human and animal studies, apart 
from a few exceptional cases.   
 
In Mendelian families (such as those with mutations in NKX2.5, GATA4 and NOTCH), 
rare variants with substantially large effects on the function of a particular gene have 
been shown to be sufficient alone to confer increased risk for CVM. This type of variant 
is located in the upper left-hand portion of the curve in Figure 5.3. However, this type of 
variant is very hard to locate, as there are only a handful of families found with this type 
of phenotype. Also the contribution of such variants to the population attributing to risk 
of disease is low. Gene identification in Mendelian families is, however, an important 
avenue to pursue if suitable families are available. In addition to the new 
pathophysiological insight obtained, it is possible that rare non-private variants with 
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lesser effects on the gene in question may subsequently be found to contribute to 
disease risk in sporadic cases (as, for example, in the case of NKX2.5). 
 
Common variants, on the contrary, would contribute significantly to the impact of CVM 
in the population but will have small effects on disease risk (lower right-hand portion of 
the curve). A study to characterize common variants will need large number of cases 
and controls in order to yield a better understanding of the contribution of these 
common variants to CVM risk.  
 
The model of low frequency intermediate-penetrance (LFIP) variants (middle of the 
curve) was utilized in my work. The genome wide association studies could not capture 
these variants as they are not ‘tagged’ by common SNPs represented in genotyping 
chips, and the resequencing method is required to detect them. Common-SNP studies 
have failed to find variants that explain more than a small fraction of the heritability in 
many complex diseases. The search for the “missing heritability” is now largely focused 
as LFIP variants.   
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Figure 5.3 The relationship between genetic effect size and allele frequency 
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5.9.2 Previous studies of common genetic variants and CVM 
 
The most well known study of a common genetic variant and CVM is the association of 
the C677T SNP in MTHFR with CVM. The 5,10-methylenetetrahydrofolate reductase 
(MTHFR) plays a pivotal role in folate metabolism. This enzyme is necessary for 
metabolizing homocysteine into methionine by catalyzing the conversion of 5.10-
methylenetetrahydrofolate to 5-methyltetrahydrofolate (5MeTHF), which in turn 
donates a methyl group to the intermediary metabolite homocysteine. The substitution 
of a cysteine (C) to thymidine (T) at position 677 has been shown to result in a 
reduction in the activity of the MTHFR enzyme, higher levels of homocysteine and 
lower levels of folate. The heterozygotes have around 65% of the wildtype enzyme 
activity but the homozygotes T allele have around 30% (Frosst et al. 1995). The effect 
of the C677T SNP on plasma levels of folate and homocysteine appears to be non-
additive. Homozygous TT individuals have significantly higher homocysteine and 
lower folate than those with CC genotype. Homozygous CT individuals have levels that 
are similar to the CC genotype. The relationship between genotype and the plasma 
levels of folate and homocysteine is influenced by folate intake, such that the effect of 
the polymorphism is much more marked in conditions of folate deficiency. Folic acid 
has been strongly suspected to reduce the risk of CVM in offspring, but the evidence 
remains inconclusive. Multiple retrospective studies have suggested that folate 
supplementation reduces the risk of CVM, but such studies have substantial risk of 
confounding and/or recall bias. A Hungarian randomized trial on birth defects suggested 
a substantial effect of a multivitamin supplement containing 0.8mg of folic acid on 
CVM (OR 0.42, 95% CI 0.19-0.98) (Czeizel et al. 1998). It is not possible to 
definitively infer a causal role for folate, as opposed to other vitamins, from that study. 
Morevover, further randomized trials of folic acid to prevent CVM are not viable now 
as it is ethically unacceptable given the established association of neural tube defect and 
folate. In this context, genetic studies examining the association between the C677T 
SNP and the risk of CVM might shed light on whether or not plasma folate levels affect 
CVM risk. Such a study would use the “Mendelian randomization” approach which 
examines the congruence between associations of genotype with a hypothesized 
intermediate risk factor and with disease risk to assess causality of the risk factor 
(Keavney et al. 2006). Unfortunately, there are only relatively few studies published to 
date, and these are in quite small numbers of individuals. Two previous meta-analysis of 
this question have been negative, however, owing to the small numbers studied so far, 
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this remains an open question. Genotyping of the C677T SNP in large numbers of cases 
and controls, together with an updated meta-analysis of all data in the literature thus far, 
may yield a more conclusive result. 
 
The work performed by Lambrechts and colleagues (Lamberechts et al. 2005) on the 
VEGF promoter haplotype using transmission disequilibrium testing in a cohort of 
approximately 250 patients identified a 1.8 fold increased risk for sporadic TOF. This 
promoter haplotype decreased the expression of VEGF. However, re-examination of 
this association in a larger number of cases and controls by Griffin et al. (Griffin et al. 
2009), suggested no significant effect of the haplotype. This far, investigation of 
common genetic variation has been restricted to the analysis of one or a few candidate 
polymorphisms. However, the majority of the successes in other complex diseases that 
have been investigated for association with common genetic variants have come from 
genome wide association study, discussed in the following section. 
 
 
5.9.3 GWAS studies of complex diseases 
 
Up till now, no genome-wide association studies (GWAS) on CVM have been 
performed. GWAS have been conducted in large numbers of unrelated cases of a wide 
variety of diseases and controls. The analysis compares the frequency of each of the 
genotypes at common SNPs throughout the genome between the cases and the controls. 
Among the best examples of GWAS of complex diseases is that of coronary heart 
disease (CHD). Four GWAS of CHD published in 2007 have shown association 
between common SNPs in chromosome 9p21 region (~100kb) and risk of CHD 
(Consortium 2007; Helgadottir et al. 2007; McPherson et al. 2007; Samani et al. 2007). 
These studies typed 100,000 or more SNPs in more than 1000 cases and more than 1000 
controls. The positive results were confirmed in a further large number of cases and 
controls. Collectively, they found SNPs across >100kb in the 9p21 region associated 
with CHD with p values approximately 1x10-6 and odds ratio of 1.2-2.0. Therefore, 
using the rationale of previous studies on other complex diseases for investigation of 
CVM, one might hope to discover association of some common variants across the 
genome with CVM. The few variants that have been identified in this work, in 
particularly BMP4 c.-171C>G, which was significantly different between cases and 
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controls with a p value of 0.00007, warrant further investigation by typing in replication 
cohorts of cases and controls. 
 
 
5.9.4 LFIP variants and complex diseases 
 
The work of Cohen, Hobbs and colleagues, taken in context with the results of recent 
GWAS studies of coronary heart disease, powerfully illustrates the fact that the genetic 
architecture of complex diseases can include both common and rare variants in the same 
genes (Cohen et al. 2006). It has invariably been observed that the rare variants have 
higher effects on diseases risk than do the common variants. Systematic sequencing of 
candidate genes in approximately 1000 cases of disease and an equal number of controls 
would give adequate power to identify (gene wise) individually rare variants which 
when taken together conferred odds ratios of less than 2. The recent developments in 
sequencing technology render these experiments potentially within reach, although they 
remain very expensive to perform and there are outstanding complex issues regarding 
analysis, particularly if whole-exome sequencing is used. Technical constraints did not 
permit such large scale sequencing of this project, as the technology to conduct these 
experiments has only recently become available. However, the results of the present 
study strongly suggest that the candidate genes that have been examined in this study 
would warrant further sequencing in larger numbers, particularly SMAD6.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 204
5.10 Copy Number Variants (CNVs) and CVM 
 
Another potential genetic mechanism that might predispose to CVM is copy number 
variation (CNV). CNV is defined as a DNA segment that is 1kb or longer with variable 
copy number in comparison with a reference genome.  This submicroscopic copy 
number variation of DNA could range from kilobases to megabases involving tandem 
duplication or complex gains or losses of chunks of sequences in the genome. CNVs 
have been demonstrated to affect gene expression, phenotypic variation and adaptation 
(Feuk et al. 2006). CNVs contribute to human genetic and phenotypic diversity. Two 
models of CNV-phenotype associations have been suggested: one model involves 
common copy number polymorphisms (CNPs) whereas the other model involves rare 
CNVs that delete or duplicate larger genomic segments and appear in hemizygous or 
trisomic state. For example higher copy number of CCL3L1 has been associated with 
lower HIV acquisition and progression (Gonzalez et al. 2005) (the first model), whereas 
3 de novo CNV deletions were significantly associated with schizophrenia when 
checked in large numbers of cases and controls independently (Stefansson et al. 2008) 
(the latter model).  
 
Before the SNP array technology to interrogate CNV was developed, comparative 
genomic hybridization (CGH) technology was utilized to characterize chromosomal 
abnormalities and subtle genomic aberrations (Barrett et al. 2004; Drazinic et al. 2005). 
De-Stefano and colleagues (De Stefano et al. 2008) investigated monozygotic twins 
with pulmonary atresia with intact ventricular septum (PA-IVS). PA-IVS is a rare CVM 
characterized by atretic pulmonary valve with the right ventricle varying in size and 
morphology among the patients. Using CGH technology, heterozygous 55-kb deletion 
on chromosome 20q13.12, which involves WFDC8 and WFDC9 genes, was identified 
in a pair of monozygotic twins. Further investigation in the family members revealed a 
WFDC8 deletion in the mother and a WFDC9 deletion in the father and an unaffected 
sibling. Thus, the twins possessed the maternal haplotype with a WFDC8 deletion and 
the paternal haplotype with a WFDC9 deletion. WFDC8 and WFDC9 genes encode a 
member of the WAP-type four-disulfide core (WFDC) domain family, which acts as 
protease inhibitors closely related to inherent immunity and inflammation (Clauss et al. 
2005). De-Stefano et al. hypothesized that double haploinsufficiency of both genes in 
combination with environmental factors might be responsible for the CVM.  
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In another study, 5218 individuals with mental retardation, autism, or congenital 
anomalies were screened with CGH array and reaffirmed with custom oligonucleotide 
arrays for changes in CNVs (Mefford et al. 2008). Mefford and colleagues identified 25 
individuals with recurrent 1.35Mb deletion in 1q21.1. Six of these individuals were 
diagnosed with CVMs. The microdeletion was de novo in 8 patients, inherited from a 
mildly affected parent in 3 patients, inherited from unaffected parent in 6 patients and of 
unknown inheritance in 9 patients. This deletion was absent in the controls, suggesting a 
degree of causative effect in the patient. However, the phenotypes observed in the 
patients showed considerable variability: mild to moderate mental retardation, 
microcephaly, cardiac abnormalities and cataracts. The wide range of phenotypic 
severity observed in these patients is similar to the 22q11 deletion, which is the most 
common microdeletion syndrome in humans, with an estimated prevalence of one in 
4000 (Goodship et al. 1998; Kobrynski and Sullivan 2007). One of the features 
associated with the deletion is CVM. More than 70% of the affected individuals (but not 
all) diagnosed with the microdeletion had various CVMs (McDonald-McGinn et al. 
1999). Phenotypic variability might arise due to variation in genetic background, 
epigenetic phenomena and environmental factor. As such, no concrete evidence could 
associate the 1q21.1 microdeletion to a specific phenotypic defect, in this case, CVM.  
 
Recently, genome-wide CNV-detection was enabled using SNP chips (e.g. the 
Affymetrix Human Genome-Wide SNP Array 6.0) and Birdseye algorithm (Korn et al. 
2008). A recent survey of 114 trios, consisting of a proband with non-syndromic 
Tetralogy of Fallot (TOF) and unaffected parents, identified 11 de novo CNVs at 10 
unique loci that were absent or very rare in 2,265 controls (Greenway et al. 2009). 
Multiplex ligation-dependent probe amplification (MLPA) was used to validate the 
CNVs and to assess another second cohort of sporadic, non-syndromic TOF cases, in 
order to reaffirm the findings were replicable. In short, a total of 17 CNVs at 10 loci in 
512 individuals with TOF that were absent or extremely rare in the controls were 
identified. Some of the loci encoded genes that have been previously implicated in 
cardiogenesis, such as TBX1, NOTCH1 and JAG1, suggesting the need to assess gene 
dosage in mutation analyses of CVM associated genes. However, my study was unable 
to detect CNVs in my list of candidate genes as it was designed to investigate the 
sequence of the genes and not the dosage of the genes. Therefore, it would be 
interesting to carry out studies on CNVs in genes of the BMP signaling pathway. This 
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would provide fascinating insights into how CNVs in this pathway might influence the 
susceptibility to CVM.  
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5.11 Strengths and limitations of this work 
 
Due to the time constraint and also the availability of technology at the start of my study, 
only five genes involved in BMP signaling were investigated in this thesis. Despite this 
limitation, the five genes were chosen with great care: ligands at the extracellular level 
(BMP2 and BMP4), receptors at the membrane (BMPR1A and BMPR2) and SMADs at 
the intracellular level (SMAD6), encompassing each level of the pathway. These genes 
were also selected based on their functions in the BMP signaling pathway and defects 
exhibited in animal models in previous literature. Screening for genetic variants in the 
candidate genes was carried out on the exonic and exon-intron boundary regions, 
including the different isoforms of the genes. This measure had enabled a thorough 
interrogation of the coding regions for rare variants. There is the possibility that 
susceptibility factors for CVM might be within the promoter, intronic or downstream 
3’regulatory regions of the candidate genes. However, variants in the coding region are 
hypothesized to have the greatest functional effects on phenotypes (Kryukov et al. 
2007).     
 
Animal models to illustrate how the SMAD6 mutations resulted in CVMs were not 
investigated. However, luciferase assay was performed to show the functional 
significance of the mutations in vitro. The SMAD6 knockout mouse generated by 
Galvin and colleagues (Galvin et al. 2000) demonstrated cardiac abnormalities as the 
patients with the SMAD6 mutations. Integrating these results, we could conclude that 
mutation in SMAD6 is pathogenic. 
 
The panel of 90 probands was re-sequenced for genetic variants in the exons of the five 
candidate genes in the BMP signaling pathway. Previous studies on non-syndromic 
CVM demonstrated that the detectable mutations in genes that conferred risk factors for 
CVM occurred in about 2-3% of the cases: for example ~2% for CITED2 (Sperling et al. 
2005) to 3% for NKX2.5 (McElhinney et al. 2003). Simple binomial probability 
suggests that if 2% of the cases with CVM were disease-associated mutations, re-
sequencing of 90 probands would yield approximately 80% power to detect at least one 
such change. For this reason, sequencing more patients will have greater power to detect 
small percentage of patients with mutation in the gene of interest. However, initial 
investigation of the 90 probands was both a feasible number to start with and gave 
adequate power to detect mutation in the candidate genes.  
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In order to reduce phenotypic heterogeneity, non-syndromic CVM patients without 
other malformations were selected. The reduced phenotypic heterogeneity should have 
increased the power to detect variants responsible for non-syndromic CVM. Available 
parents of patients were collected to allow for further investigation of the rare variants 
detected in the patients with the aim to establish whether the variant might be a de novo 
mutation or the variant might possess reduced penetrance. The collection of probands 
was restricted to Caucasian individuals and the genotyping of the rare variants identified 
were performed in Caucasian population to avoid false positives due to genetic 
heterogeneity.   
 
The broad phenotypic spectrum of the CVM of the patients collected is in tandem with 
the animal models with a single-gene defect that showed variable heart defects. Besides 
that, recruitment of patients with a particular defect would be slow and ideal number of 
patients would not be reached. The defects of the patients were documented in detail. 
Investigation of candidate genes on diverse phenotypic defects was performed in the 
hope that genotype-phenotype correlation of mutations would be observed.  
 
With the high recruitment rate of CVM patients, a replication cohort was available for 
investigation for the rare variants that were identified in the first panel of 90 patients. 
This was especially important for the re-sequencing of SMAD6 MH2 domain, as 
replication of the study was able to minimize false positive association and also to gain 
more power for genotype-phenotype correlation.  
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5.12 Future experiments 
5.12.1 Characterization of SMAD6 mechanisms 
 
The mutations identified in SMAD6 could be further investigated to illustrate the 
mechanism of the mutations in BMP signaling. There are four possibilities that might 
result in inactivation of inhibition: type I receptor-binding, competition with co-Smads, 
cooperation inhibition with Smurf1, and nuclear actions (as discussed in section 5.7). 
This would, in general, be amenable to investigation in cellular systems using 
transfection, immunoblotting, and luciferase assays. 
 
 
5.12.2 Sequencing SMAD6 in larger samples 
 
It would be useful to recruit more patients and to sequence SMAD6 in these patients. A 
larger cohort of patients might reveal more mutations in the gene and so accurately 
define the contribution of SMAD6 in the pathogenesis of CVM. In addition, more 
controls could be genotyped for the rare variants identified and the known common 
variants. The increased number of patients and controls might enable the case-control 
comparisons to reach statistical significance, especially the common variants. It would 
be particularly interesting to resequence SMAD6 in a large cohort of patients with 
malformation of the aortic valve. 
 
 
5.12.3 Further candidate gene sequencing 
This study did not interrogate all of the genes in the BMP signaling pathway, but my 
findings strongly suggest that comprehensive investigation of all genes involved in 
BMP signaling be undertaken. It would be particularly interesting to sequence SMAD7, 
another inhibitor in the signaling pathway. SMAD7 is not, however, specific to BMP 
signaling as it also inhibits TGFβ signaling, and it is for that reason that it was not 
included in this work. However, the demonstration of functional mutation in SMAD6, 
and the observation of Chen and colleagues in a SMAD7 MH2 domain knockout mouse, 
that showed majority of the mutant mice died in utero due to multiple defects in heart, 
exhibiting ventricular septal defect, non-compaction and outflow tract malformation, 
whereas the surviving adult mice displayed impaired cardiac functions and severe 
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arrhythmia (Chen et al. 2009a), published during the period of this work, strongly argue 
in favour of SMAD7 as a candidate gene for CVM.  
 
As genome-wide association studies require large samples and the common genetic 
variants interrogated explained a small fraction of disease susceptibility for any 
condition studied thus far, it has been hypothesized that LFIP variants account for a 
substantial proportion of the “missing heritability” not explained by common GWAS 
variants. Novel sequencing methods, collectively termed ‘next generation sequencing’ 
technology, which became available during the period of my study, will radically 
change the conduct of genotype/ phenotype association studies. Such technologies are 
able to sequence a human genome now less than 1 week on one instrument at a fraction 
of the cost of Sanger sequencing (Wheeler et al. 2008). Ng and colleagues developed a 
method to sequence all the protein-coding regions (‘exomes’) of the genome (Ng et al. 
2009). The proof-of-concept experiment showed that this method is feasible and cost 
effective compared to whole-genome sequencing. They demonstrated that it was 
possible to detect previously identified causal genetic variants in individuals with 
Freeman-Sheldon syndrome (FSS), when compared with eight HapMap individuals 
from three populations. They then applied this concept to search for the gene causing a 
Mendelian disorder of unknown aetiology, Miller syndrome, in four affected individuals 
in three independent kindreds. Using a recessive model, they identified a single 
candidate gene, DHODH, that caused the syndrome (Ng et al. 2010). At the time of 
writing (Nov 2010) around 15 Mendelian conditions have been successfully solved 
using whole-exome sequencing. However, as noted above, the extension of this 
technique to non-Mendelian conditions has yet to yield novel definite genes, and the 
challenges of interpreting whole-exome data in the context of incomplete penetrance, 
genetic heterogeneity, and phenocopy remain very substantial.  
 
 
5.12.4 Common variants 
 
As noted above, genome-wide association studies have been successfully carried out to 
identify genes involved in common human diseases. The Wellcome Trust Case-Control 
Consortium (WTCCC) examined ~2,000 individuals for 7 major diseases (bipolar 
disorder, coronary artery disease, Crohn’s Disease, hypertension, rheumatoid arthritis, 
type 1 diabetes and type 2 diabetes) and 3000 controls (Consortium 2007). They 
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successfully identified many new genes associated with the diseases. This study was 
possible due to a few factors: the information from the International HapMap resource 
facilitated the design and analysis of association studies, the availability of dense 
genotyping chips to probe hundreds of thousands of SNPs and most importantly, the 
assembly of large samples for each disease. In order to unravel the common variants 
predisposing to CVM using genome-wide association method, more CVM samples 
must be collected. The large sample size would require collaborations with other groups 
that were carrying out similar studies: well-characterized non-syndromic CVM patients 
of homogeneous ancestry. After genotyping, the massive number of statistical tests 
performed on the SNP data that have undergone strigent quality control procedures 
presents a high false positive rate if conventional statistical significance levels (p<0.05) 
are used. As a result, the P value of the study is set at approximately 1.0x10-8 or less. 
Besides that, an independent replication cohort of the same or larger size than the first 
set of samples is required for the SNPs selected to confirm the association. This project 
would enable us to identify the common variants across the genome that might be 
susceptible to CVM. The few variants that have been identified thus far with a p<0.05 
would be an interesting starting point. Probing of more patients and controls for these 
variants will disseminate whether these variants reach statistical significance or not. 
 
 
5.12.5 CNV studies 
 
The study conducted by Greenway and colleagues (Greenway et al. 2009), identified de 
novo CNVs in patients with isolated sporadic tetralogy of Fallot. This study implies that 
rare CNV might be another interesting factor to investigate in CVM patients in the 
future. The idea is further strengthened by the recent published findings that showed 
common CNVs play very little role in contributing to the genetic basis of common 
human diseases (bipolar disorder, breast cancer, coronary artery disease, Crohn’s 
disease, hypertension, rheumatoid arthritis, type 1 diabetes and type 2 diabetes), which 
make a major impact on public health (Craddock et al. 2010). Therefore, rare or de novo 
CNV observed in CVM patients (if any) might be a causative factor, but common CNVs 
are perhaps a less promising avenue for investigation. CNVs could be investigated using 
Affymetrix arrays and validated using multiplex ligation-dependent probe amplification 
(MLPA) for the regions of interest. Here, the availability of trio data in our collection 
would be a significant strength. 
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5.13 Conclusions 
 
This study and a study on ALK2 (ACVR1) (Smith et al. 2009) showed that mutation in 
the BMP signaling pathway plays an important part in cardiac malformation in man. 
CVM patients with rare non-synonymous variants located at important domains have 
been shown to abrogate or elevate BMP signaling showing that rare non-synonymous 
variants in the genes of the signaling pathway contribute to the predisposition to CVM. 
Further investigation of the genes involving in BMP signaling using next-generation 
sequencing technology is warranted.  
 
Besides that, this study could have implications for clinical practice. Two functionally 
significant SMAD6 variants seen in two probands having phenotypes involving the 
aorta were identified out of 46 patients with coarctation or aortic stenosis defects. 
Therefore, the prevalence of non-synonymous SMAD6 variants in this category of 
CVM was around 4%. However, the prevalence of these variants was lower (~0.46%) 
when all of the 438 CVM patients sequenced for MH2 domain of SMAD6 were 
accounted. This percentage is quite similar to the study that was carried out by Sperling 
and colleagues (Sperling et al. 2005) where three functionally significant ins/del 
mutations in serine-glycine rich junction of CITED2 protein were identified out of 392 
CVM patients with a broad phenoytpe spectrum, approximately 0.77%. If this pattern of 
predisposition of functionally significant variants to CVM was repeated throughout the 
human genome, taking into account the incomplete penetrance of such variants, it 
would be challenging to screen CVM patients and to provide genetic counseling to them 
regarding the recurrence risks to their offspring.    
 
Cardiac development is a complex biological process requiring intrinsic and correct 
spatial temporal expression of many factors. Disruption of a number of signaling 
pathways, including BMP, transforming growth factor-β, Wnt, Notch signaling have 
been implicated in cardiac development in vivo or in vitro. Studies that have 
demonstrated the cross-talk between BMPs and other signaling pathways, including 
certain transcription factors further confirmed the multifunctional role of BMPs in 
cardiac development (Chen et al. 2009b; Nakashima et al. 2005; Schwappacher et al. 
2009; Takizawa et al. 2003). Mutational investigation of candidate genes carried out by 
various groups has shed some lights on cardiac development mechanism in man, paving 
the ground for more accurate genetic counselling and new approaches for prevention of 
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CVM in those who are susceptible. This is in keeping with the advancement of 
personalized genomic medicine, which aims to predict an individual’s relative risk of 
developing a disease or transmitting a disease to the offspring based on the person’s 
genome and to offer specific treatment for each person depending on how he or she 
might respond to drugs. The best example is the mutations in BRCA genes that are 
associated with breast cancer risk, which have helped to predict more accurately the risk 
prediction in some patients (Robson and Offit 2007). The era of personalized genomics 
is potentially within reach with the advent of next generation sequencing to sequence a 
human genome in search for an individual’s risk of disease susceptibility and to 
personalize treatment; this project suggests that patients and families with CVM could 
be among those to benefit from this revolutionary change in healthcare practice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 214
Chapter 6  References 
 
Aebi M, Hornig H, Weissmann C (1987) 5' cleavage site in eukaryotic pre-mRNA 
splicing is determined by the overall 5' splice region, not by the conserved 5' GU. 
Cell 50: 237-46 
Allen SP, Bogardi J, Barlow AJ (2001) Misexpression of noggin leads to septal defects 
in the outflow tract of the chick heart. Dev. Biol. 235: 98-109 
Anderson RH (2003) Understanding the structure of the unicuspid and unicommissural 
aortic valve. J Heart Valve Dis 12: 670-3 
Andree B, Duprez D, Vorbusch B, Arnold HH, Brand T (1998) BMP-2 induces ectopic 
expression of cardiac lineage markers and interferes with somite formation in 
chicken embryos. Mech Dev 70: 119-31 
Arguello C, de la Cruz MV, Gomez CS (1975) Experimental study of the formation of 
the heart tube in the chick embryo. J Embryol Exp Morphol 33: 1-11 
Armstrong EJ, Bischoff J (2004) Heart valve development: Endothelial cell signaling 
and differentiation. Circ. Res. 95: 459-470 
Bai S, Shi X, Yang X, Cao X (2000) Smad6 as a transcriptional corepressor. J Biol 
Chem 275: 8267-70 
Bailey LB, Berry RJ (2005) Folic acid supplementation and the occurrence of 
congenital heart defects, orofacial clefts, multiple births, and miscarriage. Am J 
Clin Nutr 81: 1213S-1217S 
Bakrania P, Efthymiou M, Klein JC, Salt A, Bunyan DJ, Wyatt A, Ponting CP, Martin 
A, Williams S, Lindley V, Gilmore J, Restori M, Robson AG, Neveu MM, 
Holder GE, Collin JR, Robinson DO, Farndon P, Johansen-Berg H, Gerrelli D, 
Ragge NK (2008) Mutations in BMP4 cause eye, brain, and digit developmental 
anomalies: overlap between the BMP4 and hedgehog signaling pathways. Am J 
Hum Genet 82: 304-19 
Balemans W, Van Hul W (2002) Extracellular regulation of BMP signaling in 
vertebrates: a cocktail of modulators. Dev Biol 250: 231-50 
Bamforth SD, Braganca J, Farthing CR, Schneider JE, Broadbent C, Michell AC, 
Clarke K, Neubauer S, Norris D, Brown NA, Anderson RH, Bhattacharya S 
(2004) Cited2 controls left-right patterning and heart development through a 
Nodal-Pitx2c pathway. Nat Genet 36: 1189-96 
Baralle D, Baralle M (2005) Splicing in action: assessing disease causing sequence 
changes. J Med Genet 42: 737-48 
  
 215
Barrett MT, Scheffer A, Ben-Dor A, Sampas N, Lipson D, Kincaid R, Tsang P, Curry B, 
Baird K, Meltzer PS, Yakhini Z, Bruhn L, Laderman S (2004) Comparative 
genomic hybridization using oligonucleotide microarrays and total genomic 
DNA. Proc Natl Acad Sci U S A 101: 17765-70 
Basson CT, Bachinsky DR, Lin RC, Levi T, Elkins JA, Soults J, Grayzel D, 
Kroumpouzou E, Traill TA, Leblanc-Straceski J, Renault B, Kucherlapati R, 
Seidman JG, Seidman CE (1997) Mutations in human TBX5 [corrected] cause 
limb and cardiac malformation in Holt-Oram syndrome. Nat Genet 15: 30-5 
Ben-Shachar G, Arcilla RA, Lucas RV, Manasek FJ (1985) Ventricular trabeculations 
in the chick embryo heart and their contribution to ventricular and muscular 
septal development. Circ Res 57: 759-66 
Beppu H, Kawabata M, Hamamoto T, Chytil A, Minowa O, Noda T, Miyazono K 
(2000) BMP type II receptor is required for gastrulation and early development 
of mouse embryos. Dev. Biol. 221: 249-258 
Berget SM (1995) Exon recognition in vertebrate splicing. J Biol Chem 270: 2411-4 
Bernstein E (1996) The cardiovascular system. In Behrman, R.E, Kliegman, R.M., 
Arvin, A.M. (eds): Nelson Textbook of Pediatrics 15th ed. 
Bevan S, Woodford-Richens K, Rozen P, Eng C, Young J, Dunlop M, Neale K, Phillips 
R, Markie D, Rodriguez-Bigas M, Leggett B, Sheridan E, Hodgson S, Iwama T, 
Eccles D, Bodmer W, Houlston R, Tomlinson I (1999) Screening SMAD1, 
SMAD2, SMAD3, and SMAD5 for germline mutations in juvenile polyposis 
syndrome. Gut 45: 406-8 
Bhattacharya S, Michels CL, Leung MK, Arany ZP, Kung AL, Livingston DM (1999) 
Functional role of p35srj, a novel p300/CBP binding protein, during 
transactivation by HIF-1. Genes Dev 13: 64-75 
Blom HJ, Shaw GM, den Heijer M, Finnell RH (2006) Neural tube defects and folate: 
case far from closed. Nat Rev Neurosci 7: 724-31 
Botto LD, Lynberg MC, Erickson JD (2001) Congenital heart defects, maternal febrile 
illness, and multivitamin use: a population-based study. Epidemiology 12: 485-
90 
Botto LD, Mulinare J, Erickson JD (2000) Occurrence of congenital heart defects in 
relation to maternal mulitivitamin use. Am J Epidemiol 151: 878-84 
Brand T (2003) Heart development: molecular insights into cardiac specification and 
early morphogenesis. Dev Biol 258: 1-19 
  
 216
Braunwald E (1997) Heart Disease - a textbook of cardiovascular medicine. 5th edition. 
Saunders  
Breckenridge RA, Mohun TJ, Amaya E (2001) A role for BMP signalling in heart 
looping morphogenesis in Xenopus. Dev Biol 232: 191-203 
Brizzard BL, Chubet RG, Vizard DL (1994) Immunoaffinity purification of FLAG 
epitope-tagged bacterial alkaline phosphatase using a novel monoclonal 
antibody and peptide elution. Biotechniques 16: 730-5 
Buckingham M, Meilhac S, Zaffran S (2005) Building the mammalian heart from two 
sources of myocardial cells. Nature Reviews Genetics: 826-835 
Burn J, Brennan P, J. L, Holloway S (1998) Recurrence risks in offspring of adults with 
major heart defects: results from first cohort of British collaborative study. The 
Lanceet 351: 311-316 
Cai CL, Liang X, Shi Y, Chu PH, Pfaff SL, Chen J, Evans S (2003) Isl1 identifies a 
cardiac progenitor population that proliferates prior to differentiation and 
contributes a majority of cells to the heart. Dev Cell 5: 877-89 
Carlson BM (2004) Human embryology and developmental biology (3rd edition). 
Mosby  
Cartegni L, Chew SL, Krainer AR (2002) Listening to silence and understanding 
nonsense: exonic mutations that affect splicing. Nat Rev Genet 3: 285-98 
Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR (2003) ESEfinder: A web resource 
to identify exonic splicing enhancers. Nucleic Acids Res 31: 3568-71 
Chacko BM, Qin BY, Tiwari A, Shi G, Lam S, Hayward LJ, De Caestecker M, Lin K 
(2004) Structural basis of heteromeric smad protein assembly in TGF-beta 
signaling. Mol Cell 15: 813-23 
Chen Q, Chen H, Zheng D, Kuang C, Fang H, Zou B, Zhu W, Bu G, Jin T, Wang Z, 
Zhang X, Chen J, Field LJ, Rubart M, Shou W, Chen Y (2009a) Smad7 is 
required for the development and function of the heart. J Biol Chem 284: 292-
300 
Chen YG, Hata A, Lo RS, Wotton D, Shi Y, Pavletich N, Massague J (1998) 
Determinants of specificity in TGF-beta signal transduction. Genes Dev 12: 
2144-52 
Chen YL, Liu B, Zhou ZN, Hu RY, Fei C, Xie ZH, Ding X (2009b) Smad6 inhibits the 
transcriptional activity of Tbx6 by mediating its degradation. J Biol Chem 284: 
23481-90 
  
 217
Chocron S, Verhoeven MC, Rentzsch F (2007) Zebrafish Bmp4 regulates left-right 
asymmetry at two distinct developmental time points. Dev. Biol. 305: 577-588 
Christianson A, Howson CP, Modell B (2006) Global Report on Birth Defects: The 
Hidden Toll of Dying and Disabled Children. White Plains, NY: March of 
Dimes Birth Defects Foundation  
Christoffels VM, Habets PE, Franco D, Campione M, de Jong F, Lamers WH, Bao ZZ, 
Palmer S, Biben C, Harvey RP, Moorman AF (2000) Chamber formation and 
morphogenesis in the developing mammalian heart. Dev Biol 223: 266-78 
Clauss A, Lilja H, Lundwall A (2005) The evolution of a genetic locus encoding small 
serine proteinase inhibitors. Biochem Biophys Res Commun 333: 383-9 
Cohen JC, Boerwinkle E, Mosley TH, Jr., Hobbs HH (2006) Sequence variations in 
PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 
354: 1264-72 
Colas JF, Lawson A, Schoenwolf GC (2000) Evidence that translation of smooth 
muscle alpha-actin mRNA is delayed in the chick promyocardium until fusion of 
the bilateral heart-forming regions. Dev Dyn 218: 316-30 
Collins JS, Schwartz CE (2002) Detecting polymorphisms and mutations in candidate 
genes. Am J Hum Genet 71: 1251-2 
Consortium WTCC (2007) Genome-wide association study of 14,000 cases of seven 
common diseases and 3,000 shared controls. Nature 447: 661-78 
Constam DB, Robertson EJ (1999) Regulation of bone morphogenetic protein activity 
by pro domains and proprotein convertases. J Cell Biol 144: 139-49 
Craddock N, Hurles ME, Cardin N, Pearson RD, Plagnol V, Robson S, Vukcevic D, 
Barnes C, Conrad DF, Giannoulatou E, Holmes C, Marchini JL, Stirrups K, 
Tobin MD, Wain LV, Yau C, Aerts J, Ahmad T, Andrews TD, Arbury H, 
Attwood A, Auton A, Ball SG, Balmforth AJ, Barrett JC, Barroso I, Barton A, 
Bennett AJ, Bhaskar S, Blaszczyk K, Bowes J, Brand OJ, Braund PS, Bredin F, 
Breen G, Brown MJ, Bruce IN, Bull J, Burren OS, Burton J, Byrnes J, Caesar S, 
Clee CM, Coffey AJ, Connell JM, Cooper JD, Dominiczak AF, Downes K, 
Drummond HE, Dudakia D, Dunham A, Ebbs B, Eccles D, Edkins S, Edwards 
C, Elliot A, Emery P, Evans DM, Evans G, Eyre S, Farmer A, Ferrier IN, Feuk 
L, Fitzgerald T, Flynn E, Forbes A, Forty L, Franklyn JA, Freathy RM, Gibbs P, 
Gilbert P, Gokumen O, Gordon-Smith K, Gray E, Green E, Groves CJ, Grozeva 
D, Gwilliam R, Hall A, Hammond N, Hardy M, Harrison P, Hassanali N, 
Hebaishi H, Hines S, Hinks A, Hitman GA, Hocking L, Howard E, Howard P, 
  
 218
Howson JM, Hughes D, Hunt S, Isaacs JD, Jain M, Jewell DP, Johnson T, Jolley 
JD, Jones IR, Jones LA, et al. (2010) Genome-wide association study of CNVs 
in 16,000 cases of eight common diseases and 3,000 shared controls. Nature 464: 
713-20 
Cunnington MS, Keavney BD (2009) Genetics of coronary heart disease In Evidence-
Based Cardiology. BMJ Books  
Cunnington MS, Santibanez Koref M, Mayosi BM, Burn J, Keavney B (2010) 
Chromosome 9p21 SNPs Associated with Multiple Disease Phenotypes 
Correlate with ANRIL Expression. PLoS Genet 6: e1000899 
Czeizel AE, Dobo M, Dudas I, Gasztonyi Z, Lantos I (1998) The Hungarian 
periconceptional service as a model for community genetics. Community Genet 
1: 252-9 
Dasgupta C, Martinez AM, Zuppan CW, Shah MM, Bailey LL, Fletcher WH (2001) 
Identification of connexin43 (alpha1) gap junction gene mutations in patients 
with hypoplastic left heart syndrome by denaturing gradient gel electrophoresis 
(DGGE). Mutat Res 479: 173-86 
Dathe K, Kjaer KW, Brehm A, Meinecke P, Nurnberg P, Neto JC, Brunoni D, 
Tommerup N, Ott CE, Klopocki E, Seemann P, Mundlos S (2009) Duplications 
involving a conserved regulatory element downstream of BMP2 are associated 
with brachydactyly type A2. Am J Hum Genet 84: 483-92 
de Caestecker M (2004) The transforming growth factor-beta superfamily of receptors. 
Cytokine Growth Factor Rev 15: 1-11 
de la Cruz MV, Markwald RR (1998) Living Morphogenesis of the Heart. Boston: 
Birkhauser  
de Lange FJ, Moorman AF, Anderson RH, Manner J, Soufan AT, de Gier-de Vries C, 
Schneider MD, Webb S, van den Hoff MJ, Christoffels VM (2004) Lineage and 
morphogenetic analysis of the cardiac valves. Circ Res 95: 645-54 
De Stefano D, Li P, Xiang B, Hui P, Zambrano E (2008) Pulmonary atresia with intact 
ventricular septum (PA-IVS) in monozygotic twins. Am J Med Genet A 146A: 
525-8 
Delot EC, Bahamonde ME, Zhao M, Lyons KM (2003) BMP signaling is required for 
septation of the outflow tract of the mammalian heart. Development 130: 209-
220 
den Dunnen JT, Antonarakis SE (2000) Mutation nomenclature extensions and 
suggestions to describe complex mutations: a discussion. Hum Mutat 15: 7-12 
  
 219
Desgrosellier JS, Mundell NA, McDonnell MA, Moses HL, Barnett JV (2005) Activin 
receptor-like kinase 2 and Smad6 regulate epithelial-mesenchymal 
transformation during cardiac valve formation. Developmental Biology 280: 
201-210 
Dewulf N, Verschueren K, Lonnoy O, Moren A, Grimsby S, Vande Spiegle K, 
Miyazono K, Huylebroeck D, Ten Dijke P (1995) Distinct spatial and temporal 
expression patterns of two type I receptors for bone morphogenetic proteins 
during mouse embryogenesis. Endocrinology 136: 2652-63 
Digilio MC, Angioni A, De Santis M, Lombardo A, Giannotti A, Dallapiccola B, 
Marino B (2003) Spectrum of clinical variability in familial deletion 22q11.2: 
from full manifestation to extremely mild clinical anomalies. Clin Genet 63: 
308-13 
Digilio MC, Conti E, Sarkozy A, Mingarelli R, Dottorini T, Marino B, Pizzuti A, 
Dallapiccola B (2002) Grouping of multiple-lentigines/LEOPARD and Noonan 
syndromes on the PTPN11 gene. Am J Hum Genet 71: 389-94 
Dorak MT, Mackay RK, Relton CL, Worwood M, Parker L, Hall AG (2009) Hereditary 
hemochromatosis gene (HFE) variants are associated with birth weight and 
childhood leukemia risk. Pediatr Blood Cancer 53: 1242-8 
Drazinic CM, Ercan-Sencicek AG, Gault LM, Hisama FM, Qumsiyeh MB, Nowak NJ, 
Cubells JF, State MW (2005) Rapid array-based genomic characterization of a 
subtle structural abnormality: a patient with psychosis and 
der(18)t(5;18)(p14.1;p11.23). Am J Med Genet A 134: 282-9 
Durbin RM, Abecasis GR, Altshuler DL, Auton A, Brooks LD, Gibbs RA, Hurles ME, 
McVean GA (2010) A map of human genome variation from population-scale 
sequencing. Nature 467: 1061-73 
Ehrman LA, Yutzey KE (1999) Lack of regulation in the heart forming region of avian 
embryos. Dev Biol 207: 163-75 
Ericson A, Kallen BA (2001) Nonsteroidal anti-inflammatory drugs in early pregnancy. 
Reprod Toxicol 15: 371-5 
Eronen M, Peippo M, Hiippala A, Raatikka M, Arvio M, Johansson R, Kahkonen M 
(2002) Cardiovascular manifestations in 75 patients with Williams syndrome. J 
Med Genet 39: 554-8 
Feng XH, Derynck R (1997) A kinase subdomain of transforming growth factor-beta 
(TGF-beta) type I receptor determines the TGF-beta intracellular signaling 
specificity. EMBO J 16: 3912-23 
  
 220
Ferencz C, Loffredo CA, Correa-Villasenor A, Wilson PD (1997) Genetic and 
environmental risk factors of major cardiovascular malformations: the 
Baltimore-Washington Infant Study, 1981-1989. Mt. Kisko 
Fernandez-Guerra P, Navarrete R, Weisiger K, Desviat LR, Packman S, Ugarte M, 
Rodriguez-Pombo P (2010) Functional characterization of the novel intronic 
nucleotide change c.288+9C>T within the BCKDHA gene: understanding a 
variant presentation of maple syrup urine disease. J Inherit Metab Dis  
Feuk L, Carson AR, Scherer SW (2006) Structural variation in the human genome. Nat 
Rev Genet 7: 85-97 
Franco D, Campione M, Kelly R, Zammit PS, Buckingham M, Lamers WH, Moorman 
AF (2000) Multiple transcriptional domains, with distinct left and right 
components, in the atrial chambers of the developing heart. Circ Res 87: 984-91 
Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den 
Heijer M, Kluijtmans LA, van den Heuvel LP, et al. (1995) A candidate genetic 
risk factor for vascular disease: a common mutation in 
methylenetetrahydrofolate reductase. Nat Genet 10: 111-3 
Fujii M, Takeda K, Imamura T, Aoki H, Sampathw TK, Enomoto S, Kawabata M, Kato 
M, Ichijo H, Miyazono K (1999) Roles of Bone Morphogenetic Protein Type I 
Receptros and Smad Proteins in Osteoblast and Chondroblast Differentiation. 
Molecular Biology of the Cell 10: 3801-3813 
Fukushima T, Mashiko M, Takita K, Otake T, Endo Y, Sekikawa K, Takenoshita S 
(2003) Mutational analysis of TGF-beta type II receptor, Smad2, Smad3, Smad4, 
Smad6 and Smad7 genes in colorectal cancer. J Exp Clin Cancer Res 22: 315-20 
Galvin KM, Donovan MJ, Lynch CA, Meyer RI, Paul RJ, Lorenz JN, Fairchild-
Huntress V, Dixon KL, Dunmore JH, Gimbrone Jr MA, Falb D, Huszar D (2000) 
A role of Smad6 in development and homeostasis of the cardiovascular system. 
Nature genetics 24: 171-174 
Gao K, Masuda A, Matsuura T, Ohno K (2008) Human branch point consensus 
sequence is yUnAy. Nucleic Acids Res 36: 2257-67 
Garg V, Kathiriya IS, Barnes R, Schluterman MK, King IN, Butler CA, Rothrock CR, 
Eapen RS, Hirayama-Yamada K, Joo K, Matsuoka R, Cohen JC, Srivastava D 
(2003) GATA4 mutations cause human congenital heart defects and reveal an 
interaction with TBX5. Nature 424: 443-7 
  
 221
Garg V, Muth AN, Ransom JF, Schluterman MK, Barnes R, King IN, Grossfeld PD, 
Srivastava D (2005) Mutations in NOTCH1 cause aortic valve disease. Nature 
437: 270-4 
Gaussin V, Morley GE, Cox L, Zwijsen A, Vance KM, Emile L, Tian Y, Liu J, Hong C, 
Myers D, Conway SJea (2005) Alk3/Bmpr1a receptor is required for 
development of the atrioventricular canal into valves and annulus fibrosus. 
Circulation Research 97: 219-226 
Gaussin V, Van de Putte T, Mishina Y, Hanks MC, Zwijsen A, Huylebroeck D, 
Behringer RR, Schneider MD (2002) Endocardial cushion and myocardial 
defects after cardiac myocyte-specific conditional deletion of the bone 
morphogenetic protein receptor ALK3. Proc Natl Acad Sci U S A 99: 2878-83 
Ghosh-Choudhury N, Abboud SL, Chandrasekar B, Ghosh Choudhury G (2003) BMP-2 
regulates cardiomyocyte contractility in a phosphatidylinositol 3 kinase-
dependent manner. FEBS Lett 544: 181-4 
Goldmuntz E, Clark BJ, Mitchell LE, Jawad AF, Cuneo BF, Reed L, McDonald-
McGinn D, Chien P, Feuer J, Zackai EH, Emanuel BS, Driscoll DA (1998) 
Frequency of 22q11 deletions in patients with conotruncal defects. J Am Coll 
Cardiol 32: 492-8 
Goldmuntz E, Geiger E, Benson DW (2001) Nkx2.5 mutations in patients with tetralogy 
of fallot. Circ. Res. 104: 2545-2568 
Gonzalez E, Kulkarni H, Bolivar H, Mangano A, Sanchez R, Catano G, Nibbs RJ, 
Freedman BI, Quinones MP, Bamshad MJ, Murthy KK, Rovin BH, Bradley W, 
Clark RA, Anderson SA, O'Connell R J, Agan BK, Ahuja SS, Bologna R, Sen L, 
Dolan MJ, Ahuja SK (2005) The influence of CCL3L1 gene-containing 
segmental duplications on HIV-1/AIDS susceptibility. Science 307: 1434-40 
Goodship J, Cross I, LiLing J, Wren C (1998) A population study of chromosome 
22q11 deletions in infancy. Arch Dis Child 79: 348-51 
Goto K, Kamiya Y, Imamura T, Miyazono K, Miyazawa K (2007) Selective Inhibitory 
Effects of Smad6 on Bone Morphogenetic Protein Type I Receptors. The 
Journal of Biological Chemistry 282: 20603-20611 
Greenway SC, Pereira AC, Lin JC, DePalma SR, Israel SJ, Mesquita SM, Ergul E, 
Conta JH, Korn JM, McCarroll SA, Gorham JM, Gabriel S, Altshuler DM, 
Quintanilla-Dieck Mde L, Artunduaga MA, Eavey RD, Plenge RM, Shadick NA, 
Weinblatt ME, De Jager PL, Hafler DA, Breitbart RE, Seidman JG, Seidman CE 
  
 222
(2009) De novo copy number variants identify new genes and loci in isolated 
sporadic tetralogy of Fallot. Nat Genet 41: 931-5 
Griffin HR, Hall DH, Topf A, Eden J, Stuart AG, Parsons J, Peart I, Deanfield JE, 
O'Sullivan J, Babu-Narayan SV, Gatzoulis MA, Bu'lock FA, Bhattacharya S, 
Bentham J, Farrall M, Granados Riveron J, Brook JD, Burn J, Cordell HJ, 
Goodship JA, Keavney B (2009) Genetic variation in VEGF does not contribute 
significantly to the risk of congenital cardiovascular malformation. PLoS One 4: 
e4978 
Hanyu A, Ishidou Y, Ebisawa T, Shimanuki T, Imamura T, Miyazono K (2001) The N 
domain of Smad7 is essential for specific inhibition of transforming growth 
factor-beta signaling. J Cell Biol 155: 1017-27 
Hata A, Lagna G, Massague J, Hemmati-Brivanlou A (1998) Smad6 inhibits 
BMP/Smad1 signaling by specifically competing with the Smad4 tumor 
suppressor. Genes Dev 12: 186-97 
Heldin CH, Miyazono K, ten Dijke P (1997) TGF-beta signalling from cell membrane 
to nucleus through SMAD proteins. Nature 390: 465-71 
Helgadottir A, Thorleifsson G, Manolescu A, Gretarsdottir S, Blondal T, Jonasdottir A, 
Sigurdsson A, Baker A, Palsson A, Masson G, Gudbjartsson DF, Magnusson KP, 
Andersen K, Levey AI, Backman VM, Matthiasdottir S, Jonsdottir T, Palsson S, 
Einarsdottir H, Gunnarsdottir S, Gylfason A, Vaccarino V, Hooper WC, Reilly 
MP, Granger CB, Austin H, Rader DJ, Shah SH, Quyyumi AA, Gulcher JR, 
Thorgeirsson G, Thorsteinsdottir U, Kong A, Stefansson K (2007) A common 
variant on chromosome 9p21 affects the risk of myocardial infarction. Science 
316: 1491-3 
Hoffman JI, Kaplan S (2002) The incidence of congenital heart disease. J Am Coll 
Cardiol 39: 1890-1900 
Hoffman JI, Kaplan S, Liberthson RR (2004) Prevalence of congenital heart disease. 
Am Heart J 147: 425-39 
Howe JR, Bair JL, Sayed MG, Anderson ME, Mitros FA, Petersen GM, Velculescu VE, 
Traverso G, Vogelstein B (2001) Germline mutations of the gene encoding bone 
morphogenetic protein receptor 1A in juvenile polyposis. Nat Genet 28: 184-7 
Howe JR, Roth S, Ringold JC, Summers RW, Jarvinen HJ, Sistonen P, Tomlinson IP, 
Houlston RS, Bevan S, Mitros FA, Stone EM, Aaltonen LA (1998) Mutations in 
the SMAD4/DPC4 gene in juvenile polyposis. Science 280: 1086-8 
  
 223
Howe JR, Sayed MG, Ahmed AF, Ringold J, Larsen-Haidle J, Merg A, Mitros FA, 
Vaccaro CA, Petersen GM, Giardiello FM, Tinley ST, Aaltonen LA, Lynch HT 
(2004) The prevalence of MADH4 and BMPR1A mutations in juvenile 
polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations. J Med 
Genet 41: 484-91 
Hurle JM, Colvee E, Blanco AM (1980) Development of mouse semilunar valves. Anat 
Embryol (Berl) 160: 83-91 
Huse M, Chen YG, Massague J, Kuriyan J (1999) Crystal structure of the cytoplasmic 
domain of the type I TGF beta receptor in complex with FKBP12. Cell 96: 425-
36 
Hutson MR, Kirby ML (2007) Model systems for the study of heart development and 
disease. Cardiac neural crest and conotruncal malformations. Semin Cell Dev 
Biol 18: 101-10 
Iaizzo PA (2009) Handbook of cardiac anatomy, physiology and devices. Springer 
Sciences + Business Media  
Imamura T, Takase M, Nishihara A, Oeda E, Hanai J, Kawabata M, Miyazono K (1997) 
Smad6 inhibits signaling by the TGF-B superfamily. Nature 389: 622-626 
Ionescu-Ittu R, Marelli AJ, Mackie AS, Pilote L (2009) Prevalence of severe congenital 
heart disease after folic acid fortification of grain products: time trend analysis in 
Quebec, Canada. BMJ 338: b1673 
Jenkins KJ, Correa A, Feinstein JA, Botto L, Britt AE, Daniels SR, Elixson M, Warnes 
CA, Webb CL (2007) Noninherited risk factors and congenital cardiovascular 
defects: current knowledge: a scientific statement from the American Heart 
Association Council on Cardiovascular Disease in the Young: endorsed by the 
American Academy of Pediatrics. Circulation 115: 2995-3014 
Jiao K, Kulessa H, Tompkins K, Zhou Y, Batts L, Baldwin HS, Hogan BL (2003) An 
essential role of Bmp4 in the atrioventricular septation of the mouse heart. 
Genes Dev 17: 2362-7 
Jonson T, Gorunova L, Dawiskiba S, Andren-Sandberg A, Stenman G, ten Dijke P, 
Johansson B, Hoglund M (1999) Molecular analyses of the 15q and 18q SMAD 
genes in pancreatic cancer. Genes Chromosomes Cancer 24: 62-71 
Kameda Y (2009) Hoxa3 and signaling molecules involved in aortic arch patterning and 
remodeling. Cell Tissue Res 336: 165-78 
  
 224
Kasahara H, Lee B, Schott JJ, Benson DW, Seidman JG, Seidman CE, Izumo S (2000) 
Loss of function and inhibitory effects of human CSX/NKX2.5 homeoprotein 
mutations associated with congenital heart disease. J Clin Invest 106: 299-308 
Katagiri T, Yamaguchi A, Komaki M, Abe E, Takahashi N, Ikeda T, Rosen V, Wozney 
JM, Fujisawa-Sehara A, Suda T (1994) Bone mophogenetic protein-2 converts 
the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J. 
Cell Biol. 127: 1755-1766 
Kawabata M, Chytil A, Moses HL (1995) Cloning of a novel type II serine/threonine 
kinase receptor through interaction with the type I transforming growth factor-
beta receptor. J Biol Chem 270: 5625-30 
Kawabata M, Imamura T, Miyazono K (1998) Signal transduction by bone 
morphogenetic proteins. Cytokine Growth Factor Rev 9: 49-61 
Kawate S, Ohwada S, Hamada K, Koyama T, Takenoshita S, Morishita Y, Hagiwara K 
(2001) Mutational analysis of the Smad6 and Smad7 genes in hepatocellular 
carcinoma. Int J Mol Med 8: 49-52 
Keavney B, Danesh J, Parish S, Palmer A, Clark S, Youngman L, Delepine M, Lathrop 
M, Peto R, Collins R (2006) Fibrinogen and coronary heart disease: test of 
causality by 'Mendelian randomization'. Int J Epidemiol 35: 935-43 
Kelly RG, Brown NA, Buckingham ME (2001) The arterial pole of the mouse heart 
forms from Fgf10-expressing cells in pharyngeal mesoderm. Dev Cell 1: 435-40 
Kereszturi E, Kiraly O, Sahin-Toth M (2009) Minigene analysis of intronic variants in 
common SPINK1 haplotypes associated with chronic pancreatitis. Gut 58: 545-9 
Kinbara K, Goldfinger LE, Hansen M, Chou FL, Ginsberg MH (2003) Ras GTPases: 
integrins' friends or foes? Nat Rev Mol Cell Biol 4: 767-76 
Kirby ML (2007) Cardiac Development. Oxford University Press  
Kirby ML, Gale TF, Stewart DE (1983) Neural crest cells contribute to normal 
aorticopulmonary septation. Science 220: 1059-61 
Kirby ML, Stewart DE (1983) Neural crest origin of cardiac ganglion cells in the chick 
embryo: identification and extirpation. Dev Biol 97: 433-43 
Kirby ML, Turnage KL, 3rd, Hays BM (1985) Characterization of conotruncal 
malformations following ablation of "cardiac" neural crest. Anat Rec 213: 87-93 
Kishimoto Y, Lee KH, Zon L, Hammerschmidt M, Schulte-Merker S (1997) The 
molecular nature of zebrafish swirl: BMP2 function is essential during early 
dorsoventral patterning. Development 124: 4457-66 
  
 225
Klaus A, Saga Y, Taketo MM, Tzahor E, Birchmeier W (2007) Distinct roles of 
Wnt/beta-catenin and Bmp signaling during early cardiogenesis. Proc Natl Acad 
Sci U S A 104: 18531-6 
Kobrynski LJ, Sullivan KE (2007) Velocardiofacial syndrome, DiGeorge syndrome: the 
chromosome 22q11.2 deletion syndromes. Lancet 370: 1443-52 
Koenig BB, Cook JS, Wolsing DH, Ting J, Tiesman JP, Correa PE, Olson CA, Pecquet 
AL, Ventura F, Grant RA (1994) Characterization and cloning of a receptor for 
BMP-2 and BMP-4 from NIH 3T3 cells. Molecular and Cellular Biology 14: 
5961-5974 
Kol G, Lev-Maor G, Ast G (2005) Human-mouse comparative analysis reveals that 
branch-site plasticity contributes to splicing regulation. Hum Mol Genet 14: 
1559-68 
Kolodziej PA, Young RA (1991) Epitope tagging and protein surveillance. Methods 
Enzymol 194: 508-19 
Korchynskyi O, ten Dijke P (2001) Identification and Functional Characterization of 
Distinct Critically Important Bone Morphogenetic Protein-specific Response 
Elements in the Id1 Promoter. The Journal of Biological Chemistry 277: 4883-
4891 
Korn JM, Kuruvilla FG, McCarroll SA, Wysoker A, Nemesh J, Cawley S, Hubbell E, 
Veitch J, Collins PJ, Darvishi K, Lee C, Nizzari MM, Gabriel SB, Purcell S, 
Daly MJ, Altshuler D (2008) Integrated genotype calling and association 
analysis of SNPs, common copy number polymorphisms and rare CNVs. Nat 
Genet 40: 1253-60 
Krantz ID, Rand EB, Genin A, Hunt P, Jones M, Louis AA, Graham JM, Jr., Bhatt S, 
Piccoli DA, Spinner NB (1997) Deletions of 20p12 in Alagille syndrome: 
frequency and molecular characterization. Am J Med Genet 70: 80-6 
Kryukov GV, Pennacchio LA, Sunyaev SR (2007) Most rare missense alleles are 
deleterious in humans: implications for complex disease and association studies. 
Am J Hum Genet 80: 727-39 
Lamberechts D, Devriendt K, Driscoll DA, Goldmuntz E, Gweillig M, Vlietinck R, 
Collen D, Carmeliet P (2005) Low expression VEGF haplotype increases the 
risk for tetralogy of Fallot: a family based association study. J Med Genet 42: 
519-522 
Levin M (2005) Left-right asymmetry in embryonic development: a comprehensive 
review. Mech Dev 122: 3-25 
  
 226
Levy HL, Guldberg P, Guttler F, Hanley WB, Matalon R, Rouse BM, Trefz F, Azen C, 
Allred EN, de la Cruz F, Koch R (2001) Congenital heart disease in maternal 
phenylketonuria: report from the Maternal PKU Collaborative Study. Pediatr 
Res 49: 636-42 
Li L, Krantz ID, Deng Y, Genin A, Banta AB, Collins CC, Qi M, Trask BJ, Kuo WL, 
Cochran J, Costa T, Pierpont ME, Rand EB, Piccoli DA, Hood L, Spinner NB 
(1997) Alagille syndrome is caused by mutations in human Jagged1, which 
encodes a ligand for Notch1. Nat Genet 16: 243-51 
Lie RT, Wilcox AJ, Skjaerven R (1994) A population-based study of the risk of 
recurrence of birth defects. N Engl J Med 331: 1-4 
Lincoln J, Alfieri CM, Yutzey KE (2006) BMP and FGF regulatory pathways control 
cell lineage diversification of heart valve precursor cells. Dev Biol 292: 292-302 
Liu F, Ventura F, Doody J, Massague J (1995) Human type II receptor for bone 
morphogenetic proteins (BMPs): extension of the two-kinase receptor model to 
the BMPs. Molecular and Cellular Biology 15: 3479-3486 
Liu W, Selever J, Wang D, Lu MF, Moses KA, Schwartz RJ, Martin JF (2004) Bmp4 
signaling is required for outflow-tract septation and branchial-arch artery 
remodeling. Dev. Biol. 101 
Liu Y, Bourgeois CF, Pang S, Kudla M, Dreumont N, Kister L, Sun YH, Stevenin J, 
Elliott DJ (2009) The germ cell nuclear proteins hnRNP G-T and RBMY 
activate a testis-specific exon. PLoS Genet 5: e1000707 
Lo RS, Chen YG, Shi Y, Pavletich NP, Massague J (1998) The L3 loop: a structural 
motif determining specific interactions between SMAD proteins and TGF-beta 
receptors. EMBO J 17: 996-1005 
Loffredo CA, Wilson PD, Ferencz C (2001) Maternal diabetes: an independent risk 
factor for major cardiovascular malformations with increased mortality of 
affected infants. Teratology 64: 98-106 
Lopez-Sanchez C, Garcia-Martinez V, Schoenwolf GC (2001) Localization of cells of 
the prospective neural plate, heart and somites within the primitive streak and 
epiblast of avian embryos at intermediate primitive-streak stages. Cells Tissues 
Organs 169: 334-46 
Lough J, Sugi Y (2000) Endoderm and heart development. Dev Dyn 217: 327-42 
Lowe LA, Yamada S, Kuehn MR (2001) Genetic dissection of nodal function in 
patterning the mouse embryo. Development 128: 1831-43 
  
 227
Lyons KM, Pelton RW, Hogan BL (1990) Organogenesis and pattern formation in the 
mouse: RNA distribution patterns suggest a role for bone morphogenetic 
protein-2A (BMP-2A). Development 109: 833-44 
Ma L, Lu M, Schwartz RJ, Martin JF (2005) Bmp2 is essential for cardiac cushion 
epithelial-mesenchymal transition and myocardial patterning. Development 132: 
5601-5611 
Machado RD, Aldred MA, James V, Harrison RE, Patel B, Schwalbe EC, Gruenig E, 
Janssen B, Koehler R, Seeger W, Eickelberg O, Olschewski H, Elliott CG, 
Glissmeyer E, Carlquist J, Kim M, Torbicki A, Fijalkowska A, Szewczyk G, 
Parma J, Abramowicz MJ, Galie N, Morisaki H, Kyotani S, Nakanishi N, 
Morisaki T, Humbert M, Simonneau G, Sitbon O, Soubrier F, Coulet F, Morrell 
NW, Trembath RC (2006) Mutations of the TGF-beta type II receptor BMPR2 
in pulmonary arterial hypertension. Hum Mutat 27: 121-32 
Machado RD, Pauciulo MW, Thomson JR, Lane KB, Morgan NV, Wheeler L, Phillips 
JAI, Newman J, Williams D, Nazzareno G, Manes A, McNeil K, Yacoub M, 
Mikhail G, Rogers P, Corris P, Humbert M, Donnai D, Martensson G, 
Tranebjaerg L, Loyd JE, Trembath RC, Nichols WC (2001) BMPR2 
haploinsufficiency as the inherited molecular mechanism for primary pulmonary 
hypertension. Am. J. Hum.Genet. 68: 92-102 
Manner J (2000) Cardiac looping in the chick embryo: a morphological review with 
special reference to terminological and biomechanical aspects of the looping 
process. Anat Rec 259: 248-62 
Marino B, Digilio MC, Toscano A, Anaclerio S, Giannotti A, Feltri C, de Ioris MA, 
Angioni A, Dallapiccola B (2001) Anatomic patterns of conotruncal defects 
associated with deletion 22q11. Genet Med 3: 45-8 
Marino B, Digilio MC, Toscano A, Giannotti A, Dallapiccola B (1999) Congenital heart 
diseases in children with Noonan syndrome: An expanded cardiac spectrum with 
high prevalence of atrioventricular canal. J Pediatr 135: 703-6 
Markwald RR, Fitzharris TP, Manasek FJ (1977) Structural development of endocardial 
cushions. Am J Anat 148: 85-119 
McDonald-McGinn DM, Kirschner R, Goldmuntz E, Sullivan K, Eicher P, Gerdes M, 
Moss E, Solot C, Wang P, Jacobs I, Handler S, Knightly C, Heher K, Wilson M, 
Ming JE, Grace K, Driscoll D, Pasquariello P, Randall P, Larossa D, Emanuel 
BS, Zackai EH (1999) The Philadelphia story: the 22q11.2 deletion: report on 
250 patients. Genet Couns 10: 11-24 
  
 228
McElhinney DB, Geiger E, Blinder J, Benson DW, Goldmuntz E (2003) NKX2.5 
mutations in patients with congenital heart disease. J Am Coll Cardiol 42: 1650-
5 
McElhinney DB, Krantz ID, Bason L, Piccoli DA, Emerick KM, Spinner NB, 
Goldmuntz E (2002) Analysis of cardiovascular phenotype and genotype-
phenotype correlation in individuals with a JAG1 mutation and/or Alagille 
syndrome. Circulation 106: 2567-74 
McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, Hinds DA, 
Pennacchio LA, Tybjaerg-Hansen A, Folsom AR, Boerwinkle E, Hobbs HH, 
Cohen JC (2007) A common allele on chromosome 9 associated with coronary 
heart disease. Science 316: 1488-91 
Mefford HC, Sharp AJ, Baker C, Itsara A, Jiang Z, Buysse K, Huang S, Maloney VK, 
Crolla JA, Baralle D, Collins A, Mercer C, Norga K, de Ravel T, Devriendt K, 
Bongers EM, de Leeuw N, Reardon W, Gimelli S, Bena F, Hennekam RC, Male 
A, Gaunt L, Clayton-Smith J, Simonic I, Park SM, Mehta SG, Nik-Zainal S, 
Woods CG, Firth HV, Parkin G, Fichera M, Reitano S, Lo Giudice M, Li KE, 
Casuga I, Broomer A, Conrad B, Schwerzmann M, Raber L, Gallati S, Striano P, 
Coppola A, Tolmie JL, Tobias ES, Lilley C, Armengol L, Spysschaert Y, Verloo 
P, De Coene A, Goossens L, Mortier G, Speleman F, van Binsbergen E, Nelen 
MR, Hochstenbach R, Poot M, Gallagher L, Gill M, McClellan J, King MC, 
Regan R, Skinner C, Stevenson RE, Antonarakis SE, Chen C, Estivill X, Menten 
B, Gimelli G, Gribble S, Schwartz S, Sutcliffe JS, Walsh T, Knight SJ, Sebat J, 
Romano C, Schwartz CE, Veltman JA, de Vries BB, Vermeesch JR, Barber JC, 
Willatt L, Tassabehji M, Eichler EE (2008) Recurrent rearrangements of 
chromosome 1q21.1 and variable pediatric phenotypes. N Engl J Med 359: 
1685-99 
Meilhac SM, Esner M, Kelly RG, Nicolas JF, Buckingham ME (2004) The clonal origin 
of myocardial cells in different regions of the embryonic mouse heart. Dev Cell 
6: 685-98 
Mishina Y, Suzuki A, Ueno N, Behringer RB (1995) Bmpr encodes a type I bone 
morphogenetic protein receptor that is essential for gastrulation furin mouse 
embryogenesis. Genes & Dev. 9: 3027-3037 
Miyazono K (1999) Signal transduction by bone morphogenetic protein receptors: 
functional roles of Smad proteins. Bone 25: 91-3 
  
 229
Miyazono K, Maeda S, Imamura T (2005) BMP receptor signaling: transcriptional 
targets, regulation of signals, and signaling cross-talk. Cytokine Growth Factor 
Rev 16: 251-63 
Mjaatvedt CH, Nakaoka T, Moreno-Rodriguez R, Norris RA, Kern MJ, Eisenberg CA, 
Turner D, Markwald RR (2001) The outflow tract of the heart is recruited from a 
novel heart-forming field. Developmental Biology 238: 97-109 
Momma K, Kondo C, Ando M, Matsuoka R, Takao A (1995) Tetralogy of Fallot 
associated with chromosome 22q11 deletion. Am J Cardiol 76: 618-21 
Moore KL, Persaud TVN (1998) The Developing Human (6th edition). W.B. Saunders 
Company 
MRC (1991) Prevention of neural tube defects: results of the Medical Research Council 
Vitamin Study. MRC Vitamin Study Research Group. Lancet 338: 131-7 
Murakami G, Watabe T, Takaoka K, Miyazono K, Imamura T (2003) Cooperative 
inhibition of bone morphogenetic protein signaling by Smurf1 and inhibitory 
Smads. Mol Biol Cell 14: 2809-17 
Naiche LA, Harrelson Z, Kelly RG, Papaioannou VE (2005) T-box genes in vertebrate 
development. Annu Rev Genet 39: 219-39 
Nakamura T, Colbert MC, Robbins J (2006) Neural crest cells retain multipotential 
characteristics in the developing valves and label the cardiac conduction system. 
Circ Res 98: 1547-54 
Nakashima A, Katagiri T, Tamura M (2005) Cross-talk between Wnt and bone 
morphogenetic protein 2 (BMP-2) signaling in differentiation pathway of C2C12 
myoblasts. J Biol Chem 280: 37660-8 
Naya FJ, Black BL, Wu H, Bassel-Duby R, Richardson JA, Hill JA, Olson EN (2002) 
Mitochondrial deficiency and cardiac sudden death in mice lacking the MEF2A 
transcription factor. Nat Med 8: 1303-9 
Ng SB, Buckingham KJ, Lee C, Bigham AW, Tabor HK, Dent KM, Huff CD, Shannon 
PT, Jabs EW, Nickerson DA, Shendure J, Bamshad MJ (2010) Exome 
sequencing identifies the cause of a mendelian disorder. Nat Genet 42: 30-5 
Ng SB, Turner EH, Robertson PD, Flygare SD, Bigham AW, Lee C, Shaffer T, Wong 
M, Bhattacharjee A, Eichler EE, Bamshad M, Nickerson DA, Shendure J (2009) 
Targeted capture and massively parallel sequencing of 12 human exomes. 
Nature 461: 272-6 
Nicoloso MS, Sun H, Spizzo R, Kim H, Wickramasinghe P, Shimizu M, Wojcik SE, 
Ferdin J, Kunej T, Xiao L, Manoukian S, Secreto G, Ravagnani F, Wang X, 
  
 230
Radice P, Croce CM, Davuluri RV, Calin GA (2010) Single-nucleotide 
polymorphisms inside microRNA target sites influence tumor susceptibility. 
Cancer Res 70: 2789-98 
Nishibatake M, Kirby ML, Van Mierop LH (1987) Pathogenesis of persistent truncus 
arteriosus and dextroposed aorta in the chick embryo after neural crest ablation. 
Circulation 75: 255-64 
Niwa M, Rose SD, Berget SM (1990) In vitro polyadenylation is stimulated by the 
presence of an upstream intron. Genes Dev 4: 1552-9 
Nohe A, Keating E, Knaus P, Petersen NO (2004 ) Signal transduction of bone 
morphogenetic protein receptors. Cell Signal 16: 291-299 
Noonan JA (1994) Noonan syndrome. An update and review for the primary 
pediatrician. Clin Pediatr (Phila) 33: 548-55 
Nora JJ (1968) Multifactorial inheritance hypothesis for the etiology of congenital heart 
diseases. The genetic-environmental interaction. Circulation 38: 604-17 
Nora JJ, Meyer TC (1966) Familial nature of congenital heart diseases. Pediatrics 37: 
329-34 
Nora JJ, Nora AH (1987) Maternal transmission of congenital heart diseases: new 
recurrence risk figures and the questions of cytoplasmic inheritance and 
vulnerability to teratogens. Am J Cardiol 59: 459-63 
Norton ME (1997) Teratogen update: fetal effects of indomethacin administration 
during pregnancy. Teratology 56: 282-92 
Ohno M, Sakamoto H, Shimura Y (1987) Preferential excision of the 5' proximal intron 
from mRNA precursors with two introns as mediated by the cap structure. Proc 
Natl Acad Sci U S A 84: 5187-91 
Okagawa H, Markwald RR, Sugi Y (2007) Functional BMP receptor in endocardial 
cells is required in atrioventricular cushion mesenchymal cell formation in chick. 
Dev. Biol.  
Oyen N, Poulsen G, Boyd HA, Wohlfahrt J, Jensen PK, Melbye M (2009) Recurrence 
of congenital heart defects in families. Circulation 120: 295-301 
Palomino-Doza J, Rahman TJ, Avery PJ, Mayosi BM, Farrall M, Watkins H, Edwards 
CR, Keavney B (2008) Ambulatory blood pressure is associated with 
polymorphic variation in P2X receptor genes. Hypertension 52: 980-5 
Pierpont ME, Basson CT, Benson DW, Jr., Gelb BD, Giglia TM, Goldmuntz E, McGee 
G, Sable CA, Srivastava D, Webb CL (2007) Genetic basis for congenital heart 
defects: current knowledge: a scientific statement from the American Heart 
  
 231
Association Congenital Cardiac Defects Committee, Council on Cardiovascular 
Disease in the Young: endorsed by the American Academy of Pediatrics. 
Circulation 115: 3015-38 
Posch MG, Perrot A, Schmitt K, Mittelhaus S, Esenwein EM, Stiller B, Geier C, Dietz 
R, Gessner R, Ozcelik C, Berger F (2008) Mutations in GATA4, NKX2.5, 
CRELD1, and BMP4 are infrequently found in patients with congenital cardiac 
septal defects. Am J Med Genet A 146A: 251-3 
Pradat P (1994) Recurrence risk for major congenital heart defects in Sweden: a registry 
study. Genet Epidemiol 11: 131-40 
Rivera-Feliciano J, Tabin CJ (2006) Bmp2 instructs cardiac progenitors to form the 
heart-valve-inducing field. Dev Biol 295: 580-8 
Roberts AE, Araki T, Swanson KD, Montgomery KT, Schiripo TA, Joshi VA, Li L, 
Yassin Y, Tamburino AM, Neel BG, Kucherlapati RS (2007) Germline gain-of-
function mutations in SOS1 cause Noonan syndrome. Nat Genet 39: 70-4 
Roberts KE, McElroy JJ, Wong WP, Yen E, Widlitz A, Barst RJ, Knowles JA, Morse 
JH (2004) BMPR2 mutations in pulmonary arterial hypertension with congenital 
heart disease. Eur Respir J 24: 371-4 
Robson M, Offit K (2007) Clinical practice. Management of an inherited predisposition 
to breast cancer. N Engl J Med 357: 154-62 
Rosenzweig BL, Imamura T, Okadome T, Cox GN, Yamashita H, ten Dijke P, Heldin 
CH, Miyazono K (1995) Cloning and characterization of a human type II 
receptor for bone morphogenetic proteins. Proc Natl Acad Sci U S A 92: 7632-6 
Roth S, Sistonen P, Salovaara R, Hemminki A, Loukola A, Johansson M, Avizienyte E, 
Cleary KA, Lynch P, Amos CI, Kristo P, Mecklin JP, Kellokumpu I, Jarvinen H, 
Aaltonen LA (1999) SMAD genes in juvenile polyposis. Genes Chromosomes 
Cancer 26: 54-61 
Roux PP, Blenis J (2004) ERK and p38 MAPK-activated protein kinases: a family of 
protein kinases with diverse biological functions. Microbiol Mol Biol Rev 68: 
320-344 
Rudarakanchana N, Flanagan JA, Chen H, Upton PD, Machado R, Patel D, Trembath 
RC, Morrell NW (2002) Functional analysis of bone morphogenetic protein type 
II receptor mutations underlying primary pulmonary hypertension. Hum Mol 
Genet 11: 1517-25 
Samad TA, Rebbapragada A, Bell E, Zhang Y, Sidis Y, Jeong SJ (2005) DRAGON, a 
bone morphogenetic protein co-receptor. J. Biol Chem 280: 14122-14129 
  
 232
Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, Mayer B, Dixon RJ, 
Meitinger T, Braund P, Wichmann HE, Barrett JH, Konig IR, Stevens SE, 
Szymczak S, Tregouet DA, Iles MM, Pahlke F, Pollard H, Lieb W, Cambien F, 
Fischer M, Ouwehand W, Blankenberg S, Balmforth AJ, Baessler A, Ball SG, 
Strom TM, Braenne I, Gieger C, Deloukas P, Tobin MD, Ziegler A, Thompson 
JR, Schunkert H (2007) Genomewide association analysis of coronary artery 
disease. N Engl J Med 357: 443-53 
Sansoucie DA, Cavaliere TA (1997) Transition from fetal to extrauterine circulation. 
Neonatal Netw 16: 5-12 
Satoda M, Zhao F, Diaz GA, Burn J, Goodship J, Davidson HR, Pierpont ME, Gelb BD 
(2000) Mutations in TFAP2B cause Char syndrome, a familial form of patent 
ductus arteriosus. Nat Genet 25: 42-6 
Scanlon KS, Ferencz C, Loffredo CA, Wilson PD, Correa-Villasenor A, Khoury MJ, 
Willett WC (1998) Preconceptional folate intake and malformations of the 
cardiac outflow tract. Baltimore-Washington Infant Study Group. Epidemiology 
9: 95-8 
Schardein JL (2000) Anticonvulsants. In: Chemically Induced Birth Defects. 3rd ed. 
New York, NY: Marcel Dekker: 179-235 
Schlange T, Andree B, Arnold H, Brand T (2000) BMP2 is required for early heart 
development during a distinct time period. Mechanisms of Development 91: 
259-270 
Schlueter J, Manner J, Brand T (2006) BMP is an important regulator of proepicardial 
identity in the chick embryo. Dev. Biol. 295: 546-558 
Schott JJ, Benson DW, Basson CT, Pease W, Silberbach GM, Moak JP, Maron BJ, 
Seidman CE, Seidman JG (1998) Congenital heart disease caused by mutations 
in the transcription factor NKX2-5. Science 281: 108-11 
Schubbert S, Zenker M, Rowe SL, Boll S, Klein C, Bollag G, van der Burgt I, Musante 
L, Kalscheuer V, Wehner LE, Nguyen H, West B, Zhang KY, Sistermans E, 
Rauch A, Niemeyer CM, Shannon K, Kratz CP (2006) Germline KRAS 
mutations cause Noonan syndrome. Nat Genet 38: 331-6 
Schultheiss TM, Burch JB, Lassar AB (1997) A role for bone morphogenetic proteins in 
the induction of cardiac myogenesis. Genes Dev 11: 451-62 
Schwappacher R, Weiske J, Heining E, Ezerski V, Marom B, Henis YI, Huber O, 
Knaus P (2009) Novel crosstalk to BMP signalling: cGMP-dependent kinase I 
modulates BMP receptor and Smad activity. EMBO J 28: 1537-50 
  
 233
Shi Y, Katsev S, Cai C, Evans S (2000) BMP signaling is required for heart formation 
in vertebrates. Dev Biol 224: 226-37 
Shieh JT, Srivastava D (2009) Heart malformation: what are the chances it could 
happen again? Circulation 120: 269-71 
Signori E, Bagni C, Papa S, Primerano B, Rinaldi M, Amaldi F, Fazio VM (2001) A 
somatic mutation in the 5'UTR of BRCA1 gene in sporadic breast cancer causes 
down-modulation of translation efficiency. Oncogene 20: 4596-600 
Smith KA, Joziasse IC, Chocron S, van Dinther M, Guryev V, Verhoeven MC, 
Rehmann H, van der Smagt JJ, Doevendans PA, Cuppen E, Mulder BJ, Ten 
Dijke P, Bakkers J (2009) Dominant-negative ALK2 allele associates with 
congenital heart defects. Circulation 119: 3062-9 
Smith PJ, Zhang C, Wang J, Chew SL, Zhang MQ, Krainer AR (2006) An increased 
specificity score matrix for the prediction of SF2/ASF-specific exonic splicing 
enhancers. Hum Mol Genet 15: 2490-508 
Smithells RW, Newman CG (1992) Recognition of thalidomide defects. J Med Genet 
29: 716-23 
Somi S, Buffing AAM, Moorman AFM, van der Hoff MJB (2004) Dynamic patterns of 
expression of BMP isoforms 2,4,5,6, and 7 during chicken heart development. 
The Anatomical Record Part A 279A: 636-651 
Sorrentino RP, Gajewski KM, Schulz RA (2005) GATA factors in Drosophila heart and 
blood cell development. Semin Cell Dev Biol 16: 107-16 
Souchelnytskyi S, Nakayama T, Nakao A, Moren A, Heldin CH, Christian JL, ten Dijke 
P (1998) Physical and functional interaction of murine and Xenopus Smad7 with 
bone morphogenetic protein receptors and transforming growth factor-beta 
receptors. J Biol Chem 273: 25364-70 
Sperling S, Grimm CH, Dunkel I, Mebus S, Sperling HP, Ebner A, Galli R, Lehrach H, 
Fusch C, Berger F, Hammer S (2005) Identification and functional analysis of 
CITED2 mutations in patients with congenital heart defects. Hum Mutat 26: 
575-82 
Stefansson H, Rujescu D, Cichon S, Pietilainen OP, Ingason A, Steinberg S, Fossdal R, 
Sigurdsson E, Sigmundsson T, Buizer-Voskamp JE, Hansen T, Jakobsen KD, 
Muglia P, Francks C, Matthews PM, Gylfason A, Halldorsson BV, Gudbjartsson 
D, Thorgeirsson TE, Sigurdsson A, Jonasdottir A, Bjornsson A, Mattiasdottir S, 
Blondal T, Haraldsson M, Magnusdottir BB, Giegling I, Moller HJ, Hartmann A, 
Shianna KV, Ge D, Need AC, Crombie C, Fraser G, Walker N, Lonnqvist J, 
  
 234
Suvisaari J, Tuulio-Henriksson A, Paunio T, Toulopoulou T, Bramon E, Di Forti 
M, Murray R, Ruggeri M, Vassos E, Tosato S, Walshe M, Li T, Vasilescu C, 
Muhleisen TW, Wang AG, Ullum H, Djurovic S, Melle I, Olesen J, Kiemeney 
LA, Franke B, Sabatti C, Freimer NB, Gulcher JR, Thorsteinsdottir U, Kong A, 
Andreassen OA, Ophoff RA, Georgi A, Rietschel M, Werge T, Petursson H, 
Goldstein DB, Nothen MM, Peltonen L, Collier DA, St Clair D, Stefansson K 
(2008) Large recurrent microdeletions associated with schizophrenia. Nature 
455: 232-6 
Stern CD, Yu RT, Kakizuka A, Kintner CR, Mathews LS, Vale WW, Evans RM, 
Umesono K (1995) Activin and its receptors during gastrulation and the later 
phases of mesoderm development in the chick embryo. Dev Biol 172: 192-205 
Stoss O, Stoilov P, Hartmann AM, Nayler O, Stamm S (1999) The in vivo minigene 
approach to analyze tissue-specific splicing. Brain Res Brain Res Protoc 4: 383-
94 
Stottmann RW, Choi M, Mishina Y, Meyers EN, Klingensmith J (2004) BMP receptor 
IA is required in mammalian neural crest cells for development of the cardiac 
outflow tract and ventricular myocardium. Development 131: 2205-2218 
Styrkarsdottir U, Cazier JB, Kong A, Rolfsson O, Larsen H, Bjarnadottir E, 
Johannsdottir VD, Sigurdardottir MS, Bagger Y, Christiansen C, Reynisdottir I, 
Grant SF, Jonasson K, Frigge ML, Gulcher JR, Sigurdsson G, Stefansson K 
(2003) Linkage of osteoporosis to chromosome 20p12 and association to BMP2. 
PLoS Biol 1: E69 
Suzuki S, Marazita ML, Cooper ME, Miwa N, Hing A, Jugessur A, Natsume N, 
Shimozato K, Ohbayashi N, Suzuki Y, Niimi T, Minami K, Yamamoto M, 
Altannamar TJ, Erkhembaatar T, Furukawa H, Daack-Hirsch S, L'Heureux J, 
Brandon CA, Weinberg SM, Neiswanger K, Deleyiannis FW, de Salamanca JE, 
Vieira AR, Lidral AC, Martin JF, Murray JC (2009) Mutations in BMP4 are 
associated with subepithelial, microform, and overt cleft lip. Am J Hum Genet 
84: 406-11 
Tabatabaeifar M, Schlingmann KP, Litwin M, Emre S, Bakkaloglu A, Mehls O, 
Antignac C, Schaefer F, Weber S (2009) Functional analysis of BMP4 mutations 
identified in pediatric CAKUT patients. Pediatr Nephrol 24: 2361-8 
Takizawa T, Ochiai W, Nakashima K, Taga T (2003) Enhanced gene activation by 
Notch and BMP signaling cross-talk. Nucleic Acids Res 31: 5723-31 
  
 235
Tam PP, Parameswaran M, Kinder SJ, Weinberger RP (1997) The allocation of epiblast 
cells to the embryonic heart and other mesodermal lineages: the role of 
ingression and tissue movement during gastrulation. Development 124: 1631-42 
Tellier AL, Cormier-Daire V, Abadie V, Amiel J, Sigaudy S, Bonnet D, de Lonlay-
Debeney P, Morrisseau-Durand MP, Hubert P, Michel JL, Jan D, Dollfus H, 
Baumann C, Labrune P, Lacombe D, Philip N, LeMerrer M, Briard ML, 
Munnich A, Lyonnet S (1998) CHARGE syndrome: report of 47 cases and 
review. Am J Med Genet 76: 402-9 
ten Dijke P, Yamashita J, Ichijo H, Frazen P, Laiho M, Miyazono K, Heldin CH (1994) 
Characterization of type I receptors for transforming growth factor-B and activin. 
Science 264: 101-104 
Thienpont B, Mertens L, de Ravel T, Eyskens B, Boshoff D, Maas N, Fryns JP, 
Gewillig M, Vermeesch JR, Devriendt K (2007) Submicroscopic chromosomal 
imbalances detected by array-CGH are a frequent cause of congenital heart 
defects in selected patients. Eur Heart J 28: 2778-84 
Urist MR (1965) Bone: formation by autoinduction. Science 150: 893-899 
van Beynum IM, den Heijer M, Blom HJ, Kapusta L (2007) The MTHFR 677C->T 
polymorphism and the risk of congenital heart defects: a literature review and 
meta-analysis. QJM 100: 743-53 
van den Hoff MJ, Kruithof BP, Moorman AF, Markwald RR, Wessels A (2001) 
Formation of myocardium after the initial development of the linear heart tube. 
Dev Biol 240: 61-76 
van Mierop LH, Kutsche LM (1985) Development of the ventricular septum of the heart. 
Heart Vessels 1: 114-9 
Vanhaesebroeck B, Leevers SJ, Ahmadi K, Timms J, Katso R, Driscoll PC, Woscholski 
R, Parker PJ, Waterfield MD (2001) Synthesis and function of 3-phosphorylated 
inositol lipids. Annu Rev Biochem 70: 535-602 
Visser JA, Olaso R, Verhoef-Post M, Kramer P, Themmen AP, Ingraham HA (2001) 
The serine/threonine transmembrane receptor ALK2 mediates Mullerian 
inhibiting substance signaling. Mol Endocrinol 15: 936-45 
Vissers LE, van Ravenswaaij CM, Admiraal R, Hurst JA, de Vries BB, Janssen IM, van 
der Vliet WA, Huys EH, de Jong PJ, Hamel BC, Schoenmakers EF, Brunner HG, 
Veltman JA, van Kessel AG (2004) Mutations in a new member of the 
chromodomain gene family cause CHARGE syndrome. Nat Genet 36: 955-7 
  
 236
Waldo KL, Hutson MR, Stadt HA, Zdanowicz M, Zdanowicz J, Kirby ML (2005) 
Cardiac neural crest is necessary for normal addition of the myocardium to the 
arterial pole from the secondary heart field. Dev Biol 281: 66-77 
Waldo KL, Kumiski DH, Wallis KT, Stadt HA, Hutson MR, Platt DH, Kirby ML (2001) 
Conotruncal myocardium arises from a secondary heart field. Development 128: 
3179-88 
Wang D, Kanuma T, Mizumuma H, Ibuki Y, Takenoshita S (2000a) Mutation analysis 
of the Smad6 and Smad7 gene in human ovarian cancers. Int J Oncol 17: 1087-
91 
Wang J, Sridurongrit S, Dudas M, Thomas P, Nagy A, Schneider MD, Epstein JA, 
Kaartinen V (2005a) Atrioventricular cushion transformation is mediated by 
ALK2 in the developing mouse heart. Developmental Biology 286: 299-310 
Wang M, Wang JY, Cisler J, Imaizumi K, Burton BK, Jones MC, Lamberti JJ, Godfrey 
M (1997) Three novel fibrillin mutations in exons 25 and 27: classic versus 
neonatal Marfan syndrome. Hum Mutat 9: 359-62 
Wang Q, Rao S, Topol EJ (2005b) Miscues on the "lack of MEF2A mutations" in 
coronary artery disease. J Clin Invest 115: 1399-400; author reply 1400-1 
Wang Q, Reiter RS, Huang QQ, Jin JP, Lin JJ (2001) Comparative studies on the 
expression patterns of three troponin T genes during mouse development. Anat 
Rec 263: 72-84 
Wang Q, Sigmund CD, Lin JJ (2000b) Identification of cis elements in the cardiac 
troponin T gene conferring specific expression in cardiac muscle of transgenic 
mice. Circ Res 86: 478-84 
Wang Y, Qian L, Liu D (2007) Bone morphogenetic protein-2 acts upstream of 
myocyte-specific enhancer factor 2a to control embryonic cardiac contractility. 
Cardio. Res. 74: 290-303 
Ward C (2000) Clinical significance of the bicuspid aortic valve. Heart 83: 81-5 
Webb S, Brown NA, Anderson RH, Richardson MK (2000) Relationship in the chick of 
the developing pulmonary vein to the embryonic systemic venous sinus. Anat 
Rec 259: 67-75 
Wessels A, Sedmera D (2003) Developmental anatomy of the heart: a tale of mice and 
man. Physiol Genomics 15: 165-76 
Wilson AM, Schlade-Bartusiak K, Tison JL, Macintyre G, Cox DW (2009) A minigene 
approach for analysis of ATP7B splice variants in patients with Wilson disease. 
Biochimie 91: 1342-5 
  
 237
Wilson PD, Loffredo CA, Correa-Villasenor A, Ferencz C (1998) Attributable fraction 
for cardiac malformations. Am J Epidemiol 148: 414-23 
Winnier G, Blessing M, Labosky PA, Hogan BLM (1995) Bone morphogenetic protein-
4 is required for mesoderm formation and patterning in the mouse. Gene Dev 9: 
2105-2116 
Wrana JL, Carcamo J, Attisano L, Cheifetz S, Zentella A, Lopez-Casillas F, Massague J 
(1992) The type II TGF-beta receptor signals diverse responses in cooperation 
with the type I receptor. Cold Spring Harb Symp Quant Biol 57: 81-6 
Xiao JH, Davidson I, Matthes H, Garnier JM, Chambon P (1991) Cloning, expression, 
and transcriptional properties of the human enhancer factor TEF-1. Cell 65: 551-
68 
Xu X, Yin Z, Hudson JB, Ferguson EL, Frasch M (1998) Smad proteins act in 
combination with synergistic and antagonistic regulators to target Dpp responses 
to the Drosophila mesoderm. Genes Dev 12: 2354-70 
Yaffe D, Saxel O (1977) Serial passaging and differentiation of myogenic cells isolated 
from dystrophic mouse muscle. Nature 270: 725-727 
Yamada M, Revelli JP, Eichele G, Barron M, Schwartz RJ (2000) Expression of chick 
Tbx-2, Tbx-3, and Tbx-5 genes during early heart development: evidence for 
BMP2 induction of Tbx2. Dev Biol 228: 95-105 
Yamada M, Szendro PI, Prokscha A, Schwartz RJ, Eichele G (1999) Evidence for a role 
of Smad6 in chick cardiac development. Dev. Biol. 215: 48-61 
Yang L, Cai CL, Lin L, Qyang Y, Chung C, Monteiro RM, Mummery CL, Fishman GI, 
Cogen A, Evans S (2006) Isl1Cre reveals a common Bmp pathway in heart and 
limb development. Development 133: 1575-85 
Yang X, Dormann D, Munsterberg AE, Weijer CJ (2002) Cell movement patterns 
during gastrulation in the chick are controlled by positive and negative 
chemotaxis mediated by FGF4 and FGF8. Dev Cell 3: 425-37 
Yelbuz TM, Waldo KL, Kumiski DH, Stadt HA, Wolfe RR, Leatherbury L, Kirby ML 
(2002) Shortened outflow tract leads to altered cardiac looping after neural crest 
ablation. Circulation 106: 504-10 
Zaffran S, Kelly RG, Meilhac SM, Buckingham ME, Brown NA (2004) Right 
ventricular myocardium derives from the anterior heart field. Circ Res 95: 261-8 
Zatyka M, Priestley M, Ladusans EJ, Fryer AE, Mason J, Latif F, Maher ER (2005) 
Analysis of CRELD1 as a candidate 3p25 atrioventicular septal defect locus 
(AVSD2). Clin Genet 67: 526-8 
  
 238
Zhang C, Hastings ML, Krainer AR, Zhang MQ (2007) Dual-specificity splice sites 
function alternatively as 5' and 3' splice sites. Proc Natl Acad Sci U S A 104: 
15028-33 
Zhang H, Bradley A (1996) Mice dificient for BMP2 are nonviable and have defects in 
amnion/chorion and cardiac development. Development 122: 2977-2986 
Zhang J, Cai WW (1993) Association of the common cold in the first trimester of 
pregnancy with birth defects. Pediatrics 92: 559-63 
Zhou XP, Woodford-Richens K, Lehtonen R, Kurose K, Aldred M, Hampel H, 
Launonen V, Virta S, Pilarski R, Salovaara R, Bodmer WF, Conrad BA, Dunlop 
M, Hodgson SV, Iwama T, Jarvinen H, Kellokumpu I, Kim JC, Leggett B, 
Markie D, Mecklin JP, Neale K, Phillips R, Piris J, Rozen P, Houlston RS, 
Aaltonen LA, Tomlinson IP, Eng C (2001) Germline mutations in 
BMPR1A/ALK3 cause a subset of cases of juvenile polyposis syndrome and of 
Cowden and Bannayan-Riley-Ruvalcaba syndromes. Am J Hum Genet 69: 704-
11 
Zhu H, Kavsak P, Abdollah S, Wrana JL, Thomsen GH (1999) A SMAD ubiquitin 
ligase targets the BMP pathway and affects embryonic pattern formation. Nature 
400: 687-93 
 
 
